<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Spironolactone</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Spironolactone">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Spironolactone</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Spironolactone</b>, sold under the brand name <b>Aldactone</b> among others, is a medication that is primarily used to treat fluid build-up due to heart failure, liver scarring, or kidney disease.<span class="mw-ref" id="cite_ref-AHFS2015_4-1"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It is also used in the treatment of high blood pressure, low blood potassium that does not improve with <a href="Potassium.htm#Supplementation" tppabs="https://ptable.com/wiki/compounds/A/Potassium#Supplementation" title="Potassium">supplementation</a>, early puberty in boys, acne and excessive hair growth in women, and as a part of  transgender hormone therapy  in transgender women.<span class="mw-ref" id="cite_ref-AHFS2015_4-2"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> Spironolactone is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2015_4-3"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>



<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Spironolactone</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Spironolactone.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Spironolactone.svg.png" data-file-width="1290" data-file-height="1090" data-file-type="drawing" height="199" width="235"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Spironolactone_3D_ball.png" tppabs="https://ptable.com/wiki/compounds/I/m/Spironolactone_3D_ball.png" data-file-width="2000" data-file-height="1481" data-file-type="bitmap" height="167" width="225"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˌ</span><span>s</span><span>p</span><span>aɪ</span><span>r</span><span>oʊ</span><span>n</span><span>oʊ</span><span>ˈ</span><span>l</span><span>æ</span><span>k</span><span>t</span><span>oʊ</span><span>n</span></span>/</span></span> <i title="English pronunciation respelling"><span style="font-size:90%">SPY</span>-roh-noh-<span style="font-size:90%">LAK</span>-tone</i>,<span class="mw-ref" id="cite_ref-LoughlinGenerali2006_1-0"><a href="#cite_note-LoughlinGenerali2006-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˌ</span><span>s</span><span>p</span><span>ɪər</span><span>oʊ</span><span>n</span><span>oʊ</span><span>ˈ</span><span>l</span><span>æ</span><span>k</span><span>t</span><span>oʊ</span><span>n</span></span>/</span></span> <i title="English pronunciation respelling"><span style="font-size:90%">SPEER</span>-oh-noh-<span style="font-size:90%">LAK</span>-tone</i><span class="mw-ref" id="cite_ref-ClarkHarvey2011_2-0"><a href="#cite_note-ClarkHarvey2011-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Aldactone, Spiractin, Verospiron, <a href="#Brand_names">many others</a>; combinations: Aldactazide (+<a href="Hydrochlorothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrochlorothiazide" title="Hydrochlorothiazide"><abbr>HCTZ</abbr></a>), Aldactide (+<a href="Hydroflumethiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroflumethiazide" title="Hydroflumethiazide"><abbr>HFMZ</abbr></a>), Aldactazine (+altizide), <a href="#Brand_names">others</a></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>SC-9420; NSC-150339; 7α-Acetylthiospirolactone; 7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/spironolactone.html'" tppabs="https://www.drugs.com/monograph/spironolactone.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a682627.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a682627.html'" tppabs="https://medlineplus.gov/druginfo/meds/a682627.html" class="external text external">a682627</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Spironolactone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Spironolactone'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Spironolactone" class="external text external">Spironolactone</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B3<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_3-0"><a href="#cite_note-Drugs.com_pregnancy-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_3-1"><a href="#cite_note-Drugs.com_pregnancy-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth,<span class="mw-ref" id="cite_ref-AHFS2015_4-0"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> topical<span class="mw-ref" id="cite_ref-FARIDDiamanti-Kandarakis2009_5-0"><a href="#cite_note-FARIDDiamanti-Kandarakis2009-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Antimineralocorticoid; Steroidal antiandrogen</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>C03DA01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=C03DA01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=C03DA01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=C03DA01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>60–90%<span class="mw-ref" id="cite_ref-Sica2005_6-0"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-0"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-CaroneOxberry2017_8-0"><a href="#cite_note-CaroneOxberry2017-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>Spironolactone: 88% (to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a> and <abbr>AGP</abbr>)<span class="mw-ref" id="cite_ref-TakamuraMaruyama1997_9-0"><a href="#cite_note-TakamuraMaruyama1997-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><br>Canrenone: 99.2% (to albumin)<span class="mw-ref" id="cite_ref-TakamuraMaruyama1997_9-1"><a href="#cite_note-TakamuraMaruyama1997-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver, others:<br>• Deacetylation via <abbr>CES</abbr><br>• <i>S</i>-Oxygenation via <abbr>FOM</abbr><br>• <i>S</i>-Methylation via <abbr>TMT</abbr><br>• Dethioacetylation<br>• Hydroxylation via CYP3A4<br>• Lactone hydrolysis via PON3)<span class="mw-ref" id="cite_ref-Sica2005_6-1"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-1"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-Parkinson2001_10-0"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Klaassen2007_11-0"><a href="#cite_note-Klaassen2007-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-pmid7895608_12-0"><a href="#cite_note-pmid7895608-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-BlackElliott2006_13-0"><a href="#cite_note-BlackElliott2006-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-pmid14579013_14-0"><a href="#cite_note-pmid14579013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolites</th><td><abbr>7α-TS</abbr>, <abbr>7α-TMS</abbr>, <abbr>6β-OH-7α-TMS</abbr>, canrenone, others<span class="mw-ref" id="cite_ref-Sica2005_6-2"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-2"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-SzaszBudvari-Barany1990_15-0"><a href="#cite_note-SzaszBudvari-Barany1990-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><br>(All three active)<span class="mw-ref" id="cite_ref-McDonaghGardner2011_16-0"><a href="#cite_note-McDonaghGardner2011-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>Spironolactone: 1.4 hrs<span class="mw-ref" id="cite_ref-Sica2005_6-3"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><br><abbr>7α-TMS</abbr>: 13.8 hours<span class="mw-ref" id="cite_ref-Sica2005_6-4"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><br><abbr>6β-OH-7α-TMS</abbr>: 15.0 hrs<span class="mw-ref" id="cite_ref-Sica2005_6-5"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><br>Canrenone: 16.5 hours<span class="mw-ref" id="cite_ref-Sica2005_6-6"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Urine, bile<span class="mw-ref" id="cite_ref-pmid18729003_7-3"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;"><i>S</i>-[(7<i>R</i>,8<i>R</i>,9<i>S</i>,10<i>R</i>,13<i>S</i>,14<i>S</i>,17<i>R</i>)-10,13-Dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=52-01-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=52-01-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=52-01-7" class="external text external">52-01-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/5833  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/5833'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/5833" class="external text external">5833</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2875'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2875" class="external text external">2875</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00421  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00421'" tppabs="https://www.drugbank.ca/drugs/DB00421" class="external text external">DB00421</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.5628.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.5628.html'" tppabs="http://www.chemspider.com/Chemical-Structure.5628.html" class="external text external">5628</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=27O7W4T232  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=27O7W4T232'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=27O7W4T232" class="external text external">27O7W4T232</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00443  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00443'" tppabs="https://www.kegg.jp/entry/D00443" class="external text external">D00443</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9241'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9241" class="external text external">CHEBI:9241</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1393'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1393" class="external text external">ChEMBL1393</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID6034186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID6034186'" tppabs="https://comptox.epa.gov/dashboard/DTXSID6034186" class="external text external">DTXSID6034186</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.000.122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.000.122'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.000.122" class="external text external">100.000.122</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>24</sub><span>H</span><sub>32</sub><span>O</span><sub>4</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">416.58</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC5O%5BC%40%40%5D4%28%5BC%40%40%5D3%28%5BC%40H%5D%28%5BC%40%40H%5D2%5BC%40H%5D%28SC%28%3DO%29C%29C%2FC1%3DC%2FC%28%3DO%29CC%5BC%40%5D1%28C%29%5BC%40H%5D2CC3%29CC4%29C%29CC5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC5O%5BC%40%40%5D4%28%5BC%40%40%5D3%28%5BC%40H%5D%28%5BC%40%40H%5D2%5BC%40H%5D%28SC%28%3DO%29C%29C%2FC1%3DC%2FC%28%3DO%29CC%5BC%40%5D1%28C%29%5BC%40H%5D2CC3%29CC4%29C%29CC5'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC5O%5BC%40%40%5D4%28%5BC%40%40%5D3%28%5BC%40H%5D%28%5BC%40%40H%5D2%5BC%40H%5D%28SC%28%3DO%29C%29C%2FC1%3DC%2FC%28%3DO%29CC%5BC%40%5D1%28C%29%5BC%40H%5D2CC3%29CC4%29C%29CC5" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>134 to 135<span>&nbsp;</span>°C (273 to 275<span>&nbsp;</span>°F)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C5O[C@@]4([C@@]3([C@H]([C@@H]2[C@H](SC(=O)C)C/C1=C/C(=O)CC[C@]1(C)[C@H]2CC3)CC4)C)CC5</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:LXMSZDCAJNLERA-ZHYRCANASA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470470172&page2=Spironolactone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470470172&page2=Spironolactone'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470470172&page2=Spironolactone" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects include electrolyte abnormalities, particularly high blood potassium, nausea, vomiting, headache, rashes, and a decreased desire for sex.<span class="mw-ref" id="cite_ref-AHFS2015_4-4"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In those with liver or kidney problems, extra care should be taken.<span class="mw-ref" id="cite_ref-AHFS2015_4-5"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Spironolactone has not been well studied in pregnancy and should not be used to treat high blood pressure of pregnancy.<span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_3-2"><a href="#cite_note-Drugs.com_pregnancy-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is a steroid that blocks the effects of the hormones <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a> and <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and has some estrogen-like effects.<span class="mw-ref" id="cite_ref-AHFS2015_4-6"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Deedwania2014_19-0"><a href="#cite_note-Deedwania2014-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Spironolactone belongs to a class of medications known as potassium-sparing diuretics.<span class="mw-ref" id="cite_ref-AHFS2015_4-7"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


<p>Spironolactone was discovered in 1957, and was introduced in 1959.<span class="mw-ref" id="cite_ref-OttowWeinmann2008_20-0"><a href="#cite_note-OttowWeinmann2008-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Wermuth2008_21-0"><a href="#cite_note-Wermuth2008-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Sittig1988_22-0"><a href="#cite_note-Sittig1988-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_23-0"><a href="#cite_note-WHO21st-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> It is available as a generic medication.<span class="mw-ref" id="cite_ref-AHFS2015_4-8"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In 2017, it was the 69th most commonly prescribed medication in the United States, with more than eleven million prescriptions.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Spironolactone is used primarily to treat heart failure, edematous conditions such as nephrotic syndrome or ascites in people with liver disease, essential hypertension, low blood levels of potassium, secondary hyperaldosteronism (such as occurs with liver cirrhosis), and Conn's syndrome (primary hyperaldosteronism). The most common use of spironolactone is in the treatment of heart failure.<span class="mw-ref" id="cite_ref-RoncoBellomo2017_26-0"><a href="#cite_note-RoncoBellomo2017-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of <a href="Sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium" title="Sodium">sodium</a> are reabsorbed, but it can be combined with other diuretics to increase efficacy. The classification of spironolactone as a "potassium-sparing diuretic" has been described as obsolete.<span class="mw-ref" id="cite_ref-pmid10760075_27-0"><a href="#cite_note-pmid10760075-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Spironolactone is also used to treat Bartter's syndrome due to its ability to raise potassium levels.<span class="mw-ref" id="cite_ref-EndouHosoyamada1995_28-0"><a href="#cite_note-EndouHosoyamada1995-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>Spironolactone has antiandrogenic activity. For this reason, it is frequently used to treat a variety of dermatological conditions in which androgens play a role. Some of these uses include acne, seborrhea, hirsutism, and pattern hair loss in women.<span class="mw-ref" id="cite_ref-pmid2969259_29-0"><a href="#cite_note-pmid2969259-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> Spironolactone is the most commonly used medication in the treatment of hirsutism in the United States.<span class="mw-ref" id="cite_ref-Preedy2012_30-0"><a href="#cite_note-Preedy2012-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> High doses of spironolactone, which are needed for considerable antiandrogenic effects, are not recommended for men due to the high risk of feminization and other side effects. Spironolactone is also commonly used to treat symptoms of hyperandrogenism, such as due to polycystic ovary syndrome, in women.<span class="mw-ref" id="cite_ref-pmid3143568_31-0"><a href="#cite_note-pmid3143568-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Heart_failure">Heart failure</h3></summary>
    
<p>While loop diuretics remain first-line for most people with heart failure, spironolactone has shown to reduce both morbidity and mortality in numerous studies and remains an important agent for treating fluid retention, edema, and symptoms of heart failure. Current recommendations from the American Heart Association are to use spironolactone in patients with NYHA Class II-IV heart failure who have a left ventricular ejection fraction of less than 35%.<span class="mw-ref" id="cite_ref-Yancy_e147-239_32-0"><a href="#cite_note-Yancy_e147-239-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>

<p>In a randomized evaluation which studied people with severe congestive heart failure, people treated with spironolactone were found to have a relative risk of death of 0.70 or an overall 30% relative risk reduction compared to the placebo group, indicating a significant death and morbidity benefit of the medication. People in the study's intervention arm also had fewer symptoms of heart failure and were hospitalized less frequently.<span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> Likewise, it has shown benefit for and is recommended in patients who recently suffered a heart attack and have an ejection fraction less than 40%, who develop symptoms consistent with heart failure, or have a history of diabetes mellitus. Spironolactone should be considered a good add-on agent, particularly in those patients "not" yet optimized on ACE inhibitors and beta-blockers.<span class="mw-ref" id="cite_ref-Yancy_e147-239_32-1"><a href="#cite_note-Yancy_e147-239-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> Of note, a recent randomized, double-blinded study of spironolactone in patients with symptomatic heart failure with "preserved" ejection fraction (i.e. &gt;45%) found no reduction in death from cardiovascular events, aborted cardiac arrest, or hospitalizations when spironolactone was compared to placebo.<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>

<p>It is recommended that alternatives to spironolactone be considered if serum <a href="Creatinine.htm" tppabs="https://ptable.com/wiki/compounds/A/Creatinine" title="Creatinine">creatinine</a> is greater than 2.5<span>&nbsp;</span>mg/dL (221<span>&nbsp;</span>µmol/L) in males or greater than 2<span>&nbsp;</span>mg/dL (176.8<span>&nbsp;</span>µmol/L) in females, if glomerular filtration rate is below 30<span>&nbsp;</span>mL/min or with a serum potassium of greater than 5.0<span>&nbsp;</span>mEq/L given the potential for adverse events detailed elsewhere in this article. Doses should be adjusted according to the degree of kidney function as well.<span class="mw-ref" id="cite_ref-Yancy_e147-239_32-2"><a href="#cite_note-Yancy_e147-239-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>

<p>According to a systematic review, in heart failure with preserved ejection fraction, treatment with spironolactone did not improve patient outcomes. This is based on the TOPCAT Trial examining this issue, which found that of those treated with placebo had a 20.4% incidence of negative outcome vs 18.6% incidence of negative outcome with spironolactone. However, because the p-value of the study was 0.14, and the unadjusted hazard ratio was 0.89 with a 95% confidence interval of 0.77 to 1.04, it is determined the finding had no statistical significance. Hence the finding that patient outcomes are not improved with use of spironolactone.<span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> More recently, when blood samples from 366 patients in the TOPCAT study were analyzed for presence of canrenone (an active metabolite of spironolactone), 30% of blood samples from Russia lacked detectable residues of canrenone. This led to the conclusion that the TOPCAT trial results in Russia do not reflect actual clinical experience with spironolactone in patients with preserved ejection fraction.<span class="mw-ref" id="cite_ref-Pfeffer_posthoc_36-0"><a href="#cite_note-Pfeffer_posthoc-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> The TOPCAT study results are now considered to have been invalidated. The study's prime investigator and other prominent research cardiologists are now advising physicians treating heart failure with preserved ejection fraction to consider prescribing spironolactone pending outcome of two multicenter trials of newer medications.<span class="mw-ref" id="cite_ref-CardioBrief_37-0"><a href="#cite_note-CardioBrief-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>

<p>Due to its antiandrogenic properties, spironolactone can cause effects associated with low androgen levels and hypogonadism in males. For this reason, men are typically not prescribed spironolactone for any longer than a short period of time, e.g., for an acute exacerbation of heart failure. A newer medication, <a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">eplerenone</a>, has been approved by the U.S. Food and Drug Administration for the treatment of heart failure, and lacks the antiandrogenic effects of spironolactone. As such, it is far more suitable for men for whom long-term medication is being chosen. However, eplerenone may not be as effective as spironolactone or the related medication canrenone in reducing mortality from heart failure.<span class="mw-ref" id="cite_ref-pmid22840667_38-0"><a href="#cite_note-pmid22840667-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>The clinical benefits of spironolactone as a diuretic are typically not seen until 2–3 days after dosing begins. Likewise, the maximal antihypertensive effect may not be seen for 2–3 weeks.</p>

<p>Unlike with some other diuretics, potassium supplementation should <i>not</i> be administered while taking spironolactone, as this may cause dangerous elevations in serum potassium levels resulting in hyperkalemia and potentially deadly abnormal heart rhythms.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="High_blood_pressure">High blood pressure</h3></summary>
    
<p>About 1 in 100 people with hypertension have elevated levels of aldosterone; in these people, the antihypertensive effect of spironolactone may exceed that of complex combined regimens of other antihypertensives since it targets the primary cause of the elevated blood pressure. However, a Cochrane review found adverse effects at high doses and little effect on blood pressure at low doses in the majority of people with high blood pressure.<span class="mw-ref" id="cite_ref-Bat2010_39-0"><a href="#cite_note-Bat2010-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> There is no evidence of person-oriented outcome at any dose in this group.<span class="mw-ref" id="cite_ref-Bat2010_39-1"><a href="#cite_note-Bat2010-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Skin_and_hair_conditions">Skin and hair conditions</h3></summary>
    
<p>Androgens like testosterone and DHT play a critical role in the pathogenesis of a number of dermatological conditions including oily skin, acne, seborrhea, hirsutism (excessive facial/body hair growth in women), and male pattern hair loss (androgenic alopecia).<span class="mw-ref" id="cite_ref-pmid15507105_40-0"><a href="#cite_note-pmid15507105-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-pmid28979664_41-0"><a href="#cite_note-pmid28979664-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> In demonstration of this, women with complete androgen insensitivity syndrome (CAIS) do not produce sebum or develop acne and have little to no body, pubic, or axillary hair.<span class="mw-ref" id="cite_ref-ShalitaRosso2011_42-0"><a href="#cite_note-ShalitaRosso2011-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-ZouboulisKatsambas2014_43-0"><a href="#cite_note-ZouboulisKatsambas2014-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> Moreover, men with congenital 5α-reductase type II deficiency, 5α-reductase being an enzyme that greatly potentiates the androgenic effects of testosterone in the skin, have little to no acne, scanty facial hair, reduced body hair, and reportedly no incidence of male-pattern hair loss.<span class="mw-ref" id="cite_ref-pmid16985920_44-0"><a href="#cite_note-pmid16985920-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-Sloane2002_45-0"><a href="#cite_note-Sloane2002-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span><span class="mw-ref" id="cite_ref-HannoGuzzo2014_46-0"><a href="#cite_note-HannoGuzzo2014-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span><span class="mw-ref" id="cite_ref-Harper2007_47-0"><a href="#cite_note-Harper2007-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-Blume-PeytaviWhiting2008_48-0"><a href="#cite_note-Blume-PeytaviWhiting2008-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span> Conversely, hyperandrogenism in women, for instance due to polycystic ovary syndrome (PCOS) or congenital adrenal hyperplasia (CAH), is commonly associated with acne and hirsutism as well as virilization (masculinization) in general.<span class="mw-ref" id="cite_ref-pmid15507105_40-1"><a href="#cite_note-pmid15507105-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> In accordance with the preceding, antiandrogens are highly effective in the treatment of the aforementioned androgen-dependent skin and hair conditions.<span class="mw-ref" id="cite_ref-pmid9420861_49-0"><a href="#cite_note-pmid9420861-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-pmid20082945_50-0"><a href="#cite_note-pmid20082945-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></p>

<p>Because of the antiandrogenic activity of spironolactone, it can be quite effective in treating acne in women.<span class="mw-ref" id="cite_ref-pmid22468178_51-0"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> In addition, spironolactone reduces oil that is naturally produced in the skin and can be used to treat oily skin.<span class="mw-ref" id="cite_ref-pmid28155090_52-0"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid26897386_53-0"><a href="#cite_note-pmid26897386-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-pmid28979664_41-1"><a href="#cite_note-pmid28979664-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> Though not the primary intended purpose of the medication, the ability of spironolactone to be helpful with problematic skin and acne conditions was discovered to be one of the beneficial side effects and has been quite successful.<span class="mw-ref" id="cite_ref-pmid28155090_52-1"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid26897386_53-1"><a href="#cite_note-pmid26897386-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Oftentimes, for women treating acne, spironolactone is prescribed and paired with a birth control pill.<span class="mw-ref" id="cite_ref-pmid28155090_52-2"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid26897386_53-2"><a href="#cite_note-pmid26897386-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Positive results in the pairing of these two medications have been observed, although these results may not be seen for up to three months.<span class="mw-ref" id="cite_ref-pmid28155090_52-3"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid26897386_53-3"><a href="#cite_note-pmid26897386-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Spironolactone has been reported to produce a 50 to 100% improvement in acne at sufficiently high doses.<span class="mw-ref" id="cite_ref-pmid9238337_54-0"><a href="#cite_note-pmid9238337-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> Response to treatment generally requires 1 to 3<span>&nbsp;</span>months in the case of acne and up to 6<span>&nbsp;</span>months in the case of hirsutism.<span class="mw-ref" id="cite_ref-pmid9238337_54-1"><a href="#cite_note-pmid9238337-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> Ongoing therapy is generally required to avoid relapse of symptoms.<span class="mw-ref" id="cite_ref-pmid9238337_54-2"><a href="#cite_note-pmid9238337-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> Spironolactone is commonly used in the treatment of hirsutism in women, and is considered to be a first-line antiandrogen for this indication.<span class="mw-ref" id="cite_ref-pmid24889738_55-0"><a href="#cite_note-pmid24889738-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> Spironolactone can be used in the treatment of female-pattern hair loss (pattern scalp hair loss in women).<span class="mw-ref" id="cite_ref-pmid21413648_56-0"><a href="#cite_note-pmid21413648-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> There is tentative low quality evidence supporting its use for this indication.<span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span> Although apparently effective, not all cases of female-pattern hair loss are dependent on androgens.<span class="mw-ref" id="cite_ref-pmid20128792_58-0"><a href="#cite_note-pmid20128792-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span></p>

<p>Antiandrogens like spironolactone are male-specific teratogens which can feminize male fetuses due to their antiandrogenic effects.<span class="mw-ref" id="cite_ref-pmid9420861_49-1"><a href="#cite_note-pmid9420861-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-IswaranImai1997_59-0"><a href="#cite_note-IswaranImai1997-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span><span class="mw-ref" id="cite_ref-Smith2013_60-0"><a href="#cite_note-Smith2013-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span> For this reason, it is recommended that antiandrogens only be used to treat women who are of reproductive age in conjunction with adequate contraception.<span class="mw-ref" id="cite_ref-pmid9420861_49-2"><a href="#cite_note-pmid9420861-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-IswaranImai1997_59-1"><a href="#cite_note-IswaranImai1997-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span><span class="mw-ref" id="cite_ref-Smith2013_60-1"><a href="#cite_note-Smith2013-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span> Oral contraceptives, which contain an estrogen and a progestin, are typically used for this purpose.<span class="mw-ref" id="cite_ref-pmid9420861_49-3"><a href="#cite_note-pmid9420861-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> Moreover, oral contraceptives themselves are functional antiandrogens and are independently effective in the treatment of androgen-dependent skin and hair conditions, and hence can significantly augment the effectiveness of antiandrogens in the treatment of such conditions.<span class="mw-ref" id="cite_ref-pmid9420861_49-4"><a href="#cite_note-pmid9420861-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-Ostrzenski2002_61-0"><a href="#cite_note-Ostrzenski2002-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span></p>

<p>Spironolactone is not generally used in men for the treatment of androgen-dependent dermatological conditions because of its feminizing side effects, but it is effective for such indications in men similarly.<span class="mw-ref" id="cite_ref-pmid21413648_56-1"><a href="#cite_note-pmid21413648-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> As an example, spironolactone has been reported to reduce symptoms of acne in males.<span class="mw-ref" id="cite_ref-pmid9557251_62-0"><a href="#cite_note-pmid9557251-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span> An additional example is the usefulness of spironolactone as an antiandrogen in transgender women.<span class="mw-ref" id="cite_ref-WPATH2011_63-0"><a href="#cite_note-WPATH2011-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-pmid19509099_64-0"><a href="#cite_note-pmid19509099-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-pmid2540730_65-0"><a href="#cite_note-pmid2540730-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span></p>

<p>Topical spironolactone has been found to be effective in the treatment of acne as well.<span class="mw-ref" id="cite_ref-pmid1387779_66-0"><a href="#cite_note-pmid1387779-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span> As a result, topical pharmaceutical formulations containing 2% or 5% spironolactone cream became available in Italy for the treatment of acne and hirsutism in the early 1990s.<span class="mw-ref" id="cite_ref-pmid8112074_67-0"><a href="#cite_note-pmid8112074-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-Benvenga2009_68-0"><a href="#cite_note-Benvenga2009-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> The products were discontinued in 2006 when the creams were added to the list of doping substances with a decree of the Ministry of Health that year.<span class="mw-ref" id="cite_ref-Benvenga2009_68-1"><a href="#cite_note-Benvenga2009-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Comparison">Comparison</h4></summary>
    
<p>Spironolactone, the 5α-reductase inhibitor <a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">finasteride</a>, and the nonsteroidal antiandrogen <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">flutamide</a> all appear to have similar effectiveness in the treatment of hirsutism.<span class="mw-ref" id="cite_ref-pmid24889738_55-1"><a href="#cite_note-pmid24889738-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-pmid25918921_69-0"><a href="#cite_note-pmid25918921-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span><span class="mw-ref" id="cite_ref-pmid29522176_70-0"><a href="#cite_note-pmid29522176-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span> However, some clinical research has found that the effectiveness of spironolactone for hirsutism is greater than that of finasteride but is less than that of flutamide.<span class="mw-ref" id="cite_ref-pmid24889738_55-2"><a href="#cite_note-pmid24889738-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> The combination of spironolactone with finasteride is more effective than either alone for hirsutism and the combination of spironolactone with a birth control pill is more effective than a birth control pill alone.<span class="mw-ref" id="cite_ref-pmid24889738_55-3"><a href="#cite_note-pmid24889738-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> One study showed that spironolactone or the steroidal antiandrogen cyproterone acetate both in combination with a birth control pill had equivalent effectiveness for hirsutism.<span class="mw-ref" id="cite_ref-pmid24889738_55-4"><a href="#cite_note-pmid24889738-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> Spironolactone is considered to be a first-line treatment for hirsutism, finasteride and the steroidal antiandrogen cyproterone acetate are considered to be second-line treatments, and flutamide is no longer recommended for hirsutism due to liver toxicity concerns.<span class="mw-ref" id="cite_ref-pmid24889738_55-5"><a href="#cite_note-pmid24889738-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> The nonsteroidal antiandrogen <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a> is an alternative option to flutamide with improved safety.<span class="mw-ref" id="cite_ref-pmid24455796_71-0"><a href="#cite_note-pmid24455796-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-pmid29211888_72-0"><a href="#cite_note-pmid29211888-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span></p>

<p>The combination of spironolactone with a birth control pill in the treatment of acne appears to have similar effectiveness to a birth control pill alone and the combination of a birth control pill with cyproterone acetate, flutamide, or finasteride.<span class="mw-ref" id="cite_ref-pmid28155090_52-4"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> However, this was based on low- to very-low-quality evidence.<span class="mw-ref" id="cite_ref-pmid28155090_52-5"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Spironolactone may be more effective than birth control pills in the treatment of acne, and the combination of spironolactone with a birth control pill may have greater effectiveness for acne than either alone.<span class="mw-ref" id="cite_ref-pmid22994662_73-0"><a href="#cite_note-pmid22994662-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span> In addition, some clinical research has found that flutamide is more effective than spironolactone in the treatment of acne.<span class="mw-ref" id="cite_ref-pmid28155090_52-6"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> In one study, flutamide decreased acne scores by 80% within 3<span>&nbsp;</span>months, whereas spironolactone decreased symptoms by only 40% in the same time period.<span class="mw-ref" id="cite_ref-pmid10495361_74-0"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-ShelleyShelley2001_75-0"><a href="#cite_note-ShelleyShelley2001-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span><span class="mw-ref" id="cite_ref-BalenFranks2010_76-0"><a href="#cite_note-BalenFranks2010-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> However, the use of flutamide for acne is limited by its liver toxicity.<span class="mw-ref" id="cite_ref-pmid28379593_77-0"><a href="#cite_note-pmid28379593-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-pmid28492054_78-0"><a href="#cite_note-pmid28492054-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-YasaDural2016_79-0"><a href="#cite_note-YasaDural2016-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span><span class="mw-ref" id="cite_ref-pmid28274354_80-0"><a href="#cite_note-pmid28274354-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> Bicalutamide is a potential alternative to flutamide for acne as well.<span class="mw-ref" id="cite_ref-pmid27416311_81-0"><a href="#cite_note-pmid27416311-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span><span class="mw-ref" id="cite_ref-pmid30312645_82-0"><a href="#cite_note-pmid30312645-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> Spironolactone can be considered as a first-line treatment for acne in those who have failed other standard treatments such as topical therapies and under certain other circumstances, although this is controversial due to the side effects of spironolactone and its teratogenicity.<span class="mw-ref" id="cite_ref-pmid22994662_73-1"><a href="#cite_note-pmid22994662-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span><span class="mw-ref" id="cite_ref-pmid20082945_50-1"><a href="#cite_note-pmid20082945-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></p>

<p>There is insufficient clinical evidence to compare the effectiveness of spironolactone with other antiandrogens for female-pattern hair loss.<span class="mw-ref" id="cite_ref-pmid27225981_83-0"><a href="#cite_note-pmid27225981-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> The effectiveness of spironolactone in the treatment of both acne and hirsutism appears to be dose-dependent, with higher doses being more effective than lower doses.<span class="mw-ref" id="cite_ref-pmid22994662_73-2"><a href="#cite_note-pmid22994662-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span><span class="mw-ref" id="cite_ref-pmid19370553_84-0"><a href="#cite_note-pmid19370553-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span><span class="mw-ref" id="cite_ref-Hammerstein1990_85-0"><a href="#cite_note-Hammerstein1990-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> However, higher doses also have greater side effects, such as menstrual irregularities.<span class="mw-ref" id="cite_ref-pmid28155090_52-7"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Transgender_hormone_therapy">Transgender hormone therapy</h3></summary>
    
<p>Spironolactone is frequently used as a component of feminizing hormone therapy in transgender women, especially in the United States (where cyproterone acetate is not available), usually in addition to an estrogen.<span class="mw-ref" id="cite_ref-WPATH2011_63-1"><a href="#cite_note-WPATH2011-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-pmid19509099_64-1"><a href="#cite_note-pmid19509099-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-pmid2540730_65-1"><a href="#cite_note-pmid2540730-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> Other clinical effects include decreased male pattern body hair, the induction of breast development, feminization in general, and lack of spontaneous erections.<span class="mw-ref" id="cite_ref-pmid2540730_65-2"><a href="#cite_note-pmid2540730-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> The medication is not approved for use as an antiandrogen by the Food and Drug Administration; instead, it is used off-label for such purposes.<span class="mw-ref" id="cite_ref-pmid3996628_86-0"><a href="#cite_note-pmid3996628-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Doses_and_forms">Doses and forms</h3></summary>
    
<p>Spironolactone is typically used at a low dosage of 25 to 50<span>&nbsp;</span>mg/day in the treatment of heart failure,<span class="mw-ref" id="cite_ref-IzzoSica2008_87-0"><a href="#cite_note-IzzoSica2008-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-WarrellBenz2003_88-0"><a href="#cite_note-WarrellBenz2003-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-HosenpudGreenberg2007_89-0"><a href="#cite_note-HosenpudGreenberg2007-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-RamrakhaRamrakha2012_90-0"><a href="#cite_note-RamrakhaRamrakha2012-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> while it is used at low to high dosages of 25 to 200<span>&nbsp;</span>mg/day in the treatment of essential hypertension,<span class="mw-ref" id="cite_ref-IzzoSica2008_87-1"><a href="#cite_note-IzzoSica2008-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-RamrakhaRamrakha2012_90-1"><a href="#cite_note-RamrakhaRamrakha2012-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> and at high dosages of 100 to 400<span>&nbsp;</span>mg/day for hyperaldosteronism and ascites due to cirrhosis.<span class="mw-ref" id="cite_ref-GinésArroyo2008_91-0"><a href="#cite_note-GinésArroyo2008-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-HawkeyBosch2012_92-0"><a href="#cite_note-HawkeyBosch2012-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span><span class="mw-ref" id="cite_ref-SchiffSorrell2007_93-0"><a href="#cite_note-SchiffSorrell2007-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-BlackElliott2007_94-0"><a href="#cite_note-BlackElliott2007-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> The medication is typically used at high dosages of 100 to 200<span>&nbsp;</span>mg/day in the treatment of skin and hair conditions in women,<span class="mw-ref" id="cite_ref-CarrellPeterson2010_95-0"><a href="#cite_note-CarrellPeterson2010-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-Wu2012_96-0"><a href="#cite_note-Wu2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-Hohl2017_97-0"><a href="#cite_note-Hohl2017-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span><span class="mw-ref" id="cite_ref-PreglerDeCherney2002_98-0"><a href="#cite_note-PreglerDeCherney2002-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span><span class="mw-ref" id="cite_ref-Becker2001_99-0"><a href="#cite_note-Becker2001-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> and at high dosages of 100 to 400<span>&nbsp;</span>mg/day in feminizing hormone therapy for transgender women.<span class="mw-ref" id="cite_ref-pmid28945902_100-0"><a href="#cite_note-pmid28945902-100" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></span><span class="mw-ref" id="cite_ref-pmid28159148_101-0"><a href="#cite_note-pmid28159148-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span><span class="mw-ref" id="cite_ref-WebbSafer2019_102-0"><a href="#cite_note-WebbSafer2019-102" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span></p>

<p>Spironolactone is available in the form of tablets (25<span>&nbsp;</span>mg, 50<span>&nbsp;</span>mg, 100<span>&nbsp;</span>mg; brand name Aldactone, others) and suspensions (25<span>&nbsp;</span>mg/5<span>&nbsp;</span>mL; brand name CaroSpir) for use by mouth.<span class="mw-ref" id="cite_ref-Muller1998_103-0"><a href="#cite_note-Muller1998-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span><span class="mw-ref" id="cite_ref-LeeDesai2007_104-0"><a href="#cite_note-LeeDesai2007-104" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span><span class="mw-ref" id="cite_ref-Niazi2016_105-0"><a href="#cite_note-Niazi2016-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span><span class="mw-ref" id="cite_ref-WakelinMaibach2002_106-0"><a href="#cite_note-WakelinMaibach2002-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span><span class="mw-ref" id="cite_ref-Drugs@FDA_107-0"><a href="#cite_note-Drugs@FDA-107" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span> It has also been marketed in the form of 2% and 5% topical cream in Italy for the treatment of acne and hirsutism under the brand name Spiroderm, but this product is no longer available.<span class="mw-ref" id="cite_ref-FARIDDiamanti-Kandarakis2009_5-1"><a href="#cite_note-FARIDDiamanti-Kandarakis2009-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_108-0"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span> The medication is also available in combination with other medications, such as <a href="Hydrochlorothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrochlorothiazide" title="Hydrochlorothiazide">hydrochlorothiazide</a> (brand name Aldactazide, others).<span class="mw-ref" id="cite_ref-Drugs@FDA_107-1"><a href="#cite_note-Drugs@FDA-107" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-0"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span> Spironolactone has poor water solubility, and for this reason, only oral and topical formulations have been developed; other routes of administration such as intravenous injection are not used.<span class="mw-ref" id="cite_ref-Sica2005_6-7"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The only antimineralocorticoid that is available as a solution for parenteral use is the related medication potassium canrenoate.<span class="mw-ref" id="cite_ref-pmid28634268_110-0"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Contraindications of spironolactone include hyperkalemia (high potassium levels), severe and end-stage kidney disease (due to high hyperkalemia risk, except possibly in those on dialysis), Addison's disease (adrenal insufficiency and low aldosterone levels), and concomitant use of <a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">eplerenone</a>.<span class="mw-ref" id="cite_ref-Aldactone_label_111-0"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span><span class="mw-ref" id="cite_ref-GoldsmithCovic2014_112-0"><a href="#cite_note-GoldsmithCovic2014-112" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span> It should also be used with caution in people with some neurological disorders, no urine production, acute kidney injury, or significant impairment of kidney excretory function with risk of hyperkalemia.<span class="mw-ref" id="cite_ref-Aldactone_label_111-1"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>The most common side effect of spironolactone is frequent urination. Other general side effects include dehydration, hyponatremia (low <a href="Sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium" title="Sodium">sodium</a> levels), mild hypotension (low blood pressure),<span class="mw-ref" id="cite_ref-pmid10495361_74-1"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> ataxia (muscle incoordination), drowsiness, dizziness,<span class="mw-ref" id="cite_ref-pmid10495361_74-2"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> dry skin, and rashes. Because of its antiandrogenic activity, spironolactone can, in men, cause breast tenderness, gynecomastia (breast development), feminization in general, and demasculinization, as well as sexual dysfunction including loss of libido and erectile dysfunction, although these side effects are usually confined to high doses of spironolactone.<span class="mw-ref" id="cite_ref-pmid984618_113-0"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span> At very high doses (400<span>&nbsp;</span>mg/day), spironolactone has also been associated with testicular atrophy and reversibly reduced fertility, including semen abnormalities such as decreased sperm count and motility in men.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-0"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_115-0"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> However, such doses of spironolactone are rarely used clinically.<span class="mw-ref" id="cite_ref-Aronson2009_115-1"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> In women, spironolactone can cause menstrual irregularities, breast tenderness, and breast enlargement.<span class="mw-ref" id="cite_ref-pmid2969259_29-1"><a href="#cite_note-pmid2969259-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-pmid28155090_52-8"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-CarrellPeterson2010_95-1"><a href="#cite_note-CarrellPeterson2010-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span> Aside from these adverse effects, the side effects of spironolactone in women taking high doses are minimal, and it is well tolerated.<span class="mw-ref" id="cite_ref-pmid28155090_52-9"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid10495361_74-3"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-PescovitzEugster2004_116-0"><a href="#cite_note-PescovitzEugster2004-116" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></span></p>

<p>The most important potential side effect of spironolactone is hyperkalemia (high <a href="Potassium.htm" tppabs="https://ptable.com/wiki/compounds/A/Potassium" title="Potassium">potassium</a> levels), which, in severe cases, can be life-threatening.<span class="mw-ref" id="cite_ref-Aldactone_label_111-2"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Hyperkalemia in these people can present as a non anion-gap metabolic acidosis.<span class="mw-ref" id="cite_ref-Aldactone_label_111-3"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Spironolactone may put people at a heightened risk for gastrointestinal issues like nausea, vomiting, diarrhea, cramping, and gastritis.<span class="mw-ref" id="cite_ref-Aldactone_label_111-4"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span><span class="mw-ref" id="cite_ref-117"><a href="#cite_note-117" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></span> In addition, there has been some evidence suggesting an association between use of the medication and bleeding from the stomach and duodenum,<span class="mw-ref" id="cite_ref-Aldactone_label_111-5"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> though a causal relationship between the two has not been established.<span class="mw-ref" id="cite_ref-118"><a href="#cite_note-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span> Also, spironolactone is immunosuppressive in the treatment of sarcoidosis.<span class="mw-ref" id="cite_ref-119"><a href="#cite_note-119" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></span></p>

<p>Most of the side effects of spironolactone are dose-dependent.<span class="mw-ref" id="cite_ref-pmid22468178_51-1"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> Low-dose spironolactone is generally very well tolerated.<span class="mw-ref" id="cite_ref-pmid22468178_51-2"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> Even higher doses of spironolactone, such as 100<span>&nbsp;</span>mg/day, are well tolerated in most individuals.<span class="mw-ref" id="cite_ref-pmid22468178_51-3"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> Dose-dependent side effects of spironolactone include menstrual irregularities, breast tenderness and enlargement, orthostatic hypotension, and hyperkalemia.<span class="mw-ref" id="cite_ref-pmid22468178_51-4"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> The side effects of spironolactone are usually mild and rarely result in discontinuation.<span class="mw-ref" id="cite_ref-pmid22468178_51-5"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" width="750px" style="margin-left: auto; margin-right: auto; border: none;">
<caption class="nowrap"> Side effects of spironolactone in clinical studies for acne in women</caption>
<tbody><tr><th rowspan="2">Side effect</th><th colspan="2"><abbr>RCTs</abbr> (n (<abbr>ITT</abbr>) = 326)</th><th colspan="2">Case series (n (<abbr>ITT</abbr>) = 663)</th></tr>
<tr>
<th>Number</th><th>%</th><th>Number</th><th>%</th></tr>
<tr>
<td>Menstrual irregularities</td><td>38</td><td>13.4 (of 283)</td><td>216</td><td>33.4 (of 646)</td></tr>
<tr>
<td>Breast tenderness</td><td>8</td><td>2.5</td><td>30</td><td>4.5</td></tr>
<tr>
<td>Breast enlargement</td><td>7</td><td>2.1</td><td>13</td><td>2.0</td></tr>
<tr>
<td>Dizziness/vertigo/lightheadedness</td><td>11</td><td>3.4</td><td>≥19<sup>a</sup></td><td>≥2.9</td></tr>
<tr>
<td>Headache</td><td>5</td><td>1.5</td><td>≥10<sup>a</sup></td><td>≥1.5</td></tr>
<tr>
<td>Nausea and/or vomiting</td><td>6</td><td>1.8</td><td>24</td><td>3.6</td></tr>
<tr>
<td>Weight gain<sup>b</sup></td><td>5</td><td>1.5</td><td>1</td><td>0.2</td></tr>
<tr>
<td>Abdominal pain</td><td>0</td><td>0</td><td>≥11<sup>a</sup></td><td>≥1.7</td></tr>
<tr>
<td>Polyuria</td><td>2</td><td>0.6</td><td>8</td><td>1.2</td></tr>
<tr>
<td>Fatigue/lethargy</td><td>1</td><td>0.3</td><td>≥12<sup>a</sup></td><td>≥1.8</td></tr>
<tr class="sortbottom">
<td colspan="5" style="width: 1px; font-size: small; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Precise values unavailable due to inadequate reporting. <sup>b</sup> = Not monitored in most studies. <b>Description:</b> Side effects of spironolactone (25–400<span>&nbsp;</span>mg/day) with ≥1% incidence in a 2017 hybrid systematic review of clinical studies of spironolactone for acne in women. Side effects with &lt;1% incidence included postural hypotension, depression, diarrhea, muscle pain, increased appetite, drowsiness, rashes/drug eruptions, chloasma-like skin pigmentation, polydipsia, weakness, leg edema, libido changes, and palpitations. [...] Certain side effects, like breast enlargement, reduced premenstrual symptoms, and less oily skin/greasy hair, could be beneficial. Side effects often could not be unambiguously attributed to spironolactone due concomitant use of other medications, particularly birth control pills. Hyperkalemia was rare (14/469; 3.0%) and was "invariably mild and clinically insignificant". Risk of bias was high and quality of evidence was low to very low. <b>Sources:</b> See template.</td></tr>
</tbody></table>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="High_potassium_levels">High potassium levels</h3></summary>
    
<p>Spironolactone can cause hyperkalemia, or high blood potassium levels.<span class="mw-ref" id="cite_ref-Aronson2009_115-2"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> Rarely, this can be fatal.<span class="mw-ref" id="cite_ref-Aronson2009_115-3"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> Of people with heart disease prescribed typical dosages of spironolactone, 10 to 15% develop some degree of hyperkalemia, and 6% develop severe hyperkalemia.<span class="mw-ref" id="cite_ref-Aronson2009_115-4"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> At a higher dosage, a rate of hyperkalemia of 24% has been observed.<span class="mw-ref" id="cite_ref-pmid26404748_120-0"><a href="#cite_note-pmid26404748-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span> An abrupt and major increase in the rate of hospitalization due to hyperkalemia from 0.2% to 11% and in the rate of death due to hyperkalemia from 0.3 per 1,000 to 2.0 per 1,000 between early 1994 and late 2001 has been attributed to a parallel rise in the number of prescriptions written for spironolactone upon the publication of the Randomized Aldactone Evaluation Study (RALES) in July 1999.<span class="mw-ref" id="cite_ref-Aronson2009_115-5"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span><span class="mw-ref" id="cite_ref-pmid26404748_120-1"><a href="#cite_note-pmid26404748-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span><span class="mw-ref" id="cite_ref-pmid15295047_121-0"><a href="#cite_note-pmid15295047-121" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span><span class="mw-ref" id="cite_ref-RoncoBellomo2017_26-1"><a href="#cite_note-RoncoBellomo2017-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> However, another population-based study in Scotland failed to replicate these findings.<span class="mw-ref" id="cite_ref-pmid22942339_122-0"><a href="#cite_note-pmid22942339-122" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></span><span class="mw-ref" id="cite_ref-pmid20483947_123-0"><a href="#cite_note-pmid20483947-123" style="counter-reset: mw-Ref 123;"><span class="mw-reflink-text">[123]</span></a></span> The risk of hyperkalemia with spironolactone is greatest in the elderly, in people with renal impairment (e.g., due to chronic kidney disease or diabetic nephropathy), in people taking certain other medications (including <abbr>ACE</abbr> inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, and <a href="Potassium.htm" tppabs="https://ptable.com/wiki/compounds/A/Potassium" title="Potassium">potassium</a> supplements), and at higher dosages of spironolactone.<span class="mw-ref" id="cite_ref-Aronson2009_115-6"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span><span class="mw-ref" id="cite_ref-RoncoBellomo2017_26-2"><a href="#cite_note-RoncoBellomo2017-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>

<p>Although spironolactone poses an important risk of hyperkalemia in the elderly, in those with kidney or cardiovascular disease, and/or in those taking medications or supplements which increase circulating potassium levels, a large retrospective study found that the rate of hyperkalemia in young women without such characteristics who had been treated with high doses of spironolactone for dermatological conditions did not differ from that of controls.<span class="mw-ref" id="cite_ref-pmid28155090_52-10"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid26897386_53-4"><a href="#cite_note-pmid26897386-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-pmid25796182_124-0"><a href="#cite_note-pmid25796182-124" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span> This was the conclusion of a 2017 hybrid systematic review of studies of spironolactone for acne in women as well, which found that hyperkalemia was rare and was invariably mild and clinically insignificant.<span class="mw-ref" id="cite_ref-pmid28155090_52-11"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> These findings suggest that hyperkalemia may not be a significant risk in such individuals, and that routine monitoring of circulating potassium levels may be unnecessary in this population.<span class="mw-ref" id="cite_ref-pmid28155090_52-12"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid26897386_53-5"><a href="#cite_note-pmid26897386-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-pmid25796182_124-1"><a href="#cite_note-pmid25796182-124" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span> However, other sources have claimed that hyperkalemia can nonetheless also occur in people with more normal renal function and presumably without such risk factors.<span class="mw-ref" id="cite_ref-RoncoBellomo2017_26-3"><a href="#cite_note-RoncoBellomo2017-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Occasional testing on a case-by-case basis in those with known risk factors may be justified.<span class="mw-ref" id="cite_ref-pmid28155090_52-13"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Side effects of spironolactone which may be indicative of hyperkalemia and if persistent could justify serum potassium testing include nausea, fatigue, and particularly muscle weakness.<span class="mw-ref" id="cite_ref-pmid28155090_52-14"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Notably, non-use of routine potassium monitoring with spironolactone in young women would reduce costs associated with its use.<span class="mw-ref" id="cite_ref-pmid28155090_52-15"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Breast_changes">Breast changes</h3></summary>
    
<p>Spironolactone frequently causes breast pain and breast enlargement in women.<span class="mw-ref" id="cite_ref-Becker2001_99-1"><a href="#cite_note-Becker2001-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span><span class="mw-ref" id="cite_ref-TsioufisSchmieder2016_125-0"><a href="#cite_note-TsioufisSchmieder2016-125" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span> This is "probably because of estrogenic effects on target tissue."<span class="mw-ref" id="cite_ref-Aronson2009_115-7"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> At low doses, breast tenderness has been reported in only 5% of women, but at high doses, it has been reported in up to 40% of women.<span class="mw-ref" id="cite_ref-ConnJacobs1998_126-0"><a href="#cite_note-ConnJacobs1998-126" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></span><span class="mw-ref" id="cite_ref-pmid22468178_51-6"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> Breast enlargement may occur in 26% of women at high doses and is described as mild.<span class="mw-ref" id="cite_ref-pmid10495361_74-4"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> Some women regard spironolactone-induced breast enlargement as a positive effect.<span class="mw-ref" id="cite_ref-pmid28155090_52-16"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>

<p>Spironolactone also commonly and dose-dependently produces gynecomastia (breast development) as a side effect in men.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-1"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span><span class="mw-ref" id="cite_ref-TsioufisSchmieder2016_125-1"><a href="#cite_note-TsioufisSchmieder2016-125" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span><span class="mw-ref" id="cite_ref-Elsevier2014_127-0"><a href="#cite_note-Elsevier2014-127" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span><span class="mw-ref" id="cite_ref-McInnes2008_128-0"><a href="#cite_note-McInnes2008-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> At low doses, the rate is only 5 to 10%,<span class="mw-ref" id="cite_ref-McInnes2008_128-1"><a href="#cite_note-McInnes2008-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> but at high doses, up to or exceeding 50% of men may develop gynecomastia.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-2"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span><span class="mw-ref" id="cite_ref-TsioufisSchmieder2016_125-2"><a href="#cite_note-TsioufisSchmieder2016-125" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span><span class="mw-ref" id="cite_ref-Elsevier2014_127-1"><a href="#cite_note-Elsevier2014-127" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span> In the RALES, 9.1% of men taking 25<span>&nbsp;</span>mg/day spironolactone developed gynecomastia, compared to 1.3% of controls.<span class="mw-ref" id="cite_ref-pmid15134800_129-0"><a href="#cite_note-pmid15134800-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span> Conversely, in studies of healthy men given high-dose spironolactone, gynecomastia occurred in 3 of 10 (30%) at 100<span>&nbsp;</span>mg/day, in 5 of 8 (62.5%) at 200<span>&nbsp;</span>mg/day, and in 6 of 9 (66.7%) at 400<span>&nbsp;</span>mg/day, relative to none of 12 controls.<span class="mw-ref" id="cite_ref-pmid8094898_130-0"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span><span class="mw-ref" id="cite_ref-Wilcox2008_131-0"><a href="#cite_note-Wilcox2008-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span> The severity of gynecomastia with spironolactone varies considerably, but is usually mild.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-3"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span> As with breast enlargement caused by spironolactone in women, gynecomastia due to spironolactone in men is often although inconsistently accompanied by breast tenderness.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-4"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span> In the RALES, only 1.7% of men developed breast pain, relative to 0.1% of controls.<span class="mw-ref" id="cite_ref-pmid15134800_129-1"><a href="#cite_note-pmid15134800-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span></p>

<p>The time to onset of spironolactone-induced gynecomastia has been found to be 27 ± 20 months at low doses and 9 ± 12 months at high doses.<span class="mw-ref" id="cite_ref-pmid15134800_129-2"><a href="#cite_note-pmid15134800-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span> Gynecomastia induced by spironolactone usually regresses after a few weeks following discontinuation of the medication.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-5"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span> However, after a sufficient duration of gynecomastia being present (e.g., one year), hyalinization and fibrosis of the tissue occurs and drug-induced gynecomastia may become irreversible.<span class="mw-ref" id="cite_ref-pmid18983216_132-0"><a href="#cite_note-pmid18983216-132" style="counter-reset: mw-Ref 132;"><span class="mw-reflink-text">[132]</span></a></span><span class="mw-ref" id="cite_ref-pmid11546925_133-0"><a href="#cite_note-pmid11546925-133" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Menstrual_disturbances">Menstrual disturbances</h3></summary>
    
<p>Spironolactone at higher doses can cause menstrual irregularities as a side effect in women.<span class="mw-ref" id="cite_ref-pmid22468178_51-7"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> These irregularities include metrorrhagia (intermenstrual bleeding), amenorrhea (absence of menstruation), and breakthrough bleeding.<span class="mw-ref" id="cite_ref-pmid22468178_51-8"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> They are common during spironolactone therapy, with 10 to 50% of women experiencing them at moderate doses and almost all experiencing them at a high doses.<span class="mw-ref" id="cite_ref-pmid10495361_74-5"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_115-8"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> For example, about 20% of women experienced menstrual irregularities with 50 to 100<span>&nbsp;</span>mg/day spironolactone, whereas about 70% experienced menstrual irregularities at 200<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-pmid22468178_51-9"><a href="#cite_note-pmid22468178-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> Most women taking moderate doses of spironolactone develop amenorrhea, and normal menstruation usually returns within two months of discontinuation.<span class="mw-ref" id="cite_ref-Aronson2009_115-9"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> Spironolactone produces an irregular and anovulatory pattern of menstrual cycles.<span class="mw-ref" id="cite_ref-pmid10495361_74-6"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> It is also associated with metrorrhagia and menorrhagia (heavy menstrual bleeding) in large percentages of women,<span class="mw-ref" id="cite_ref-Becker2001_99-2"><a href="#cite_note-Becker2001-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> as well as with polymenorrhea (short menstrual cycles).<span class="mw-ref" id="cite_ref-pmid16076921_134-0"><a href="#cite_note-pmid16076921-134" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span><span class="mw-ref" id="cite_ref-pmid10792338_135-0"><a href="#cite_note-pmid10792338-135" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></span> The medication reportedly has no birth control effect.<span class="mw-ref" id="cite_ref-RabeGrunwald2009_136-0"><a href="#cite_note-RabeGrunwald2009-136" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span></p>

<p>It has been suggested that the weak progestogenic activity of spironolactone is responsible for these effects, although this has not been established and spironolactone has been shown to possess insignificant progestogenic and antiprogestogenic activity even at high dosages in women.<span class="mw-ref" id="cite_ref-pmid10495361_74-7"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-0"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid2744183_138-0"><a href="#cite_note-pmid2744183-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span> An alternative proposed cause is inhibition of 17α-hydroxylase and hence sex steroid metabolism by spironolactone and consequent changes in sex hormone levels.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-6"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span> Indeed, CYP17A1 genotype is associated with polymenorrhea.<span class="mw-ref" id="cite_ref-pmid32038990_139-0"><a href="#cite_note-pmid32038990-139" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> Regardless of their mechanism, the menstrual disturbances associated with spironolactone can usually be controlled well by concomitant treatment with a birth control pill, due to the progestin component.<span class="mw-ref" id="cite_ref-pmid10495361_74-8"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-JemecRevuz2006_140-0"><a href="#cite_note-JemecRevuz2006-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mood_changes">Mood changes</h3></summary>
    
<p>Research is mixed on whether antimineralocorticoids like spironolactone have positive or negative effects on mood.<span class="mw-ref" id="cite_ref-pmid25459896_141-0"><a href="#cite_note-pmid25459896-141" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span><span class="mw-ref" id="cite_ref-Schultebraucks2016_142-0"><a href="#cite_note-Schultebraucks2016-142" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span><span class="mw-ref" id="cite_ref-pmid10367986_143-0"><a href="#cite_note-pmid10367986-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span> In any case, it is possible that spironolactone might have the capacity to increase the risk of depressive symptoms.<span class="mw-ref" id="cite_ref-pmid25459896_141-1"><a href="#cite_note-pmid25459896-141" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span><span class="mw-ref" id="cite_ref-Schultebraucks2016_142-1"><a href="#cite_note-Schultebraucks2016-142" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span><span class="mw-ref" id="cite_ref-pmid10367986_143-1"><a href="#cite_note-pmid10367986-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span> However, a 2017 hybrid systematic review found that the incidence of depression in women treated with spironolactone for acne was less than 1%.<span class="mw-ref" id="cite_ref-pmid28155090_52-17"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Likewise, a 10-year observational study found that the incidence of depression in 196<span>&nbsp;</span>transgender women taking high-dose spironolactone in combination with an estrogen was less than 1%.<span class="mw-ref" id="cite_ref-BassonPrior1997_144-0"><a href="#cite_note-BassonPrior1997-144" style="counter-reset: mw-Ref 144;"><span class="mw-reflink-text">[144]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Rare_reactions">Rare reactions</h3></summary>
    
<p>Aside from hyperkalemia, spironolactone may rarely cause adverse reactions such as anaphylaxis, kidney failure,<span class="mw-ref" id="cite_ref-pmid19006114_145-0"><a href="#cite_note-pmid19006114-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span> hepatitis (two reported cases, neither serious),<span class="mw-ref" id="cite_ref-ThaiSinclair2001_146-0"><a href="#cite_note-ThaiSinclair2001-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span> agranulocytosis, DRESS syndrome, Stevens–Johnson syndrome or toxic epidermal necrolysis.<span class="mw-ref" id="cite_ref-147"><a href="#cite_note-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span><span class="mw-ref" id="cite_ref-148"><a href="#cite_note-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span> Five cases of breast cancer in patients who took spironolactone for prolonged periods of time have been reported.<span class="mw-ref" id="cite_ref-Aronson2009_115-10"><a href="#cite_note-Aronson2009-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span><span class="mw-ref" id="cite_ref-McInnes2008_128-2"><a href="#cite_note-McInnes2008-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Spironolactone_bodies">Spironolactone bodies</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:177px"><img src="../I/m/Spironolactone_bodies.png" tppabs="https://ptable.com/wiki/compounds/I/m/Spironolactone_bodies.png" data-file-width="862" data-file-height="643" data-file-type="bitmap" height="131" width="175"><div class="thumbcaption" style="text-align: left">Micrograph (H&amp;E stain) of an adrenal gland showing spironolactone bodies.</div></div></div>

<p>Long-term administration of spironolactone gives the histologic characteristic of "spironolactone bodies" in the adrenal cortex. Spironolactone bodies are eosinophilic, round, concentrically laminated cytoplasmic inclusions surrounded by clear halos in preparations stained with <a href="Haematoxylin.htm" tppabs="https://ptable.com/wiki/compounds/A/Hematoxylin" title="Hematoxylin" class="mw-redirect">hematoxylin</a> and <a href="Eosin.htm" tppabs="https://ptable.com/wiki/compounds/A/Eosin" title="Eosin">eosin</a>.<span class="mw-ref" id="cite_ref-pmid7195152_149-0"><a href="#cite_note-pmid7195152-149" style="counter-reset: mw-Ref 149;"><span class="mw-reflink-text">[149]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pregnancy_and_breastfeeding">Pregnancy and breastfeeding</h3></summary>
    
<p>In the United States, spironolactone is considered pregnancy category C meaning that it is unclear if it is safe for use during pregnancy.<span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_3-3"><a href="#cite_note-Drugs.com_pregnancy-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2015_4-9"><a href="#cite_note-AHFS2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It is able to cross the placenta.<span class="mw-ref" id="cite_ref-Becker2001_99-3"><a href="#cite_note-Becker2001-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> Likewise, it has been found to be present in the breast milk of lactating mothers and, while the effects of spironolactone or its metabolites have not been extensively studied in breastfeeding infants, it is generally recommended that women also not take the medication while nursing.<span class="mw-ref" id="cite_ref-Aldactone_label_111-6"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> However, only very small amounts of spironolactone and its metabolite canrenone enter breast milk, and the amount received by an infant during breastfeeding (&lt;0.5% of the mother's dose) is considered to be insignificant.<span class="mw-ref" id="cite_ref-Ainsworth2014_150-0"><a href="#cite_note-Ainsworth2014-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span></p>

<p>A study found that spironolactone was not associated with teratogenicity in the offspring of rats.<span class="mw-ref" id="cite_ref-Little2006_151-0"><a href="#cite_note-Little2006-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-RubinRamsey2008_152-0"><a href="#cite_note-RubinRamsey2008-152" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span><span class="mw-ref" id="cite_ref-BriggsFreeman2011_153-0"><a href="#cite_note-BriggsFreeman2011-153" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span> Because it is an antiandrogen, however, spironolactone could theoretically have the potential to cause feminization of male fetuses at sufficient doses.<span class="mw-ref" id="cite_ref-Little2006_151-1"><a href="#cite_note-Little2006-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-RubinRamsey2008_152-1"><a href="#cite_note-RubinRamsey2008-152" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span> In accordance, a subsequent study found that partial feminization of the genitalia occurred in the male offspring of rats that received doses of spironolactone that were five times higher than those normally used in humans (200<span>&nbsp;</span>mg/kg per day).<span class="mw-ref" id="cite_ref-Little2006_151-2"><a href="#cite_note-Little2006-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-BriggsFreeman2011_153-1"><a href="#cite_note-BriggsFreeman2011-153" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span> Another study found permanent, dose-related reproductive tract abnormalities rat offspring of both sexes at lower doses (50 to 100<span>&nbsp;</span>mg/kg per day).<span class="mw-ref" id="cite_ref-BriggsFreeman2011_153-2"><a href="#cite_note-BriggsFreeman2011-153" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span></p>

<p>In practice however, although experience is limited, spironolactone has never been reported to cause observable feminization or any other congenital defects in humans.<span class="mw-ref" id="cite_ref-Little2006_151-3"><a href="#cite_note-Little2006-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-RubinRamsey2008_152-2"><a href="#cite_note-RubinRamsey2008-152" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span><span class="mw-ref" id="cite_ref-ElkayamGleicher1998_154-0"><a href="#cite_note-ElkayamGleicher1998-154" style="counter-reset: mw-Ref 154;"><span class="mw-reflink-text">[154]</span></a></span><span class="mw-ref" id="cite_ref-Schaefer2001_155-0"><a href="#cite_note-Schaefer2001-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span> Among 31 human newborns exposed to spironolactone in the first trimester, there were no signs of any specific birth defects.<span class="mw-ref" id="cite_ref-Schaefer2001_155-1"><a href="#cite_note-Schaefer2001-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span> A case report described a woman who was prescribed spironolactone during pregnancy with triplets and delivered all three (one boy and two girls) healthy; there was no feminization in the boy.<span class="mw-ref" id="cite_ref-Schaefer2001_155-2"><a href="#cite_note-Schaefer2001-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span> In addition, spironolactone has been used at high doses to treat pregnant women with Bartter's syndrome, and none of the infants (three boys, two girls) showed toxicity, including feminization in the male infants.<span class="mw-ref" id="cite_ref-Ainsworth2014_150-1"><a href="#cite_note-Ainsworth2014-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span><span class="mw-ref" id="cite_ref-Little2006_151-4"><a href="#cite_note-Little2006-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span> There are similar findings, albeit also limited, for another antiandrogen, cyproterone acetate (prominent genital defects in male rats, but no human  abnormalities (including feminization of male fetuses) at both a low dose of 2<span>&nbsp;</span>mg/day or high doses of 50 to 100<span>&nbsp;</span>mg/day).<span class="mw-ref" id="cite_ref-Schaefer2001_155-3"><a href="#cite_note-Schaefer2001-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span> In any case, spironolactone is nonetheless not recommended during pregnancy due to theoretical concerns relating to feminization of males and also to potential alteration of fetal potassium levels.<span class="mw-ref" id="cite_ref-Little2006_151-5"><a href="#cite_note-Little2006-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-Upfal2006_156-0"><a href="#cite_note-Upfal2006-156" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span></p>

<p>A 2019 systematic review found insufficient evidence that spironolactone causes birth defects in humans.<span class="mw-ref" id="cite_ref-pmid30352280_157-0"><a href="#cite_note-pmid30352280-157" style="counter-reset: mw-Ref 157;"><span class="mw-reflink-text">[157]</span></a></span> However, there was also insufficient evidence to be certain that it does not.<span class="mw-ref" id="cite_ref-pmid30352280_157-1"><a href="#cite_note-pmid30352280-157" style="counter-reset: mw-Ref 157;"><span class="mw-reflink-text">[157]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>Spironolactone is relatively safe in acute overdose.<span class="mw-ref" id="cite_ref-Aldactone_label_111-7"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Symptoms following an acute overdose of spironolactone may include drowsiness, confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, and diarrhea.<span class="mw-ref" id="cite_ref-Aldactone_label_111-8"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> In rare cases, hyponatremia, hyperkalemia, or hepatic coma may occur in individuals with severe liver disease.<span class="mw-ref" id="cite_ref-Aldactone_label_111-9"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> However, these adverse reactions are unlikely in the event of an acute overdose.<span class="mw-ref" id="cite_ref-Aldactone_label_111-10"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Hyperkalemia can occur following an overdose of spironolactone, and this is especially so in people with decreased kidney function.<span class="mw-ref" id="cite_ref-Aldactone_label_111-11"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Spironolactone has been studied at extremely high oral doses of up to 2,400<span>&nbsp;</span>mg per day in clinical trials.<span class="mw-ref" id="cite_ref-pmid28634268_110-1"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span><span class="mw-ref" id="cite_ref-pmid15134797_158-0"><a href="#cite_note-pmid15134797-158" style="counter-reset: mw-Ref 158;"><span class="mw-reflink-text">[158]</span></a></span> Its oral median lethal dose (LD<sub>50</sub>) is more than 1,000<span>&nbsp;</span>mg/kg in mice, rats, and rabbits.<span class="mw-ref" id="cite_ref-Aldactone_label_111-12"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></p>

<p>There is no specific antidote for overdose of spironolactone.<span class="mw-ref" id="cite_ref-Aldactone_label_111-13"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Treatment may consist of induction of vomiting or stomach evacuation by gastric lavage.<span class="mw-ref" id="cite_ref-Aldactone_label_111-14"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> The treatment of spironolactone overdose is supportive, with the purpose of maintaining hydration, electrolyte balance, and vital functions.<span class="mw-ref" id="cite_ref-Aldactone_label_111-15"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Spironolactone should be discontinued in people with impaired kidney function or hyperkalemia.<span class="mw-ref" id="cite_ref-Aldactone_label_111-16"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Spironolactone often increases serum <a href="Potassium.htm" tppabs="https://ptable.com/wiki/compounds/A/Potassium" title="Potassium">potassium</a> levels and can cause hyperkalemia, a very serious condition. Therefore, it is recommended that people using this medication avoid potassium supplements and salt substitutes containing potassium.<span class="mw-ref" id="cite_ref-159"><a href="#cite_note-159" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span> Physicians must be careful to monitor potassium levels in both males and females who are taking spironolactone as a diuretic, especially during the first twelve months of use and whenever the dosage is increased. Doctors may also recommend that some patients may be advised to limit dietary consumption of potassium-rich foods. However, recent data suggests that both potassium monitoring and dietary restriction of potassium intake is unnecessary in healthy young women taking spironolactone for acne.<span class="mw-ref" id="cite_ref-160"><a href="#cite_note-160" style="counter-reset: mw-Ref 160;"><span class="mw-reflink-text">[160]</span></a></span> Spironolactone together with <a href="Trimethoprim/sulfamethoxazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Trimethoprim/sulfamethoxazole" title="Trimethoprim/sulfamethoxazole">trimethoprim/sulfamethoxazole</a> increases the likelihood of hyperkalemia, especially in the elderly. The trimethoprim portion acts to prevent potassium excretion in the distal tubule of the nephron.<span class="mw-ref" id="cite_ref-161"><a href="#cite_note-161" style="counter-reset: mw-Ref 161;"><span class="mw-reflink-text">[161]</span></a></span></p>

<p>Spironolactone has been reported to induce the enzymes CYP3A4 and certain UDP-glucuronosyltransferases (UGTs), which can result in interactions with various medications.<span class="mw-ref" id="cite_ref-Parkinson2001_10-1"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Davis2009_162-0"><a href="#cite_note-Davis2009-162" style="counter-reset: mw-Ref 162;"><span class="mw-reflink-text">[162]</span></a></span><span class="mw-ref" id="cite_ref-pmid1826112_163-0"><a href="#cite_note-pmid1826112-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> However, it has also been reported that metabolites of spironolactone irreversibly inhibit CYP3A4.<span class="mw-ref" id="cite_ref-Wolverton2007_164-0"><a href="#cite_note-Wolverton2007-164" style="counter-reset: mw-Ref 164;"><span class="mw-reflink-text">[164]</span></a></span> In any case, spironolactone has been found to reduce the bioavailability of oral estradiol, which could be due to induction of estradiol metabolism via CYP3A4.<span class="mw-ref" id="cite_ref-pmid29756046_165-0"><a href="#cite_note-pmid29756046-165" style="counter-reset: mw-Ref 165;"><span class="mw-reflink-text">[165]</span></a></span> Spironolactone has also been found to inhibit UGT2B7.<span class="mw-ref" id="cite_ref-JhajraRamesh_Varkhede2012_166-0"><a href="#cite_note-JhajraRamesh_Varkhede2012-166" style="counter-reset: mw-Ref 166;"><span class="mw-reflink-text">[166]</span></a></span> Spironolactone can also have numerous other interactions, most commonly with other cardiac and blood pressure medications, for instance <a href="Digoxin.htm" tppabs="https://ptable.com/wiki/compounds/A/Digoxin" title="Digoxin">digoxin</a>.<span class="mw-ref" id="cite_ref-Aldactone_label_111-17"><a href="#cite_note-Aldactone_label-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></p>

<p>Licorice, which has indirect mineralocorticoid activity by inhibiting mineralocorticoid metabolism, has been found to inhibit the antimineralocorticoid effects of spironolactone.<span class="mw-ref" id="cite_ref-pmid27450358_167-0"><a href="#cite_note-pmid27450358-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-pmid17113210_168-0"><a href="#cite_note-pmid17113210-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span><span class="mw-ref" id="cite_ref-pmid13991036_169-0"><a href="#cite_note-pmid13991036-169" style="counter-reset: mw-Ref 169;"><span class="mw-reflink-text">[169]</span></a></span> Moreover, the addition of licorice to spironolactone has been found to reduce the antimineralocorticoid side effects of spironolactone in women treated with it for hyperandrogenism, and licorice hence may be used to reduce these side effects in women treated with spironolactone as an antiandrogen who are bothered by them.<span class="mw-ref" id="cite_ref-pmid27450358_167-1"><a href="#cite_note-pmid27450358-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-pmid17113210_168-1"><a href="#cite_note-pmid17113210-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span> On the opposite end of the spectrum, spironolactone is useful in reversing licorice-induced hypokalemia.<span class="mw-ref" id="cite_ref-pmid23185686_170-0"><a href="#cite_note-pmid23185686-170" style="counter-reset: mw-Ref 170;"><span class="mw-reflink-text">[170]</span></a></span><span class="mw-ref" id="cite_ref-pmid12640291_171-0"><a href="#cite_note-pmid12640291-171" style="counter-reset: mw-Ref 171;"><span class="mw-reflink-text">[171]</span></a></span> <a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin</a> and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to attenuate the diuresis and natriuresis induced by spironolactone, but, not to affect its antihypertensive effect.<span class="mw-ref" id="cite_ref-EndouHosoyamada1995_28-1"><a href="#cite_note-EndouHosoyamada1995-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-pmid17362671_172-0"><a href="#cite_note-pmid17362671-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span></p>

<p>Some research has suggested that spironolactone might be able to interfere with the effectiveness of antidepressant treatment. As the medication acts as an antimineralocorticoid, it is thought that it might be able to reduce the effectiveness of certain antidepressants by interfering with normalization of the hypothalamic–pituitary–adrenal axis and by increasing levels of glucocorticoids such as <a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">cortisol</a>.<span class="mw-ref" id="cite_ref-173"><a href="#cite_note-173" style="counter-reset: mw-Ref 173;"><span class="mw-reflink-text">[173]</span></a></span><span class="mw-ref" id="cite_ref-pmid19909979_174-0"><a href="#cite_note-pmid19909979-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> However, other research contradicts this hypothesis and has suggested that spironolactone might actually produce antidepressant effects, for instance studies showing antidepressant-like effects of spironolactone in animals.<span class="mw-ref" id="cite_ref-pmid21515309_175-0"><a href="#cite_note-pmid21515309-175" style="counter-reset: mw-Ref 175;"><span class="mw-reflink-text">[175]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    

<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/7α-Thiomethylspironolactone.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/7%CE%B1-Thiomethylspironolactone.svg.png" data-file-width="1290" data-file-height="885" data-file-type="drawing" height="151" width="220"><div class="thumbcaption" style="text-align: left">7α-Thiomethylspironolactone, the major active form of spironolactone. It accounts for about 80% of the potassium-sparing effect of spironolactone.<span class="mw-ref" id="cite_ref-Sica2005_6-8"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-AgustiBourgeois2013_176-0"><a href="#cite_note-AgustiBourgeois2013-176" style="counter-reset: mw-Ref 176;"><span class="mw-reflink-text">[176]</span></a></span><span class="mw-ref" id="cite_ref-CancerOrganization2001_177-0"><a href="#cite_note-CancerOrganization2001-177" style="counter-reset: mw-Ref 177;"><span class="mw-reflink-text">[177]</span></a></span></div></div></div>
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Canrenone.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Canrenone.svg.png" data-file-width="512" data-file-height="359" data-file-type="drawing" height="154" width="220"><div class="thumbcaption" style="text-align: left">Canrenone, the second major active form of spironolactone. It accounts for around 10 to 25% of the potassium-sparing effect of spironolactone.<span class="mw-ref" id="cite_ref-GinésArroyo2008_91-1"><a href="#cite_note-GinésArroyo2008-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></div></div></div>

<p>The pharmacodynamics of spironolactone are characterized by high antimineralocorticoid activity, moderate antiandrogenic activity, and weak steroidogenesis inhibition, among other more minor activities.<span class="mw-ref" id="cite_ref-pmid28634268_110-2"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span><span class="mw-ref" id="cite_ref-pmid984618_113-1"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8094898_130-1"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span> Spironolactone is a prodrug, so most of its actions are actually mediated by its various active metabolites.<span class="mw-ref" id="cite_ref-pmid28634268_110-3"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span> The major active forms of spironolactone are 7α-thiomethylspironolactone (7α-TMS) and canrenone (7α-desthioacetyl-δ<sup>6</sup>-spironolactone).<span class="mw-ref" id="cite_ref-Sica2005_6-9"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid28634268_110-4"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span></p>

<p>Spironolactone is a potent antimineralocorticoid.<span class="mw-ref" id="cite_ref-Sica2005_6-10"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> That is, it is an antagonist of the mineralocorticoid receptor (MR), the biological target of mineralocorticoids like <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a> and 11-deoxycorticosterone.<span class="mw-ref" id="cite_ref-Sica2005_6-11"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> By blocking the MR, spironolactone inhibits the effects of mineralocorticoids in the body.<span class="mw-ref" id="cite_ref-Sica2005_6-12"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The antimineralocorticoid activity of spironolactone is responsible for its therapeutic efficacy in the treatment of edema, high blood pressure, heart failure, hyperaldosteronism, and ascites due to cirrhosis.<span class="mw-ref" id="cite_ref-Feldman2008_178-0"><a href="#cite_note-Feldman2008-178" style="counter-reset: mw-Ref 178;"><span class="mw-reflink-text">[178]</span></a></span><span class="mw-ref" id="cite_ref-Health2015_179-0"><a href="#cite_note-Health2015-179" style="counter-reset: mw-Ref 179;"><span class="mw-reflink-text">[179]</span></a></span> It is also responsible for many of the side effects of spironolactone, such as urinary frequency, dehydration, hyponatremia, low blood pressure, fatigue, dizziness, metabolic acidosis, decreased kidney function, and its risk of hyperkalemia.<span class="mw-ref" id="cite_ref-pmid24456327_180-0"><a href="#cite_note-pmid24456327-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span> Due to the antimineralocorticoid activity of spironolactone, levels of <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a> are significantly increased by the medication, probably reflecting an attempt of the body to maintain homeostasis.<span class="mw-ref" id="cite_ref-pmid9420861_49-5"><a href="#cite_note-pmid9420861-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-pmid10495361_74-9"><a href="#cite_note-pmid10495361-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></p>

<p>Spironolactone is a moderate antiandrogen.<span class="mw-ref" id="cite_ref-pmid984618_113-2"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-1"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid1826112_163-1"><a href="#cite_note-pmid1826112-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> That is, it is an antagonist of the androgen receptor (AR), the biological target of androgens like <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT).<span class="mw-ref" id="cite_ref-pmid984618_113-3"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-2"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid1826112_163-2"><a href="#cite_note-pmid1826112-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> By blocking the AR, spironolactone inhibits the effects of androgens in the body.<span class="mw-ref" id="cite_ref-pmid984618_113-4"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-3"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid1826112_163-3"><a href="#cite_note-pmid1826112-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> The antiandrogenic activity of spironolactone is mainly responsible for its therapeutic efficacy in the treatment of androgen-dependent skin and hair conditions like acne, seborrhea, hirsutism, and pattern hair loss and hyperandrogenism in women, precocious puberty in boys with testotoxicosis, and as a component of feminizing hormone therapy for transgender women.<span class="mw-ref" id="cite_ref-pmid8144871_137-4"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid29756046_165-1"><a href="#cite_note-pmid29756046-165" style="counter-reset: mw-Ref 165;"><span class="mw-reflink-text">[165]</span></a></span><span class="mw-ref" id="cite_ref-pmid11322868_181-0"><a href="#cite_note-pmid11322868-181" style="counter-reset: mw-Ref 181;"><span class="mw-reflink-text">[181]</span></a></span> It is also primarily responsible for some of its side effects, like breast tenderness, gynecomastia, feminization, and demasculinization in men.<span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-7"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span><span class="mw-ref" id="cite_ref-pmid11322868_181-1"><a href="#cite_note-pmid11322868-181" style="counter-reset: mw-Ref 181;"><span class="mw-reflink-text">[181]</span></a></span> Blockade of androgen signaling in the breast disinhibits the actions of <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogens</a> in this tissue.<span class="mw-ref" id="cite_ref-StraussIII2013_182-0"><a href="#cite_note-StraussIII2013-182" style="counter-reset: mw-Ref 182;"><span class="mw-reflink-text">[182]</span></a></span> Although useful as an antiandrogen in women, who have low testosterone levels compared to men,<span class="mw-ref" id="cite_ref-pmid2941190_183-0"><a href="#cite_note-pmid2941190-183" style="counter-reset: mw-Ref 183;"><span class="mw-reflink-text">[183]</span></a></span><span class="mw-ref" id="cite_ref-GregoryTravis2015_184-0"><a href="#cite_note-GregoryTravis2015-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span> spironolactone is described as having relatively weak antiandrogenic activity.<span class="mw-ref" id="cite_ref-Wu2012_96-1"><a href="#cite_note-Wu2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-pmid11322868_181-2"><a href="#cite_note-pmid11322868-181" style="counter-reset: mw-Ref 181;"><span class="mw-reflink-text">[181]</span></a></span><span class="mw-ref" id="cite_ref-BenniVemer1990_185-0"><a href="#cite_note-BenniVemer1990-185" style="counter-reset: mw-Ref 185;"><span class="mw-reflink-text">[185]</span></a></span><span class="mw-ref" id="cite_ref-pmid8915726_186-0"><a href="#cite_note-pmid8915726-186" style="counter-reset: mw-Ref 186;"><span class="mw-reflink-text">[186]</span></a></span></p>

<p>Spironolactone is a weak steroidogenesis inhibitor.<span class="mw-ref" id="cite_ref-pmid984618_113-5"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8094898_130-2"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-5"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid6786868_187-0"><a href="#cite_note-pmid6786868-187" style="counter-reset: mw-Ref 187;"><span class="mw-reflink-text">[187]</span></a></span> That is, it inhibits steroidogenic enzymes, or enzymes involved in the production of steroid hormones.<span class="mw-ref" id="cite_ref-pmid984618_113-6"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8094898_130-3"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-6"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid6786868_187-1"><a href="#cite_note-pmid6786868-187" style="counter-reset: mw-Ref 187;"><span class="mw-reflink-text">[187]</span></a></span> Spironolactone and/or its metabolites have been found <i>in vitro</i> to weakly inhibit a broad array of steroidogenic enzymes including cholesterol side-chain cleavage enzyme, 17α-hydroxylase, 17,20-lyase, 5α-reductase, 3β-hydroxysteroid dehydrogenase, 11β-hydroxylase, 21-hydroxylase, and aldosterone synthase (18-hydroxylase).<span class="mw-ref" id="cite_ref-pmid8144871_137-7"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid6786868_187-2"><a href="#cite_note-pmid6786868-187" style="counter-reset: mw-Ref 187;"><span class="mw-reflink-text">[187]</span></a></span><span class="mw-ref" id="cite_ref-pmid26001184_188-0"><a href="#cite_note-pmid26001184-188" style="counter-reset: mw-Ref 188;"><span class="mw-reflink-text">[188]</span></a></span><span class="mw-ref" id="cite_ref-pmid18819053_189-0"><a href="#cite_note-pmid18819053-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span> However, although very high doses of spironolactone can considerably decrease steroid hormone levels in animals, spironolactone has shown mixed and inconsistent effects on steroid hormone levels in clinical studies, even at high clinical doses.<span class="mw-ref" id="cite_ref-pmid28155090_52-18"><a href="#cite_note-pmid28155090-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-pmid984618_113-7"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8094898_130-4"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span><span class="mw-ref" id="cite_ref-pmid8144871_137-8"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-pmid1826112_163-4"><a href="#cite_note-pmid1826112-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span> In any case, the levels of most steroid hormones, including testosterone and <a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">cortisol</a>, are usually unchanged by spironolactone in humans, which may in part be related to compensatory upregulation of their synthesis.<span class="mw-ref" id="cite_ref-pmid984618_113-8"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8094898_130-5"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span><span class="mw-ref" id="cite_ref-WattsFaingold2009_190-0"><a href="#cite_note-WattsFaingold2009-190" style="counter-reset: mw-Ref 190;"><span class="mw-reflink-text">[190]</span></a></span> The weak steroidogenesis inhibition of spironolactone might contribute to its antiandrogenic efficacy to some degree and may explain its side effect of menstrual irregularities in women.<span class="mw-ref" id="cite_ref-pmid984618_113-9"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-SeldinGiebisch1997_114-8"><a href="#cite_note-SeldinGiebisch1997-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span> However, its androgen synthesis inhibition is probably clinically insignificant.<span class="mw-ref" id="cite_ref-pmid9238337_54-3"><a href="#cite_note-pmid9238337-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></p>

<p>Spironolactone has been found in some studies to increase levels of <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>, an <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogen</a>, although many other studies have found no changes in estradiol levels.<span class="mw-ref" id="cite_ref-pmid984618_113-10"><a href="#cite_note-pmid984618-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-pmid8094898_130-6"><a href="#cite_note-pmid8094898-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span> The mechanism of how spironolactone increases estradiol levels is unclear, but it may involve inhibition of the inactivation of estradiol into <a href="Estrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrone" title="Estrone">estrone</a> and enhancement of the peripheral conversion of testosterone into estradiol.<span class="mw-ref" id="cite_ref-pmid12477487_191-0"><a href="#cite_note-pmid12477487-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span><span class="mw-ref" id="cite_ref-pmid907238_192-0"><a href="#cite_note-pmid907238-192" style="counter-reset: mw-Ref 192;"><span class="mw-reflink-text">[192]</span></a></span> It is notable that spironolactone has been found <i>in vitro</i> to act as a weak inhibitor of 17β-hydroxysteroid dehydrogenase 2, an enzyme that is involved in the conversion of estradiol into estrone.<span class="mw-ref" id="cite_ref-pmid12570693_193-0"><a href="#cite_note-pmid12570693-193" style="counter-reset: mw-Ref 193;"><span class="mw-reflink-text">[193]</span></a></span><span class="mw-ref" id="cite_ref-pmid19601747_194-0"><a href="#cite_note-pmid19601747-194" style="counter-reset: mw-Ref 194;"><span class="mw-reflink-text">[194]</span></a></span> Increased levels of estradiol with spironolactone may be involved in its preservation of bone density and in its side effects such as breast tenderness, breast enlargement, and gynecomastia in women and men.<span class="mw-ref" id="cite_ref-pmid12477487_191-1"><a href="#cite_note-pmid12477487-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span><span class="mw-ref" id="cite_ref-pmid24189467_195-0"><a href="#cite_note-pmid24189467-195" style="counter-reset: mw-Ref 195;"><span class="mw-reflink-text">[195]</span></a></span><span class="mw-ref" id="cite_ref-pmid26230882_196-0"><a href="#cite_note-pmid26230882-196" style="counter-reset: mw-Ref 196;"><span class="mw-reflink-text">[196]</span></a></span></p>

<p>In response to the antimineralocorticoid activity spironolactone, and in an attempt to maintain homeostasis, the body increases aldosterone production in the adrenal cortex.<span class="mw-ref" id="cite_ref-Adams2014_197-0"><a href="#cite_note-Adams2014-197" style="counter-reset: mw-Ref 197;"><span class="mw-reflink-text">[197]</span></a></span><span class="mw-ref" id="cite_ref-pmid22836869_198-0"><a href="#cite_note-pmid22836869-198" style="counter-reset: mw-Ref 198;"><span class="mw-reflink-text">[198]</span></a></span><span class="mw-ref" id="cite_ref-pmid17035932_199-0"><a href="#cite_note-pmid17035932-199" style="counter-reset: mw-Ref 199;"><span class="mw-reflink-text">[199]</span></a></span> Some studies have found that levels of <a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">cortisol</a>, a glucocorticoid hormone that is also produced in the adrenal cortex, are increased as well.<span class="mw-ref" id="cite_ref-pmid22836869_198-1"><a href="#cite_note-pmid22836869-198" style="counter-reset: mw-Ref 198;"><span class="mw-reflink-text">[198]</span></a></span><span class="mw-ref" id="cite_ref-pmid17035932_199-1"><a href="#cite_note-pmid17035932-199" style="counter-reset: mw-Ref 199;"><span class="mw-reflink-text">[199]</span></a></span><span class="mw-ref" id="cite_ref-pmid27519144_200-0"><a href="#cite_note-pmid27519144-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span> However, other clinical studies have found no change in cortisol levels with spironolactone,<span class="mw-ref" id="cite_ref-pmid8144871_137-9"><a href="#cite_note-pmid8144871-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span><span class="mw-ref" id="cite_ref-FalconeHurd2007_201-0"><a href="#cite_note-FalconeHurd2007-201" style="counter-reset: mw-Ref 201;"><span class="mw-reflink-text">[201]</span></a></span><span class="mw-ref" id="cite_ref-Hammerstein1990_85-1"><a href="#cite_note-Hammerstein1990-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span><span class="mw-ref" id="cite_ref-pmid628197_202-0"><a href="#cite_note-pmid628197-202" style="counter-reset: mw-Ref 202;"><span class="mw-reflink-text">[202]</span></a></span> and those that have found increases often have observed only small changes.<span class="mw-ref" id="cite_ref-pmid21095280_203-0"><a href="#cite_note-pmid21095280-203" style="counter-reset: mw-Ref 203;"><span class="mw-reflink-text">[203]</span></a></span> In accordance, spironolactone has not been associated with conventional glucocorticoid medication effects or side effects.<span class="mw-ref" id="cite_ref-KuntzKuntz2009_204-0"><a href="#cite_note-KuntzKuntz2009-204" style="counter-reset: mw-Ref 204;"><span class="mw-reflink-text">[204]</span></a></span><span class="mw-ref" id="cite_ref-MelmedPolonsky2011_205-0"><a href="#cite_note-MelmedPolonsky2011-205" style="counter-reset: mw-Ref 205;"><span class="mw-reflink-text">[205]</span></a></span></p>

<p>Other activities of spironolactone may include very weak interactions with the estrogen and progesterone receptors and agonism of the pregnane X receptor.<span class="mw-ref" id="cite_ref-Hammerstein1990_85-2"><a href="#cite_note-Hammerstein1990-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span><span class="mw-ref" id="cite_ref-pmid12372848_206-0"><a href="#cite_note-pmid12372848-206" style="counter-reset: mw-Ref 206;"><span class="mw-reflink-text">[206]</span></a></span> These activities could contribute to the menstrual irregularities and breast side effects of spironolactone and to its drug interactions, respectively.<span class="mw-ref" id="cite_ref-pmid27072668_207-0"><a href="#cite_note-pmid27072668-207" style="counter-reset: mw-Ref 207;"><span class="mw-reflink-text">[207]</span></a></span><span class="mw-ref" id="cite_ref-Delyani2000_208-0"><a href="#cite_note-Delyani2000-208" style="counter-reset: mw-Ref 208;"><span class="mw-reflink-text">[208]</span></a></span><span class="mw-ref" id="cite_ref-pmid9727070_209-0"><a href="#cite_note-pmid9727070-209" style="counter-reset: mw-Ref 209;"><span class="mw-reflink-text">[209]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>The pharmacokinetics of spironolactone have not been studied well, which is in part because it is an old medication that was developed in the 1950s.<span class="mw-ref" id="cite_ref-Wilcox2008_131-1"><a href="#cite_note-Wilcox2008-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span> Nonetheless, much has been elucidated about the pharmacokinetics of spironolactone over the decades.<span class="mw-ref" id="cite_ref-pmid363379_210-0"><a href="#cite_note-pmid363379-210" style="counter-reset: mw-Ref 210;"><span class="mw-reflink-text">[210]</span></a></span><span class="mw-ref" id="cite_ref-pmid6369882_211-0"><a href="#cite_note-pmid6369882-211" style="counter-reset: mw-Ref 211;"><span class="mw-reflink-text">[211]</span></a></span><span class="mw-ref" id="cite_ref-pmid3333882_212-0"><a href="#cite_note-pmid3333882-212" style="counter-reset: mw-Ref 212;"><span class="mw-reflink-text">[212]</span></a></span><span class="mw-ref" id="cite_ref-pmid15947888_213-0"><a href="#cite_note-pmid15947888-213" style="counter-reset: mw-Ref 213;"><span class="mw-reflink-text">[213]</span></a></span><span class="mw-ref" id="cite_ref-pmid22099505_214-0"><a href="#cite_note-pmid22099505-214" style="counter-reset: mw-Ref 214;"><span class="mw-reflink-text">[214]</span></a></span><span class="mw-ref" id="cite_ref-pmid21771637_215-0"><a href="#cite_note-pmid21771637-215" style="counter-reset: mw-Ref 215;"><span class="mw-reflink-text">[215]</span></a></span><span class="mw-ref" id="cite_ref-pmid26939027_216-0"><a href="#cite_note-pmid26939027-216" style="counter-reset: mw-Ref 216;"><span class="mw-reflink-text">[216]</span></a></span><span class="mw-ref" id="cite_ref-pmid27830348_217-0"><a href="#cite_note-pmid27830348-217" style="counter-reset: mw-Ref 217;"><span class="mw-reflink-text">[217]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Absorption">Absorption</h4></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:402px"><img src="../I/m/Spironolactone_and_metabolite_levels_after_a_single_oral_dose_of_100_mg_spironolactone.png" tppabs="https://ptable.com/wiki/compounds/I/m/Spironolactone_and_metabolite_levels_after_a_single_oral_dose_of_100_mg_spironolactone.png" data-file-width="1676" data-file-height="1151" data-file-type="bitmap" height="275" width="400"><div class="thumbcaption" style="text-align: left">Levels of spironolactone and its major active metabolites after a single oral dose of 100<span>&nbsp;</span>mg spironolactone in humans.<span class="mw-ref" id="cite_ref-pmid8818057_218-0"><a href="#cite_note-pmid8818057-218" style="counter-reset: mw-Ref 218;"><span class="mw-reflink-text">[218]</span></a></span></div></div></div>

<p>The bioavailability of spironolactone when taken by mouth is 60 to 90%.<span class="mw-ref" id="cite_ref-Sica2005_6-13"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-4"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-CaroneOxberry2017_8-1"><a href="#cite_note-CaroneOxberry2017-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> The bioavailability of spironolactone and its metabolites increases significantly (+22–95% increases in levels) when spironolactone is taken with food, although it is uncertain whether this further increases the therapeutic effects of the medication.<span class="mw-ref" id="cite_ref-DeinumRiksen2015_219-0"><a href="#cite_note-DeinumRiksen2015-219" style="counter-reset: mw-Ref 219;"><span class="mw-reflink-text">[219]</span></a></span><span class="mw-ref" id="cite_ref-pmid3769384_220-0"><a href="#cite_note-pmid3769384-220" style="counter-reset: mw-Ref 220;"><span class="mw-reflink-text">[220]</span></a></span><span class="mw-ref" id="cite_ref-pmid872489_221-0"><a href="#cite_note-pmid872489-221" style="counter-reset: mw-Ref 221;"><span class="mw-reflink-text">[221]</span></a></span> The increase in bioavailability is thought to be due to promotion of the gastric dissolution and absorption of spironolactone, as well as due to a decrease of the first-pass metabolism.<span class="mw-ref" id="cite_ref-DeinumRiksen2015_219-1"><a href="#cite_note-DeinumRiksen2015-219" style="counter-reset: mw-Ref 219;"><span class="mw-reflink-text">[219]</span></a></span><span class="mw-ref" id="cite_ref-Saini-ChohanHatch2009_222-0"><a href="#cite_note-Saini-ChohanHatch2009-222" style="counter-reset: mw-Ref 222;"><span class="mw-reflink-text">[222]</span></a></span><span class="mw-ref" id="cite_ref-Al-HadiyaBelal2002_223-0"><a href="#cite_note-Al-HadiyaBelal2002-223" style="counter-reset: mw-Ref 223;"><span class="mw-reflink-text">[223]</span></a></span> The relationship between a single dose of spironolactone and plasma levels of canrenone, a major active metabolite of spironolactone, has been found to be linear across a dose range of 25 to 200<span>&nbsp;</span>mg spironolactone.<span class="mw-ref" id="cite_ref-Wu2012_96-2"><a href="#cite_note-Wu2012-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span> Steady-state concentrations of spironolactone are achieved within 8 to 10<span>&nbsp;</span>days of treatment initiation.<span class="mw-ref" id="cite_ref-CancerOrganization2001_177-1"><a href="#cite_note-CancerOrganization2001-177" style="counter-reset: mw-Ref 177;"><span class="mw-reflink-text">[177]</span></a></span><span class="mw-ref" id="cite_ref-Elsevier2019_224-0"><a href="#cite_note-Elsevier2019-224" style="counter-reset: mw-Ref 224;"><span class="mw-reflink-text">[224]</span></a></span></p>

<p>Little or no systemic absorption has been observed with topical spironolactone.<span class="mw-ref" id="cite_ref-pmid3411088_225-0"><a href="#cite_note-pmid3411088-225" style="counter-reset: mw-Ref 225;"><span class="mw-reflink-text">[225]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Distribution">Distribution</h4></summary>
    
<p>Spironolactone and its metabolite canrenone are highly plasma protein bound, with percentages of 88.0% and 99.2%, respectively.<span class="mw-ref" id="cite_ref-Sica2005_6-14"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-TakamuraMaruyama1997_9-2"><a href="#cite_note-TakamuraMaruyama1997-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Spironolactone is bound equivalently to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a> and α<sub>1</sub>-acid glycoprotein, while canrenone is bound only to albumin.<span class="mw-ref" id="cite_ref-Sica2005_6-15"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-TakamuraMaruyama1997_9-3"><a href="#cite_note-TakamuraMaruyama1997-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Spironolactone and its metabolite 7α-thiospironolactone show very low or negligible affinity for sex hormone-binding globulin (SHBG).<span class="mw-ref" id="cite_ref-pmid86546_226-0"><a href="#cite_note-pmid86546-226" style="counter-reset: mw-Ref 226;"><span class="mw-reflink-text">[226]</span></a></span><span class="mw-ref" id="cite_ref-pmid7195405_227-0"><a href="#cite_note-pmid7195405-227" style="counter-reset: mw-Ref 227;"><span class="mw-reflink-text">[227]</span></a></span> In accordance, a study of high-dosage spironolactone treatment found no change in steroid binding capacity related to SHBG or to corticosteroid-binding globulin (CBG), suggesting that spironolactone does not displace steroid hormones from their carrier proteins.<span class="mw-ref" id="cite_ref-pmid7189544_228-0"><a href="#cite_note-pmid7189544-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span> This is in contradiction with widespread statements that spironolactone increases free estradiol levels by displacing estradiol from SHBG.<span class="mw-ref" id="cite_ref-Hammerstein1990_85-3"><a href="#cite_note-Hammerstein1990-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span><span class="mw-ref" id="cite_ref-BlandIII2009_229-0"><a href="#cite_note-BlandIII2009-229" style="counter-reset: mw-Ref 229;"><span class="mw-reflink-text">[229]</span></a></span></p>

<p>Spironolactone appears to cross the blood–brain barrier.<span class="mw-ref" id="cite_ref-pmid25376974_230-0"><a href="#cite_note-pmid25376974-230" style="counter-reset: mw-Ref 230;"><span class="mw-reflink-text">[230]</span></a></span><span class="mw-ref" id="cite_ref-pmid22351473_231-0"><a href="#cite_note-pmid22351473-231" style="counter-reset: mw-Ref 231;"><span class="mw-reflink-text">[231]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Metabolism">Metabolism</h4></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:402px"><img src="../I/m/Spironolactone_metabolism.png" tppabs="https://ptable.com/wiki/compounds/I/m/Spironolactone_metabolism.png" data-file-width="2570" data-file-height="2100" data-file-type="bitmap" height="327" width="400"><div class="thumbcaption" style="text-align: left">Spironolactone metabolism in humans.<span class="mw-ref" id="cite_ref-pmid1629288_232-0"><a href="#cite_note-pmid1629288-232" style="counter-reset: mw-Ref 232;"><span class="mw-reflink-text">[232]</span></a></span> Canrenone may be further reduced (into di-, tetra-, and hexahydrogenated metabolites), hydroxylated, and conjugated (e.g., glucuronidated).<span class="mw-ref" id="cite_ref-pmid1629288_232-1"><a href="#cite_note-pmid1629288-232" style="counter-reset: mw-Ref 232;"><span class="mw-reflink-text">[232]</span></a></span></div></div></div>

<p>Spironolactone is rapidly and extensively metabolized in the liver upon oral administration and has a very short terminal half-life of 1.4 hours.<span class="mw-ref" id="cite_ref-Sica2005_6-16"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-5"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> The major metabolites of spironolactone are 7α-thiomethylspironolactone (7α-TMS), 6β-hydroxy-7α-thiomethylspironolactone (6β-OH-7α-TMS), and canrenone (7α-desthioacetyl-δ<sup>6</sup>-spironolactone).<span class="mw-ref" id="cite_ref-Sica2005_6-17"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-6"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-AgustiBourgeois2013_176-1"><a href="#cite_note-AgustiBourgeois2013-176" style="counter-reset: mw-Ref 176;"><span class="mw-reflink-text">[176]</span></a></span> These metabolites have much longer elimination half-lives than spironolactone of 13.8 hours, 15.0 hours, and 16.5 hours, respectively, and are responsible for the therapeutic effects of the medication.<span class="mw-ref" id="cite_ref-Sica2005_6-18"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid18729003_7-7"><a href="#cite_note-pmid18729003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> As such, spironolactone is a prodrug.<span class="mw-ref" id="cite_ref-Oxford2003_233-0"><a href="#cite_note-Oxford2003-233" style="counter-reset: mw-Ref 233;"><span class="mw-reflink-text">[233]</span></a></span> The 7α-thiomethylated metabolites of spironolactone were not known for many years and it was originally thought that canrenone was the major active metabolite of the medication, but subsequent research identified 7α-TMS as the major metabolite.<span class="mw-ref" id="cite_ref-Sica2005_6-19"><a href="#cite_note-Sica2005-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-AgustiBourgeois2013_176-2"><a href="#cite_note-AgustiBourgeois2013-176" style="counter-reset: mw-Ref 176;"><span class="mw-reflink-text">[176]</span></a></span><span class="mw-ref" id="cite_ref-CancerOrganization2001_177-2"><a href="#cite_note-CancerOrganization2001-177" style="counter-reset: mw-Ref 177;"><span class="mw-reflink-text">[177]</span></a></span> Other known but more minor metabolites of spironolactone include 7α-thiospironolactone (7α-TS), which is an important intermediate to the major metabolites of spironolactone,<span class="mw-ref" id="cite_ref-Parkinson2001_10-2"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> as well as the 7α-methyl ethyl ester of spironolactone and the 6β-hydroxy-7α-methyl ethyl ester of spironolactone.<span class="mw-ref" id="cite_ref-SzaszBudvari-Barany1990_15-1"><a href="#cite_note-SzaszBudvari-Barany1990-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>Spironolactone is hydrolyzed or deacetylated at the thioester of the C7α position into 7α-TS by carboxylesterases.<span class="mw-ref" id="cite_ref-Parkinson2001_10-3"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-AnzenbacherZanger2012_234-0"><a href="#cite_note-AnzenbacherZanger2012-234" style="counter-reset: mw-Ref 234;"><span class="mw-reflink-text">[234]</span></a></span> Following formation of 7α-TS, it is <i>S</i>-oxygenated by flavin-containing monooxygenases to form an electrophilic sulfenic acid metabolite.<span class="mw-ref" id="cite_ref-Parkinson2001_10-4"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> This metabolite is involved in the CYP450 inhibition of spironolactone, and also binds covalently to other proteins.<span class="mw-ref" id="cite_ref-Parkinson2001_10-5"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> 7α-TS is also <i>S</i>-methylated into 7α-TMS, a transformation catalyzed by thiol <i>S</i>-methyltransferase.<span class="mw-ref" id="cite_ref-Parkinson2001_10-6"><a href="#cite_note-Parkinson2001-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Unlike the related medication <a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">eplerenone</a>, spironolactone is said to not be metabolized by CYP3A4.<span class="mw-ref" id="cite_ref-SmithPh.D.2014_235-0"><a href="#cite_note-SmithPh.D.2014-235" style="counter-reset: mw-Ref 235;"><span class="mw-reflink-text">[235]</span></a></span> However, hepatic CYP3A4 is likely responsible for the 6β-hydroxylation of 7α-TMS into 6β-OH-7α-TMS.<span class="mw-ref" id="cite_ref-Klaassen2007_11-1"><a href="#cite_note-Klaassen2007-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-Montellano2015_236-0"><a href="#cite_note-Montellano2015-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span> 7α-TMS may also be hydroxylated at the C3α and C3β positions.<span class="mw-ref" id="cite_ref-pmid7895608_12-1"><a href="#cite_note-pmid7895608-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Spironolactone is dethioacetylated into canrenone.<span class="mw-ref" id="cite_ref-BlackElliott2006_13-1"><a href="#cite_note-BlackElliott2006-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Finally, the C17 γ-lactone ring of spironolactone is hydrolyzed by the paraoxonase PON3.<span class="mw-ref" id="cite_ref-pmid14579013_14-1"><a href="#cite_note-pmid14579013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-AcademicPress2012_237-0"><a href="#cite_note-AcademicPress2012-237" style="counter-reset: mw-Ref 237;"><span class="mw-reflink-text">[237]</span></a></span> It was originally thought to be hydrolyzed by PON1, but this was due to contamination with PON3.<span class="mw-ref" id="cite_ref-pmid14579013_14-2"><a href="#cite_note-pmid14579013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="margin-left: auto; margin-right: auto; border: none;">
<caption class="nowrap"> Pharmacokinetics of 100<span>&nbsp;</span>mg/day spironolactone and its metabolites</caption>
<tbody><tr>
<th>Compound</th><th><abbr>C<sub>max</sub></abbr> <span style="font-size:85%;">(day 1)</span></th><th><abbr>C<sub>max</sub></abbr> <span style="font-size:85%;">(day 15)</span></th><th><abbr>AUC</abbr> <span style="font-size:85%;">(day 15)</span></th><th><abbr>t<sub>1/2</sub></abbr></th></tr>
<tr>
<td>Spironolactone</td><td>72<span>&nbsp;</span>ng/mL (173<span>&nbsp;</span>nmol/L)</td><td>80<span>&nbsp;</span>ng/mL (192<span>&nbsp;</span>nmol/L)</td><td>231<span>&nbsp;</span>ng•hour/mL (555<span>&nbsp;</span>nmol•hour/L)</td><td>1.4<span>&nbsp;</span>hours</td></tr>
<tr>
<td>Canrenone</td><td>155<span>&nbsp;</span>ng/mL (455<span>&nbsp;</span>nmol/L)</td><td>181<span>&nbsp;</span>ng/mL (532<span>&nbsp;</span>nmol/L)</td><td>2,173<span>&nbsp;</span>ng•hour/mL (6,382<span>&nbsp;</span>nmol•hour/L)</td><td>16.5<span>&nbsp;</span>hours</td></tr>
<tr>
<td><abbr>7α-TMS</abbr></td><td>359<span>&nbsp;</span>ng/mL (924<span>&nbsp;</span>nmol/L)</td><td>391<span>&nbsp;</span>ng/mL (1,006<span>&nbsp;</span>nmol/L)</td><td>2,804<span>&nbsp;</span>ng•hour/mL (7,216<span>&nbsp;</span>nmol•hour/L)</td><td>13.8<span>&nbsp;</span>hours</td></tr>
<tr>
<td><abbr>6β-OH-7α-TMS</abbr></td><td>101<span>&nbsp;</span>ng/mL (250<span>&nbsp;</span>nmol/L)</td><td>125<span>&nbsp;</span>ng/mL (309<span>&nbsp;</span>nmol/L)</td><td>1,727<span>&nbsp;</span>ng•hour/mL (4,269<span>&nbsp;</span>nmol•hour/L)</td><td>15.0<span>&nbsp;</span>hours</td></tr>
<tr class="sortbottom">
<td colspan="5" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Sources:</b> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Elimination">Elimination</h4></summary>
    
<p>The majority of spironolactone is eliminated by the kidneys, while minimal amounts are handled by biliary excretion.<span class="mw-ref" id="cite_ref-Brittain2002_238-0"><a href="#cite_note-Brittain2002-238" style="counter-reset: mw-Ref 238;"><span class="mw-reflink-text">[238]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    


<p>Spironolactone, also known as <i>7α-acetylthiospirolactone</i>, is a steroidal 17α-spirolactone, or more simply a spirolactone.<span class="mw-ref" id="cite_ref-pmid28634268_110-5"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span> It can most appropriately be conceptualized as a derivative of progesterone,<span class="mw-ref" id="cite_ref-pmid15134800_129-3"><a href="#cite_note-pmid15134800-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span><span class="mw-ref" id="cite_ref-JamesonGroot2010_239-0"><a href="#cite_note-JamesonGroot2010-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span><span class="mw-ref" id="cite_ref-Elsevier2019_224-1"><a href="#cite_note-Elsevier2019-224" style="counter-reset: mw-Ref 224;"><span class="mw-reflink-text">[224]</span></a></span> itself also a potent antimineralocorticoid, in which a hydroxyl group has been substituted at the C17α position (as in 17α-hydroxyprogesterone), the acetyl group at the C17β position has been cyclized with the C17α hydroxyl group to form a spiro 21-carboxylic acid γ-lactone ring, and an acetylthio group has been substituted in at the C7α position.<span class="mw-ref" id="cite_ref-Elks2014_240-0"><a href="#cite_note-Elks2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span><span class="mw-ref" id="cite_ref-PubChem_241-0"><a href="#cite_note-PubChem-241" style="counter-reset: mw-Ref 241;"><span class="mw-reflink-text">[241]</span></a></span><span class="mw-ref" id="cite_ref-ChemSpider_242-0"><a href="#cite_note-ChemSpider-242" style="counter-reset: mw-Ref 242;"><span class="mw-reflink-text">[242]</span></a></span> These structural modifications of progesterone confer increased oral bioavailability and potency,<span class="mw-ref" id="cite_ref-pmid8616985_243-0"><a href="#cite_note-pmid8616985-243" style="counter-reset: mw-Ref 243;"><span class="mw-reflink-text">[243]</span></a></span> potent antiandrogenic activity, and strongly reduced progestogenic activity.<span class="mw-ref" id="cite_ref-pmid16101407_244-0"><a href="#cite_note-pmid16101407-244" style="counter-reset: mw-Ref 244;"><span class="mw-reflink-text">[244]</span></a></span> The C7α substitution is likely responsible for or involved in the antiandrogenic activity of spironolactone, as 7α-thioprogesterone (SC-8365), unlike progesterone,<span class="mw-ref" id="cite_ref-pmid16112947_245-0"><a href="#cite_note-pmid16112947-245" style="counter-reset: mw-Ref 245;"><span class="mw-reflink-text">[245]</span></a></span> is an antiandrogen with similar affinity to the AR as that of spironolactone.<span class="mw-ref" id="cite_ref-pmid263288_246-0"><a href="#cite_note-pmid263288-246" style="counter-reset: mw-Ref 246;"><span class="mw-reflink-text">[246]</span></a></span> In addition, the C7α substitution appears to be responsible for the loss of progestogenic activity and good oral bioavailability of spironolactone, as SC-5233, the analogue of spironolactone without a C7α substitution, has potent progestogenic activity but very poor oral bioavailability similarly to progesterone.<span class="mw-ref" id="cite_ref-pmid16112947_245-1"><a href="#cite_note-pmid16112947-245" style="counter-reset: mw-Ref 245;"><span class="mw-reflink-text">[245]</span></a></span><span class="mw-ref" id="cite_ref-pmid13601900_247-0"><a href="#cite_note-pmid13601900-247" style="counter-reset: mw-Ref 247;"><span class="mw-reflink-text">[247]</span></a></span><span class="mw-ref" id="cite_ref-Butterworth1961_248-0"><a href="#cite_note-Butterworth1961-248" style="counter-reset: mw-Ref 248;"><span class="mw-reflink-text">[248]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Names">Names</h3></summary>
    
<p>Spironolactone is also known by the following equivalent chemical names:<span class="mw-ref" id="cite_ref-Elks2014_240-1"><a href="#cite_note-Elks2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span><span class="mw-ref" id="cite_ref-PubChem_241-1"><a href="#cite_note-PubChem-241" style="counter-reset: mw-Ref 241;"><span class="mw-reflink-text">[241]</span></a></span><span class="mw-ref" id="cite_ref-ChemSpider_242-1"><a href="#cite_note-ChemSpider-242" style="counter-reset: mw-Ref 242;"><span class="mw-reflink-text">[242]</span></a></span></p>

<ul><li>7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone</li>
<li>7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17β-carbolactone</li>
<li>3-(3-Oxo-7α-acetylthio-17β-hydroxyandrost-4-en-17α-yl)propionic acid lactone</li>
<li>7α-Acetylthio-17α-(2-carboxyethyl)androst-4-en-17β-ol-3-one γ-lactone</li>
<li>7α-Acetylthio-17α-(2-carboxyethyl)testosterone γ-lactone</li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Analogues">Analogues</h3></summary>
    
<span>
</span><table role="presentation" cellpadding="0" style="border-spacing:0; clear:right; float:right;">
<tbody><tr>
<td><div class="thumb tright">
<div class="thumbinner" style="width:552px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: aliceblue;margin-bottom:3px;"> Chemical structures of spirolactones</div>
<div style="position:relative; width:550px; height:351px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:550px; position:absolute"> <figure-inline><span><img src="../I/m/Spirolactone_structures.png" tppabs="https://ptable.com/wiki/compounds/I/m/Spirolactone_structures.png" data-file-width="2600" data-file-height="1640" data-file-type="bitmap" height="347" width="550"></span></figure-inline>
</div> 
<div style="text-align:center; font-size:14px; line-height:110%;">
<div style="background-color:transparent; color:black"><div id="annotation_53x134" style="position:absolute; left:53px; top:134px;      line-height:110% "><span style="background-color:transparent; ">Progesterone</span></div>
<div id="annotation_235x134" style="position:absolute; left:235px; top:134px;      line-height:110% "><span style="background-color:transparent; ">Spirolactone</span></div>
<div id="annotation_420x134" style="position:absolute; left:420px; top:134px;      line-height:110% "><span style="background-color:transparent; ">Canrenone</span></div>
<div id="annotation_53x322" style="position:absolute; left:53px; top:322px;      line-height:110% "><span style="background-color:transparent; ">Spironolactone</span></div>
<div id="annotation_235x322" style="position:absolute; left:235px; top:322px;      line-height:110% "><span style="background-color:transparent; "><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></span></div>
<div id="annotation_420x322" style="position:absolute; left:420px; top:322px;      line-height:110% "><span style="background-color:transparent; ">Spirorenone</span></div></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline><span><img src="../I/m/Interactive_icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18"></span></figure-inline></div>Chemical structures of progesterone and spirolactones (steroid-17α-spirolactones).</div>
</div>
</div></td></tr>
</tbody></table>

<p>Spironolactone is closely related structurally to other clinically used spirolactones such as canrenone, potassium canrenoate, <a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">drospirenone</a>, and <a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">eplerenone</a>, as well as to the never-marketed spirolactones SC-5233 (6,7-dihydrocanrenone; 7α-desthioacetylspironolactone), SC-8109 (19-nor-6,7-dihydrocanrenone), spiroxasone, prorenone (SC-23133), mexrenone (SC-25152, ZK-32055), dicirenone (SC-26304), spirorenone (ZK-35973), and mespirenone (ZK-94679).<span class="mw-ref" id="cite_ref-pmid28634268_110-6"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Synthesis">Synthesis</h3></summary>
    
<p>Chemical syntheses of spironolactone and its analogues and derivatives have been described and reviewed.<span class="mw-ref" id="cite_ref-pmid28041953_249-0"><a href="#cite_note-pmid28041953-249" style="counter-reset: mw-Ref 249;"><span class="mw-reflink-text">[249]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>The natriuretic effects of progesterone were demonstrated in 1955, and the development of spironolactone as a synthetic antimineralocorticoid analogue of progesterone shortly followed this.<span class="mw-ref" id="cite_ref-pmid15134800_129-4"><a href="#cite_note-pmid15134800-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span><span class="mw-ref" id="cite_ref-JamesonGroot2010_239-1"><a href="#cite_note-JamesonGroot2010-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span><span class="mw-ref" id="cite_ref-pmid13486053_250-0"><a href="#cite_note-pmid13486053-250" style="counter-reset: mw-Ref 250;"><span class="mw-reflink-text">[250]</span></a></span><span class="mw-ref" id="cite_ref-pmid13486054_251-0"><a href="#cite_note-pmid13486054-251" style="counter-reset: mw-Ref 251;"><span class="mw-reflink-text">[251]</span></a></span> Spironolactone was first synthesized in 1957,<span class="mw-ref" id="cite_ref-OttowWeinmann2008_20-1"><a href="#cite_note-OttowWeinmann2008-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-pmid13486053_250-1"><a href="#cite_note-pmid13486053-250" style="counter-reset: mw-Ref 250;"><span class="mw-reflink-text">[250]</span></a></span><span class="mw-ref" id="cite_ref-pmid13486054_251-1"><a href="#cite_note-pmid13486054-251" style="counter-reset: mw-Ref 251;"><span class="mw-reflink-text">[251]</span></a></span> was patented between 1958 and 1961,<span class="mw-ref" id="cite_ref-EngelKleemann2014_252-0"><a href="#cite_note-EngelKleemann2014-252" style="counter-reset: mw-Ref 252;"><span class="mw-reflink-text">[252]</span></a></span><span class="mw-ref" id="cite_ref-LandauAchilladelis1999_253-0"><a href="#cite_note-LandauAchilladelis1999-253" style="counter-reset: mw-Ref 253;"><span class="mw-reflink-text">[253]</span></a></span> and was first marketed, as an antimineralocorticoid, in 1959.<span class="mw-ref" id="cite_ref-Jugdutt2014_254-0"><a href="#cite_note-Jugdutt2014-254" style="counter-reset: mw-Ref 254;"><span class="mw-reflink-text">[254]</span></a></span><span class="mw-ref" id="cite_ref-Wermuth2011_255-0"><a href="#cite_note-Wermuth2011-255" style="counter-reset: mw-Ref 255;"><span class="mw-reflink-text">[255]</span></a></span> Gynecomastia was first reported with spironolactone in 1962,<span class="mw-ref" id="cite_ref-pmid28634268_110-7"><a href="#cite_note-pmid28634268-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span><span class="mw-ref" id="cite_ref-Smith1962_256-0"><a href="#cite_note-Smith1962-256" style="counter-reset: mw-Ref 256;"><span class="mw-reflink-text">[256]</span></a></span> and the antiandrogenic activity of the medication was first described in 1969.<span class="mw-ref" id="cite_ref-pmid5344274_257-0"><a href="#cite_note-pmid5344274-257" style="counter-reset: mw-Ref 257;"><span class="mw-reflink-text">[257]</span></a></span> This shortly followed the discovery in 1967 that gynecomastia is an important and major side effect of AR antagonists.<span class="mw-ref" id="cite_ref-pmid148431_258-0"><a href="#cite_note-pmid148431-258" style="counter-reset: mw-Ref 258;"><span class="mw-reflink-text">[258]</span></a></span><span class="mw-ref" id="cite_ref-NeillJohansson1968_259-0"><a href="#cite_note-NeillJohansson1968-259" style="counter-reset: mw-Ref 259;"><span class="mw-reflink-text">[259]</span></a></span> Spironolactone was first studied in the treatment of hirsutism in women in 1978.<span class="mw-ref" id="cite_ref-pmid6205409_260-0"><a href="#cite_note-pmid6205409-260" style="counter-reset: mw-Ref 260;"><span class="mw-reflink-text">[260]</span></a></span><span class="mw-ref" id="cite_ref-pmid27450358_167-2"><a href="#cite_note-pmid27450358-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-pmid717935_261-0"><a href="#cite_note-pmid717935-261" style="counter-reset: mw-Ref 261;"><span class="mw-reflink-text">[261]</span></a></span><span class="mw-ref" id="cite_ref-pmid488407_262-0"><a href="#cite_note-pmid488407-262" style="counter-reset: mw-Ref 262;"><span class="mw-reflink-text">[262]</span></a></span><span class="mw-ref" id="cite_ref-pmid7410528_263-0"><a href="#cite_note-pmid7410528-263" style="counter-reset: mw-Ref 263;"><span class="mw-reflink-text">[263]</span></a></span> It has since become the most widely used antiandrogen for dermatological indications in women in the United States.<span class="mw-ref" id="cite_ref-WakelinMaibach2002_106-1"><a href="#cite_note-WakelinMaibach2002-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span><span class="mw-ref" id="cite_ref-Curtis2014_264-0"><a href="#cite_note-Curtis2014-264" style="counter-reset: mw-Ref 264;"><span class="mw-reflink-text">[264]</span></a></span><span class="mw-ref" id="cite_ref-ShahBhathena2004_265-0"><a href="#cite_note-ShahBhathena2004-265" style="counter-reset: mw-Ref 265;"><span class="mw-reflink-text">[265]</span></a></span><span class="mw-ref" id="cite_ref-Hillard2013_266-0"><a href="#cite_note-Hillard2013-266" style="counter-reset: mw-Ref 266;"><span class="mw-reflink-text">[266]</span></a></span> Spironolactone was first studied as an antiandrogen in transgender women in 1986, and has since become widely adopted for this purpose as well, particularly in the United States where cyproterone acetate is not available.<span class="mw-ref" id="cite_ref-DahlFeldman2006_267-0"><a href="#cite_note-DahlFeldman2006-267" style="counter-reset: mw-Ref 267;"><span class="mw-reflink-text">[267]</span></a></span><span class="mw-ref" id="cite_ref-PriorVigna1986_268-0"><a href="#cite_note-PriorVigna1986-268" style="counter-reset: mw-Ref 268;"><span class="mw-reflink-text">[268]</span></a></span><span class="mw-ref" id="cite_ref-FisherMaggi2015_269-0"><a href="#cite_note-FisherMaggi2015-269" style="counter-reset: mw-Ref 269;"><span class="mw-reflink-text">[269]</span></a></span></p>

<p>Early oral spironolactone tablets showed poor absorption.<span class="mw-ref" id="cite_ref-Dorfman2016_270-0"><a href="#cite_note-Dorfman2016-270" style="counter-reset: mw-Ref 270;"><span class="mw-reflink-text">[270]</span></a></span> The formulation was eventually changed to a micronized formulation with particle sizes of less than 50<span>&nbsp;</span>μg, which resulted in approximately 4-fold increased potency.<span class="mw-ref" id="cite_ref-Dorfman2016_270-1"><a href="#cite_note-Dorfman2016-270" style="counter-reset: mw-Ref 270;"><span class="mw-reflink-text">[270]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generic_names">Generic names</h3></summary>
    
<p>The English, French, and generic name of the medication is <i>spironolactone</i> and this is its <abbr>INN</abbr>, <abbr>USAN</abbr>, <abbr>USP</abbr>, <abbr>BAN</abbr>, <abbr>DCF</abbr>, and <abbr>JAN</abbr>.<span class="mw-ref" id="cite_ref-IndexNominum2000_108-1"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-1"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_240-2"><a href="#cite_note-Elks2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall1999_271-0"><a href="#cite_note-MortonHall1999-271" style="counter-reset: mw-Ref 271;"><span class="mw-reflink-text">[271]</span></a></span> Its name is <i>spironolactonum</i> in Latin, <i>spironolacton</i> in German, <i>espironolactona</i> in Spanish and Portuguese, and <i>spironolattone</i> in Italian (which is also its <abbr>DCIT</abbr>).<span class="mw-ref" id="cite_ref-IndexNominum2000_108-2"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-2"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall1999_271-1"><a href="#cite_note-MortonHall1999-271" style="counter-reset: mw-Ref 271;"><span class="mw-reflink-text">[271]</span></a></span></p>

<p>Spironolactone is also known by its developmental code names <i>SC-9420</i> and <i>NSC-150339</i>.<span class="mw-ref" id="cite_ref-IndexNominum2000_108-3"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-3"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_240-3"><a href="#cite_note-Elks2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>Spironolactone is marketed under a large number of brand names throughout the world.<span class="mw-ref" id="cite_ref-IndexNominum2000_108-4"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-4"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span> The major brand name of spironolactone is Aldactone.<span class="mw-ref" id="cite_ref-IndexNominum2000_108-5"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-5"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span> Other important brand names include Aldactone-A, Berlactone, CaroSpir, Espironolactona, Espironolactona Genfar, Novo-Spiroton, Prilactone (veterinary), Spiractin, Spiridon, Spirix, Spiroctan, Spiroderm (discontinued),<span class="mw-ref" id="cite_ref-FARIDDiamanti-Kandarakis2009_5-2"><a href="#cite_note-FARIDDiamanti-Kandarakis2009-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Spirogamma, Spirohexal, Spirolon, Spirolone, Spiron, Spironolactone Actavis, Spironolactone Orion, Spironolactone Teva, Spirotone, Tempora (veterinary), Uractone, Uractonum, Verospiron, and Vivitar.<span class="mw-ref" id="cite_ref-IndexNominum2000_108-6"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-6"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span></p>

<p>Spironolactone is also formulated in combination with a variety of other medications, including with <a href="Hydrochlorothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrochlorothiazide" title="Hydrochlorothiazide">hydrochlorothiazide</a> as Aldactazide, with <a href="Hydroflumethiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroflumethiazide" title="Hydroflumethiazide">hydroflumethiazide</a> as Aldactide, Lasilacton, Lasilactone, and Spiromide, with altizide as Aldactacine and Aldactazine, with <a href="Furosemide.htm" tppabs="https://ptable.com/wiki/compounds/A/Furosemide" title="Furosemide">furosemide</a> as Fruselac, with <a href="Benazepril.htm" tppabs="https://ptable.com/wiki/compounds/A/Benazepril" title="Benazepril">benazepril</a> as Cardalis (veterinary), with <a href="Metolazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Metolazone" title="Metolazone">metolazone</a> as Metolactone, with <a href="Bendroflumethiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bendroflumethiazide" title="Bendroflumethiazide">bendroflumethiazide</a> as Sali-Aldopur, and with <a href="Torasemide.htm" tppabs="https://ptable.com/wiki/compounds/A/Torasemide" title="Torasemide">torasemide</a> as Dytor Plus, Torlactone, and Zator Plus.<span class="mw-ref" id="cite_ref-Drugs.com_109-7"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Availability">Availability</h3></summary>
    
<p>Spironolactone is marketed widely throughout the world and is available in almost every country, including in the United States, Canada, the United Kingdom, other European countries, Australia, New Zealand, South Africa, Central and South America, and East and Southeast Asia.<span class="mw-ref" id="cite_ref-IndexNominum2000_108-7"><a href="#cite_note-IndexNominum2000-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_109-8"><a href="#cite_note-Drugs.com-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Usage">Usage</h3></summary>
    
<p>There was a total of 17.2<span>&nbsp;</span>million prescriptions for spironolactone in the United States between the beginning of 2003 and the end of 2005.<span class="mw-ref" id="cite_ref-Jjemba2008_272-0"><a href="#cite_note-Jjemba2008-272" style="counter-reset: mw-Ref 272;"><span class="mw-reflink-text">[272]</span></a></span> There was a total of 12.0<span>&nbsp;</span>million prescriptions for spironolactone in the United States in 2016 alone.<span class="mw-ref" id="cite_ref-DrugStats2016_273-0"><a href="#cite_note-DrugStats2016-273" style="counter-reset: mw-Ref 273;"><span class="mw-reflink-text">[273]</span></a></span> It was the 66th top prescribed medication in the United States in 2016.<span class="mw-ref" id="cite_ref-DrugStats2016_273-1"><a href="#cite_note-DrugStats2016-273" style="counter-reset: mw-Ref 273;"><span class="mw-reflink-text">[273]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Prostate_conditions">Prostate conditions</h3></summary>
    
<p>Spironolactone has been studied at a high dosage in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate).<span class="mw-ref" id="cite_ref-Springer2012_274-0"><a href="#cite_note-Springer2012-274" style="counter-reset: mw-Ref 274;"><span class="mw-reflink-text">[274]</span></a></span><span class="mw-ref" id="cite_ref-pmid1702565_275-0"><a href="#cite_note-pmid1702565-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span><span class="mw-ref" id="cite_ref-pmid4104441_276-0"><a href="#cite_note-pmid4104441-276" style="counter-reset: mw-Ref 276;"><span class="mw-reflink-text">[276]</span></a></span> It was found to be better than placebo in terms of symptom relief following three months of treatment.<span class="mw-ref" id="cite_ref-Springer2012_274-1"><a href="#cite_note-Springer2012-274" style="counter-reset: mw-Ref 274;"><span class="mw-reflink-text">[274]</span></a></span><span class="mw-ref" id="cite_ref-pmid1702565_275-1"><a href="#cite_note-pmid1702565-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span> However, this was not maintained after six months of treatment, by which point the improvements had largely disappeared.<span class="mw-ref" id="cite_ref-Springer2012_274-2"><a href="#cite_note-Springer2012-274" style="counter-reset: mw-Ref 274;"><span class="mw-reflink-text">[274]</span></a></span><span class="mw-ref" id="cite_ref-pmid1702565_275-2"><a href="#cite_note-pmid1702565-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span><span class="mw-ref" id="cite_ref-pmid4104441_276-1"><a href="#cite_note-pmid4104441-276" style="counter-reset: mw-Ref 276;"><span class="mw-reflink-text">[276]</span></a></span> Moreover, no difference was observed between spironolactone and placebo with regard to volume of residual urine or prostate size.<span class="mw-ref" id="cite_ref-Springer2012_274-3"><a href="#cite_note-Springer2012-274" style="counter-reset: mw-Ref 274;"><span class="mw-reflink-text">[274]</span></a></span><span class="mw-ref" id="cite_ref-pmid1702565_275-3"><a href="#cite_note-pmid1702565-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span> Gynecomastia was observed in about 5% of people.<span class="mw-ref" id="cite_ref-pmid1702565_275-4"><a href="#cite_note-pmid1702565-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span> On the basis of these results, it has been said that spironolactone has no place in the treatment of BPH.<span class="mw-ref" id="cite_ref-pmid1702565_275-5"><a href="#cite_note-pmid1702565-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span></p>

<p>Spironolactone has been studied and used limitedly in the treatment of prostate cancer.<span class="mw-ref" id="cite_ref-pmid29603164_277-0"><a href="#cite_note-pmid29603164-277" style="counter-reset: mw-Ref 277;"><span class="mw-reflink-text">[277]</span></a></span><span class="mw-ref" id="cite_ref-pmid3540320_278-0"><a href="#cite_note-pmid3540320-278" style="counter-reset: mw-Ref 278;"><span class="mw-reflink-text">[278]</span></a></span><span class="mw-ref" id="cite_ref-EndouHosoyamada1995_28-2"><a href="#cite_note-EndouHosoyamada1995-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Epstein–Barr_virus">Epstein–Barr virus</h3></summary>
    
<p>Spironolactone has been found to block Epstein–Barr virus (EBV) production and that of other human herpesviruses by inhibiting the function of an EBV protein SM, which is essential for infectious virus production.<span class="mw-ref" id="cite_ref-Verma2016_279-0"><a href="#cite_note-Verma2016-279" style="counter-reset: mw-Ref 279;"><span class="mw-reflink-text">[279]</span></a></span> This effect of spironolactone was determined to be independent of its antimineralocorticoid actions.<span class="mw-ref" id="cite_ref-Verma2016_279-1"><a href="#cite_note-Verma2016-279" style="counter-reset: mw-Ref 279;"><span class="mw-reflink-text">[279]</span></a></span> Thus, spironolactone or compounds based on it have the potential to yield novel antiviral medications with a distinct mechanism of action and limited toxicity.<span class="mw-ref" id="cite_ref-Verma2016_279-2"><a href="#cite_note-Verma2016-279" style="counter-reset: mw-Ref 279;"><span class="mw-reflink-text">[279]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Other_conditions">Other conditions</h3></summary>
    
<p>Spironolactone has been studied in the treatment of rosacea in both males and females.<span class="mw-ref" id="cite_ref-pmid15389184_280-0"><a href="#cite_note-pmid15389184-280" style="counter-reset: mw-Ref 280;"><span class="mw-reflink-text">[280]</span></a></span><span class="mw-ref" id="cite_ref-GiurcăneanuMarinescu2016_281-0"><a href="#cite_note-GiurcăneanuMarinescu2016-281" style="counter-reset: mw-Ref 281;"><span class="mw-reflink-text">[281]</span></a></span><span class="mw-ref" id="cite_ref-Wollina2014_282-0"><a href="#cite_note-Wollina2014-282" style="counter-reset: mw-Ref 282;"><span class="mw-reflink-text">[282]</span></a></span><span class="mw-ref" id="cite_ref-pmid9557251_62-1"><a href="#cite_note-pmid9557251-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span><span class="mw-ref" id="cite_ref-pmid23594595_283-0"><a href="#cite_note-pmid23594595-283" style="counter-reset: mw-Ref 283;"><span class="mw-reflink-text">[283]</span></a></span></p>

<p>Spironolactone has been studied in fibromyalgia in women.<span class="mw-ref" id="cite_ref-WernzeHerdegen2014_284-0"><a href="#cite_note-WernzeHerdegen2014-284" style="counter-reset: mw-Ref 284;"><span class="mw-reflink-text">[284]</span></a></span><span class="mw-ref" id="cite_ref-Kalso2014_285-0"><a href="#cite_note-Kalso2014-285" style="counter-reset: mw-Ref 285;"><span class="mw-reflink-text">[285]</span></a></span> It has also been studied in bulimia nervosa in women, but was not found to be effective.<span class="mw-ref" id="cite_ref-pmid22946772_286-0"><a href="#cite_note-pmid22946772-286" style="counter-reset: mw-Ref 286;"><span class="mw-reflink-text">[286]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-LoughlinGenerali2006-1"> <span id="mw-reference-text-cite_note-LoughlinGenerali2006-1" class="mw-reference-text"><cite id="CITEREFKevin_R._LoughlinJoyce_A._Generali2006" class="citation book cs1">Kevin R. Loughlin; Joyce A. Generali (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=fhEFkBxEtH8C&pg=PA131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fhEFkBxEtH8C&pg=PA131'" tppabs="https://books.google.com/books?id=fhEFkBxEtH8C&pg=PA131" class="external text external"><i>The Guide to Off-label Prescription Drugs: New Uses for FDA-approved Prescription Drugs</i></a>. Simon and Schuster. pp.<span>&nbsp;</span>131–. ISBN<span>&nbsp;</span><bdi>978-0-7432-8667-1</bdi>.</cite></span></li><li id="cite_note-ClarkHarvey2011-2"> <span id="mw-reference-text-cite_note-ClarkHarvey2011-2" class="mw-reference-text"><cite id="CITEREFMichelle_A._ClarkRichard_A._HarveyRichard_FinkelJose_A._Rey2011" class="citation book cs1">Michelle A. Clark; Richard A. Harvey; Richard Finkel; Jose A. Rey; Karen Whalen (15 December 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=Y558dgp_PjoC&pg=PA337  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Y558dgp_PjoC&pg=PA337'" tppabs="https://books.google.com/books?id=Y558dgp_PjoC&pg=PA337" class="external text external"><i>Pharmacology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>286, 337. ISBN<span>&nbsp;</span><bdi>978-1-4511-1314-3</bdi>.</cite></span></li><li id="cite_note-Drugs.com_pregnancy-3"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/spironolactone.html'" tppabs="https://www.drugs.com/pregnancy/spironolactone.html" class="external text external">"Spironolactone Pregnancy and Breastfeeding Warnings"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20151202081203/http://www.drugs.com/pregnancy/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151202081203/http://www.drugs.com/pregnancy/spironolactone.html'" tppabs="https://web.archive.org/web/20151202081203/http://www.drugs.com/pregnancy/spironolactone.html" class="external text external">Archived</a> from the original on 2 December 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">29 November</span> 2015</span>.</cite></span></li><li id="cite_note-AHFS2015-4"> <span id="mw-reference-text-cite_note-AHFS2015-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/spironolactone.html'" tppabs="https://www.drugs.com/monograph/spironolactone.html" class="external text external">"Spironolactone"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20151116054857/http://www.drugs.com/monograph/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151116054857/http://www.drugs.com/monograph/spironolactone.html'" tppabs="https://web.archive.org/web/20151116054857/http://www.drugs.com/monograph/spironolactone.html" class="external text external">Archived</a> from the original on 16 November 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">24 October</span> 2015</span>.</cite></span></li><li id="cite_note-FARIDDiamanti-Kandarakis2009-5"> <span id="mw-reference-text-cite_note-FARIDDiamanti-Kandarakis2009-5" class="mw-reference-text"><cite id="CITEREFNADIR_R._FARIDEvanthia_Diamanti-Kandarakis2009" class="citation book cs1">NADIR R. FARID; Evanthia Diamanti-Kandarakis (27 February 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=fgMYVxmPDnMC&pg=PA235  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fgMYVxmPDnMC&pg=PA235'" tppabs="https://books.google.com/books?id=fgMYVxmPDnMC&pg=PA235" class="external text external"><i>Diagnosis and Management of Polycystic Ovary Syndrome</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>235–. ISBN<span>&nbsp;</span><bdi>978-0-387-09718-3</bdi>.</cite></span></li><li id="cite_note-Sica2005-6"> <span id="mw-reference-text-cite_note-Sica2005-6" class="mw-reference-text"><cite id="CITEREFSica2005" class="citation journal cs1">Sica, Domenic A. (2005). "Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis". <i>Heart Failure Reviews</i>. <b>10</b> (1): 23–29. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10741-005-2345-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10741-005-2345-1'" tppabs="https://doi.org/10.1007%2Fs10741-005-2345-1" class="external text external">10.1007/s10741-005-2345-1</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1382-4147  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1382-4147'" tppabs="https://www.worldcat.org/issn/1382-4147" class="external text external">1382-4147</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15947888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15947888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15947888" class="external text external">15947888</a>.</cite></span></li><li id="cite_note-pmid18729003-7"> <span id="mw-reference-text-cite_note-pmid18729003-7" class="mw-reference-text"><cite id="CITEREFMaronLeopold2008" class="citation journal cs1">Maron BA, Leopold JA (2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967484  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967484'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967484" class="external text external">"Mineralocorticoid receptor antagonists and endothelial function"</a>. <i>Curr Opin Investig Drugs</i>. <b>9</b> (9): 963–9. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967484  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967484'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967484" class="external text external">2967484</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18729003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18729003'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18729003" class="external text external">18729003</a>.</cite></span></li><li id="cite_note-CaroneOxberry2017-8"> <span id="mw-reference-text-cite_note-CaroneOxberry2017-8" class="mw-reference-text"><cite id="CITEREFCaroneOxberryTwycrossCharlesworth2017" class="citation journal cs1">Carone, Laura; Oxberry, Stephen G.; Twycross, Robert; Charlesworth, Sarah; Mihalyo, Mary; Wilcock, Andrew (2017). "Spironolactone". <i>Journal of Pain and Symptom Management</i>. <b>53</b> (2): 288–292. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jpainsymman.2016.12.320  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jpainsymman.2016.12.320'" tppabs="https://doi.org/10.1016%2Fj.jpainsymman.2016.12.320" class="external text external">10.1016/j.jpainsymman.2016.12.320</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0885-3924  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0885-3924'" tppabs="https://www.worldcat.org/issn/0885-3924" class="external text external">0885-3924</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28024992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28024992'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28024992" class="external text external">28024992</a>.</cite></span></li><li id="cite_note-TakamuraMaruyama1997-9"> <span id="mw-reference-text-cite_note-TakamuraMaruyama1997-9" class="mw-reference-text"><cite id="CITEREFTakamuraMaruyamaAhmedSuenaga1997" class="citation journal cs1">Takamura, Norito; Maruyama, Toru; Ahmed, Shamim; Suenaga, Ayaka; Otagiri, Masaki (1997). "Interactions of Aldosterone Antagonist Diuretics with Human Serum Proteins". <i>Pharmaceutical Research</i>. <b>14</b> (4): 522–526. doi:<a href="javascript:if(confirm('https://doi.org/10.1023%2FA%3A1012168020545  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1023%2FA%3A1012168020545'" tppabs="https://doi.org/10.1023%2FA%3A1012168020545" class="external text external">10.1023/A:1012168020545</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0724-8741  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0724-8741'" tppabs="https://www.worldcat.org/issn/0724-8741" class="external text external">0724-8741</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9144743  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9144743'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9144743" class="external text external">9144743</a>.</cite></span></li><li id="cite_note-Parkinson2001-10"> <span id="mw-reference-text-cite_note-Parkinson2001-10" class="mw-reference-text"><cite id="CITEREFAndrew_Parkinson2001" class="citation book cs1">Andrew Parkinson (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=pAovcgAACAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=pAovcgAACAAJ'" tppabs="https://books.google.com/books?id=pAovcgAACAAJ" class="external text external"><i>Biotransformation of Xenobiotics</i></a>. McGraw-Hill. pp.<span>&nbsp;</span>137–138, 169, 171, 180, 195, 208.</cite></span></li><li id="cite_note-Klaassen2007-11"> <span id="mw-reference-text-cite_note-Klaassen2007-11" class="mw-reference-text"><cite id="CITEREFCurtis_D._Klaassen2007" class="citation book cs1">Curtis D. Klaassen (11 December 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=4yi7-j48uhIC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4yi7-j48uhIC'" tppabs="https://books.google.com/books?id=4yi7-j48uhIC" class="external text external"><i>Casarett &amp; Doull's Toxicology: The Basic Science of Poisons, Seventh Edition</i></a>. McGraw Hill Professional. p.<span>&nbsp;</span>173. ISBN<span>&nbsp;</span><bdi>978-0-07-159351-9</bdi>. <q>Some P450 enzymes (such as the rate enzyme CYP2A1) preferentially catalyze the 6α-hydroxylation reaction, whereas other P450 enzymes (such as the CYP3A enzymes in all mammalian species) preferentially catalyze the 6β-hydroxylation reaction (which is a major route of hepatic steroid biotransformation).</q></cite></span></li><li id="cite_note-pmid7895608-12"> <span id="mw-reference-text-cite_note-pmid7895608-12" class="mw-reference-text"><cite id="CITEREFLosPitzenbergerRamjitCoddington1994" class="citation journal cs1">Los LE, Pitzenberger SM, Ramjit HG, Coddington AB, Colby HD (1994). <a href="javascript:if(confirm('http://dmd.aspetjournals.org/content/22/6/903  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://dmd.aspetjournals.org/content/22/6/903'" tppabs="http://dmd.aspetjournals.org/content/22/6/903" class="external text external">"Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites"</a>. <i>Drug Metab. Dispos</i>. <b>22</b> (6): 903–8. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7895608  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7895608'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7895608" class="external text external">7895608</a>.</cite></span></li><li id="cite_note-BlackElliott2006-13"> <span id="mw-reference-text-cite_note-BlackElliott2006-13" class="mw-reference-text"><cite id="CITEREFHenry_R._BlackWilliam_Elliott2006" class="citation book cs1">Henry R. Black; William Elliott (28 December 2006). <a href="javascript:if(confirm('https://books.google.com/books?id=42Fcmne6_w8C&pg=PA295  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=42Fcmne6_w8C&pg=PA295'" tppabs="https://books.google.com/books?id=42Fcmne6_w8C&pg=PA295" class="external text external"><i>Hypertension: A Companion to Braunwald's Heart Disease</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>295–. ISBN<span>&nbsp;</span><bdi>978-1-4377-1078-6</bdi>.</cite></span></li><li id="cite_note-pmid14579013-14"> <span id="mw-reference-text-cite_note-pmid14579013-14" class="mw-reference-text"><cite id="CITEREFDraganovLa_Du2004" class="citation journal cs1">Draganov DI, La Du BN (January 2004). "Pharmacogenetics of paraoxonases: a brief review". <i>Naunyn Schmiedebergs Arch. Pharmacol</i>. <b>369</b> (1): 78–88. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00210-003-0833-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00210-003-0833-1'" tppabs="https://doi.org/10.1007%2Fs00210-003-0833-1" class="external text external">10.1007/s00210-003-0833-1</a>. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/2027.42%2F46312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/2027.42%2F46312'" tppabs="https://hdl.handle.net/2027.42%2F46312" class="external text external">2027.42/46312</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14579013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14579013'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14579013" class="external text external">14579013</a>.</cite></span></li><li id="cite_note-SzaszBudvari-Barany1990-15"> <span id="mw-reference-text-cite_note-SzaszBudvari-Barany1990-15" class="mw-reference-text"><cite id="CITEREFGyorgy_SzaszZsuzsanna_Budvari-Barany1990" class="citation book cs1">Gyorgy Szasz; Zsuzsanna Budvari-Barany (19 December 1990). <a href="javascript:if(confirm('https://books.google.com/books?id=LMl4Sd38q4kC&pg=PA91  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=LMl4Sd38q4kC&pg=PA91'" tppabs="https://books.google.com/books?id=LMl4Sd38q4kC&pg=PA91" class="external text external"><i>Pharmaceutical Chemistry of Antihypertensive Agents</i></a>. CRC Press. pp.<span>&nbsp;</span>91–. ISBN<span>&nbsp;</span><bdi>978-0-8493-4724-5</bdi>.</cite></span></li><li id="cite_note-McDonaghGardner2011-16"> <span id="mw-reference-text-cite_note-McDonaghGardner2011-16" class="mw-reference-text"><cite id="CITEREFTheresa_A._McDonaghRoy_S._GardnerAndrew_L._ClarkHenry_Dargie2011" class="citation book cs1">Theresa A. McDonagh; Roy S. Gardner; Andrew L. Clark; Henry Dargie (14 July 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=KDDCiTQyGLsC&pg=PA403  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KDDCiTQyGLsC&pg=PA403'" tppabs="https://books.google.com/books?id=KDDCiTQyGLsC&pg=PA403" class="external text external"><i>Oxford Textbook of Heart Failure</i></a>. OUP Oxford. pp.<span>&nbsp;</span>403–. ISBN<span>&nbsp;</span><bdi>978-0-19-957772-9</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170327090209/https://books.google.com/books?id=KDDCiTQyGLsC&pg=PA403  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170327090209/https://books.google.com/books?id=KDDCiTQyGLsC&pg=PA403'" tppabs="https://web.archive.org/web/20170327090209/https://books.google.com/books?id=KDDCiTQyGLsC&pg=PA403" class="external text external">Archived</a> from the original on 27 March 2017.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFFriedman2015" class="citation journal cs1">Friedman, Adam J. (1 October 2015). "Spironolactone for Adult Female Acne". <i>Cutis</i>. <b>96</b> (4): 216–217. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2326-6929  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2326-6929'" tppabs="https://www.worldcat.org/issn/2326-6929" class="external text external">2326-6929</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27141564  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27141564'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27141564" class="external text external">27141564</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFMaizes2015" class="citation book cs1">Maizes, Victoria (2015). <a href="javascript:if(confirm('https://books.google.com/books?id=uveJCgAAQBAJ&pg=PA746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=uveJCgAAQBAJ&pg=PA746'" tppabs="https://books.google.com/books?id=uveJCgAAQBAJ&pg=PA746" class="external text external"><i>Integrative Women's Health</i></a> (2 ed.). p.<span>&nbsp;</span>746. ISBN<span>&nbsp;</span><bdi>9780190214807</bdi>.</cite></span></li><li id="cite_note-Deedwania2014-19"> <span id="mw-reference-text-cite_note-Deedwania2014-19" class="mw-reference-text"><cite id="CITEREFPrakash_C_Deedwania2014" class="citation book cs1">Prakash C Deedwania (30 January 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=k8bUAgAAQBAJ&pg=PA47  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=k8bUAgAAQBAJ&pg=PA47'" tppabs="https://books.google.com/books?id=k8bUAgAAQBAJ&pg=PA47" class="external text external"><i>Drug &amp; Device Selection in Heart Failure</i></a>. JP Medical Ltd. pp.<span>&nbsp;</span>47–. ISBN<span>&nbsp;</span><bdi>978-93-5090-723-8</bdi>.</cite></span></li><li id="cite_note-OttowWeinmann2008-20"> <span id="mw-reference-text-cite_note-OttowWeinmann2008-20" class="mw-reference-text"><cite id="CITEREFEckhard_OttowHilmar_Weinmann2008" class="citation book cs1">Eckhard Ottow; Hilmar Weinmann (9 July 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=iATfLbPgRugC&pg=PA410  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=iATfLbPgRugC&pg=PA410'" tppabs="https://books.google.com/books?id=iATfLbPgRugC&pg=PA410" class="external text external"><i>Nuclear Receptors As Drug Targets</i></a>. John Wiley &amp; Sons. p.<span>&nbsp;</span>410. ISBN<span>&nbsp;</span><bdi>978-3-527-62330-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130621121614/http://books.google.com/books?id=iATfLbPgRugC&pg=PA410  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130621121614/http://books.google.com/books?id=iATfLbPgRugC&pg=PA410'" tppabs="https://web.archive.org/web/20130621121614/http://books.google.com/books?id=iATfLbPgRugC&pg=PA410" class="external text external">Archived</a> from the original on 21 June 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">28 May</span> 2012</span>.</cite></span></li><li id="cite_note-Wermuth2008-21"> <span id="mw-reference-text-cite_note-Wermuth2008-21" class="mw-reference-text"><cite id="CITEREFCamille_Georges_Wermuth2008" class="citation book cs1">Camille Georges Wermuth (24 July 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34'" tppabs="https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34" class="external text external"><i>The Practice of Medicinal Chemistry</i></a>. Academic Press. p.<span>&nbsp;</span>34. ISBN<span>&nbsp;</span><bdi>978-0-12-374194-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130621115634/http://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130621115634/http://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34'" tppabs="https://web.archive.org/web/20130621115634/http://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34" class="external text external">Archived</a> from the original on 21 June 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">27 May</span> 2012</span>.</cite></span></li><li id="cite_note-Sittig1988-22"> <span id="mw-reference-text-cite_note-Sittig1988-22" class="mw-reference-text"><cite id="CITEREFMarshall_Sittig1988" class="citation book cs1">Marshall Sittig (1988). <a href="javascript:if(confirm('https://books.google.com/books?id=XCsJgUnclbcC&pg=PA1385  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=XCsJgUnclbcC&pg=PA1385'" tppabs="https://books.google.com/books?id=XCsJgUnclbcC&pg=PA1385" class="external text external"><i>Pharmaceutical Manufacturing Encyclopedia</i></a>. William Andrew. p.<span>&nbsp;</span>1385. ISBN<span>&nbsp;</span><bdi>978-0-8155-1144-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130620225714/http://books.google.com/books?id=XCsJgUnclbcC&pg=PA1385  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130620225714/http://books.google.com/books?id=XCsJgUnclbcC&pg=PA1385'" tppabs="https://web.archive.org/web/20130620225714/http://books.google.com/books?id=XCsJgUnclbcC&pg=PA1385" class="external text external">Archived</a> from the original on 20 June 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">27 May</span> 2012</span>.</cite></span></li><li id="cite_note-WHO21st-23"> <span id="mw-reference-text-cite_note-WHO21st-23" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/Spironolactone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/Spironolactone'" tppabs="https://clincalc.com/DrugStats/Drugs/Spironolactone" class="external text external">"Spironolactone - Drug Usage Statistics"</a>. <i>ClinCalc</i>. 23 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-RoncoBellomo2017-26"> <span id="mw-reference-text-cite_note-RoncoBellomo2017-26" class="mw-reference-text"><cite id="CITEREFClaudio_RoncoRinaldo_BellomoJohn_A._KellumZaccaria_Ricci2017" class="citation book cs1">Claudio Ronco; Rinaldo Bellomo; John A. Kellum; Zaccaria Ricci (14 December 2017). <a href="javascript:if(confirm('https://books.google.com/books?id=HTdDDwAAQBAJ&pg=PA371  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=HTdDDwAAQBAJ&pg=PA371'" tppabs="https://books.google.com/books?id=HTdDDwAAQBAJ&pg=PA371" class="external text external"><i>Critical Care Nephrology E-Book</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>371–. ISBN<span>&nbsp;</span><bdi>978-0-323-51199-5</bdi>.</cite></span></li><li id="cite_note-pmid10760075-27"> <span id="mw-reference-text-cite_note-pmid10760075-27" class="mw-reference-text"><cite id="CITEREFDelyani2000" class="citation journal cs1">Delyani JA (April 2000). "Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology". <i>Kidney Int</i>. <b>57</b> (4): 1408–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1523-1755.2000.00983.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1523-1755.2000.00983.x'" tppabs="https://doi.org/10.1046%2Fj.1523-1755.2000.00983.x" class="external text external">10.1046/j.1523-1755.2000.00983.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10760075  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10760075'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10760075" class="external text external">10760075</a>. <q>When spironolactone was developed nearly 30 years ago, the scientific study of aldosterone was limited to effects on epithelial ion transport, and even this knowledge was in its infancy. As a result, spironolactone was classified as a potassium-sparing diuretic. Given that the compelling evidence of the role of aldosterone in the pathophysiology of cardiovascular disease extends beyond ion transport, this classification is presently obsolete.</q></cite></span></li><li id="cite_note-EndouHosoyamada1995-28"> <span id="mw-reference-text-cite_note-EndouHosoyamada1995-28" class="mw-reference-text"><cite id="CITEREFEndouHosoyamada1995" class="citation book cs1">Endou, H.; Hosoyamada, M. (1995). "Potassium-Retaining Diuretics: Aldosterone Antagonists". <i>Diuretics</i>. Handbook of Experimental Pharmacology. <b>117</b>. pp.<span>&nbsp;</span>335–361. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-642-79565-7_9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-642-79565-7_9'" tppabs="https://doi.org/10.1007%2F978-3-642-79565-7_9" class="external text external">10.1007/978-3-642-79565-7_9</a>. ISBN<span>&nbsp;</span><bdi>978-3-642-79567-1</bdi>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0171-2004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0171-2004'" tppabs="https://www.worldcat.org/issn/0171-2004" class="external text external">0171-2004</a>.</cite></span></li><li id="cite_note-pmid2969259-29"> <span id="mw-reference-text-cite_note-pmid2969259-29" class="mw-reference-text"><cite id="CITEREFHughesCunliffe1988" class="citation journal cs1">Hughes BR, Cunliffe WJ (May 1988). "Tolerance of spironolactone". <i>The British Journal of Dermatology</i>. <b>118</b> (5): 687–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2133.1988.tb02571.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2133.1988.tb02571.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2133.1988.tb02571.x" class="external text external">10.1111/j.1365-2133.1988.tb02571.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2969259  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2969259'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2969259" class="external text external">2969259</a>.</cite></span></li><li id="cite_note-Preedy2012-30"> <span id="mw-reference-text-cite_note-Preedy2012-30" class="mw-reference-text"><cite id="CITEREFVictor_R._Preedy2012" class="citation book cs1">Victor R. Preedy (1 January 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=7N3nEX6eL_MC&pg=PA132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7N3nEX6eL_MC&pg=PA132'" tppabs="https://books.google.com/books?id=7N3nEX6eL_MC&pg=PA132" class="external text external"><i>Handbook of Hair in Health and Disease</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>132–. ISBN<span>&nbsp;</span><bdi>978-90-8686-728-8</bdi>.</cite></span></li><li id="cite_note-pmid3143568-31"> <span id="mw-reference-text-cite_note-pmid3143568-31" class="mw-reference-text"><cite id="CITEREFLoySeibel1988" class="citation journal cs1">Loy R, Seibel MM (December 1988). "Evaluation and therapy of polycystic ovarian syndrome". <i>Endocrinology and Metabolism Clinics of North America</i>. <b>17</b> (4): 785–813. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0889-8529%2818%2930410-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0889-8529%2818%2930410-9'" tppabs="https://doi.org/10.1016%2FS0889-8529%2818%2930410-9" class="external text external">10.1016/S0889-8529(18)30410-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3143568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3143568'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3143568" class="external text external">3143568</a>.</cite></span></li><li id="cite_note-Yancy_e147-239-32"> <span id="mw-reference-text-cite_note-Yancy_e147-239-32" class="mw-reference-text"><cite id="CITEREFYancyJessupBozkurtButler2013" class="citation journal cs1">Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,  American College of Cardiology, Foundation; American Heart Association Task Force on Practice, Guidelines (15 October 2013). "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". <i>Journal of the American College of Cardiology</i>. <b>62</b> (16): e147–239. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2013.05.019  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2013.05.019'" tppabs="https://doi.org/10.1016%2Fj.jacc.2013.05.019" class="external text external">10.1016/j.jacc.2013.05.019</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23747642  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23747642'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23747642" class="external text external">23747642</a>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFPittZannadRemmeCody1999" class="citation journal cs1">Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999). <a href="javascript:if(confirm('https://semanticscholar.org/paper/78058c51ef390c715b72cf5bf8339ce4c8d5646b  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/78058c51ef390c715b72cf5bf8339ce4c8d5646b'" tppabs="https://semanticscholar.org/paper/78058c51ef390c715b72cf5bf8339ce4c8d5646b" class="external text external">"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators"</a>. <i>N Engl J Med</i>. <b>341</b> (10): 709–17. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM199909023411001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM199909023411001'" tppabs="https://doi.org/10.1056%2FNEJM199909023411001" class="external text external">10.1056/NEJM199909023411001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10471456  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10471456'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10471456" class="external text external">10471456</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite id="CITEREFPittPfefferAssmannBoineau2014" class="citation journal cs1">Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (10 April 2014). <a href="javascript:if(confirm('http://espace.library.uq.edu.au/view/UQ:406430/UQ406430_OA.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://espace.library.uq.edu.au/view/UQ:406430/UQ406430_OA.pdf'" tppabs="http://espace.library.uq.edu.au/view/UQ:406430/UQ406430_OA.pdf" class="external text external">"Spironolactone for heart failure with preserved ejection fraction"</a> <span class="cs1-format">(PDF)</span>. <i>The New England Journal of Medicine</i>. <b>370</b> (15): 1383–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2Fnejmoa1313731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2Fnejmoa1313731'" tppabs="https://doi.org/10.1056%2Fnejmoa1313731" class="external text external">10.1056/nejmoa1313731</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24716680  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24716680'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24716680" class="external text external">24716680</a>.</cite></span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text"><cite id="CITEREFPitt_B.2014" class="citation journal cs1">Pitt B.;  et al. (2014). <a href="javascript:if(confirm('http://content.nejm.org/cgi/content/full/370/15/709  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://content.nejm.org/cgi/content/full/370/15/709'" tppabs="http://content.nejm.org/cgi/content/full/370/15/709" class="external text external">"Spironolactone for Heart Failure with Preserved Ejection Fraction"</a>. <i>N Engl J Med</i>. <b>370</b> (15): 1383–1392. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa1313731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa1313731'" tppabs="https://doi.org/10.1056%2FNEJMoa1313731" class="external text external">10.1056/NEJMoa1313731</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24716680  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24716680'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24716680" class="external text external">24716680</a>.</cite></span></li><li id="cite_note-Pfeffer_posthoc-36"> <span id="mw-reference-text-cite_note-Pfeffer_posthoc-36" class="mw-reference-text"><cite id="CITEREFPfefferde_DenusDesaiLeclair2017" class="citation journal cs1">Pfeffer, Marc; de Denus, Simon; Desai, Akshay; Leclair, Gregoire; Pitt, Bertram; Solomon, Scott; Lavoie, Joel; Rouleau, Jean; O'Meara, Eileen (2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590224  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590224'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590224" class="external text external">"Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation"</a>. <i>N Engl J Med</i>. <b>376</b> (17): 1690–1692. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMc1612601  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMc1612601'" tppabs="https://doi.org/10.1056%2FNEJMc1612601" class="external text external">10.1056/NEJMc1612601</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590224  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590224'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590224" class="external text external">5590224</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28445660  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28445660'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28445660" class="external text external">28445660</a>.</cite></span></li><li id="cite_note-CardioBrief-37"> <span id="mw-reference-text-cite_note-CardioBrief-37" class="mw-reference-text"><cite id="CITEREFHusten2017" class="citation web cs1">Husten, Larry (27 April 2017) [2017]. <a href="javascript:if(confirm('http://cardiobrief.org/2017/04/26/serious-questions-raised-about-integrity-of-international-trials/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://cardiobrief.org/2017/04/26/serious-questions-raised-about-integrity-of-international-trials/'" tppabs="http://cardiobrief.org/2017/04/26/serious-questions-raised-about-integrity-of-international-trials/" class="external text external">"Serious Questions Raised About Integrity Of International Trials"</a>. <i>CardioBrief.org</i>.</cite></span></li><li id="cite_note-pmid22840667-38"> <span id="mw-reference-text-cite_note-pmid22840667-38" class="mw-reference-text"><cite id="CITEREFChatterjeeMoellerShahBolorunduro2012" class="citation journal cs1">Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, Mukherjee D (2012). "Eplerenone is not superior to older and less expensive aldosterone antagonists". <i>Am. J. Med</i>. <b>125</b> (8): 817–25. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.amjmed.2011.12.018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.amjmed.2011.12.018'" tppabs="https://doi.org/10.1016%2Fj.amjmed.2011.12.018" class="external text external">10.1016/j.amjmed.2011.12.018</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22840667  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22840667'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22840667" class="external text external">22840667</a>.</cite></span></li><li id="cite_note-Bat2010-39"> <span id="mw-reference-text-cite_note-Bat2010-39" class="mw-reference-text"><cite id="CITEREFBatterinkStablerTejaniFowkes2010" class="citation journal cs1">Batterink, J; Stabler, SN; Tejani, AM; Fowkes, CT (4 August 2010). "Spironolactone for hypertension". <i>The Cochrane Database of Systematic Reviews</i> (8): CD008169. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD008169.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD008169.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD008169.pub2" class="external text external">10.1002/14651858.CD008169.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20687095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20687095'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20687095" class="external text external">20687095</a>.</cite></span></li><li id="cite_note-pmid15507105-40"> <span id="mw-reference-text-cite_note-pmid15507105-40" class="mw-reference-text"><cite id="CITEREFZouboulisDegitz2004" class="citation journal cs1">Zouboulis CC, Degitz K (2004). "Androgen action on human skin -- from basic research to clinical significance". <i>Exp. Dermatol</i>. 13 Suppl 4: 5–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1600-0625.2004.00255.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1600-0625.2004.00255.x'" tppabs="https://doi.org/10.1111%2Fj.1600-0625.2004.00255.x" class="external text external">10.1111/j.1600-0625.2004.00255.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15507105  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15507105'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15507105" class="external text external">15507105</a>.</cite></span></li><li id="cite_note-pmid28979664-41"> <span id="mw-reference-text-cite_note-pmid28979664-41" class="mw-reference-text"><cite id="CITEREFEndlyMiller2017" class="citation journal cs1">Endly DC, Miller RA (August 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605215  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605215'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605215" class="external text external">"Oily Skin: A review of Treatment Options"</a>. <i>J Clin Aesthet Dermatol</i>. <b>10</b> (8): 49–55. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605215  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605215'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605215" class="external text external">5605215</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28979664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28979664'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28979664" class="external text external">28979664</a>.</cite></span></li><li id="cite_note-ShalitaRosso2011-42"> <span id="mw-reference-text-cite_note-ShalitaRosso2011-42" class="mw-reference-text"><cite id="CITEREFAlan_R._ShalitaJames_Q._Del_RossoGuy_Webster2011" class="citation book cs1">Alan R. Shalita; James Q. Del Rosso; Guy Webster (21 March 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=CIPOBQAAQBAJ&pg=PA33  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=CIPOBQAAQBAJ&pg=PA33'" tppabs="https://books.google.com/books?id=CIPOBQAAQBAJ&pg=PA33" class="external text external"><i>Acne Vulgaris</i></a>. CRC Press. pp.<span>&nbsp;</span>33–. ISBN<span>&nbsp;</span><bdi>978-1-61631-009-7</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20161209210819/https://books.google.com/books?id=CIPOBQAAQBAJ&pg=PA33  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161209210819/https://books.google.com/books?id=CIPOBQAAQBAJ&pg=PA33'" tppabs="https://web.archive.org/web/20161209210819/https://books.google.com/books?id=CIPOBQAAQBAJ&pg=PA33" class="external text external">Archived</a> from the original on 9 December 2016.</cite></span></li><li id="cite_note-ZouboulisKatsambas2014-43"> <span id="mw-reference-text-cite_note-ZouboulisKatsambas2014-43" class="mw-reference-text"><cite id="CITEREFChristos_C._ZouboulisAndreas_D._KatsambasAlbert_M._Kligman2014" class="citation book cs1">Christos C. Zouboulis; Andreas D. Katsambas; Albert M. Kligman (28 July 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=vnQqBAAAQBAJ&pg=PA121  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vnQqBAAAQBAJ&pg=PA121'" tppabs="https://books.google.com/books?id=vnQqBAAAQBAJ&pg=PA121" class="external text external"><i>Pathogenesis and Treatment of Acne and Rosacea</i></a>. Springer. pp.<span>&nbsp;</span>121–. ISBN<span>&nbsp;</span><bdi>978-3-540-69375-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20161210040108/https://books.google.com/books?id=vnQqBAAAQBAJ&pg=PA121  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161210040108/https://books.google.com/books?id=vnQqBAAAQBAJ&pg=PA121'" tppabs="https://web.archive.org/web/20161210040108/https://books.google.com/books?id=vnQqBAAAQBAJ&pg=PA121" class="external text external">Archived</a> from the original on 10 December 2016.</cite></span></li><li id="cite_note-pmid16985920-44"> <span id="mw-reference-text-cite_note-pmid16985920-44" class="mw-reference-text"><cite id="CITEREFMarks2004" class="citation journal cs1">Marks LS (2004). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472916  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472916'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472916" class="external text external">"5alpha-reductase: history and clinical importance"</a>. <i>Rev Urol</i>. 6 Suppl 9: S11–21. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472916  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472916'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472916" class="external text external">1472916</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16985920  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16985920'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16985920" class="external text external">16985920</a>.</cite></span></li><li id="cite_note-Sloane2002-45"> <span id="mw-reference-text-cite_note-Sloane2002-45" class="mw-reference-text"><cite id="CITEREFEthel_Sloane2002" class="citation book cs1">Ethel Sloane (2002). <a href="javascript:if(confirm('https://books.google.com/books?id=kqcYyk7zlHYC&pg=PA160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=kqcYyk7zlHYC&pg=PA160'" tppabs="https://books.google.com/books?id=kqcYyk7zlHYC&pg=PA160" class="external text external"><i>Biology of Women</i></a>. Cengage Learning. pp.<span>&nbsp;</span>160–. ISBN<span>&nbsp;</span><bdi>978-0-7668-1142-3</bdi>.</cite></span></li><li id="cite_note-HannoGuzzo2014-46"> <span id="mw-reference-text-cite_note-HannoGuzzo2014-46" class="mw-reference-text"><cite id="CITEREFPhilip_M_HannoThomas_J._GuzzoS._Bruce_MalkowiczAlan_J._Wein2014" class="citation book cs1">Philip M Hanno; Thomas J. Guzzo; S. Bruce Malkowicz; Alan J. Wein (26 January 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=OQTbAgAAQBAJ&pg=PA782  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=OQTbAgAAQBAJ&pg=PA782'" tppabs="https://books.google.com/books?id=OQTbAgAAQBAJ&pg=PA782" class="external text external"><i>Penn Clinical Manual of Urology E-Book: Expert Consult - Online</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>782–. ISBN<span>&nbsp;</span><bdi>978-0-323-24466-4</bdi>.</cite></span></li><li id="cite_note-Harper2007-47"> <span id="mw-reference-text-cite_note-Harper2007-47" class="mw-reference-text"><cite id="CITEREFCatherine_Harper2007" class="citation book cs1">Catherine Harper (1 August 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=fM6vAwAAQBAJ&pg=PA123  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fM6vAwAAQBAJ&pg=PA123'" tppabs="https://books.google.com/books?id=fM6vAwAAQBAJ&pg=PA123" class="external text external"><i>Intersex</i></a>. Berg. pp.<span>&nbsp;</span>123–. ISBN<span>&nbsp;</span><bdi>978-1-84788-339-1</bdi>.</cite></span></li><li id="cite_note-Blume-PeytaviWhiting2008-48"> <span id="mw-reference-text-cite_note-Blume-PeytaviWhiting2008-48" class="mw-reference-text"><cite id="CITEREFUlrike_Blume-PeytaviDavid_A._WhitingRalph_M._Trüeb2008" class="citation book cs1">Ulrike Blume-Peytavi; David A. Whiting; Ralph M. Trüeb (26 June 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=pHrX2-huQCoC&pg=PA161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=pHrX2-huQCoC&pg=PA161'" tppabs="https://books.google.com/books?id=pHrX2-huQCoC&pg=PA161" class="external text external"><i>Hair Growth and Disorders</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>161–162. ISBN<span>&nbsp;</span><bdi>978-3-540-46911-7</bdi>.</cite></span></li><li id="cite_note-pmid9420861-49"> <span id="mw-reference-text-cite_note-pmid9420861-49" class="mw-reference-text"><cite id="CITEREFDiamanti-KandarakisTolisDuleba1995" class="citation journal cs1">Diamanti-Kandarakis E, Tolis G, Duleba AJ (1995). "Androgens and therapeutic aspects of antiandrogens in women". <i>J. Soc. Gynecol. Investig</i>. <b>2</b> (4): 577–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F107155769500200401  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F107155769500200401'" tppabs="https://doi.org/10.1177%2F107155769500200401" class="external text external">10.1177/107155769500200401</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9420861  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9420861'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9420861" class="external text external">9420861</a>.</cite></span></li><li id="cite_note-pmid20082945-50"> <span id="mw-reference-text-cite_note-pmid20082945-50" class="mw-reference-text"><cite id="CITEREFKatsambasDessinioti2010" class="citation journal cs1">Katsambas AD, Dessinioti C (2010). "Hormonal therapy for acne: why not as first line therapy? facts and controversies". <i>Clin. Dermatol</i>. <b>28</b> (1): 17–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.clindermatol.2009.03.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.clindermatol.2009.03.006'" tppabs="https://doi.org/10.1016%2Fj.clindermatol.2009.03.006" class="external text external">10.1016/j.clindermatol.2009.03.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20082945  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20082945'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20082945" class="external text external">20082945</a>.</cite></span></li><li id="cite_note-pmid22468178-51"> <span id="mw-reference-text-cite_note-pmid22468178-51" class="mw-reference-text"><cite id="CITEREFKimDel_Rosso2012" class="citation journal cs1">Kim, Grace; Del Rosso, James (March 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315877  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315877'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315877" class="external text external">"Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris"</a>. <i>J Clinical and Aesthetic Dermatology</i>. <b>5</b> (3): 37–50. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315877  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315877'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315877" class="external text external">3315877</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22468178  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22468178'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22468178" class="external text external">22468178</a>.</cite></span></li><li id="cite_note-pmid28155090-52"> <span id="mw-reference-text-cite_note-pmid28155090-52" class="mw-reference-text"><cite id="CITEREFLaytonEadyWhitehouseDel_Rosso2017" class="citation journal cs1">Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ (April 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360829  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360829'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360829" class="external text external">"Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review"</a>. <i>Am J Clin Dermatol</i>. <b>18</b> (2): 169–191. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40257-016-0245-x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40257-016-0245-x'" tppabs="https://doi.org/10.1007%2Fs40257-016-0245-x" class="external text external">10.1007/s40257-016-0245-x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360829  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360829'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360829" class="external text external">5360829</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28155090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28155090'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28155090" class="external text external">28155090</a>.</cite></span></li><li id="cite_note-pmid26897386-53"> <span id="mw-reference-text-cite_note-pmid26897386-53" class="mw-reference-text"><cite id="CITEREFZaengleinPathySchlosserAlikhan2016" class="citation journal cs1">Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R (2016). "Guidelines of care for the management of acne vulgaris". <i>J. Am. Acad. Dermatol</i>. <b>74</b> (5): 945–73.e33. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2015.12.037  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2015.12.037'" tppabs="https://doi.org/10.1016%2Fj.jaad.2015.12.037" class="external text external">10.1016/j.jaad.2015.12.037</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26897386  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26897386'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26897386" class="external text external">26897386</a>.</cite></span></li><li id="cite_note-pmid9238337-54"> <span id="mw-reference-text-cite_note-pmid9238337-54" class="mw-reference-text"><cite id="CITEREFShaw1996" class="citation journal cs1">Shaw JC (October 1996). "Antiandrogen and hormonal treatment of acne". <i>Dermatol Clin</i>. <b>14</b> (4): 803–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0733-8635%2805%2970405-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0733-8635%2805%2970405-8'" tppabs="https://doi.org/10.1016%2FS0733-8635%2805%2970405-8" class="external text external">10.1016/S0733-8635(05)70405-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9238337  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9238337'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9238337" class="external text external">9238337</a>.</cite></span></li><li id="cite_note-pmid24889738-55"> <span id="mw-reference-text-cite_note-pmid24889738-55" class="mw-reference-text"><cite id="CITEREFSomaniTurvy2014" class="citation journal cs1">Somani N, Turvy D (July 2014). "Hirsutism: an evidence-based treatment update". <i>Am J Clin Dermatol</i>. <b>15</b> (3): 247–66. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40257-014-0078-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40257-014-0078-4'" tppabs="https://doi.org/10.1007%2Fs40257-014-0078-4" class="external text external">10.1007/s40257-014-0078-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24889738  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24889738'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24889738" class="external text external">24889738</a>.</cite></span></li><li id="cite_note-pmid21413648-56"> <span id="mw-reference-text-cite_note-pmid21413648-56" class="mw-reference-text"><cite id="CITEREFRathnayakeSinclair2010" class="citation journal cs1">Rathnayake D, Sinclair R (2010). "Use of spironolactone in dermatology". <i>Skinmed</i>. <b>8</b> (6): 328–32, quiz 333. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21413648  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21413648'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21413648" class="external text external">21413648</a>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text"><cite id="CITEREFHARFMANNBECHTEL2015" class="citation journal cs1">HARFMANN, KATYA L.; BECHTEL, MARK A. (March 2015). "Hair Loss in Women". <i>Clinical Obstetrics and Gynecology</i>. <b>58</b> (1): 185–199. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FGRF.0000000000000081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FGRF.0000000000000081'" tppabs="https://doi.org/10.1097%2FGRF.0000000000000081" class="external text external">10.1097/GRF.0000000000000081</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25517757  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25517757'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25517757" class="external text external">25517757</a>.</cite></span></li><li id="cite_note-pmid20128792-58"> <span id="mw-reference-text-cite_note-pmid20128792-58" class="mw-reference-text"><cite id="CITEREFCousenMessenger2010" class="citation journal cs1">Cousen P, Messenger A (2010). "Female pattern hair loss in complete androgen insensitivity syndrome". <i>Br. J. Dermatol</i>. <b>162</b> (5): 1135–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2133.2010.09661.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2133.2010.09661.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2133.2010.09661.x" class="external text external">10.1111/j.1365-2133.2010.09661.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20128792  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20128792'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20128792" class="external text external">20128792</a>.</cite></span></li><li id="cite_note-IswaranImai1997-59"> <span id="mw-reference-text-cite_note-IswaranImai1997-59" class="mw-reference-text"><cite id="CITEREFIswaranImaiBettonSiddall1997" class="citation journal cs1">Iswaran TJ, Imai M, Betton GR, Siddall RA (May 1997). "An overview of animal toxicology studies with bicalutamide (ICI 176,334)". <i>The Journal of Toxicological Sciences</i>. <b>22</b> (2): 75–88. doi:<a href="javascript:if(confirm('https://doi.org/10.2131%2Fjts.22.2_75  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2131%2Fjts.22.2_75'" tppabs="https://doi.org/10.2131%2Fjts.22.2_75" class="external text external">10.2131/jts.22.2_75</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9198005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9198005'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9198005" class="external text external">9198005</a>.</cite></span></li><li id="cite_note-Smith2013-60"> <span id="mw-reference-text-cite_note-Smith2013-60" class="mw-reference-text"><cite id="CITEREFSmith2013" class="citation book cs1">Smith RE (4 April 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306'" tppabs="https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306" class="external text external"><i>Medicinal Chemistry – Fusion of Traditional and Western Medicine</i></a>. Bentham Science Publishers. pp.<span>&nbsp;</span>306–. ISBN<span>&nbsp;</span><bdi>978-1-60805-149-6</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160529034219/https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160529034219/https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306'" tppabs="https://web.archive.org/web/20160529034219/https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306" class="external text external">Archived</a> from the original on 29 May 2016.</cite></span></li><li id="cite_note-Ostrzenski2002-61"> <span id="mw-reference-text-cite_note-Ostrzenski2002-61" class="mw-reference-text"><cite id="CITEREFAdam_Ostrzenski2002" class="citation book cs1">Adam Ostrzenski (2002). <a href="javascript:if(confirm('https://books.google.com/books?id=TYlZsGdwqrQC&pg=PA86  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=TYlZsGdwqrQC&pg=PA86'" tppabs="https://books.google.com/books?id=TYlZsGdwqrQC&pg=PA86" class="external text external"><i>Gynecology: Integrating Conventional, Complementary, and Natural Alternative Therapy</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>86–. ISBN<span>&nbsp;</span><bdi>978-0-7817-2761-7</bdi>.</cite></span></li><li id="cite_note-pmid9557251-62"> <span id="mw-reference-text-cite_note-pmid9557251-62" class="mw-reference-text"><cite id="CITEREFSchmidt1998" class="citation journal cs1">Schmidt JB (1998). "Other antiandrogens". <i>Dermatology (Basel)</i>. <b>196</b> (1): 153–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000017850  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000017850'" tppabs="https://doi.org/10.1159%2F000017850" class="external text external">10.1159/000017850</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9557251  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9557251'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9557251" class="external text external">9557251</a>.</cite></span></li><li id="cite_note-WPATH2011-63"> <span id="mw-reference-text-cite_note-WPATH2011-63" class="mw-reference-text"><cite id="CITEREFThe_World_Professional_Association_for_Transgender_Health_(WPATH)2011" class="citation web cs1">The World Professional Association for Transgender Health (WPATH) (2011). <a href="javascript:if(confirm('https://web.archive.org/web/20120523064935/http://www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120523064935/http://www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf'" tppabs="https://web.archive.org/web/20120523064935/http://www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf" class="external text external">"Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf'" tppabs="http://www.wpath.org/documents/Standards%20of%20Care_FullBook_1g-1.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 23 May 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">27 May</span> 2012</span>.</cite></span></li><li id="cite_note-pmid19509099-64"> <span id="mw-reference-text-cite_note-pmid19509099-64" class="mw-reference-text"><cite id="CITEREFHembreeCohen-KettenisDelemarre-van_de_Waal2009" class="citation journal cs1">Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA,  et al. (September 2009). <a href="javascript:if(confirm('http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=19509099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=19509099'" tppabs="http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=19509099" class="external text external">"Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline"</a>. <i>The Journal of Clinical Endocrinology and Metabolism</i>. <b>94</b> (9): 3132–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2009-0345  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2009-0345'" tppabs="https://doi.org/10.1210%2Fjc.2009-0345" class="external text external">10.1210/jc.2009-0345</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19509099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19509099'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19509099" class="external text external">19509099</a>.</cite></span></li><li id="cite_note-pmid2540730-65"> <span id="mw-reference-text-cite_note-pmid2540730-65" class="mw-reference-text"><cite id="CITEREFPriorVignaWatson1989" class="citation journal cs1">Prior JC, Vigna YM, Watson D (February 1989). "Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism". <i>Archives of Sexual Behavior</i>. <b>18</b> (1): 49–57. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fbf01579291  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fbf01579291'" tppabs="https://doi.org/10.1007%2Fbf01579291" class="external text external">10.1007/bf01579291</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2540730  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2540730'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2540730" class="external text external">2540730</a>.</cite></span></li><li id="cite_note-pmid1387779-66"> <span id="mw-reference-text-cite_note-pmid1387779-66" class="mw-reference-text"><cite id="CITEREFCunliffeBottomley1992" class="citation journal cs1">Cunliffe WJ, Bottomley WW (September 1992). "Antiandrogens and acne. A topical approach?". <i>Arch Dermatol</i>. <b>128</b> (9): 1261–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Farchderm.1992.01680190117017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchderm.1992.01680190117017'" tppabs="https://doi.org/10.1001%2Farchderm.1992.01680190117017" class="external text external">10.1001/archderm.1992.01680190117017</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1387779  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1387779'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1387779" class="external text external">1387779</a>.</cite></span></li><li id="cite_note-pmid8112074-67"> <span id="mw-reference-text-cite_note-pmid8112074-67" class="mw-reference-text"><cite id="CITEREFVincenziTrevisiFarinaStinchi1993" class="citation journal cs1">Vincenzi C, Trevisi P, Farina P, Stinchi C, Tosti A (November 1993). "Facial contact dermatitis due to spironolactone in an anti-acne cream". <i>Contact Derm</i>. <b>29</b> (5): 277–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1600-0536.1993.tb03569.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1600-0536.1993.tb03569.x'" tppabs="https://doi.org/10.1111%2Fj.1600-0536.1993.tb03569.x" class="external text external">10.1111/j.1600-0536.1993.tb03569.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8112074  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8112074'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8112074" class="external text external">8112074</a>.</cite></span></li><li id="cite_note-Benvenga2009-68"> <span id="mw-reference-text-cite_note-Benvenga2009-68" class="mw-reference-text"><cite id="CITEREFBenvenga2009" class="citation book cs1">Benvenga, Salvatore (2009). "Therapy of Hirsutism". <i>Diagnosis and Management of Polycystic Ovary Syndrome</i>. pp.<span>&nbsp;</span>233–242. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-0-387-09718-3_19  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-0-387-09718-3_19'" tppabs="https://doi.org/10.1007%2F978-0-387-09718-3_19" class="external text external">10.1007/978-0-387-09718-3_19</a>. ISBN<span>&nbsp;</span><bdi>978-0-387-09717-6</bdi>.</cite></span></li><li id="cite_note-pmid25918921-69"> <span id="mw-reference-text-cite_note-pmid25918921-69" class="mw-reference-text"><cite id="CITEREFvan_ZuurenFedorowiczCarterPandis2015" class="citation journal cs1">van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N (April 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481758  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481758'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481758" class="external text external">"Interventions for hirsutism (excluding laser and photoepilation therapy alone)"</a>. <i>Cochrane Database Syst Rev</i> (4): CD010334. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD010334.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD010334.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD010334.pub2" class="external text external">10.1002/14651858.CD010334.pub2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481758  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481758'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481758" class="external text external">6481758</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25918921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25918921'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25918921" class="external text external">25918921</a>.</cite></span></li><li id="cite_note-pmid29522176-70"> <span id="mw-reference-text-cite_note-pmid29522176-70" class="mw-reference-text"><cite id="CITEREFBarrionuevoNabhanAltayarWang2018" class="citation journal cs1">Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, Martin KA, Murad MH (April 2018). "Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis". <i>J. Clin. Endocrinol. Metab</i>. <b>103</b> (4): 1258–1264. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2017-02052  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2017-02052'" tppabs="https://doi.org/10.1210%2Fjc.2017-02052" class="external text external">10.1210/jc.2017-02052</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29522176  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29522176'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29522176" class="external text external">29522176</a>.</cite></span></li><li id="cite_note-pmid24455796-71"> <span id="mw-reference-text-cite_note-pmid24455796-71" class="mw-reference-text"><cite id="CITEREFErem2013" class="citation journal cs1">Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". <i>Acta Clin Belg</i>. <b>68</b> (4): 268–74. doi:<a href="javascript:if(confirm('https://doi.org/10.2143%2FACB.3267  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2143%2FACB.3267'" tppabs="https://doi.org/10.2143%2FACB.3267" class="external text external">10.2143/ACB.3267</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24455796  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24455796'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24455796" class="external text external">24455796</a>.</cite></span></li><li id="cite_note-pmid29211888-72"> <span id="mw-reference-text-cite_note-pmid29211888-72" class="mw-reference-text"><cite id="CITEREFMorettiGuccioneDi_GiacintoSimonelli2018" class="citation journal cs1">Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A (March 2018). "Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial". <i>J. Clin. Endocrinol. Metab</i>. <b>103</b> (3): 824–838. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2017-01186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2017-01186'" tppabs="https://doi.org/10.1210%2Fjc.2017-01186" class="external text external">10.1210/jc.2017-01186</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29211888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29211888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29211888" class="external text external">29211888</a>.</cite></span></li><li id="cite_note-pmid22994662-73"> <span id="mw-reference-text-cite_note-pmid22994662-73" class="mw-reference-text"><cite id="CITEREFKamangarShinkai2012" class="citation journal cs1">Kamangar F, Shinkai K (October 2012). "Acne in the adult female patient: a practical approach". <i>Int. J. Dermatol</i>. <b>51</b> (10): 1162–74. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-4632.2012.05519.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-4632.2012.05519.x'" tppabs="https://doi.org/10.1111%2Fj.1365-4632.2012.05519.x" class="external text external">10.1111/j.1365-4632.2012.05519.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22994662  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22994662'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22994662" class="external text external">22994662</a>.</cite></span></li><li id="cite_note-pmid10495361-74"> <span id="mw-reference-text-cite_note-pmid10495361-74" class="mw-reference-text"><cite id="CITEREFDiamanti-Kandarakis1999" class="citation journal cs1">Diamanti-Kandarakis E (September 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA707  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA707'" tppabs="https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA707" class="external text external">"Current aspects of antiandrogen therapy in women"</a>. <i>Curr. Pharm. Des</i>. <b>5</b> (9): 707–23. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10495361  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10495361'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10495361" class="external text external">10495361</a>.</cite></span></li><li id="cite_note-ShelleyShelley2001-75"> <span id="mw-reference-text-cite_note-ShelleyShelley2001-75" class="mw-reference-text"><cite id="CITEREFWalter_Brown_ShelleyE._Dorinda_Shelley2001" class="citation book cs1">Walter Brown Shelley; E. Dorinda Shelley (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=vuJsAAAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vuJsAAAAMAAJ'" tppabs="https://books.google.com/books?id=vuJsAAAAMAAJ" class="external text external"><i>Advanced Dermatologic Therapy II</i></a>. W. B. Saunders. ISBN<span>&nbsp;</span><bdi>978-0-7216-8258-7</bdi>.</cite></span></li><li id="cite_note-BalenFranks2010-76"> <span id="mw-reference-text-cite_note-BalenFranks2010-76" class="mw-reference-text"><cite id="CITEREFAdam_BalenStephen_FranksRoy_HomburgSean_Kehoe2010" class="citation book cs1">Adam Balen; Stephen Franks; Roy Homburg; Sean Kehoe (October 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=0rtUBAAAQBAJ&pg=PA132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0rtUBAAAQBAJ&pg=PA132'" tppabs="https://books.google.com/books?id=0rtUBAAAQBAJ&pg=PA132" class="external text external"><i>Current Management of Polycystic Ovary Syndrome</i></a>. Cambridge University Press. pp.<span>&nbsp;</span>132–. ISBN<span>&nbsp;</span><bdi>978-1-906985-41-7</bdi>.</cite></span></li><li id="cite_note-pmid28379593-77"> <span id="mw-reference-text-cite_note-pmid28379593-77" class="mw-reference-text"><cite id="CITEREFGiorgettidi_MuzioGiorgettiGirolami2017" class="citation journal cs1">Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (March 2017). "Flutamide-induced hepatotoxicity: ethical and scientific issues". <i>Eur Rev Med Pharmacol Sci</i>. <b>21</b> (1 Suppl): 69–77. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28379593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28379593'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28379593" class="external text external">28379593</a>.</cite></span></li><li id="cite_note-pmid28492054-78"> <span id="mw-reference-text-cite_note-pmid28492054-78" class="mw-reference-text"><cite id="CITEREFTrivediShinkaiMurase2017" class="citation journal cs1">Trivedi MK, Shinkai K, Murase JE (March 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026" class="external text external">"A Review of hormone-based therapies to treat adult acne vulgaris in women"</a>. <i>Int J Womens Dermatol</i>. <b>3</b> (1): 44–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijwd.2017.02.018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijwd.2017.02.018'" tppabs="https://doi.org/10.1016%2Fj.ijwd.2017.02.018" class="external text external">10.1016/j.ijwd.2017.02.018</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419026" class="external text external">5419026</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28492054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28492054'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28492054" class="external text external">28492054</a>.</cite></span></li><li id="cite_note-YasaDural2016-79"> <span id="mw-reference-text-cite_note-YasaDural2016-79" class="mw-reference-text"><cite id="CITEREFYasaDuralBastuUğurlucan2016" class="citation journal cs1">Yasa, Cenk; Dural, Özlem; Bastu, Ercan; Uğurlucan, Funda Güngör (2016). "Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome". <i>Gynecology Obstetrics &amp; Reproductive Medicine</i>: 1. doi:<a href="javascript:if(confirm('https://doi.org/10.21613%2FGORM.2016.613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.21613%2FGORM.2016.613'" tppabs="https://doi.org/10.21613%2FGORM.2016.613" class="external text external">10.21613/GORM.2016.613</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1300-4751  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1300-4751'" tppabs="https://www.worldcat.org/issn/1300-4751" class="external text external">1300-4751</a>.</cite></span></li><li id="cite_note-pmid28274354-80"> <span id="mw-reference-text-cite_note-pmid28274354-80" class="mw-reference-text"><cite id="CITEREFBarrosThiboutot2017" class="citation journal cs1">Barros B, Thiboutot D (2017). "Hormonal therapies for acne". <i>Clin. Dermatol</i>. <b>35</b> (2): 168–172. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.clindermatol.2016.10.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.clindermatol.2016.10.009'" tppabs="https://doi.org/10.1016%2Fj.clindermatol.2016.10.009" class="external text external">10.1016/j.clindermatol.2016.10.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28274354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28274354'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28274354" class="external text external">28274354</a>.</cite></span></li><li id="cite_note-pmid27416311-81"> <span id="mw-reference-text-cite_note-pmid27416311-81" class="mw-reference-text"><cite id="CITEREFHassounChahalSivamaniLarsen2016" class="citation journal cs1">Hassoun LA, Chahal DS, Sivamani RK, Larsen LN (June 2016). "The use of hormonal agents in the treatment of acne". <i>Semin Cutan Med Surg</i>. <b>35</b> (2): 68–73. doi:<a href="javascript:if(confirm('https://doi.org/10.12788%2Fj.sder.2016.027  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.12788%2Fj.sder.2016.027'" tppabs="https://doi.org/10.12788%2Fj.sder.2016.027" class="external text external">10.12788/j.sder.2016.027</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27416311  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27416311'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27416311" class="external text external">27416311</a>.</cite></span></li><li id="cite_note-pmid30312645-82"> <span id="mw-reference-text-cite_note-pmid30312645-82" class="mw-reference-text"><cite id="CITEREFAzarchiBienenfeldLo_SiccoMarchbein2018" class="citation journal cs1">Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR (October 2018). "Androgens in Women: Hormone modulating therapies for skin disease (Part II)". <i>J. Am. Acad. Dermatol</i>. <b>80</b> (6): 1509–1521. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2018.08.061  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2018.08.061'" tppabs="https://doi.org/10.1016%2Fj.jaad.2018.08.061" class="external text external">10.1016/j.jaad.2018.08.061</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30312645  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30312645'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30312645" class="external text external">30312645</a>.</cite></span></li><li id="cite_note-pmid27225981-83"> <span id="mw-reference-text-cite_note-pmid27225981-83" class="mw-reference-text"><cite id="CITEREFvan_ZuurenFedorowiczSchoones2016" class="citation journal cs1">van Zuuren EJ, Fedorowicz Z, Schoones J (May 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957" class="external text external">"Interventions for female pattern hair loss"</a>. <i>Cochrane Database Syst Rev</i> (5): CD007628. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD007628.pub4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD007628.pub4'" tppabs="https://doi.org/10.1002%2F14651858.CD007628.pub4" class="external text external">10.1002/14651858.CD007628.pub4</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457957" class="external text external">6457957</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27225981  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27225981'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27225981" class="external text external">27225981</a>.</cite></span></li><li id="cite_note-pmid19370553-84"> <span id="mw-reference-text-cite_note-pmid19370553-84" class="mw-reference-text"><cite id="CITEREFBrownFarquharLeeToomath2009" class="citation journal cs1">Brown J, Farquhar C, Lee O, Toomath R, Jepson RG (April 2009). "Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne". <i>Cochrane Database Syst Rev</i> (2): CD000194. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD000194.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD000194.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD000194.pub2" class="external text external">10.1002/14651858.CD000194.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19370553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19370553'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19370553" class="external text external">19370553</a>.</cite></span></li><li id="cite_note-Hammerstein1990-85"> <span id="mw-reference-text-cite_note-Hammerstein1990-85" class="mw-reference-text"><cite id="CITEREFHammerstein1990" class="citation book cs1">Hammerstein, J. (1990). "Antiandrogens: Clinical Aspects". <i>Hair and Hair Diseases</i>. pp.<span>&nbsp;</span>827–886. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-642-74612-3_35  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-642-74612-3_35'" tppabs="https://doi.org/10.1007%2F978-3-642-74612-3_35" class="external text external">10.1007/978-3-642-74612-3_35</a>. ISBN<span>&nbsp;</span><bdi>978-3-642-74614-7</bdi>.</cite></span></li><li id="cite_note-pmid3996628-86"> <span id="mw-reference-text-cite_note-pmid3996628-86" class="mw-reference-text"><cite id="CITEREFGivens1985" class="citation journal cs1">Givens JR (June 1985). "Treatment of hirsutism with spironolactone". <i>Fertil. Steril</i>. <b>43</b> (6): 841–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0015-0282%2816%2948609-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0015-0282%2816%2948609-7'" tppabs="https://doi.org/10.1016%2FS0015-0282%2816%2948609-7" class="external text external">10.1016/S0015-0282(16)48609-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3996628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3996628'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3996628" class="external text external">3996628</a>.</cite></span></li><li id="cite_note-IzzoSica2008-87"> <span id="mw-reference-text-cite_note-IzzoSica2008-87" class="mw-reference-text"><cite id="CITEREFJoseph_L._IzzoDomenic_A._SicaHenry_Richard_Black2008" class="citation book cs1">Joseph L. Izzo; Domenic A. Sica; Henry Richard Black (2008). <a href="javascript:if(confirm('https://books.google.com/books?id=Sw9-Am4RvCMC&pg=PA444  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Sw9-Am4RvCMC&pg=PA444'" tppabs="https://books.google.com/books?id=Sw9-Am4RvCMC&pg=PA444" class="external text external"><i>Hypertension Primer</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>444–. ISBN<span>&nbsp;</span><bdi>978-0-7817-8205-0</bdi>. <q>Table C131.2. Doses of aldosterone antagonists in various clinical conditions. Drug: Spironolactone (Aldactone). Usual dose ranges (total mg/d). Essential hypertension: 25-200. Hyperaldosteronism [(and PCOS)]: 50-200. Heart failure: 25-50.</q></cite></span></li><li id="cite_note-WarrellBenz2003-88"> <span id="mw-reference-text-cite_note-WarrellBenz2003-88" class="mw-reference-text"><cite id="CITEREFDavid_A._WarrellEdward_J._BenzTimothy_M._CoxJohn_D._Firth2003" class="citation book cs1">David A. Warrell; Edward J. Benz; Timothy M. Cox; John D. Firth (2003). <a href="javascript:if(confirm('https://books.google.com/books?id=_s65U1n9Lf8C&pg=RA1-PA965  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_s65U1n9Lf8C&pg=RA1-PA965'" tppabs="https://books.google.com/books?id=_s65U1n9Lf8C&pg=RA1-PA965" class="external text external"><i>Oxford Textbook of Medicine</i></a>. Oxford University Press. pp.<span>&nbsp;</span>1–. ISBN<span>&nbsp;</span><bdi>978-0-19-262922-7</bdi>. <q>Spironolactone 25 mg/day should be given routinely to all patients with congestive heart failure. [...] It is not known whether higher doses of spironolactone than 25 mg/day are also associated with a beneficial effect on mortality.</q></cite></span></li><li id="cite_note-HosenpudGreenberg2007-89"> <span id="mw-reference-text-cite_note-HosenpudGreenberg2007-89" class="mw-reference-text"><cite id="CITEREFJeffrey_D._HosenpudBarry_H._Greenberg2007" class="citation book cs1">Jeffrey D. Hosenpud; Barry H. Greenberg (2007). <a href="javascript:if(confirm('https://books.google.com/books?id=PV8A8282d2EC&pg=PA483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=PV8A8282d2EC&pg=PA483'" tppabs="https://books.google.com/books?id=PV8A8282d2EC&pg=PA483" class="external text external"><i>Congestive Heart Failure</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>483–. ISBN<span>&nbsp;</span><bdi>978-0-7817-6285-4</bdi>. <q>The first clinical trial demonstrating the benefits of aldosterone receptor blockade in [heart failure] was the Randomized Aldosterone Evaluation Study (RALES), in which 1,633 patients with NYHA Class III-IV chronic [heart failure], already receiving ACEIs, were randomized to spironolactone versus placebo (111). Patients were initiated on 12.5 or 25 mg of spironolactone daily and were titrated to 25 mg daily, with the possibility of increasing to 50 mg.</q></cite></span></li><li id="cite_note-RamrakhaRamrakha2012-90"> <span id="mw-reference-text-cite_note-RamrakhaRamrakha2012-90" class="mw-reference-text"><cite id="CITEREFPunit_S._RamrakhaPunit_RamrakhaJonathan_Hill2012" class="citation book cs1">Punit S. Ramrakha; Punit Ramrakha; Jonathan Hill (23 February 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=b0n9gaziBfIC&pg=PA107  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=b0n9gaziBfIC&pg=PA107'" tppabs="https://books.google.com/books?id=b0n9gaziBfIC&pg=PA107" class="external text external"><i>Oxford Handbook of Cardiology</i></a>. OUP Oxford. pp.<span>&nbsp;</span>107–. ISBN<span>&nbsp;</span><bdi>978-0-19-964321-9</bdi>. <q>Table 2.6 Doses for commonly used aldosterone antagonists. Agent: Spironolactone. Heart failure. Starting dose: 25 mg daily. Target dose: 50 mg daily. Hypertension. Starting dose: 100 mg daily. Target dose: 25-200 mg daily.</q></cite></span></li><li id="cite_note-GinésArroyo2008-91"> <span id="mw-reference-text-cite_note-GinésArroyo2008-91" class="mw-reference-text"><cite id="CITEREFPere_GinésVicente_ArroyoJuan_RodésRobert_W._Schrier2008" class="citation book cs1">Pere Ginés; Vicente Arroyo; Juan Rodés; Robert W. Schrier (15 April 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=Z3PARx4oYDgC&pg=PA231  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Z3PARx4oYDgC&pg=PA231'" tppabs="https://books.google.com/books?id=Z3PARx4oYDgC&pg=PA231" class="external text external"><i>Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>229, 231. ISBN<span>&nbsp;</span><bdi>978-1-4051-4370-7</bdi>. <q>The most rational treatment of cirrhotic patients with ascites appears to be the administration of an aldosterone antagonist. A stepwise equential therapy with increasing oral doses of an aldosterone antagonist (up to 400 mg/day) may be effective in mobilizing ascites in 60-80% of non-azotemic cirrhotic patients with ascites who do not respond to bed rest and dietary sodium restriction (11,12,74). The effective dosage of aldosterone antagonists depends on plasma aldosterone levels (75). Patients with moderately increased plasma levels require low doses of those drugs (100-150 mg/day), whereas patients with marked hyperaldosteronism may require as much as 200-400 mg/day. A further increase of the dosage up to 500-600 mg/day is of limited usefulness (11,12).</q></cite></span></li><li id="cite_note-HawkeyBosch2012-92"> <span id="mw-reference-text-cite_note-HawkeyBosch2012-92" class="mw-reference-text"><cite id="CITEREFC._J._HawkeyJaime_BoschJoel_E._RichterGuadalupe_Garcia-Tsao,_Francis_K._L._Chan2012" class="citation book cs1">C. J. Hawkey; Jaime Bosch; Joel E. Richter; Guadalupe Garcia-Tsao, Francis K. L. Chan (2 March 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=5Mrl2t6P9QwC&pg=PA739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5Mrl2t6P9QwC&pg=PA739'" tppabs="https://books.google.com/books?id=5Mrl2t6P9QwC&pg=PA739" class="external text external"><i>Textbook of Clinical Gastroenterology and Hepatology</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>739–. ISBN<span>&nbsp;</span><bdi>978-1-118-32142-3</bdi>. <q>Patients with new onset ascites respond to spironolactone 50-100 mg/day and the dose may be increased progressively if needed. Patients with prior episodes of ascites should receive the combination of spironolactone 100 mg/day with furosemide (20-40 mg/day) [12-14]. If there is no response, compliance with diet and medications should be confirmed and diuretics may then be increased in a stepwise fashion every 5-7 days by doubling doses to a maximal dose of spironolactone of 400 mg/day and a maximal dose of furosemide of 160 mg/day.</q></cite></span></li><li id="cite_note-SchiffSorrell2007-93"> <span id="mw-reference-text-cite_note-SchiffSorrell2007-93" class="mw-reference-text"><cite id="CITEREFEugene_R._SchiffMichael_F._SorrellWillis_C._Maddrey2007" class="citation book cs1">Eugene R. Schiff; Michael F. Sorrell; Willis C. Maddrey (2007). <a href="javascript:if(confirm('https://books.google.com/books?id=2tIl51sVIxIC&pg=PA547  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2tIl51sVIxIC&pg=PA547'" tppabs="https://books.google.com/books?id=2tIl51sVIxIC&pg=PA547" class="external text external"><i>Schiff's Diseases of the Liver</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>547–. ISBN<span>&nbsp;</span><bdi>978-0-7817-6040-9</bdi>. <q>The response to spironolactone depends on the degree of hyperaldosteronism. Patients with a normal or slightly increased plasma concentration of aldosterone usually respond to low doses of spironolactone (100 to 150 mg/day), but as much as 300 to 400 mg/day may be needed to antagonize the tubular effect of aldosterone in patients with marked hyperaldosteronism. The basic drug for the treatment of ascites, therefore, is spironolactone.</q></cite></span></li><li id="cite_note-BlackElliott2007-94"> <span id="mw-reference-text-cite_note-BlackElliott2007-94" class="mw-reference-text"><cite id="CITEREFHenry_Richard_BlackWilliam_J._Elliott_(M.D.)2007" class="citation book cs1">Henry Richard Black; William J. Elliott (M.D.) (1 January 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=0M5CSezPhAUC&pg=PA114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0M5CSezPhAUC&pg=PA114'" tppabs="https://books.google.com/books?id=0M5CSezPhAUC&pg=PA114" class="external text external"><i>Hypertension: A Companion to Braunwald's Heart Disease</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>114–. ISBN<span>&nbsp;</span><bdi>978-1-4160-3053-9</bdi>. <q>The hypertension associated with primary aldosteronism is salt and water dependent and is best treated by sustained salt and water depletion (Fig. 9-9).39-41 The usual doses of diuretics are hydrochlorothiazide, 12.5 to 50 mg/day, or furosemide, 80 to 180 mg/day, in combination with either spironolactone, 100 to 200 mg/day, or amiloride, 10 to 20 mg/day.</q></cite></span></li><li id="cite_note-CarrellPeterson2010-95"> <span id="mw-reference-text-cite_note-CarrellPeterson2010-95" class="mw-reference-text"><cite id="CITEREFDouglas_T._CarrellC._Matthew_Peterson2010" class="citation book cs1">Douglas T. Carrell; C. Matthew Peterson (23 March 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=lcBEheiufVcC&pg=PA162  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=lcBEheiufVcC&pg=PA162'" tppabs="https://books.google.com/books?id=lcBEheiufVcC&pg=PA162" class="external text external"><i>Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>162–. ISBN<span>&nbsp;</span><bdi>978-1-4419-1436-1</bdi>. <q>A modest improvement in hirsutism can be anticipated in 70-80% of women using even the minimum of 100 mg of spironolactone per day for 6 months [157]. [...] The most common dosage is 100-200 mg per day in a divided dosage. Women treated with 200 mg/day show a greater reduction in hair shaft diameter than women receiving 100 mg/day [159]. [...] Menstrual irregularity (usually metrorrhagia), is the most common side effect of spironolactone and occurs in over 50% of patients with a dosage of 200 mg/day [159]. [...] Patients must be counseled to use contraception while taking spironolactone because it theoretically can feminize a male fetus.</q></cite></span></li><li id="cite_note-Wu2012-96"> <span id="mw-reference-text-cite_note-Wu2012-96" class="mw-reference-text"><cite id="CITEREFJashin_J._Wu2012" class="citation book cs1">Jashin J. Wu (18 October 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=Tqpsm5WKKlcC&pg=PA364  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Tqpsm5WKKlcC&pg=PA364'" tppabs="https://books.google.com/books?id=Tqpsm5WKKlcC&pg=PA364" class="external text external"><i>Comprehensive Dermatologic Drug Therapy E-Book</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>364–. ISBN<span>&nbsp;</span><bdi>978-1-4557-3801-4</bdi>. <q>Spironolactone is an aldosterone antagonist and a relatively weak antiandrogen that blocks the AR and inhibits androgen biosynthesis. Spironolactone does not inhibit 5α-reductase. [...] The progestational activity of spironolactone is variable. The drug influences the ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH) by reducing the response of LH to GnRH. [...] In a dose range of 25-200 mg a linear relationship between a single dose of spironolactone and plasma levels of canrenone occurs within 96 hours. [...] Common doses [of spironolactone for dermatological indications] range between 50 and 200 mg daily, with 100 mg daily typically being better tolerated than higher dosages.20</q></cite></span></li><li id="cite_note-Hohl2017-97"> <span id="mw-reference-text-cite_note-Hohl2017-97" class="mw-reference-text"><cite id="CITEREFAlexandre_Hohl2017" class="citation book cs1">Alexandre Hohl (30 March 2017). <a href="javascript:if(confirm('https://books.google.com/books?id=Et6TDgAAQBAJ&pg=PA333  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Et6TDgAAQBAJ&pg=PA333'" tppabs="https://books.google.com/books?id=Et6TDgAAQBAJ&pg=PA333" class="external text external"><i>Testosterone: From Basic to Clinical Aspects</i></a>. Springer. pp.<span>&nbsp;</span>333–. ISBN<span>&nbsp;</span><bdi>978-3-319-46086-4</bdi>. <q>Doses [of spironolactone for hirsutism and PCOS] used in clinical studies have varied from 50 to 400 mg daily; although 100-mg/day are usually effective for the treatment of hirsutism, higher doses (200-300 mg/day) may be preferable in extremely hirsute or markedly obese women. Thus, the initial recommended dosage is 100 mg/day, gradually increasing it by increments of 25 mg/day every 3 months up to 200 mg/day on the basis of the response. [...] In patients with normal renal function, hyperkalemia is almost never seen.</q></cite></span></li><li id="cite_note-PreglerDeCherney2002-98"> <span id="mw-reference-text-cite_note-PreglerDeCherney2002-98" class="mw-reference-text"><cite id="CITEREFJanet_P._PreglerAlan_H._DeCherney2002" class="citation book cs1">Janet P. Pregler; Alan H. DeCherney (2002). <a href="javascript:if(confirm('https://books.google.com/books?id=zC99_it1C5YC&pg=PA593  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=zC99_it1C5YC&pg=PA593'" tppabs="https://books.google.com/books?id=zC99_it1C5YC&pg=PA593" class="external text external"><i>Women's Health: Principles and Clinical Practice</i></a>. PMPH-USA. pp.<span>&nbsp;</span>593–. ISBN<span>&nbsp;</span><bdi>978-1-55009-170-0</bdi>. <q>Effective and safe dosages of spironolactone range between 50 and 400 mg orally daily. However, the most commonly prescribed regimen is 200 mg daily for the initial treatment of hirsutism and 100 mg daily for maintenance therapy.</q></cite></span></li><li id="cite_note-Becker2001-99"> <span id="mw-reference-text-cite_note-Becker2001-99" class="mw-reference-text"><cite id="CITEREFKenneth_L._Becker2001" class="citation book cs1">Kenneth L. Becker (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196'" tppabs="https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196" class="external text external"><i>Principles and Practice of Endocrinology and Metabolism</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>708, 777, 1087, 1196. ISBN<span>&nbsp;</span><bdi>978-0-7817-1750-2</bdi>. <q>Spironolactone has been used successfully in dosages of 100 to 200 mg daily for the treatment of idiopathic hirsutism and hirsutism associated with polycystic ovarian disease (see Chaps. 96 and 101).184 [...] Spironolactone also is both an antiandrogen and a progestagen, and this explains many of its distressing side effects; decreased libido, mastodynia, and gynecomastia may occur in 50% or more of men, and menometrorrhagia and breast pain may occur in an equally large number of women taking the drug.27</q></cite></span></li><li id="cite_note-pmid28945902-100"> <span id="mw-reference-text-cite_note-pmid28945902-100" class="mw-reference-text"><cite id="CITEREFHembreeCohen-KettenisGoorenHannema2017" class="citation journal cs1">Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline". <i>J. Clin. Endocrinol. Metab</i>. <b>102</b> (11): 3869–3903. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2017-01658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2017-01658'" tppabs="https://doi.org/10.1210%2Fjc.2017-01658" class="external text external">10.1210/jc.2017-01658</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28945902  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28945902'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28945902" class="external text external">28945902</a>. <q>Hormone Regimens in Transgender Persons. Transgender females. Antiandrogens. Spironolactone. 100–300 mg/d.</q></cite></span></li><li id="cite_note-pmid28159148-101"> <span id="mw-reference-text-cite_note-pmid28159148-101" class="mw-reference-text"><cite id="CITEREFWespDeutsch2017" class="citation journal cs1">Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". <i>Psychiatr. Clin. North Am</i>. <b>40</b> (1): 99–111. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.psc.2016.10.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.psc.2016.10.006'" tppabs="https://doi.org/10.1016%2Fj.psc.2016.10.006" class="external text external">10.1016/j.psc.2016.10.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28159148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28159148'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28159148" class="external text external">28159148</a>. <q>Table 3. Recommended antiandrogen dose. Drug: Spironolactone. Initial Dose (mg/d): 100. Maximum Dose (mg/d): 400. Comments: Usually divided into twice daily dosing. Pills come in 25, 50, or 100 mg doses and can be titrated up as tolerated. Taking earlier in day may prevent urinary frequency during night.</q></cite></span></li><li id="cite_note-WebbSafer2019-102"> <span id="mw-reference-text-cite_note-WebbSafer2019-102" class="mw-reference-text"><cite id="CITEREFRebecca_WebbJoshua_D._Safer2019" class="citation book cs1">Rebecca Webb; Joshua D. Safer (2019). <span class="cs1-lock-subscription"><a href="javascript:if(confirm('https://www.sciencedirect.com/science/article/pii/B9780323479127000287  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sciencedirect.com/science/article/pii/B9780323479127000287'" tppabs="https://www.sciencedirect.com/science/article/pii/B9780323479127000287" class="external text external">"Chapter 28 – Transgender Hormonal Treatment"</a></span>. <i>Yen &amp; Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management</i> (8th ed.). Elsevier Health Sciences. pp.<span>&nbsp;</span>709–716.e1. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FB978-0-323-47912-7.00028-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FB978-0-323-47912-7.00028-7'" tppabs="https://doi.org/10.1016%2FB978-0-323-47912-7.00028-7" class="external text external">10.1016/B978-0-323-47912-7.00028-7</a> (inactive 20 March 2020). ISBN<span>&nbsp;</span><bdi>978-0-323-58232-2</bdi>. <q>Spironolactone 100–200 mg/day (up to 400 mg).</q></cite></span></li><li id="cite_note-Muller1998-103"> <span id="mw-reference-text-cite_note-Muller1998-103" class="mw-reference-text"><cite id="CITEREFMuller1998" class="citation book cs1">Muller (19 June 1998). <a href="javascript:if(confirm('https://books.google.com/books?id=2HBPHmclMWIC&pg=PA44  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2HBPHmclMWIC&pg=PA44'" tppabs="https://books.google.com/books?id=2HBPHmclMWIC&pg=PA44" class="external text external"><i>European Drug Index: European Drug Registrations, Fourth Edition</i></a>. CRC Press. pp.<span>&nbsp;</span>44–. ISBN<span>&nbsp;</span><bdi>978-3-7692-2114-5</bdi>.</cite></span></li><li id="cite_note-LeeDesai2007-104"> <span id="mw-reference-text-cite_note-LeeDesai2007-104" class="mw-reference-text"><cite id="CITEREFMary_LeeArchana_Desai2007" class="citation book cs1">Mary Lee; Archana Desai (2007). <a href="javascript:if(confirm('https://books.google.com/books?id=v0rLyVSc8EYC&pg=PA312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=v0rLyVSc8EYC&pg=PA312'" tppabs="https://books.google.com/books?id=v0rLyVSc8EYC&pg=PA312" class="external text external"><i>Gibaldi's Drug Delivery Systems in Pharmaceutical Care</i></a>. ASHP. pp.<span>&nbsp;</span>312–. ISBN<span>&nbsp;</span><bdi>978-1-58528-136-7</bdi>.</cite></span></li><li id="cite_note-Niazi2016-105"> <span id="mw-reference-text-cite_note-Niazi2016-105" class="mw-reference-text"><cite id="CITEREFSarfaraz_K._Niazi2016" class="citation book cs1">Sarfaraz K. Niazi (19 April 2016). <a href="javascript:if(confirm('https://books.google.com/books?id=XprMBQAAQBAJ&pg=PA470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=XprMBQAAQBAJ&pg=PA470'" tppabs="https://books.google.com/books?id=XprMBQAAQBAJ&pg=PA470" class="external text external"><i>Handbook of Pharmaceutical Manufacturing Formulations, Second Edition: Volume One, Compressed Solid Products</i></a>. CRC Press. pp.<span>&nbsp;</span>470–. ISBN<span>&nbsp;</span><bdi>978-1-4200-8117-6</bdi>.</cite></span></li><li id="cite_note-WakelinMaibach2002-106"> <span id="mw-reference-text-cite_note-WakelinMaibach2002-106" class="mw-reference-text"><cite id="CITEREFSarah_H._WakelinHoward_I._MaibachClive_B._Archer2002" class="citation book cs1">Sarah H. Wakelin; Howard I. Maibach; Clive B. Archer (1 June 2002). <a href="javascript:if(confirm('https://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA35  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA35'" tppabs="https://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA35" class="external text external"><i>Systemic Drug Treatment in Dermatology: A Handbook</i></a>. CRC Press. pp.<span>&nbsp;</span>32, 35. ISBN<span>&nbsp;</span><bdi>978-1-84076-013-2</bdi>.</cite></span></li><li id="cite_note-Drugs@FDA-107"> <span id="mw-reference-text-cite_note-Drugs@FDA-107" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/scripts/cder/daf/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/scripts/cder/daf/'" tppabs="http://www.accessdata.fda.gov/scripts/cder/daf/" class="external text external">"Drugs@FDA: FDA Approved Drug Products"</a>. United States Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">14 August</span> 2018</span>.</cite></span></li><li id="cite_note-IndexNominum2000-108"> <span id="mw-reference-text-cite_note-IndexNominum2000-108" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA960  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA960'" tppabs="https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA960" class="external text external"><i>Index Nominum 2000: International Drug Directory</i></a>. Taylor &amp; Francis. January 2000. pp.<span>&nbsp;</span>960–. ISBN<span>&nbsp;</span><bdi>978-3-88763-075-1</bdi>.</cite></span></li><li id="cite_note-Drugs.com-109"> <span id="mw-reference-text-cite_note-Drugs.com-109" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/spironolactone.html'" tppabs="https://www.drugs.com/international/spironolactone.html" class="external text external">"Spironolactone"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20161202040938/https://www.drugs.com/international/spironolactone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161202040938/https://www.drugs.com/international/spironolactone.html'" tppabs="https://web.archive.org/web/20161202040938/https://www.drugs.com/international/spironolactone.html" class="external text external">Archived</a> from the original on 2 December 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">1 December</span> 2016</span>.</cite></span></li><li id="cite_note-pmid28634268-110"> <span id="mw-reference-text-cite_note-pmid28634268-110" class="mw-reference-text"><cite id="CITEREFKolkhofBärfacker2017" class="citation journal cs1">Kolkhof P, Bärfacker L (2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394" class="external text external">"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development"</a>. <i>J. Endocrinol</i>. <b>234</b> (1): T125–T140. doi:<a href="javascript:if(confirm('https://doi.org/10.1530%2FJOE-16-0600  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2FJOE-16-0600'" tppabs="https://doi.org/10.1530%2FJOE-16-0600" class="external text external">10.1530/JOE-16-0600</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488394" class="external text external">5488394</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28634268  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28634268'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28634268" class="external text external">28634268</a>.</cite></span></li><li id="cite_note-Aldactone_label-111"> <span id="mw-reference-text-cite_note-Aldactone_label-111" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc" class="external text external">"Aldactone- spironolactone tablet, film coated"</a>. <i>DailyMed</i>. 29 November 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">1 January</span> 2020</span>.</cite></span></li><li id="cite_note-GoldsmithCovic2014-112"> <span id="mw-reference-text-cite_note-GoldsmithCovic2014-112" class="mw-reference-text"><cite id="CITEREFDavid_GoldsmithAdrian_CovicJonas_Spaak2014" class="citation book cs1">David Goldsmith; Adrian Covic; Jonas Spaak (12 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=GvZWBQAAQBAJ&pg=PA167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GvZWBQAAQBAJ&pg=PA167'" tppabs="https://books.google.com/books?id=GvZWBQAAQBAJ&pg=PA167" class="external text external"><i>Cardio-Renal Clinical Challenges</i></a>. Springer. pp.<span>&nbsp;</span>167–. ISBN<span>&nbsp;</span><bdi>978-3-319-09162-4</bdi>.</cite></span></li><li id="cite_note-pmid984618-113"> <span id="mw-reference-text-cite_note-pmid984618-113" class="mw-reference-text"><cite id="CITEREFLoriaux1976" class="citation journal cs1">Loriaux, D. Lynn (November 1976). "Spironolactone and endocrine dysfunction". <i>Annals of Internal Medicine</i>. <b>85</b> (5): 630–6. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-85-5-630  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-85-5-630'" tppabs="https://doi.org/10.7326%2F0003-4819-85-5-630" class="external text external">10.7326/0003-4819-85-5-630</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/984618  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/984618'" tppabs="https://pubmed.ncbi.nlm.nih.gov/984618" class="external text external">984618</a>.</cite></span></li><li id="cite_note-SeldinGiebisch1997-114"> <span id="mw-reference-text-cite_note-SeldinGiebisch1997-114" class="mw-reference-text"><cite id="CITEREFDonald_W._SeldinGerhard_H._Giebisch1997" class="citation book cs1">Donald W. Seldin; Gerhard H. Giebisch (23 September 1997). <a href="javascript:if(confirm('https://books.google.com/books?id=VHcsrw6unuAC&pg=PA630  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=VHcsrw6unuAC&pg=PA630'" tppabs="https://books.google.com/books?id=VHcsrw6unuAC&pg=PA630" class="external text external"><i>Diuretic Agents: Clinical Physiology and Pharmacology</i></a>. Academic Press. pp.<span>&nbsp;</span>630–632. ISBN<span>&nbsp;</span><bdi>978-0-08-053046-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140704201956/http://books.google.com/books?id=VHcsrw6unuAC&pg=PA630  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140704201956/http://books.google.com/books?id=VHcsrw6unuAC&pg=PA630'" tppabs="https://web.archive.org/web/20140704201956/http://books.google.com/books?id=VHcsrw6unuAC&pg=PA630" class="external text external">Archived</a> from the original on 4 July 2014. <q>The incidence of spironolactone in men is dose related. It is estimated that 50% of men treated with ≥150 mg/day of spironolactone will develop gynecomastia. The degree of gynecomastia varies considerably from patient to patient but in most instances causes mild symptoms. Associated breast tenderness is common but an inconsistent feature.</q></cite></span></li><li id="cite_note-Aronson2009-115"> <span id="mw-reference-text-cite_note-Aronson2009-115" class="mw-reference-text"><cite id="CITEREFJeffrey_K._Aronson2009" class="citation book cs1">Jeffrey K. Aronson (2 March 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=oeBgU3UwgZkC&pg=PA255  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=oeBgU3UwgZkC&pg=PA255'" tppabs="https://books.google.com/books?id=oeBgU3UwgZkC&pg=PA255" class="external text external"><i>Meyler's Side Effects of Cardiovascular Drugs</i></a>. Elsevier. pp.<span>&nbsp;</span>253–258. ISBN<span>&nbsp;</span><bdi>978-0-08-093289-7</bdi>. <q>Spironolactone causes breast tenderness and enlargement, mastodynia, infertility, cholasma, altered vaginal lubrica- tion, and reduced libido in women, probably because of estrogenic effects on target tissue.</q></cite></span></li><li id="cite_note-PescovitzEugster2004-116"> <span id="mw-reference-text-cite_note-PescovitzEugster2004-116" class="mw-reference-text"><cite id="CITEREFOra_Hirsch_PescovitzErica_A._Eugster2004" class="citation book cs1">Ora Hirsch Pescovitz; Erica A. Eugster (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=9gvBlktAT6YC&pg=PA368  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9gvBlktAT6YC&pg=PA368'" tppabs="https://books.google.com/books?id=9gvBlktAT6YC&pg=PA368" class="external text external"><i>Pediatric Endocrinology: Mechanisms, Manifestations, and Management</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>368–. ISBN<span>&nbsp;</span><bdi>978-0-7817-4059-3</bdi>.</cite></span></li><li id="cite_note-117"> <span id="mw-reference-text-cite_note-117" class="mw-reference-text"><cite id="CITEREFU.S._National_Library_of_Medicine2019" class="citation web cs1">U.S. National Library of Medicine (2019). <a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a682627.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a682627.html'" tppabs="https://medlineplus.gov/druginfo/meds/a682627.html" class="external text external">"Spironolactone"</a>. <i>MedlinePlus</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2019</span>.</cite></span></li><li id="cite_note-118"> <span id="mw-reference-text-cite_note-118" class="mw-reference-text"><cite id="CITEREFVerhammeMosisDieleman2006" class="citation journal cs1">Verhamme K, Mosis G, Dieleman JP,  et al. (2006). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539051'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539051" class="external text external">"Spironolactone and risk of upper gastrointestinal events: population based case-control study"</a>. <i>Br Med J</i>. <b>333</b> (7563): 330–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.38883.479549.2F  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.38883.479549.2F'" tppabs="https://doi.org/10.1136%2Fbmj.38883.479549.2F" class="external text external">10.1136/bmj.38883.479549.2F</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539051'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539051" class="external text external">1539051</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16840442  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16840442'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16840442" class="external text external">16840442</a>.</cite></span></li><li id="cite_note-119"> <span id="mw-reference-text-cite_note-119" class="mw-reference-text"><cite id="CITEREFWandelt-Freerksen_E.1977" class="citation journal cs1">Wandelt-Freerksen E. (1977). "Aldactone in the treatment of sarcoidosis of the lungs". <i>JZ Erkr Atmungsorgane</i>. <b>149</b> (1): 156–9. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/607621  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/607621'" tppabs="https://pubmed.ncbi.nlm.nih.gov/607621" class="external text external">607621</a>.</cite></span></li><li id="cite_note-pmid26404748-120"> <span id="mw-reference-text-cite_note-pmid26404748-120" class="mw-reference-text"><cite id="CITEREFLainscakPellicciaRosanoVitale2015" class="citation journal cs1">Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015). "Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone". <i>Int. J. Cardiol</i>. <b>200</b>: 25–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ijcard.2015.05.127  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ijcard.2015.05.127'" tppabs="https://doi.org/10.1016%2Fj.ijcard.2015.05.127" class="external text external">10.1016/j.ijcard.2015.05.127</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26404748  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26404748'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26404748" class="external text external">26404748</a>.</cite></span></li><li id="cite_note-pmid15295047-121"> <span id="mw-reference-text-cite_note-pmid15295047-121" class="mw-reference-text"><cite id="CITEREFJuurlinkMamdaniLeeKopp2004" class="citation journal cs1">Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004). "Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study". <i>N. Engl. J. Med</i>. <b>351</b> (6): 543–51. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa040135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa040135'" tppabs="https://doi.org/10.1056%2FNEJMoa040135" class="external text external">10.1056/NEJMoa040135</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15295047  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15295047'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15295047" class="external text external">15295047</a>.</cite></span></li><li id="cite_note-pmid22942339-122"> <span id="mw-reference-text-cite_note-pmid22942339-122" class="mw-reference-text"><cite id="CITEREFZannadGattis_StoughRossignolBauersachs2012" class="citation journal cs1">Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B (November 2012). "Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice". <i>Eur. Heart J</i>. <b>33</b> (22): 2782–95. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Feurheartj%2Fehs257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Feurheartj%2Fehs257'" tppabs="https://doi.org/10.1093%2Feurheartj%2Fehs257" class="external text external">10.1093/eurheartj/ehs257</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22942339  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22942339'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22942339" class="external text external">22942339</a>.</cite></span></li><li id="cite_note-pmid20483947-123"> <span id="mw-reference-text-cite_note-pmid20483947-123" class="mw-reference-text"><cite id="CITEREFWeiStruthersFaheyWatson2010" class="citation journal cs1">Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM (May 2010). "Spironolactone use and renal toxicity: population based longitudinal analysis". <i>BMJ</i>. <b>340</b>: c1768. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fbmj.c1768  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fbmj.c1768'" tppabs="https://doi.org/10.1136%2Fbmj.c1768" class="external text external">10.1136/bmj.c1768</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20483947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20483947'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20483947" class="external text external">20483947</a>.</cite></span></li><li id="cite_note-pmid25796182-124"> <span id="mw-reference-text-cite_note-pmid25796182-124" class="mw-reference-text"><cite id="CITEREFPlovanichWengMostaghimi2015" class="citation journal cs1">Plovanich M, Weng QY, Mostaghimi A (2015). "Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne". <i>JAMA Dermatol</i>. <b>151</b> (9): 941–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjamadermatol.2015.34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjamadermatol.2015.34'" tppabs="https://doi.org/10.1001%2Fjamadermatol.2015.34" class="external text external">10.1001/jamadermatol.2015.34</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25796182  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25796182'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25796182" class="external text external">25796182</a>.</cite></span></li><li id="cite_note-TsioufisSchmieder2016-125"> <span id="mw-reference-text-cite_note-TsioufisSchmieder2016-125" class="mw-reference-text"><cite id="CITEREFCostas_TsioufisRoland_SchmiederGiuseppe_Mancia2016" class="citation book cs1">Costas Tsioufis; Roland Schmieder; Giuseppe Mancia (15 August 2016). <a href="javascript:if(confirm('https://books.google.com/books?id=MFfYDAAAQBAJ&pg=PA44  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=MFfYDAAAQBAJ&pg=PA44'" tppabs="https://books.google.com/books?id=MFfYDAAAQBAJ&pg=PA44" class="external text external"><i>Interventional Therapies for Secondary and Essential Hypertension</i></a>. Springer. p.<span>&nbsp;</span>44. ISBN<span>&nbsp;</span><bdi>978-3-319-34141-5</bdi>. <q>Gynecomastia is dose related and reaches almost 50% with high spironolactone doses (&gt;150 mg daily), while it is much less common (5–10%) with low doses (25–50 mg spironolactone daily) [135].</q></cite></span></li><li id="cite_note-ConnJacobs1998-126"> <span id="mw-reference-text-cite_note-ConnJacobs1998-126" class="mw-reference-text"><cite id="CITEREFConnJacobs1998" class="citation journal cs1">Conn, Jennifer J.; Jacobs, Howard S. (1998). "Managing hirsutism in gynaecological practice". <i>BJOG: An International Journal of Obstetrics and Gynaecology</i>. <b>105</b> (7): 687–696. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1471-0528.1998.tb10197.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1471-0528.1998.tb10197.x'" tppabs="https://doi.org/10.1111%2Fj.1471-0528.1998.tb10197.x" class="external text external">10.1111/j.1471-0528.1998.tb10197.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1470-0328  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1470-0328'" tppabs="https://www.worldcat.org/issn/1470-0328" class="external text external">1470-0328</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9692407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9692407'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9692407" class="external text external">9692407</a>. <q>Breast tenderness is not uncommon and is recorded in up to 40% of women taking higher doses63.</q></cite></span></li><li id="cite_note-Elsevier2014-127"> <span id="mw-reference-text-cite_note-Elsevier2014-127" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=NfqxAwAAQBAJ&pg=PA293  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=NfqxAwAAQBAJ&pg=PA293'" tppabs="https://books.google.com/books?id=NfqxAwAAQBAJ&pg=PA293" class="external text external"><i>Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions</i></a>. Elsevier Science. 1 December 2014. p.<span>&nbsp;</span>293. ISBN<span>&nbsp;</span><bdi>978-0-444-63391-0</bdi>. <q>It is well known that gynecomastia is a side effect of spironolactone in men and occurs in a dose-dependent manner in ~7% of cases with doses of &lt;50 mg per day, and up to 50% of cases with doses of &gt;150 mg per day [40,41].</q></cite></span></li><li id="cite_note-McInnes2008-128"> <span id="mw-reference-text-cite_note-McInnes2008-128" class="mw-reference-text"><cite id="CITEREFGordon_T._McInnes2008" class="citation book cs1">Gordon T. McInnes (2008). <a href="javascript:if(confirm('https://books.google.com/books?id=9nqP9iz7NNAC&pg=PA125  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9nqP9iz7NNAC&pg=PA125'" tppabs="https://books.google.com/books?id=9nqP9iz7NNAC&pg=PA125" class="external text external"><i>Clinical Pharmacology and Therapeutics of Hypertension</i></a>. Elsevier. p.<span>&nbsp;</span>125. ISBN<span>&nbsp;</span><bdi>978-0-444-51757-9</bdi>. <q>Spironolactone lacks specificty for mineralocorticoid receptors and binds to both progesterone and dihydrotestosterone receptors. This can lead to various endocrine side effects that can limit the use of spironolactone. In females spironolactone can induce menstrual disturbances, breast enlargement and breast tenderness.78 In men spironolactone can induce gynecomastia and impotence. In RALES gynaecomastia or breast pain was reported by 10% of the men in the spironolactone group and 1% of the men in the placebo group (p&lt;0.001), causing more patients in the spironolactone group than in the placebo group to discontinue treatment, despite a mean spironolactone dose of 26 mg.18</q></cite></span></li><li id="cite_note-pmid15134800-129"> <span id="mw-reference-text-cite_note-pmid15134800-129" class="mw-reference-text"><cite id="CITEREFMénard2004" class="citation journal cs1">Ménard J (2004). "The 45-year story of the development of an anti-aldosterone more specific than spironolactone". <i>Mol. Cell. Endocrinol</i>. <b>217</b> (1–2): 45–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.mce.2003.10.008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.mce.2003.10.008'" tppabs="https://doi.org/10.1016%2Fj.mce.2003.10.008" class="external text external">10.1016/j.mce.2003.10.008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15134800  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15134800'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15134800" class="external text external">15134800</a>. <q>[Spironolactone] was synthesized after the demonstration of the natriuretic effect of progesterone (Landau et al., 1955).</q></cite></span></li><li id="cite_note-pmid8094898-130"> <span id="mw-reference-text-cite_note-pmid8094898-130" class="mw-reference-text"><cite id="CITEREFThompsonCarter1993" class="citation journal cs1">Thompson DF, Carter JR (1993). "Drug-induced gynecomastia". <i>Pharmacotherapy</i>. <b>13</b> (1): 37–45. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fj.1875-9114.1993.tb02688.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fj.1875-9114.1993.tb02688.x'" tppabs="https://doi.org/10.1002%2Fj.1875-9114.1993.tb02688.x" class="external text external">10.1002/j.1875-9114.1993.tb02688.x</a> (inactive 20 March 2020). PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8094898  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8094898'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8094898" class="external text external">8094898</a>.</cite></span></li><li id="cite_note-Wilcox2008-131"> <span id="mw-reference-text-cite_note-Wilcox2008-131" class="mw-reference-text"><cite id="CITEREFChristopher_S._Wilcox2008" class="citation book cs1">Christopher S. Wilcox (22 August 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=XcnpBdq84MEC&pg=PA607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=XcnpBdq84MEC&pg=PA607'" tppabs="https://books.google.com/books?id=XcnpBdq84MEC&pg=PA607" class="external text external"><i>Therapy in Nephrology and Hypertension E-Book: A Companion to Brenner &amp; Rector's The Kidney</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>607–. ISBN<span>&nbsp;</span><bdi>978-1-4377-1124-0</bdi>.</cite></span></li><li id="cite_note-pmid18983216-132"> <span id="mw-reference-text-cite_note-pmid18983216-132" class="mw-reference-text"><cite id="CITEREFEckmanDobs2008" class="citation journal cs1">Eckman A, Dobs A (November 2008). "Drug-induced gynecomastia". <i>Expert Opin Drug Saf</i>. <b>7</b> (6): 691–702. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14740330802442382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14740330802442382'" tppabs="https://doi.org/10.1517%2F14740330802442382" class="external text external">10.1517/14740330802442382</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18983216  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18983216'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18983216" class="external text external">18983216</a>.</cite></span></li><li id="cite_note-pmid11546925-133"> <span id="mw-reference-text-cite_note-pmid11546925-133" class="mw-reference-text"><cite id="CITEREFMathurBraunstein1997" class="citation journal cs1">Mathur R, Braunstein GD (1997). "Gynecomastia: pathomechanisms and treatment strategies". <i>Horm. Res</i>. <b>48</b> (3): 95–102. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000185497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000185497'" tppabs="https://doi.org/10.1159%2F000185497" class="external text external">10.1159/000185497</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11546925  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11546925'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11546925" class="external text external">11546925</a>.</cite></span></li><li id="cite_note-pmid16076921-134"> <span id="mw-reference-text-cite_note-pmid16076921-134" class="mw-reference-text"><cite id="CITEREFChristyFranksCross2005" class="citation journal cs1">Christy NA, Franks AS, Cross LB (September 2005). "Spironolactone for hirsutism in polycystic ovary syndrome". <i>Ann Pharmacother</i>. <b>39</b> (9): 1517–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1345%2Faph.1G025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1345%2Faph.1G025'" tppabs="https://doi.org/10.1345%2Faph.1G025" class="external text external">10.1345/aph.1G025</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16076921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16076921'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16076921" class="external text external">16076921</a>.</cite></span></li><li id="cite_note-pmid10792338-135"> <span id="mw-reference-text-cite_note-pmid10792338-135" class="mw-reference-text"><cite id="CITEREFSpritzerLisboaMattielloLhullier2000" class="citation journal cs1">Spritzer PM, Lisboa KO, Mattiello S, Lhullier F (May 2000). "Spironolactone as a single agent for long-term therapy of hirsute patients". <i>Clin. Endocrinol. (Oxf)</i>. <b>52</b> (5): 587–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2265.2000.00982.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2265.2000.00982.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2265.2000.00982.x" class="external text external">10.1046/j.1365-2265.2000.00982.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10792338  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10792338'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10792338" class="external text external">10792338</a>.</cite></span></li><li id="cite_note-RabeGrunwald2009-136"> <span id="mw-reference-text-cite_note-RabeGrunwald2009-136" class="mw-reference-text"><cite id="CITEREFRabeGrunwaldFeldmannRunnebaum2009" class="citation journal cs1">Rabe, T.; Grunwald, K.; Feldmann, K.; Runnebaum, B. (2009). "Treatment of hyperandrogenism in women". <i>Gynecological Endocrinology</i>. <b>10</b> (sup3): 1–44. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513599609045658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513599609045658'" tppabs="https://doi.org/10.3109%2F09513599609045658" class="external text external">10.3109/09513599609045658</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0951-3590  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0951-3590'" tppabs="https://www.worldcat.org/issn/0951-3590" class="external text external">0951-3590</a>.</cite></span></li><li id="cite_note-pmid8144871-137"> <span id="mw-reference-text-cite_note-pmid8144871-137" class="mw-reference-text"><cite id="CITEREFMcMullenVan_Herle1993" class="citation journal cs1">McMullen GR, Van Herle AJ (December 1993). "Hirsutism and the effectiveness of spironolactone in its management". <i>J. Endocrinol. Invest</i>. <b>16</b> (11): 925–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF03348960  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF03348960'" tppabs="https://doi.org/10.1007%2FBF03348960" class="external text external">10.1007/BF03348960</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8144871  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8144871'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8144871" class="external text external">8144871</a>.</cite></span></li><li id="cite_note-pmid2744183-138"> <span id="mw-reference-text-cite_note-pmid2744183-138" class="mw-reference-text"><cite id="CITEREFNakajimaBrumstedRiddickGibson1989" class="citation journal cs1">Nakajima ST, Brumsted JR, Riddick DH, Gibson M (1989). "Absence of progestational activity of oral spironolactone". <i>Fertil. Steril</i>. <b>52</b> (1): 155–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0015-0282%2816%2960807-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0015-0282%2816%2960807-5'" tppabs="https://doi.org/10.1016%2Fs0015-0282%2816%2960807-5" class="external text external">10.1016/s0015-0282(16)60807-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2744183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2744183'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2744183" class="external text external">2744183</a>.</cite></span></li><li id="cite_note-pmid32038990-139"> <span id="mw-reference-text-cite_note-pmid32038990-139" class="mw-reference-text"><cite id="CITEREFOlssonOlsson2020" class="citation journal cs1">Olsson HL, Olsson ML (2020). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993118  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993118'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993118" class="external text external">"The Menstrual Cycle and Risk of Breast Cancer: A Review"</a>. <i>Front Oncol</i>. <b>10</b>: 21. doi:<a href="javascript:if(confirm('https://doi.org/10.3389%2Ffonc.2020.00021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3389%2Ffonc.2020.00021'" tppabs="https://doi.org/10.3389%2Ffonc.2020.00021" class="external text external">10.3389/fonc.2020.00021</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993118  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993118'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993118" class="external text external">6993118</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32038990  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32038990'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32038990" class="external text external">32038990</a>.</cite></span></li><li id="cite_note-JemecRevuz2006-140"> <span id="mw-reference-text-cite_note-JemecRevuz2006-140" class="mw-reference-text"><cite id="CITEREFGregor_JemecJean_RevuzJames_J._Leyden2006" class="citation book cs1">Gregor Jemec; Jean Revuz; James J. Leyden (24 November 2006). <a href="javascript:if(confirm('https://books.google.com/books?id=hpKFsXwcKlgC&pg=PA125  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=hpKFsXwcKlgC&pg=PA125'" tppabs="https://books.google.com/books?id=hpKFsXwcKlgC&pg=PA125" class="external text external"><i>Hidradenitis Suppurativa</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>125–. ISBN<span>&nbsp;</span><bdi>978-3-540-33101-8</bdi>.</cite></span></li><li id="cite_note-pmid25459896-141"> <span id="mw-reference-text-cite_note-pmid25459896-141" class="mw-reference-text"><cite id="CITEREFter_HeegdeDe_RijkVinkers2015" class="citation journal cs1">ter Heegde F, De Rijk RH, Vinkers CH (February 2015). "The brain mineralocorticoid receptor and stress resilience". <i>Psychoneuroendocrinology</i>. <b>52</b>: 92–110. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.psyneuen.2014.10.022  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.psyneuen.2014.10.022'" tppabs="https://doi.org/10.1016%2Fj.psyneuen.2014.10.022" class="external text external">10.1016/j.psyneuen.2014.10.022</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25459896  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25459896'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25459896" class="external text external">25459896</a>.</cite></span></li><li id="cite_note-Schultebraucks2016-142"> <span id="mw-reference-text-cite_note-Schultebraucks2016-142" class="mw-reference-text"><cite id="CITEREFSchultebraucks2016" class="citation journal cs1">Schultebraucks, Katharina (2016). <a href="javascript:if(confirm('https://refubium.fu-berlin.de/handle/fub188/2739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://refubium.fu-berlin.de/handle/fub188/2739'" tppabs="https://refubium.fu-berlin.de/handle/fub188/2739" class="external text external">"The Role of the Mineralocorticoid Receptor for Cognitive Function, Mood and Social Cognition"</a> <span class="cs1-format">(PDF)</span>. doi:<a href="javascript:if(confirm('https://doi.org/10.17169%2Frefubium-6940  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.17169%2Frefubium-6940'" tppabs="https://doi.org/10.17169%2Frefubium-6940" class="external text external">10.17169/refubium-6940</a>. <q>[...] Taken together, there is evidence that the MR influences mood in healthy participants and patients with psychiatric disorders. However, due to the heterogeneous findings, it still remains unclear whether MR stimulation (e.g. fludrocortisone) or rather MR blockage (e.g. spironolactone) leads to better mood.</q></cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li><li id="cite_note-pmid10367986-143"> <span id="mw-reference-text-cite_note-pmid10367986-143" class="mw-reference-text"><cite id="CITEREFHolsboer1999" class="citation journal cs1">Holsboer F (1999). "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety". <i>J Psychiatr Res</i>. <b>33</b> (3): 181–214. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-3956%2898%2990056-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-3956%2898%2990056-5'" tppabs="https://doi.org/10.1016%2FS0022-3956%2898%2990056-5" class="external text external">10.1016/S0022-3956(98)90056-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10367986  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10367986'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10367986" class="external text external">10367986</a>.</cite></span></li><li id="cite_note-BassonPrior1997-144"> <span id="mw-reference-text-cite_note-BassonPrior1997-144" class="mw-reference-text"><cite id="CITEREFBassonPrior1998" class="citation book cs1">Basson, Rosemary; Prior, Jerilynn C (1998). <a href="javascript:if(confirm('https://books.google.com/books?id=zJBvR-Zy7LgC&pg=PA286  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=zJBvR-Zy7LgC&pg=PA286'" tppabs="https://books.google.com/books?id=zJBvR-Zy7LgC&pg=PA286" class="external text external">"Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual"</a>.  In Denny, Dallas (ed.). <i>Current Concepts in Transgender Identity</i>. Taylor &amp; Francis. pp.<span>&nbsp;</span>277–296. doi:<a href="javascript:if(confirm('https://doi.org/10.4324%2F9780203775134-28  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4324%2F9780203775134-28'" tppabs="https://doi.org/10.4324%2F9780203775134-28" class="external text external">10.4324/9780203775134-28</a> (inactive 20 March 2020). ISBN<span>&nbsp;</span><bdi>978-1134821105</bdi>.</cite></span></li><li id="cite_note-pmid19006114-145"> <span id="mw-reference-text-cite_note-pmid19006114-145" class="mw-reference-text"><cite id="CITEREFLopesLourençoMascarenhasAzevedo2008" class="citation journal cs1">Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P (November 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652974'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652974" class="external text external">"Safety of spironolactone use in ambulatory heart failure patients"</a>. <i>Clin Cardiol</i>. <b>31</b> (11): 509–13. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fclc.20284  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fclc.20284'" tppabs="https://doi.org/10.1002%2Fclc.20284" class="external text external">10.1002/clc.20284</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652974'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652974" class="external text external">6652974</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19006114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19006114'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19006114" class="external text external">19006114</a>.</cite></span></li><li id="cite_note-ThaiSinclair2001-146"> <span id="mw-reference-text-cite_note-ThaiSinclair2001-146" class="mw-reference-text"><cite id="CITEREFThaiSinclair2001" class="citation journal cs1">Thai, Keng-Ee; Sinclair, Rodney D (2001). "Spironolactone-induced hepatitis". <i>Australasian Journal of Dermatology</i>. <b>42</b> (3): 180–182. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1440-0960.2001.00510.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1440-0960.2001.00510.x'" tppabs="https://doi.org/10.1046%2Fj.1440-0960.2001.00510.x" class="external text external">10.1046/j.1440-0960.2001.00510.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0004-8380  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0004-8380'" tppabs="https://www.worldcat.org/issn/0004-8380" class="external text external">0004-8380</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11488711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11488711'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11488711" class="external text external">11488711</a>.</cite></span></li><li id="cite_note-147"> <span id="mw-reference-text-cite_note-147" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20150310163603/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150310163603/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm'" tppabs="https://web.archive.org/web/20150310163603/https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm" class="external text external">"Aldactazide (spironolactone/hydrochlorothiazide) Tablets"</a>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm'" tppabs="https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258786.htm" class="external text external">the original</a> on 10 March 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">3 March</span> 2014</span>.</cite></span></li><li id="cite_note-148"> <span id="mw-reference-text-cite_note-148" class="mw-reference-text">online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7699#f_adverse-reactions</span></li><li id="cite_note-pmid7195152-149"> <span id="mw-reference-text-cite_note-pmid7195152-149" class="mw-reference-text"><cite id="CITEREFAibaSuzukiKageyamaMurai1981" class="citation journal cs1">Aiba M, Suzuki H, Kageyama K, Murai M, Tazaki H, Abe O, Saruta T (June 1981). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903848  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903848'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903848" class="external text external">"Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa"</a>. <i>Am. J. Pathol</i>. <b>103</b> (3): 404–10. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903848  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903848'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1903848" class="external text external">1903848</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7195152  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7195152'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7195152" class="external text external">7195152</a>.</cite></span></li><li id="cite_note-Ainsworth2014-150"> <span id="mw-reference-text-cite_note-Ainsworth2014-150" class="mw-reference-text"><cite id="CITEREFSean_B._Ainsworth2014" class="citation book cs1">Sean B. Ainsworth (10 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA486  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA486'" tppabs="https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA486" class="external text external"><i>Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>486–. ISBN<span>&nbsp;</span><bdi>978-1-118-81959-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA486  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA486'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA486" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-Little2006-151"> <span id="mw-reference-text-cite_note-Little2006-151" class="mw-reference-text"><cite id="CITEREFBertis_Little2006" class="citation book cs1">Bertis Little (29 September 2006). <a href="javascript:if(confirm('https://books.google.com/books?id=lnySHcBjXsEC&pg=PA63  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=lnySHcBjXsEC&pg=PA63'" tppabs="https://books.google.com/books?id=lnySHcBjXsEC&pg=PA63" class="external text external"><i>Drugs and Pregnancy: A Handbook</i></a>. CRC Press. pp.<span>&nbsp;</span>63–. ISBN<span>&nbsp;</span><bdi>978-0-340-80917-4</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=lnySHcBjXsEC&pg=PA63  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=lnySHcBjXsEC&pg=PA63'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=lnySHcBjXsEC&pg=PA63" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-RubinRamsey2008-152"> <span id="mw-reference-text-cite_note-RubinRamsey2008-152" class="mw-reference-text"><cite id="CITEREFPeter_C._RubinMargaret_Ramsey2008" class="citation book cs1">Peter C. Rubin; Margaret Ramsey (30 April 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=2zHGHec53oMC&pg=PA83  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2zHGHec53oMC&pg=PA83'" tppabs="https://books.google.com/books?id=2zHGHec53oMC&pg=PA83" class="external text external"><i>Prescribing in Pregnancy</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>83–. ISBN<span>&nbsp;</span><bdi>978-0-470-69555-5</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=2zHGHec53oMC&pg=PA83  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=2zHGHec53oMC&pg=PA83'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=2zHGHec53oMC&pg=PA83" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-BriggsFreeman2011-153"> <span id="mw-reference-text-cite_note-BriggsFreeman2011-153" class="mw-reference-text"><cite id="CITEREFGerald_G._BriggsRoger_K._FreemanSumner_J._Yaffe2011" class="citation book cs1">Gerald G. Briggs; Roger K. Freeman; Sumner J. Yaffe (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=OIgTE4aynrMC&pg=PA1349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=OIgTE4aynrMC&pg=PA1349'" tppabs="https://books.google.com/books?id=OIgTE4aynrMC&pg=PA1349" class="external text external"><i>Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1349–. ISBN<span>&nbsp;</span><bdi>978-1-60831-708-0</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=OIgTE4aynrMC&pg=PA1349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=OIgTE4aynrMC&pg=PA1349'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=OIgTE4aynrMC&pg=PA1349" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-ElkayamGleicher1998-154"> <span id="mw-reference-text-cite_note-ElkayamGleicher1998-154" class="mw-reference-text"><cite id="CITEREFUri_ElkayamNorbert_Gleicher1998" class="citation book cs1">Uri Elkayam; Norbert Gleicher (23 June 1998). <a href="javascript:if(confirm('https://books.google.com/books?id=z6E-Hgeu1nYC&pg=PA353  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=z6E-Hgeu1nYC&pg=PA353'" tppabs="https://books.google.com/books?id=z6E-Hgeu1nYC&pg=PA353" class="external text external"><i>Cardiac Problems in Pregnancy: Diagnosis and Management of Maternal and Fetal Heart Disease</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>353–. ISBN<span>&nbsp;</span><bdi>978-0-471-16358-9</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=z6E-Hgeu1nYC&pg=PA353  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=z6E-Hgeu1nYC&pg=PA353'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=z6E-Hgeu1nYC&pg=PA353" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-Schaefer2001-155"> <span id="mw-reference-text-cite_note-Schaefer2001-155" class="mw-reference-text"><cite id="CITEREFChristof_Schaefer2001" class="citation book cs1">Christof Schaefer (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=CE569saGK70C&pg=PA115  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=CE569saGK70C&pg=PA115'" tppabs="https://books.google.com/books?id=CE569saGK70C&pg=PA115" class="external text external"><i>Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment</i></a>. Gulf Professional Publishing. pp.<span>&nbsp;</span>115, 143. ISBN<span>&nbsp;</span><bdi>978-0-444-50763-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=CE569saGK70C&pg=PA115  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=CE569saGK70C&pg=PA115'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=CE569saGK70C&pg=PA115" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-Upfal2006-156"> <span id="mw-reference-text-cite_note-Upfal2006-156" class="mw-reference-text"><cite id="CITEREFJonathan_Upfal2006" class="citation book cs1">Jonathan Upfal (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA671  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA671'" tppabs="https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA671" class="external text external"><i>Australian Drug Guide</i></a>. Black Inc. pp.<span>&nbsp;</span>671–. ISBN<span>&nbsp;</span><bdi>978-1-86395-174-6</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908165041/https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA671  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908165041/https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA671'" tppabs="https://web.archive.org/web/20170908165041/https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA671" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-pmid30352280-157"> <span id="mw-reference-text-cite_note-pmid30352280-157" class="mw-reference-text"><cite id="CITEREFLiszewskiBoull2019" class="citation journal cs1">Liszewski W, Boull C (April 2019). "Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review". <i>J. Am. Acad. Dermatol</i>. <b>80</b> (4): 1147–1148. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2018.10.023  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2018.10.023'" tppabs="https://doi.org/10.1016%2Fj.jaad.2018.10.023" class="external text external">10.1016/j.jaad.2018.10.023</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30352280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30352280'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30352280" class="external text external">30352280</a>.</cite></span></li><li id="cite_note-pmid15134797-158"> <span id="mw-reference-text-cite_note-pmid15134797-158" class="mw-reference-text"><cite id="CITEREFGarthwaiteMcMahon2004" class="citation journal cs1">Garthwaite SM, McMahon EG (March 2004). "The evolution of aldosterone antagonists". <i>Mol. Cell. Endocrinol</i>. <b>217</b> (1–2): 27–31. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.mce.2003.10.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.mce.2003.10.005'" tppabs="https://doi.org/10.1016%2Fj.mce.2003.10.005" class="external text external">10.1016/j.mce.2003.10.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15134797  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15134797'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15134797" class="external text external">15134797</a>.</cite></span></li><li id="cite_note-159"> <span id="mw-reference-text-cite_note-159" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20061115185827/http://www.losalt.com/docs/lo_salt_web_advice.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20061115185827/http://www.losalt.com/docs/lo_salt_web_advice.pdf'" tppabs="https://web.archive.org/web/20061115185827/http://www.losalt.com/docs/lo_salt_web_advice.pdf" class="external text external">"Advisory Statement"</a> <span class="cs1-format">(PDF)</span>. Klinge Chemicals / LoSalt. Archived from <a href="javascript:if(confirm('http://www.losalt.com/docs/lo_salt_web_advice.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.losalt.com/docs/lo_salt_web_advice.pdf'" tppabs="http://www.losalt.com/docs/lo_salt_web_advice.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 15 November 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">15 March</span> 2007</span>.</cite></span></li><li id="cite_note-160"> <span id="mw-reference-text-cite_note-160" class="mw-reference-text"><cite class="citation journal cs1">Plovanich M, Weng QY, Mostaghimi A (2015). "Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne". <i>JAMA Dermatology</i>. <b>151</b> (9): 941–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjamadermatol.2015.34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjamadermatol.2015.34'" tppabs="https://doi.org/10.1001%2Fjamadermatol.2015.34" class="external text external">10.1001/jamadermatol.2015.34</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25796182  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25796182'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25796182" class="external text external">25796182</a>.</cite></span></li><li id="cite_note-161"> <span id="mw-reference-text-cite_note-161" class="mw-reference-text"><cite id="CITEREFJuvetGourineniRaviZarich2013" class="citation journal cs1">Juvet T, Gourineni V, Ravi S, Zarich S (September 2013). "Life-threatening hyperkalemia: a potentially lethal drug combination". <i>Connecticut Medicine</i>. <b>77</b> (8): 491–493. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24156179  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24156179'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24156179" class="external text external">24156179</a>.</cite></span></li><li id="cite_note-Davis2009-162"> <span id="mw-reference-text-cite_note-Davis2009-162" class="mw-reference-text"><cite id="CITEREFMellar_P._Davis2009" class="citation book cs1">Mellar P. Davis (28 May 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=aEzg6i2nPMQC&pg=PA222  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=aEzg6i2nPMQC&pg=PA222'" tppabs="https://books.google.com/books?id=aEzg6i2nPMQC&pg=PA222" class="external text external"><i>Opioids in Cancer Pain</i></a>. OUP Oxford. pp.<span>&nbsp;</span>222–. ISBN<span>&nbsp;</span><bdi>978-0-19-923664-0</bdi>.</cite></span></li><li id="cite_note-pmid1826112-163"> <span id="mw-reference-text-cite_note-pmid1826112-163" class="mw-reference-text"><cite id="CITEREFShaw1991" class="citation journal cs1">Shaw JC (February 1991). "Spironolactone in dermatologic therapy". <i>J. Am. Acad. Dermatol</i>. <b>24</b> (2 Pt 1): 236–43. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0190-9622%2891%2970034-Y  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0190-9622%2891%2970034-Y'" tppabs="https://doi.org/10.1016%2F0190-9622%2891%2970034-Y" class="external text external">10.1016/0190-9622(91)70034-Y</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1826112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1826112'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1826112" class="external text external">1826112</a>.</cite></span></li><li id="cite_note-Wolverton2007-164"> <span id="mw-reference-text-cite_note-Wolverton2007-164" class="mw-reference-text"><cite id="CITEREFStephen_E._Wolverton2007" class="citation book cs1">Stephen E. Wolverton (8 March 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=AaJwq_X6U6MC&pg=PT2677  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=AaJwq_X6U6MC&pg=PT2677'" tppabs="https://books.google.com/books?id=AaJwq_X6U6MC&pg=PT2677" class="external text external"><i>Comprehensive Dermatologic Drug Therapy</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2677–. ISBN<span>&nbsp;</span><bdi>978-1-4377-2070-9</bdi>.</cite></span></li><li id="cite_note-pmid29756046-165"> <span id="mw-reference-text-cite_note-pmid29756046-165" class="mw-reference-text"><cite id="CITEREFLeinungFeustelJoseph2018" class="citation journal cs1">Leinung MC, Feustel PJ, Joseph J (2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393" class="external text external">"Hormonal Treatment of Transgender Women with Oral Estradiol"</a>. <i>Transgend Health</i>. <b>3</b> (1): 74–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1089%2Ftrgh.2017.0035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1089%2Ftrgh.2017.0035'" tppabs="https://doi.org/10.1089%2Ftrgh.2017.0035" class="external text external">10.1089/trgh.2017.0035</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944393" class="external text external">5944393</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29756046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29756046'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29756046" class="external text external">29756046</a>.</cite></span></li><li id="cite_note-JhajraRamesh_Varkhede2012-166"> <span id="mw-reference-text-cite_note-JhajraRamesh_Varkhede2012-166" class="mw-reference-text"><cite id="CITEREFJhajraRamesh_VarkhedeSuresh_AhireVidyasagar_Naik2012" class="citation book cs1">Jhajra, Shalu; Ramesh Varkhede, Ninad; Suresh Ahire, Deepak; Vidyasagar Naik, Bukke; Prasad, Bhagwat; Paliwal, Jyoti; Singh, Saranjit (2012). <i>Encyclopedia of Drug Metabolism and Interactions</i>. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F9780470921920.edm028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F9780470921920.edm028'" tppabs="https://doi.org/10.1002%2F9780470921920.edm028" class="external text external">10.1002/9780470921920.edm028</a>. ISBN<span>&nbsp;</span><bdi>9780470921920</bdi>.</cite></span></li><li id="cite_note-pmid27450358-167"> <span id="mw-reference-text-cite_note-pmid27450358-167" class="mw-reference-text"><cite id="CITEREFArmaniniAndrisaniBordinSabbadin2016" class="citation journal cs1">Armanini D, Andrisani A, Bordin L, Sabbadin C (2016). "Spironolactone in the treatment of polycystic ovary syndrome". <i>Expert Opin Pharmacother</i>. <b>17</b> (13): 1713–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F14656566.2016.1215430  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F14656566.2016.1215430'" tppabs="https://doi.org/10.1080%2F14656566.2016.1215430" class="external text external">10.1080/14656566.2016.1215430</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27450358  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27450358'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27450358" class="external text external">27450358</a>.</cite></span></li><li id="cite_note-pmid17113210-168"> <span id="mw-reference-text-cite_note-pmid17113210-168" class="mw-reference-text"><cite id="CITEREFArmaniniCastelloScaroniBonanni2007" class="citation journal cs1">Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P (2007). "Treatment of polycystic ovary syndrome with spironolactone plus licorice". <i>Eur. J. Obstet. Gynecol. Reprod. Biol</i>. <b>131</b> (1): 61–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejogrb.2006.10.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejogrb.2006.10.013'" tppabs="https://doi.org/10.1016%2Fj.ejogrb.2006.10.013" class="external text external">10.1016/j.ejogrb.2006.10.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17113210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17113210'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17113210" class="external text external">17113210</a>.</cite></span></li><li id="cite_note-pmid13991036-169"> <span id="mw-reference-text-cite_note-pmid13991036-169" class="mw-reference-text"><cite id="CITEREFSALASSAMATTOXROSEVEAR1962" class="citation journal cs1">SALASSA RM, MATTOX VR, ROSEVEAR JW (1962). "Inhibition of the "mineralocorticoid" activity of licorice by spironolactone". <i>J. Clin. Endocrinol. Metab</i>. <b>22</b> (11): 1156–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-22-11-1156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-22-11-1156'" tppabs="https://doi.org/10.1210%2Fjcem-22-11-1156" class="external text external">10.1210/jcem-22-11-1156</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/13991036  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/13991036'" tppabs="https://pubmed.ncbi.nlm.nih.gov/13991036" class="external text external">13991036</a>.</cite></span></li><li id="cite_note-pmid23185686-170"> <span id="mw-reference-text-cite_note-pmid23185686-170" class="mw-reference-text"><cite id="CITEREFOmarKomarovaEl-GhonemiFathy2012" class="citation journal cs1">Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, Yerramadha MR, Ali Y, Helal E, Camporesi EM (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498851  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498851'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498851" class="external text external">"Licorice abuse: time to send a warning message"</a>. <i>Ther Adv Endocrinol Metab</i>. <b>3</b> (4): 125–38. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F2042018812454322  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F2042018812454322'" tppabs="https://doi.org/10.1177%2F2042018812454322" class="external text external">10.1177/2042018812454322</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498851  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498851'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498851" class="external text external">3498851</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23185686  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23185686'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23185686" class="external text external">23185686</a>.</cite></span></li><li id="cite_note-pmid12640291-171"> <span id="mw-reference-text-cite_note-pmid12640291-171" class="mw-reference-text"><cite id="CITEREFLinYangChauHalperin2003" class="citation journal cs1">Lin SH, Yang SS, Chau T, Halperin ML (2003). "An unusual cause of hypokalemic paralysis: chronic licorice ingestion". <i>Am. J. Med. Sci</i>. <b>325</b> (3): 153–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00000441-200303000-00008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00000441-200303000-00008'" tppabs="https://doi.org/10.1097%2F00000441-200303000-00008" class="external text external">10.1097/00000441-200303000-00008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12640291  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12640291'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12640291" class="external text external">12640291</a>.</cite></span></li><li id="cite_note-pmid17362671-172"> <span id="mw-reference-text-cite_note-pmid17362671-172" class="mw-reference-text"><cite id="CITEREFParthasarathyMacDonald2007" class="citation journal cs1">Parthasarathy HK, MacDonald TM (2007). "Mineralocorticoid receptor antagonists". <i>Curr. Hypertens. Rep</i>. <b>9</b> (1): 45–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11906-007-0009-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11906-007-0009-3'" tppabs="https://doi.org/10.1007%2Fs11906-007-0009-3" class="external text external">10.1007/s11906-007-0009-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17362671  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17362671'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17362671" class="external text external">17362671</a>.</cite></span></li><li id="cite_note-173"> <span id="mw-reference-text-cite_note-173" class="mw-reference-text">Holsboer, F. The Rationale for Corticotropin-Releasing Hormone Receptor (CRH-R) Antagonists to Treat Depression and Anxiety. J. Psychiatr. Res. 33, 181–214 (1999).</span></li><li id="cite_note-pmid19909979-174"> <span id="mw-reference-text-cite_note-pmid19909979-174" class="mw-reference-text"><cite id="CITEREFOtteHinkelmannMoritz2010" class="citation journal cs1">Otte C, Hinkelmann K, Moritz S,  et al. (April 2010). "Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study". <i>J Psychiatr Res</i>. <b>44</b> (6): 339–46. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jpsychires.2009.10.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jpsychires.2009.10.006'" tppabs="https://doi.org/10.1016%2Fj.jpsychires.2009.10.006" class="external text external">10.1016/j.jpsychires.2009.10.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19909979  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19909979'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19909979" class="external text external">19909979</a>.</cite></span></li><li id="cite_note-pmid21515309-175"> <span id="mw-reference-text-cite_note-pmid21515309-175" class="mw-reference-text"><cite id="CITEREFMostalac-Preciadode_GortariLópez-Rubalcava2011" class="citation journal cs1">Mostalac-Preciado CR, de Gortari P, López-Rubalcava C (September 2011). "Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system". <i>Behav. Brain Res</i>. <b>223</b> (1): 88–98. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.bbr.2011.04.008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.bbr.2011.04.008'" tppabs="https://doi.org/10.1016%2Fj.bbr.2011.04.008" class="external text external">10.1016/j.bbr.2011.04.008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21515309  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21515309'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21515309" class="external text external">21515309</a>.</cite></span></li><li id="cite_note-AgustiBourgeois2013-176"> <span id="mw-reference-text-cite_note-AgustiBourgeois2013-176" class="mw-reference-text"><cite id="CITEREFAgustiBourgeoisCartiserFessi2013" class="citation journal cs1">Agusti, Géraldine; Bourgeois, Sandrine; Cartiser, Nathalie; Fessi, Hatem; Le Borgne, Marc; Lomberget, Thierry (2013). "A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone". <i>Steroids</i>. <b>78</b> (1): 102–107. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.steroids.2012.09.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.steroids.2012.09.005'" tppabs="https://doi.org/10.1016%2Fj.steroids.2012.09.005" class="external text external">10.1016/j.steroids.2012.09.005</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0039-128X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0039-128X'" tppabs="https://www.worldcat.org/issn/0039-128X" class="external text external">0039-128X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23063964  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23063964'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23063964" class="external text external">23063964</a>.</cite></span></li><li id="cite_note-CancerOrganization2001-177"> <span id="mw-reference-text-cite_note-CancerOrganization2001-177" class="mw-reference-text"><cite id="CITEREFInternational_Agency_for_Research_on_CancerWorld_Health_Organization2001" class="citation book cs1">International Agency for Research on Cancer; World Health Organization (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=l965aqw_LSkC&pg=PA325  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=l965aqw_LSkC&pg=PA325'" tppabs="https://books.google.com/books?id=l965aqw_LSkC&pg=PA325" class="external text external"><i>Some Thyrotropic Agents</i></a>. World Health Organization. pp.<span>&nbsp;</span>325–. ISBN<span>&nbsp;</span><bdi>978-92-832-1279-9</bdi>.</cite></span></li><li id="cite_note-Feldman2008-178"> <span id="mw-reference-text-cite_note-Feldman2008-178" class="mw-reference-text"><cite id="CITEREFArthur_M._Feldman2008" class="citation book cs1">Arthur M. Feldman (15 April 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=6IfumyQQ35wC&pg=PA89  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=6IfumyQQ35wC&pg=PA89'" tppabs="https://books.google.com/books?id=6IfumyQQ35wC&pg=PA89" class="external text external"><i>Heart Failure: Pharmacologic Management</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>89–103. ISBN<span>&nbsp;</span><bdi>978-1-4051-7253-0</bdi>.</cite></span></li><li id="cite_note-Health2015-179"> <span id="mw-reference-text-cite_note-Health2015-179" class="mw-reference-text"><cite id="CITEREFWolter_Kluwer_Health2015" class="citation book cs1">Wolter Kluwer Health (15 June 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=AK1fDwAAQBAJ&pg=PA248  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=AK1fDwAAQBAJ&pg=PA248'" tppabs="https://books.google.com/books?id=AK1fDwAAQBAJ&pg=PA248" class="external text external"><i>Pharmacology, 6th Ed, Karen Walar, 2015: Pharmacology</i></a>. Bukupedia. pp.<span>&nbsp;</span>248–249. GGKEY:N57K51AQ0UA.</cite></span></li><li id="cite_note-pmid24456327-180"> <span id="mw-reference-text-cite_note-pmid24456327-180" class="mw-reference-text"><cite id="CITEREFTamargoSeguraRuilope2014" class="citation journal cs1">Tamargo J, Segura J, Ruilope LM (April 2014). "Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents". <i>Expert Opin Pharmacother</i>. <b>15</b> (5): 605–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14656566.2014.879117  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14656566.2014.879117'" tppabs="https://doi.org/10.1517%2F14656566.2014.879117" class="external text external">10.1517/14656566.2014.879117</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24456327  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24456327'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24456327" class="external text external">24456327</a>.</cite></span></li><li id="cite_note-pmid11322868-181"> <span id="mw-reference-text-cite_note-pmid11322868-181" class="mw-reference-text"><cite id="CITEREFDoggrellBrown2001" class="citation journal cs1">Doggrell SA, Brown L (May 2001). "The spironolactone renaissance". <i>Expert Opin Investig Drugs</i>. <b>10</b> (5): 943–54. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F13543784.10.5.943  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F13543784.10.5.943'" tppabs="https://doi.org/10.1517%2F13543784.10.5.943" class="external text external">10.1517/13543784.10.5.943</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11322868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11322868'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11322868" class="external text external">11322868</a>.</cite></span></li><li id="cite_note-StraussIII2013-182"> <span id="mw-reference-text-cite_note-StraussIII2013-182" class="mw-reference-text"><cite id="CITEREFJerome_F._StraussJerome_F._Strauss,_IIIRobert_L._Barbieri2013" class="citation book cs1">Jerome F. Strauss; Jerome F. Strauss, III; Robert L. Barbieri (13 September 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA237  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA237'" tppabs="https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA237" class="external text external"><i>Yen and Jaffe's Reproductive Endocrinology</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>237–. ISBN<span>&nbsp;</span><bdi>978-1-4557-2758-2</bdi>.</cite></span></li><li id="cite_note-pmid2941190-183"> <span id="mw-reference-text-cite_note-pmid2941190-183" class="mw-reference-text"><cite id="CITEREFTremblay1986" class="citation journal cs1">Tremblay RR (May 1986). "Treatment of hirsutism with spironolactone". <i>Clin Endocrinol Metab</i>. <b>15</b> (2): 363–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0300-595X%2886%2980030-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0300-595X%2886%2980030-5'" tppabs="https://doi.org/10.1016%2FS0300-595X%2886%2980030-5" class="external text external">10.1016/S0300-595X(86)80030-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2941190  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2941190'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2941190" class="external text external">2941190</a>.</cite></span></li><li id="cite_note-GregoryTravis2015-184"> <span id="mw-reference-text-cite_note-GregoryTravis2015-184" class="mw-reference-text"><cite id="CITEREFHaff,_G._GregoryTriplett,_N._Travis2015" class="citation book cs1">Haff, G. Gregory; Triplett, N. Travis (23 September 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=bfuXCgAAQBAJ&pg=PA76  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=bfuXCgAAQBAJ&pg=PA76'" tppabs="https://books.google.com/books?id=bfuXCgAAQBAJ&pg=PA76" class="external text external"><i>Essentials of Strength Training and Conditioning 4th Edition</i></a>. Human Kinetics. pp.<span>&nbsp;</span>76–. ISBN<span>&nbsp;</span><bdi>978-1-4925-0162-6</bdi>.</cite></span></li><li id="cite_note-BenniVemer1990-185"> <span id="mw-reference-text-cite_note-BenniVemer1990-185" class="mw-reference-text"><cite id="CITEREFH.J.T._Coelingh_BenniH.M._Vemer1990" class="citation book cs1">H.J.T. Coelingh Benni; H.M. Vemer (15 December 1990). <a href="javascript:if(confirm('https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA152  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA152'" tppabs="https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA152" class="external text external"><i>Chronic Hyperandrogenic Anovulation</i></a>. CRC Press. pp.<span>&nbsp;</span>152–. ISBN<span>&nbsp;</span><bdi>978-1-85070-322-8</bdi>.</cite></span></li><li id="cite_note-pmid8915726-186"> <span id="mw-reference-text-cite_note-pmid8915726-186" class="mw-reference-text"><cite class="citation journal cs1">Shaw JC (November 1996). "Antiandrogen therapy in dermatology". <i>Int. J. Dermatol</i>. <b>35</b> (11): 770–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-4362.1996.tb02970.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-4362.1996.tb02970.x'" tppabs="https://doi.org/10.1111%2Fj.1365-4362.1996.tb02970.x" class="external text external">10.1111/j.1365-4362.1996.tb02970.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8915726  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8915726'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8915726" class="external text external">8915726</a>.</cite></span></li><li id="cite_note-pmid6786868-187"> <span id="mw-reference-text-cite_note-pmid6786868-187" class="mw-reference-text"><cite id="CITEREFColby1981" class="citation journal cs1">Colby HD (April 1981). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568425  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568425'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568425" class="external text external">"Chemical suppression of steroidogenesis"</a>. <i>Environ. Health Perspect</i>. <b>38</b>: 119–27. doi:<a href="javascript:if(confirm('https://doi.org/10.1289%2Fehp.8138119  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1289%2Fehp.8138119'" tppabs="https://doi.org/10.1289%2Fehp.8138119" class="external text external">10.1289/ehp.8138119</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568425  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568425'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568425" class="external text external">1568425</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6786868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6786868'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6786868" class="external text external">6786868</a>.</cite></span></li><li id="cite_note-pmid26001184-188"> <span id="mw-reference-text-cite_note-pmid26001184-188" class="mw-reference-text"><cite id="CITEREFRoccaVenturellaMocciaroDi_Cello2015" class="citation journal cs1">Rocca ML, Venturella R, Mocciaro R, Di Cello A, Sacchinelli A, Russo V, Trapasso S, Zullo F, Morelli M (June 2015). "Polycystic ovary syndrome: chemical pharmacotherapy". <i>Expert Opin Pharmacother</i>. <b>16</b> (9): 1369–93. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14656566.2015.1047344  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14656566.2015.1047344'" tppabs="https://doi.org/10.1517%2F14656566.2015.1047344" class="external text external">10.1517/14656566.2015.1047344</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26001184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26001184'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26001184" class="external text external">26001184</a>.</cite></span></li><li id="cite_note-pmid18819053-189"> <span id="mw-reference-text-cite_note-pmid18819053-189" class="mw-reference-text"><cite id="CITEREFYeYamashitaPollockSasano2009" class="citation journal cs1">Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE (January 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277847  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277847'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277847" class="external text external">"Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis"</a>. <i>Horm. Metab. Res</i>. <b>41</b> (1): 35–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1055%2Fs-0028-1087188  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1055%2Fs-0028-1087188'" tppabs="https://doi.org/10.1055%2Fs-0028-1087188" class="external text external">10.1055/s-0028-1087188</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277847  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277847'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277847" class="external text external">4277847</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18819053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18819053'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18819053" class="external text external">18819053</a>.</cite></span></li><li id="cite_note-WattsFaingold2009-190"> <span id="mw-reference-text-cite_note-WattsFaingold2009-190" class="mw-reference-text"><cite id="CITEREFStephanie_WattsCarl_FaingoldGeorge_DunawayLynn_Crespo2009" class="citation book cs1">Stephanie Watts; Carl Faingold; George Dunaway; Lynn Crespo (1 April 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=kfsrz_-OrMQC&pg=PA472  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=kfsrz_-OrMQC&pg=PA472'" tppabs="https://books.google.com/books?id=kfsrz_-OrMQC&pg=PA472" class="external text external"><i>Brody's Human Pharmacology - E-Book</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>472–. ISBN<span>&nbsp;</span><bdi>978-0-323-07575-6</bdi>.</cite></span></li><li id="cite_note-pmid12477487-191"> <span id="mw-reference-text-cite_note-pmid12477487-191" class="mw-reference-text"><cite id="CITEREFSatohItohSekiItoh2002" class="citation journal cs1">Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I (October 2002). "On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production". <i>The Journal of Steroid Biochemistry and Molecular Biology</i>. <b>82</b> (2–3): 209–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0960-0760%2802%2900154-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0960-0760%2802%2900154-1'" tppabs="https://doi.org/10.1016%2FS0960-0760%2802%2900154-1" class="external text external">10.1016/S0960-0760(02)00154-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12477487  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12477487'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12477487" class="external text external">12477487</a>.</cite></span></li><li id="cite_note-pmid907238-192"> <span id="mw-reference-text-cite_note-pmid907238-192" class="mw-reference-text"><cite id="CITEREFRoseUnderwoodNewmarkKisch1977" class="citation journal cs1">Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (October 1977). "Pathophysiology of spironolactone-induced gynecomastia". <i>Annals of Internal Medicine</i>. <b>87</b> (4): 398–403. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-87-4-398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-87-4-398'" tppabs="https://doi.org/10.7326%2F0003-4819-87-4-398" class="external text external">10.7326/0003-4819-87-4-398</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/907238  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/907238'" tppabs="https://pubmed.ncbi.nlm.nih.gov/907238" class="external text external">907238</a>.</cite></span></li><li id="cite_note-pmid12570693-193"> <span id="mw-reference-text-cite_note-pmid12570693-193" class="mw-reference-text"><cite id="CITEREFPoirier2003" class="citation journal cs1">Poirier D (2003). "Inhibitors of 17 beta-hydroxysteroid dehydrogenases". <i>Curr. Med. Chem</i>. <b>10</b> (6): 453–77. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F0929867033368222  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F0929867033368222'" tppabs="https://doi.org/10.2174%2F0929867033368222" class="external text external">10.2174/0929867033368222</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12570693  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12570693'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12570693" class="external text external">12570693</a>.</cite></span></li><li id="cite_note-pmid19601747-194"> <span id="mw-reference-text-cite_note-pmid19601747-194" class="mw-reference-text"><cite id="CITEREFPoirier2009" class="citation journal cs1">Poirier D (2009). "Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases". <i>Anticancer Agents Med Chem</i>. <b>9</b> (6): 642–60. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F187152009788680000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F187152009788680000'" tppabs="https://doi.org/10.2174%2F187152009788680000" class="external text external">10.2174/187152009788680000</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19601747  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19601747'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19601747" class="external text external">19601747</a>.</cite></span></li><li id="cite_note-pmid24189467-195"> <span id="mw-reference-text-cite_note-pmid24189467-195" class="mw-reference-text"><cite id="CITEREFBiggarAndersenWohlfahrtMelbye2013" class="citation journal cs1">Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M (2013). "Spironolactone use and the risk of breast and gynecologic cancers". <i>Cancer Epidemiol</i>. <b>37</b> (6): 870–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.canep.2013.10.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.canep.2013.10.004'" tppabs="https://doi.org/10.1016%2Fj.canep.2013.10.004" class="external text external">10.1016/j.canep.2013.10.004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24189467  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24189467'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24189467" class="external text external">24189467</a>.</cite></span></li><li id="cite_note-pmid26230882-196"> <span id="mw-reference-text-cite_note-pmid26230882-196" class="mw-reference-text"><cite id="CITEREFSoubhyeAlardvan_AntwerpenDufrasne2015" class="citation journal cs1">Soubhye J, Alard IC, van Antwerpen P, Dufrasne F (2015). "Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis". <i>Future Med Chem</i>. <b>7</b> (11): 1431–56. doi:<a href="javascript:if(confirm('https://doi.org/10.4155%2Ffmc.15.74  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4155%2Ffmc.15.74'" tppabs="https://doi.org/10.4155%2Ffmc.15.74" class="external text external">10.4155/fmc.15.74</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26230882  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26230882'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26230882" class="external text external">26230882</a>.</cite></span></li><li id="cite_note-Adams2014-197"> <span id="mw-reference-text-cite_note-Adams2014-197" class="mw-reference-text"><cite id="CITEREFKirkwood_F._Adams2014" class="citation book cs1">Kirkwood F. Adams (28 October 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=KNWlBAAAQBAJ&pg=PA562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KNWlBAAAQBAJ&pg=PA562'" tppabs="https://books.google.com/books?id=KNWlBAAAQBAJ&pg=PA562" class="external text external"><i>Pharmacologic Approaches to Heart Failure, An Issue of Heart Failure Clinics, E-Book</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>562–. ISBN<span>&nbsp;</span><bdi>978-0-323-32612-4</bdi>.</cite></span></li><li id="cite_note-pmid22836869-198"> <span id="mw-reference-text-cite_note-pmid22836869-198" class="mw-reference-text"><cite id="CITEREFBerardelliKaramouzisD'AngeloZichi2013" class="citation journal cs1">Berardelli R, Karamouzis I, D'Angelo V, Zichi C, Fussotto B, Giordano R, Ghigo E, Arvat E (February 2013). "Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans". <i>Endocrine</i>. <b>43</b> (1): 51–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs12020-012-9750-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs12020-012-9750-8'" tppabs="https://doi.org/10.1007%2Fs12020-012-9750-8" class="external text external">10.1007/s12020-012-9750-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22836869  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22836869'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22836869" class="external text external">22836869</a>.</cite></span></li><li id="cite_note-pmid17035932-199"> <span id="mw-reference-text-cite_note-pmid17035932-199" class="mw-reference-text"><cite id="CITEREFOtteMoritzYassouridis2007" class="citation journal cs1">Otte C, Moritz S, Yassouridis A,  et al. (January 2007). "Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition". <i>Neuropsychopharmacology</i>. <b>32</b> (1): 232–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.npp.1301217  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.npp.1301217'" tppabs="https://doi.org/10.1038%2Fsj.npp.1301217" class="external text external">10.1038/sj.npp.1301217</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17035932  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17035932'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17035932" class="external text external">17035932</a>.</cite></span></li><li id="cite_note-pmid27519144-200"> <span id="mw-reference-text-cite_note-pmid27519144-200" class="mw-reference-text"><cite id="CITEREFHinkelmannHellmann-RegenWingenfeldKuehl2016" class="citation journal cs1">Hinkelmann K, Hellmann-Regen J, Wingenfeld K, Kuehl LK, Mews M, Fleischer J, Heuser I, Otte C (November 2016). "Mineralocorticoid receptor function in depressed patients and healthy individuals". <i>Prog. Neuropsychopharmacol. Biol. Psychiatry</i>. <b>71</b>: 183–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pnpbp.2016.08.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pnpbp.2016.08.003'" tppabs="https://doi.org/10.1016%2Fj.pnpbp.2016.08.003" class="external text external">10.1016/j.pnpbp.2016.08.003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27519144  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27519144'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27519144" class="external text external">27519144</a>.</cite></span></li><li id="cite_note-FalconeHurd2007-201"> <span id="mw-reference-text-cite_note-FalconeHurd2007-201" class="mw-reference-text"><cite id="CITEREFTommaso_FalconeWilliam_W._Hurd2007" class="citation book cs1">Tommaso Falcone; William W. Hurd (1 January 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA271  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA271'" tppabs="https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA271" class="external text external"><i>Clinical Reproductive Medicine and Surgery</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>271–. ISBN<span>&nbsp;</span><bdi>978-0-323-03309-1</bdi>.</cite></span></li><li id="cite_note-pmid628197-202"> <span id="mw-reference-text-cite_note-pmid628197-202" class="mw-reference-text"><cite id="CITEREFAbshagenSpörlL'age1978" class="citation journal cs1">Abshagen U, Spörl S, L'age M (February 1978). "Non-interaction of spironolactone medication and cortisol metabolism in man". <i>Klin. Wochenschr</i>. <b>56</b> (3): 135–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF01478568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF01478568'" tppabs="https://doi.org/10.1007%2FBF01478568" class="external text external">10.1007/BF01478568</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/628197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/628197'" tppabs="https://pubmed.ncbi.nlm.nih.gov/628197" class="external text external">628197</a>.</cite></span></li><li id="cite_note-pmid21095280-203"> <span id="mw-reference-text-cite_note-pmid21095280-203" class="mw-reference-text"><cite id="CITEREFYamajiTsutamotoKawaharaNishiyama2010" class="citation journal cs1">Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M (November 2010). "Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure". <i>Am. Heart J</i>. <b>160</b> (5): 915–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ahj.2010.04.024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ahj.2010.04.024'" tppabs="https://doi.org/10.1016%2Fj.ahj.2010.04.024" class="external text external">10.1016/j.ahj.2010.04.024</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21095280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21095280'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21095280" class="external text external">21095280</a>.</cite></span></li><li id="cite_note-KuntzKuntz2009-204"> <span id="mw-reference-text-cite_note-KuntzKuntz2009-204" class="mw-reference-text"><cite id="CITEREFErwin_KuntzHans-Dieter_Kuntz2009" class="citation book cs1">Erwin Kuntz; Hans-Dieter Kuntz (11 March 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=oL6d9KuVqLQC&pg=PA312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=oL6d9KuVqLQC&pg=PA312'" tppabs="https://books.google.com/books?id=oL6d9KuVqLQC&pg=PA312" class="external text external"><i>Hepatology: Textbook and Atlas</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>312–. ISBN<span>&nbsp;</span><bdi>978-3-540-76839-5</bdi>.</cite></span></li><li id="cite_note-MelmedPolonsky2011-205"> <span id="mw-reference-text-cite_note-MelmedPolonsky2011-205" class="mw-reference-text"><cite id="CITEREFShlomo_MelmedKenneth_S._PolonskyP._Reed_LarsenHenry_M._Kronenberg2011" class="citation book cs1">Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (12 May 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=nbg1QOAObicC&pg=PA571  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=nbg1QOAObicC&pg=PA571'" tppabs="https://books.google.com/books?id=nbg1QOAObicC&pg=PA571" class="external text external"><i>Williams Textbook of Endocrinology E-Book</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>571–. ISBN<span>&nbsp;</span><bdi>978-1-4377-3600-7</bdi>.</cite></span></li><li id="cite_note-pmid12372848-206"> <span id="mw-reference-text-cite_note-pmid12372848-206" class="mw-reference-text"><cite id="CITEREFKliewerGoodwinWillson2002" class="citation journal cs1">Kliewer SA, Goodwin B, Willson TM (October 2002). "The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism". <i>Endocr. Rev</i>. <b>23</b> (5): 687–702. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fer.2001-0038  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fer.2001-0038'" tppabs="https://doi.org/10.1210%2Fer.2001-0038" class="external text external">10.1210/er.2001-0038</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12372848  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12372848'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12372848" class="external text external">12372848</a>.</cite></span></li><li id="cite_note-pmid27072668-207"> <span id="mw-reference-text-cite_note-pmid27072668-207" class="mw-reference-text"><cite id="CITEREFSabbadinAndrisaniZermianiDonà2016" class="citation journal cs1">Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, Boscaro M, Ambrosini G, Armanini D (2016). "Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI". <i>J. Endocrinol. Invest</i>. <b>39</b> (9): 1015–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40618-016-0466-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40618-016-0466-0'" tppabs="https://doi.org/10.1007%2Fs40618-016-0466-0" class="external text external">10.1007/s40618-016-0466-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27072668  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27072668'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27072668" class="external text external">27072668</a>.</cite></span></li><li id="cite_note-Delyani2000-208"> <span id="mw-reference-text-cite_note-Delyani2000-208" class="mw-reference-text"><cite class="citation journal cs1">Delyani, John A (2000). "Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology". <i>Kidney International</i>. <b>57</b> (4): 1408–1411. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1523-1755.2000.00983.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1523-1755.2000.00983.x'" tppabs="https://doi.org/10.1046%2Fj.1523-1755.2000.00983.x" class="external text external">10.1046/j.1523-1755.2000.00983.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0085-2538  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0085-2538'" tppabs="https://www.worldcat.org/issn/0085-2538" class="external text external">0085-2538</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10760075  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10760075'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10760075" class="external text external">10760075</a>.</cite></span></li><li id="cite_note-pmid9727070-209"> <span id="mw-reference-text-cite_note-pmid9727070-209" class="mw-reference-text"><cite id="CITEREFLehmannMcKeeWatsonWillson1998" class="citation journal cs1">Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (September 1998). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967" class="external text external">"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions"</a>. <i>J. Clin. Invest</i>. <b>102</b> (5): 1016–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1172%2FJCI3703  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1172%2FJCI3703'" tppabs="https://doi.org/10.1172%2FJCI3703" class="external text external">10.1172/JCI3703</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967" class="external text external">508967</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9727070  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9727070'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9727070" class="external text external">9727070</a>.</cite></span></li><li id="cite_note-pmid363379-210"> <span id="mw-reference-text-cite_note-pmid363379-210" class="mw-reference-text"><cite id="CITEREFKarim1978" class="citation journal cs1">Karim A (1978). "Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability". <i>Drug Metab. Rev</i>. <b>8</b> (1): 151–88. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F03602537808993782  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F03602537808993782'" tppabs="https://doi.org/10.3109%2F03602537808993782" class="external text external">10.3109/03602537808993782</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/363379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/363379'" tppabs="https://pubmed.ncbi.nlm.nih.gov/363379" class="external text external">363379</a>.</cite></span></li><li id="cite_note-pmid6369882-211"> <span id="mw-reference-text-cite_note-pmid6369882-211" class="mw-reference-text"><cite id="CITEREFBeermann1984" class="citation journal cs1">Beermann B (1984). "Aspects on pharmacokinetics of some diuretics". <i>Acta Pharmacol Toxicol (Copenh)</i>. 54 Suppl 1: 17–29. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1600-0773.1984.tb03626.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1600-0773.1984.tb03626.x'" tppabs="https://doi.org/10.1111%2Fj.1600-0773.1984.tb03626.x" class="external text external">10.1111/j.1600-0773.1984.tb03626.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6369882  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6369882'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6369882" class="external text external">6369882</a>.</cite></span></li><li id="cite_note-pmid3333882-212"> <span id="mw-reference-text-cite_note-pmid3333882-212" class="mw-reference-text"><cite id="CITEREFOverdiekMerkus1987" class="citation journal cs1">Overdiek HW, Merkus FW (1987). "The metabolism and biopharmaceutics of spironolactone in man". <i>Rev Drug Metab Drug Interact</i>. <b>5</b> (4): 273–302. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2FDMDI.1987.5.4.273  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2FDMDI.1987.5.4.273'" tppabs="https://doi.org/10.1515%2FDMDI.1987.5.4.273" class="external text external">10.1515/DMDI.1987.5.4.273</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3333882  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3333882'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3333882" class="external text external">3333882</a>.</cite></span></li><li id="cite_note-pmid15947888-213"> <span id="mw-reference-text-cite_note-pmid15947888-213" class="mw-reference-text"><cite class="citation journal cs1">Sica DA (January 2005). "Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis". <i>Heart Fail Rev</i>. <b>10</b> (1): 23–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10741-005-2345-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10741-005-2345-1'" tppabs="https://doi.org/10.1007%2Fs10741-005-2345-1" class="external text external">10.1007/s10741-005-2345-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15947888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15947888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15947888" class="external text external">15947888</a>.</cite></span></li><li id="cite_note-pmid22099505-214"> <span id="mw-reference-text-cite_note-pmid22099505-214" class="mw-reference-text"><cite id="CITEREFBrater2011" class="citation journal cs1">Brater DC (November 2011). "Update in diuretic therapy: clinical pharmacology". <i>Semin. Nephrol</i>. <b>31</b> (6): 483–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.semnephrol.2011.09.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.semnephrol.2011.09.003'" tppabs="https://doi.org/10.1016%2Fj.semnephrol.2011.09.003" class="external text external">10.1016/j.semnephrol.2011.09.003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22099505  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22099505'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22099505" class="external text external">22099505</a>.</cite></span></li><li id="cite_note-pmid21771637-215"> <span id="mw-reference-text-cite_note-pmid21771637-215" class="mw-reference-text"><cite id="CITEREFKolkhofBorden2012" class="citation journal cs1">Kolkhof P, Borden SA (March 2012). "Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics". <i>Mol. Cell. Endocrinol</i>. <b>350</b> (2): 310–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.mce.2011.06.025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.mce.2011.06.025'" tppabs="https://doi.org/10.1016%2Fj.mce.2011.06.025" class="external text external">10.1016/j.mce.2011.06.025</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21771637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21771637'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21771637" class="external text external">21771637</a>.</cite></span></li><li id="cite_note-pmid26939027-216"> <span id="mw-reference-text-cite_note-pmid26939027-216" class="mw-reference-text"><cite id="CITEREFYangYoung2016" class="citation journal cs1">Yang J, Young MJ (April 2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". <i>Curr Opin Pharmacol</i>. <b>27</b>: 78–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.coph.2016.02.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.coph.2016.02.005'" tppabs="https://doi.org/10.1016%2Fj.coph.2016.02.005" class="external text external">10.1016/j.coph.2016.02.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26939027  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26939027'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26939027" class="external text external">26939027</a>.</cite></span></li><li id="cite_note-pmid27830348-217"> <span id="mw-reference-text-cite_note-pmid27830348-217" class="mw-reference-text"><cite id="CITEREFKolkhofJaisserKimFilippatos2017" class="citation book cs1">Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B (2017). <i>Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside</i>. <i>Handb Exp Pharmacol</i>. Handbook of Experimental Pharmacology. <b>243</b>. pp.<span>&nbsp;</span>271–305. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F164_2016_76  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F164_2016_76'" tppabs="https://doi.org/10.1007%2F164_2016_76" class="external text external">10.1007/164_2016_76</a>. ISBN<span>&nbsp;</span><bdi>978-3-319-59658-7</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27830348  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27830348'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27830348" class="external text external">27830348</a>.</cite></span></li><li id="cite_note-pmid8818057-218"> <span id="mw-reference-text-cite_note-pmid8818057-218" class="mw-reference-text"><cite id="CITEREFJankowskiSkorek-JankowskaLamparczyk1996" class="citation journal cs1">Jankowski A, Skorek-Jankowska A, Lamparczyk H (June 1996). "Simultaneous determination of spironolactone and its metabolites in human plasma". <i>J Pharm Biomed Anal</i>. <b>14</b> (8–10): 1359–65. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0731-7085%2896%2901767-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0731-7085%2896%2901767-0'" tppabs="https://doi.org/10.1016%2FS0731-7085%2896%2901767-0" class="external text external">10.1016/S0731-7085(96)01767-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8818057  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8818057'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8818057" class="external text external">8818057</a>.</cite></span></li><li id="cite_note-DeinumRiksen2015-219"> <span id="mw-reference-text-cite_note-DeinumRiksen2015-219" class="mw-reference-text"><cite id="CITEREFDeinumRiksenLenders2015" class="citation journal cs1">Deinum, Jaap; Riksen, Niels P.; Lenders, Jacques W.M. (2015). "Pharmacological treatment of aldosterone excess". <i>Pharmacology &amp; Therapeutics</i>. <b>154</b>: 120–133. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pharmthera.2015.07.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pharmthera.2015.07.006'" tppabs="https://doi.org/10.1016%2Fj.pharmthera.2015.07.006" class="external text external">10.1016/j.pharmthera.2015.07.006</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0163-7258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0163-7258'" tppabs="https://www.worldcat.org/issn/0163-7258" class="external text external">0163-7258</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26213109  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26213109'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26213109" class="external text external">26213109</a>.</cite></span></li><li id="cite_note-pmid3769384-220"> <span id="mw-reference-text-cite_note-pmid3769384-220" class="mw-reference-text"><cite id="CITEREFOverdiekMerkus1986" class="citation journal cs1">Overdiek HW, Merkus FW (November 1986). "Influence of food on the bioavailability of spironolactone". <i>Clinical Pharmacology and Therapeutics</i>. <b>40</b> (5): 531–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fclpt.1986.219  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fclpt.1986.219'" tppabs="https://doi.org/10.1038%2Fclpt.1986.219" class="external text external">10.1038/clpt.1986.219</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3769384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3769384'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3769384" class="external text external">3769384</a>.</cite></span></li><li id="cite_note-pmid872489-221"> <span id="mw-reference-text-cite_note-pmid872489-221" class="mw-reference-text"><cite id="CITEREFMelanderDanielsonSchersténThulin1977" class="citation journal cs1">Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E (July 1977). "Enhancement by food of canrenone bioavailability from spironolactone". <i>Clinical Pharmacology and Therapeutics</i>. <b>22</b> (1): 100–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcpt1977221100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcpt1977221100'" tppabs="https://doi.org/10.1002%2Fcpt1977221100" class="external text external">10.1002/cpt1977221100</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/872489  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/872489'" tppabs="https://pubmed.ncbi.nlm.nih.gov/872489" class="external text external">872489</a>.</cite></span></li><li id="cite_note-Saini-ChohanHatch2009-222"> <span id="mw-reference-text-cite_note-Saini-ChohanHatch2009-222" class="mw-reference-text"><cite id="CITEREFSaini-ChohanHatch2009" class="citation journal cs1">Saini-Chohan, Harjot; Hatch, Grant (2009). "Biological Actions and Metabolism of Currently Used Pharmacological Agents for the Treatment of Congestive Heart Failure". <i>Current Drug Metabolism</i>. <b>10</b> (3): 206–219. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F138920009787846314  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F138920009787846314'" tppabs="https://doi.org/10.2174%2F138920009787846314" class="external text external">10.2174/138920009787846314</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1389-2002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1389-2002'" tppabs="https://www.worldcat.org/issn/1389-2002" class="external text external">1389-2002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19442083  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19442083'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19442083" class="external text external">19442083</a>.</cite></span></li><li id="cite_note-Al-HadiyaBelal2002-223"> <span id="mw-reference-text-cite_note-Al-HadiyaBelal2002-223" class="mw-reference-text"><cite id="CITEREFAl-HadiyaBelalAsiriGubara2002" class="citation book cs1">Al-Hadiya, Badraddin M.H.; Belal, Fathalla; Asiri, Yousif A.; Gubara, Othman A. (2002). <i>Spironolactone</i>. <i>Analytical Profiles of Drug Substances and Excipients^</i>. Analytical Profiles of Drug Substances and Excipients. <b>29</b>. pp.<span>&nbsp;</span>261–320. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1075-6280%2802%2929009-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1075-6280%2802%2929009-6'" tppabs="https://doi.org/10.1016%2FS1075-6280%2802%2929009-6" class="external text external">10.1016/S1075-6280(02)29009-6</a>. ISBN<span>&nbsp;</span><bdi>9780122608292</bdi>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1075-6280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1075-6280'" tppabs="https://www.worldcat.org/issn/1075-6280" class="external text external">1075-6280</a>.</cite></span></li><li id="cite_note-Elsevier2019-224"> <span id="mw-reference-text-cite_note-Elsevier2019-224" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=5daEDwAAQBAJ&pg=PA11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5daEDwAAQBAJ&pg=PA11'" tppabs="https://books.google.com/books?id=5daEDwAAQBAJ&pg=PA11" class="external text external"><i>Aldosterone</i></a>. Elsevier Science. 23 January 2019. pp.<span>&nbsp;</span>11, 46. ISBN<span>&nbsp;</span><bdi>978-0-12-817783-9</bdi>. <q>In addition to spironolactone, which is a derivative of progesterone [...]</q></cite></span></li><li id="cite_note-pmid3411088-225"> <span id="mw-reference-text-cite_note-pmid3411088-225" class="mw-reference-text"><cite id="CITEREFReyValterioLocatelliRamelet1988" class="citation journal cs1">Rey FO, Valterio C, Locatelli L, Ramelet AA, Felber JP (April 1988). "Lack of endocrine systemic side effects after topical application of spironolactone in man". <i>J. Endocrinol. Invest</i>. <b>11</b> (4): 273–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF03350151  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF03350151'" tppabs="https://doi.org/10.1007%2FBF03350151" class="external text external">10.1007/BF03350151</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3411088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3411088'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3411088" class="external text external">3411088</a>.</cite></span></li><li id="cite_note-pmid86546-226"> <span id="mw-reference-text-cite_note-pmid86546-226" class="mw-reference-text"><cite id="CITEREFRifkaPitaVigerskyWilson1978" class="citation journal cs1">Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL (1978). "Interaction of digitalis and spironolactone with human sex steroid receptors". <i>J. Clin. Endocrinol. Metab</i>. <b>46</b> (2): 338–44. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-46-2-338  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-46-2-338'" tppabs="https://doi.org/10.1210%2Fjcem-46-2-338" class="external text external">10.1210/jcem-46-2-338</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/86546  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/86546'" tppabs="https://pubmed.ncbi.nlm.nih.gov/86546" class="external text external">86546</a>.</cite></span></li><li id="cite_note-pmid7195405-227"> <span id="mw-reference-text-cite_note-pmid7195405-227" class="mw-reference-text"><cite id="CITEREFPugeatDunnNisula1981" class="citation journal cs1">Pugeat MM, Dunn JF, Nisula BC (1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". <i>J. Clin. Endocrinol. Metab</i>. <b>53</b> (1): 69–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-53-1-69  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-53-1-69'" tppabs="https://doi.org/10.1210%2Fjcem-53-1-69" class="external text external">10.1210/jcem-53-1-69</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7195405  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7195405'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7195405" class="external text external">7195405</a>.</cite></span></li><li id="cite_note-pmid7189544-228"> <span id="mw-reference-text-cite_note-pmid7189544-228" class="mw-reference-text"><cite id="CITEREFKaulhausenRohnerSiedekLafosse1980" class="citation journal cs1">Kaulhausen H, Rohner HG, Siedek M, Lafosse M, Breuer H (1980). "[Binding capacity of sex hormone binding globulin and corticosteroid binding globulin in serum of male patients with liver cirrhosis (author's transl)]". <i>J. Clin. Chem. Clin. Biochem.</i> (in German). <b>18</b> (2): 137–43. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7189544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7189544'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7189544" class="external text external">7189544</a>.</cite></span></li><li id="cite_note-BlandIII2009-229"> <span id="mw-reference-text-cite_note-BlandIII2009-229" class="mw-reference-text"><cite id="CITEREFKirby_I._BlandEdward_M._Copeland_III2009" class="citation book cs1">Kirby I. Bland; Edward M. Copeland III (9 September 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=1u4x_iGiHNEC&pg=PA161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=1u4x_iGiHNEC&pg=PA161'" tppabs="https://books.google.com/books?id=1u4x_iGiHNEC&pg=PA161" class="external text external"><i>The Breast: Comprehensive Management of Benign and Malignant Diseases</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>161–. ISBN<span>&nbsp;</span><bdi>978-1-4377-1121-9</bdi>.</cite></span></li><li id="cite_note-pmid25376974-230"> <span id="mw-reference-text-cite_note-pmid25376974-230" class="mw-reference-text"><cite id="CITEREFMurckBüttnerKircherKonrad2014" class="citation journal cs1">Murck H, Büttner M, Kircher T, Konrad C (2014). "Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression". <i>Nephron Physiol</i>. <b>128</b> (1–2): 17–25. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000368265  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000368265'" tppabs="https://doi.org/10.1159%2F000368265" class="external text external">10.1159/000368265</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25376974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25376974'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25376974" class="external text external">25376974</a>.</cite></span></li><li id="cite_note-pmid22351473-231"> <span id="mw-reference-text-cite_note-pmid22351473-231" class="mw-reference-text"><cite id="CITEREFKünzel2012" class="citation journal cs1">Künzel HE (March 2012). "Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways". <i>Horm. Metab. Res</i>. <b>44</b> (3): 202–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1055%2Fs-0032-1301921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1055%2Fs-0032-1301921'" tppabs="https://doi.org/10.1055%2Fs-0032-1301921" class="external text external">10.1055/s-0032-1301921</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22351473  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22351473'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22351473" class="external text external">22351473</a>.</cite></span></li><li id="cite_note-pmid1629288-232"> <span id="mw-reference-text-cite_note-pmid1629288-232" class="mw-reference-text"><cite id="CITEREFVarinThe_Minh_TuBenoîtVilleneuve1992" class="citation journal cs1">Varin F, The Minh Tu, Benoît F, Villeneuve JP, Théorêt Y (February 1992). "High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction". <i>J. Chromatogr</i>. <b>574</b> (1): 57–64. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0378-4347%2892%2980097-A  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0378-4347%2892%2980097-A'" tppabs="https://doi.org/10.1016%2F0378-4347%2892%2980097-A" class="external text external">10.1016/0378-4347(92)80097-A</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1629288  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1629288'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1629288" class="external text external">1629288</a>.</cite></span></li><li id="cite_note-Oxford2003-233"> <span id="mw-reference-text-cite_note-Oxford2003-233" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=_s65U1n9Lf8C&pg=RA1-PA962  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_s65U1n9Lf8C&pg=RA1-PA962'" tppabs="https://books.google.com/books?id=_s65U1n9Lf8C&pg=RA1-PA962" class="external text external"><i>Oxford Textbook of Medicine: Vol. 1</i></a>. Oxford University Press. 2003. pp.<span>&nbsp;</span>1–. ISBN<span>&nbsp;</span><bdi>978-0-19-262922-7</bdi>.</cite></span></li><li id="cite_note-AnzenbacherZanger2012-234"> <span id="mw-reference-text-cite_note-AnzenbacherZanger2012-234" class="mw-reference-text"><cite id="CITEREFPavel_AnzenbacherUlrich_M._Zanger2012" class="citation book cs1">Pavel Anzenbacher; Ulrich M. Zanger (23 February 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=f-XHh17NfwgC&pg=PA166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=f-XHh17NfwgC&pg=PA166'" tppabs="https://books.google.com/books?id=f-XHh17NfwgC&pg=PA166" class="external text external"><i>Metabolism of Drugs and Other Xenobiotics</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>166, 169. ISBN<span>&nbsp;</span><bdi>978-3-527-64632-6</bdi>.</cite></span></li><li id="cite_note-SmithPh.D.2014-235"> <span id="mw-reference-text-cite_note-SmithPh.D.2014-235" class="mw-reference-text"><cite id="CITEREFBlaine_T._SmithParamount_Wellness_Institute_Brian_Luke_Seaward,_Ph.D.Visiting_Professor_University_of_Oklahoma_College_of_Pharmacy_Blaine_T_Smith2014" class="citation book cs1">Blaine T. Smith; Paramount Wellness Institute Brian Luke Seaward, Ph.D.; Visiting Professor University of Oklahoma College of Pharmacy Blaine T Smith (1 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=7P-9BQAAQBAJ&pg=PA169  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7P-9BQAAQBAJ&pg=PA169'" tppabs="https://books.google.com/books?id=7P-9BQAAQBAJ&pg=PA169" class="external text external"><i>Pharmacology for Nurses</i></a>. Jones &amp; Bartlett Publishers. pp.<span>&nbsp;</span>169–. ISBN<span>&nbsp;</span><bdi>978-1-4496-8940-7</bdi>.</cite></span></li><li id="cite_note-Montellano2015-236"> <span id="mw-reference-text-cite_note-Montellano2015-236" class="mw-reference-text"><cite id="CITEREFPaul_R._Ortiz_de_Montellano2015" class="citation book cs1">Paul R. Ortiz de Montellano (13 March 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=abZnBwAAQBAJ&pg=PA867  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=abZnBwAAQBAJ&pg=PA867'" tppabs="https://books.google.com/books?id=abZnBwAAQBAJ&pg=PA867" class="external text external"><i>Cytochrome P450: Structure, Mechanism, and Biochemistry</i></a>. Springer. pp.<span>&nbsp;</span>867–. ISBN<span>&nbsp;</span><bdi>978-3-319-12108-6</bdi>. <q>CYP3A4 catalyzes 6β-hydroxylation of progesterone, cortisol, and testosterone; this reaction accounts for a considerable amount of hormone inactivation, particularly when it is orally administered.</q></cite></span></li><li id="cite_note-AcademicPress2012-237"> <span id="mw-reference-text-cite_note-AcademicPress2012-237" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=sC8h4KM0nmYC&pg=PA69  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=sC8h4KM0nmYC&pg=PA69'" tppabs="https://books.google.com/books?id=sC8h4KM0nmYC&pg=PA69" class="external text external"><i>Advances in Clinical Chemistry</i></a>. Academic Press. 31 December 2012. pp.<span>&nbsp;</span>69–. ISBN<span>&nbsp;</span><bdi>978-0-12-405852-1</bdi>.</cite></span></li><li id="cite_note-Brittain2002-238"> <span id="mw-reference-text-cite_note-Brittain2002-238" class="mw-reference-text"><cite id="CITEREFHarry_G._Brittain2002" class="citation book cs1">Harry G. Brittain (26 November 2002). <a href="javascript:if(confirm('https://books.google.com/books?id=RMN5zMW64ZEC&pg=PA309  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=RMN5zMW64ZEC&pg=PA309'" tppabs="https://books.google.com/books?id=RMN5zMW64ZEC&pg=PA309" class="external text external"><i>Analytical Profiles of Drug Substances and Excipients</i></a>. Academic Press. p.<span>&nbsp;</span>309. ISBN<span>&nbsp;</span><bdi>978-0-12-260829-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130621104609/http://books.google.com/books?id=RMN5zMW64ZEC&pg=PA309  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130621104609/http://books.google.com/books?id=RMN5zMW64ZEC&pg=PA309'" tppabs="https://web.archive.org/web/20130621104609/http://books.google.com/books?id=RMN5zMW64ZEC&pg=PA309" class="external text external">Archived</a> from the original on 21 June 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">27 May</span> 2012</span>.</cite></span></li><li id="cite_note-JamesonGroot2010-239"> <span id="mw-reference-text-cite_note-JamesonGroot2010-239" class="mw-reference-text"><cite id="CITEREFJ._Larry_JamesonLeslie_J._De_Groot2010" class="citation book cs1">J. Larry Jameson; Leslie J. De Groot (18 May 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401'" tppabs="https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401" class="external text external"><i>Endocrinology - E-Book: Adult and Pediatric</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2401–. ISBN<span>&nbsp;</span><bdi>978-1-4557-1126-0</bdi>. <q>[Spironolactone] is a potent antimineralocorticoid which was developed as a progestational analog [...]</q></cite></span></li><li id="cite_note-Elks2014-240"> <span id="mw-reference-text-cite_note-Elks2014-240" class="mw-reference-text"><cite id="CITEREFJ._Elks2014" class="citation book cs1">J. Elks (14 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1111'" tppabs="https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1111" class="external text external"><i>The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies</i></a>. Springer. p.<span>&nbsp;</span>1111. ISBN<span>&nbsp;</span><bdi>978-1-4757-2085-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170215024945/https://books.google.com/books?id=0vXTBwAAQBAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170215024945/https://books.google.com/books?id=0vXTBwAAQBAJ'" tppabs="https://web.archive.org/web/20170215024945/https://books.google.com/books?id=0vXTBwAAQBAJ" class="external text external">Archived</a> from the original on 15 February 2017.</cite></span></li><li id="cite_note-PubChem-241"> <span id="mw-reference-text-cite_note-PubChem-241" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/5833  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/5833'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/5833" class="external text external">"Spironolactone"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160630101052/http://pubchem.ncbi.nlm.nih.gov/compound/5833/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160630101052/http://pubchem.ncbi.nlm.nih.gov/compound/5833/'" tppabs="https://web.archive.org/web/20160630101052/http://pubchem.ncbi.nlm.nih.gov/compound/5833/" class="external text external">Archived</a> from the original on 30 June 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">4 July</span> 2017</span>.</cite></span></li><li id="cite_note-ChemSpider-242"> <span id="mw-reference-text-cite_note-ChemSpider-242" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.5628.html?rid=b578a389-d64b-4ec2-ae20-309e5f3abd11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.5628.html?rid=b578a389-d64b-4ec2-ae20-309e5f3abd11'" tppabs="http://www.chemspider.com/Chemical-Structure.5628.html?rid=b578a389-d64b-4ec2-ae20-309e5f3abd11" class="external text external">"Spironolactone <span>|</span> C24H32O4S <span>|</span> ChemSpider"</a>.</cite></span></li><li id="cite_note-pmid8616985-243"> <span id="mw-reference-text-cite_note-pmid8616985-243" class="mw-reference-text"><cite id="CITEREFSimon1995" class="citation journal cs1">Simon JA (1995). "Micronized progesterone: vaginal and oral uses". <i>Clin Obstet Gynecol</i>. <b>38</b> (4): 902–14. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00003081-199538040-00024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00003081-199538040-00024'" tppabs="https://doi.org/10.1097%2F00003081-199538040-00024" class="external text external">10.1097/00003081-199538040-00024</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8616985  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8616985'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8616985" class="external text external">8616985</a>.</cite></span></li><li id="cite_note-pmid16101407-244"> <span id="mw-reference-text-cite_note-pmid16101407-244" class="mw-reference-text"><cite id="CITEREFHuLiMcMahonLala2005" class="citation journal cs1">Hu X, Li S, McMahon EG, Lala DS, Rudolph AE (2005). "Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone". <i>Mini Rev Med Chem</i>. <b>5</b> (8): 709–18. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F1389557054553811  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F1389557054553811'" tppabs="https://doi.org/10.2174%2F1389557054553811" class="external text external">10.2174/1389557054553811</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16101407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16101407'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16101407" class="external text external">16101407</a>.</cite></span></li><li id="cite_note-pmid16112947-245"> <span id="mw-reference-text-cite_note-pmid16112947-245" class="mw-reference-text"><cite id="CITEREFKuhl2005" class="citation journal cs1">Kuhl H (2005). <a href="javascript:if(confirm('http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf'" tppabs="http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf" class="external text external">"Pharmacology of estrogens and progestogens: influence of different routes of administration"</a> <span class="cs1-format">(PDF)</span>. <i>Climacteric</i>. 8 Suppl 1: 3–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13697130500148875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13697130500148875'" tppabs="https://doi.org/10.1080%2F13697130500148875" class="external text external">10.1080/13697130500148875</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16112947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16112947'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16112947" class="external text external">16112947</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160822055012/http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160822055012/http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf'" tppabs="https://web.archive.org/web/20160822055012/http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 22 August 2016.</cite></span></li><li id="cite_note-pmid263288-246"> <span id="mw-reference-text-cite_note-pmid263288-246" class="mw-reference-text"><cite id="CITEREFCutlerPitaRifkaMenard1978" class="citation journal cs1">Cutler GB, Pita JC, Rifka SM, Menard RH, Sauer MA, Loriaux DL (July 1978). "SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate". <i>J. Clin. Endocrinol. Metab</i>. <b>47</b> (1): 171–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-47-1-171  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-47-1-171'" tppabs="https://doi.org/10.1210%2Fjcem-47-1-171" class="external text external">10.1210/jcem-47-1-171</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/263288  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/263288'" tppabs="https://pubmed.ncbi.nlm.nih.gov/263288" class="external text external">263288</a>.</cite></span></li><li id="cite_note-pmid13601900-247"> <span id="mw-reference-text-cite_note-pmid13601900-247" class="mw-reference-text"><cite id="CITEREFHertzTullner1958" class="citation journal cs1">Hertz R, Tullner WW (1958). "Progestational activity of certain steroid-17-spirolactones". <i>Proc. Soc. Exp. Biol. Med</i>. <b>99</b> (2): 451–2. doi:<a href="javascript:if(confirm('https://doi.org/10.3181%2F00379727-99-24380  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3181%2F00379727-99-24380'" tppabs="https://doi.org/10.3181%2F00379727-99-24380" class="external text external">10.3181/00379727-99-24380</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/13601900  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/13601900'" tppabs="https://pubmed.ncbi.nlm.nih.gov/13601900" class="external text external">13601900</a>.</cite></span></li><li id="cite_note-Butterworth1961-248"> <span id="mw-reference-text-cite_note-Butterworth1961-248" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=wvIfAQAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=wvIfAQAAMAAJ'" tppabs="https://books.google.com/books?id=wvIfAQAAMAAJ" class="external text external"><i>The British Encyclopaedia of Medical Practice: Medical progress</i></a>. Butterworth &amp; Company. 1961. p.<span>&nbsp;</span>302. <q>Cena and Kagawa first synthesized 3-(3-oxo-17β-hydroxy-4-androsten-17α-yl)-propionic acid-gamma-lactone and later prepared its 19-nor analogue. These compounds were designated SC-5233 and SC-8109, respectively. Both have anti-aldosterone activity and most of the early work on aldosterone antagonism was done with their aid. SC-5233 is not appreciably absorbed when given by mouth and the parenteral dose is large.</q></cite></span></li><li id="cite_note-pmid28041953-249"> <span id="mw-reference-text-cite_note-pmid28041953-249" class="mw-reference-text"><cite id="CITEREFLarikSaeedShahzadFaisal2017" class="citation journal cs1">Larik FA, Saeed A, Shahzad D, Faisal M, El-Seedi H, Mehfooz H, Channar PA (February 2017). "Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives". <i>Steroids</i>. <b>118</b>: 76–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.steroids.2016.12.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.steroids.2016.12.010'" tppabs="https://doi.org/10.1016%2Fj.steroids.2016.12.010" class="external text external">10.1016/j.steroids.2016.12.010</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28041953  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28041953'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28041953" class="external text external">28041953</a>.</cite></span></li><li id="cite_note-pmid13486053-250"> <span id="mw-reference-text-cite_note-pmid13486053-250" class="mw-reference-text"><cite id="CITEREFKagawaCellaVan_Arman1957" class="citation journal cs1">Kagawa CM, Cella JA, Van Arman CG (1957). "Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt". <i>Science</i>. <b>126</b> (3281): 1015–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.126.3281.1015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.126.3281.1015'" tppabs="https://doi.org/10.1126%2Fscience.126.3281.1015" class="external text external">10.1126/science.126.3281.1015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/13486053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/13486053'" tppabs="https://pubmed.ncbi.nlm.nih.gov/13486053" class="external text external">13486053</a>.</cite></span></li><li id="cite_note-pmid13486054-251"> <span id="mw-reference-text-cite_note-pmid13486054-251" class="mw-reference-text"><cite id="CITEREFLiddle1957" class="citation journal cs1">Liddle GW (1957). "Sodium diuresis induced by steroidal antagonists of aldosterone". <i>Science</i>. <b>126</b> (3281): 1016–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.126.3281.1016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.126.3281.1016'" tppabs="https://doi.org/10.1126%2Fscience.126.3281.1016" class="external text external">10.1126/science.126.3281.1016</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/13486054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/13486054'" tppabs="https://pubmed.ncbi.nlm.nih.gov/13486054" class="external text external">13486054</a>.</cite></span></li><li id="cite_note-EngelKleemann2014-252"> <span id="mw-reference-text-cite_note-EngelKleemann2014-252" class="mw-reference-text"><cite id="CITEREFJürgen_EngelAxel_KleemannBernhard_KutscherDietmar_Reichert2014" class="citation book cs1">Jürgen Engel; Axel Kleemann; Bernhard Kutscher; Dietmar Reichert (14 May 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1279  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1279'" tppabs="https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1279" class="external text external"><i>Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs</i></a>. Thieme. pp.<span>&nbsp;</span>1279–1280. ISBN<span>&nbsp;</span><bdi>978-3-13-179275-4</bdi>.</cite></span></li><li id="cite_note-LandauAchilladelis1999-253"> <span id="mw-reference-text-cite_note-LandauAchilladelis1999-253" class="mw-reference-text"><cite id="CITEREFRalph_LandauBasil_AchilladelisAlexander_Scriabine1999" class="citation book cs1">Ralph Landau; Basil Achilladelis; Alexander Scriabine (1999). <a href="javascript:if(confirm('https://books.google.com/books?id=IH4lPs6S1bMC&pg=PA198  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=IH4lPs6S1bMC&pg=PA198'" tppabs="https://books.google.com/books?id=IH4lPs6S1bMC&pg=PA198" class="external text external"><i>Pharmaceutical Innovation: Revolutionizing Human Health</i></a>. Chemical Heritage Foundation. pp.<span>&nbsp;</span>198–. ISBN<span>&nbsp;</span><bdi>978-0-941901-21-5</bdi>. <q>Spironolactone was patented in 1961 and has been used since then to treat heart failure, liver cirrhosis, and nephrotic syndrome.</q></cite></span></li><li id="cite_note-Jugdutt2014-254"> <span id="mw-reference-text-cite_note-Jugdutt2014-254" class="mw-reference-text"><cite id="CITEREFBodh_I._Jugdutt2014" class="citation book cs1">Bodh I. Jugdutt (19 February 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0e23BAAAQBAJ&pg=PA175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0e23BAAAQBAJ&pg=PA175'" tppabs="https://books.google.com/books?id=0e23BAAAQBAJ&pg=PA175" class="external text external"><i>Aging and Heart Failure: Mechanisms and Management</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>175–. ISBN<span>&nbsp;</span><bdi>978-1-4939-0268-2</bdi>.</cite></span></li><li id="cite_note-Wermuth2011-255"> <span id="mw-reference-text-cite_note-Wermuth2011-255" class="mw-reference-text"><cite id="CITEREFCamille_Georges_Wermuth2011" class="citation book cs1">Camille Georges Wermuth (2 May 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34'" tppabs="https://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34" class="external text external"><i>The Practice of Medicinal Chemistry</i></a>. Academic Press. pp.<span>&nbsp;</span>34–. ISBN<span>&nbsp;</span><bdi>978-0-08-056877-5</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20130621115634/http://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130621115634/http://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34'" tppabs="https://web.archive.org/web/20130621115634/http://books.google.com/books?id=Qmt1_DQkCpEC&pg=PA34" class="external text external">Archived</a> from the original on 21 June 2013.</cite></span></li><li id="cite_note-Smith1962-256"> <span id="mw-reference-text-cite_note-Smith1962-256" class="mw-reference-text"><cite id="CITEREFSmith1962" class="citation journal cs1">Smith, W.G. (1962). "Spironolactone and gynaecomastia". <i>The Lancet</i>. <b>280</b> (7261): 886. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2862%2990668-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2862%2990668-2'" tppabs="https://doi.org/10.1016%2FS0140-6736%2862%2990668-2" class="external text external">10.1016/S0140-6736(62)90668-2</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0140-6736  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0140-6736'" tppabs="https://www.worldcat.org/issn/0140-6736" class="external text external">0140-6736</a>.</cite></span></li><li id="cite_note-pmid5344274-257"> <span id="mw-reference-text-cite_note-pmid5344274-257" class="mw-reference-text"><cite id="CITEREFSteelmanBrooksMorganPatanelli1969" class="citation journal cs1">Steelman SL, Brooks JR, Morgan ER, Patanelli DJ (1969). "Anti-androgenic activity of spironolactone". <i>Steroids</i>. <b>14</b> (4): 449–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0039-128x%2869%2980007-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0039-128x%2869%2980007-3'" tppabs="https://doi.org/10.1016%2Fs0039-128x%2869%2980007-3" class="external text external">10.1016/s0039-128x(69)80007-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/5344274  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/5344274'" tppabs="https://pubmed.ncbi.nlm.nih.gov/5344274" class="external text external">5344274</a>.</cite></span></li><li id="cite_note-pmid148431-258"> <span id="mw-reference-text-cite_note-pmid148431-258" class="mw-reference-text"><cite id="CITEREFStewartPochi1978" class="citation journal cs1">Stewart ME, Pochi PE (April 1978). "Antiandrogens and the skin". <i>Int. J. Dermatol</i>. <b>17</b> (3): 167–79. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-4362.1978.tb06057.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-4362.1978.tb06057.x'" tppabs="https://doi.org/10.1111%2Fj.1365-4362.1978.tb06057.x" class="external text external">10.1111/j.1365-4362.1978.tb06057.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/148431  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/148431'" tppabs="https://pubmed.ncbi.nlm.nih.gov/148431" class="external text external">148431</a>.</cite></span></li><li id="cite_note-NeillJohansson1968-259"> <span id="mw-reference-text-cite_note-NeillJohansson1968-259" class="mw-reference-text"><cite id="CITEREFNeillJohanssonDattaKnobil1968" class="citation journal cs1">Neill JD, Johansson ED, Datta JK, Knobil, E (1968). "Endocrinology: Relationship Between the Plasma Levels of Luteinizing Hormone and Progesterone During the Normal Menstrual Cycle". <i>Obstetrical &amp; Gynecological Survey</i>. <b>23</b> (3): 271–277. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00006254-196803000-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00006254-196803000-00006'" tppabs="https://doi.org/10.1097%2F00006254-196803000-00006" class="external text external">10.1097/00006254-196803000-00006</a>. <q>17a-methyl-B-nortestosterone (Benorterone) (SKF-7690) has satisfactorily undergone extensive pharmacologic and toxicologic studies in animals, plus preliminary clinical studies in humans with somewhat encouraging results. It was therefore subjected to further clinical trials, especially in relation to the treatment of acne vulgaris. This communication reports the promptly reversible development of gynecomastia in 12 of 13 postpuberal males who participated in such a clinical study. It is believed that this complication has not been reported previously with a nonestrogenic antiandrogenic agent.</q></cite></span></li><li id="cite_note-pmid6205409-260"> <span id="mw-reference-text-cite_note-pmid6205409-260" class="mw-reference-text"><cite id="CITEREFTindallChangLoblCunningham1984" class="citation journal cs1">Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". <i>Pharmacol. Ther</i>. <b>24</b> (3): 367–400. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0163-7258%2884%2990010-X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0163-7258%2884%2990010-X'" tppabs="https://doi.org/10.1016%2F0163-7258%2884%2990010-X" class="external text external">10.1016/0163-7258(84)90010-X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6205409  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6205409'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6205409" class="external text external">6205409</a>.</cite></span></li><li id="cite_note-pmid717935-261"> <span id="mw-reference-text-cite_note-pmid717935-261" class="mw-reference-text"><cite id="CITEREFOberHennessy1978" class="citation journal cs1">Ober KP, Hennessy JF (1978). "Spironolactone therapy for hirsutism in a hyperandrogenic woman". <i>Ann. Intern. Med</i>. <b>89</b> (5 Pt 1): 643–4. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-89-5-643  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-89-5-643'" tppabs="https://doi.org/10.7326%2F0003-4819-89-5-643" class="external text external">10.7326/0003-4819-89-5-643</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/717935  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/717935'" tppabs="https://pubmed.ncbi.nlm.nih.gov/717935" class="external text external">717935</a>.</cite></span></li><li id="cite_note-pmid488407-262"> <span id="mw-reference-text-cite_note-pmid488407-262" class="mw-reference-text"><cite id="CITEREFBoisselleTremblay1979" class="citation journal cs1">Boisselle A, Tremblay RR (1979). "New therapeutic approach to the hirsute patient". <i>Fertil. Steril</i>. <b>32</b> (3): 276–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0015-0282%2816%2944232-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0015-0282%2816%2944232-9'" tppabs="https://doi.org/10.1016%2Fs0015-0282%2816%2944232-9" class="external text external">10.1016/s0015-0282(16)44232-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/488407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/488407'" tppabs="https://pubmed.ncbi.nlm.nih.gov/488407" class="external text external">488407</a>.</cite></span></li><li id="cite_note-pmid7410528-263"> <span id="mw-reference-text-cite_note-pmid7410528-263" class="mw-reference-text"><cite id="CITEREFShapiroEvron1980" class="citation journal cs1">Shapiro G, Evron S (1980). "A novel use of spironolactone: treatment of hirsutism". <i>J. Clin. Endocrinol. Metab</i>. <b>51</b> (3): 429–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-51-3-429  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-51-3-429'" tppabs="https://doi.org/10.1210%2Fjcem-51-3-429" class="external text external">10.1210/jcem-51-3-429</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7410528  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7410528'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7410528" class="external text external">7410528</a>.</cite></span></li><li id="cite_note-Curtis2014-264"> <span id="mw-reference-text-cite_note-Curtis2014-264" class="mw-reference-text"><cite id="CITEREFMichele_Curtis2014" class="citation book cs1">Michele Curtis (2014). <a href="javascript:if(confirm('https://books.google.com/books?id=w2AGBAAAQBAJ&pg=PA47  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=w2AGBAAAQBAJ&pg=PA47'" tppabs="https://books.google.com/books?id=w2AGBAAAQBAJ&pg=PA47" class="external text external"><i>Glass' Office Gynecology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>47–. ISBN<span>&nbsp;</span><bdi>978-1-60831-820-9</bdi>.</cite></span></li><li id="cite_note-ShahBhathena2004-265"> <span id="mw-reference-text-cite_note-ShahBhathena2004-265" class="mw-reference-text"><cite id="CITEREFDuru_ShahR._K._BhathenaSafala_Shroff2004" class="citation book cs1">Duru Shah; R. K. Bhathena; Safala Shroff (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=Jxd03OBIn9wC&pg=PA78  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Jxd03OBIn9wC&pg=PA78'" tppabs="https://books.google.com/books?id=Jxd03OBIn9wC&pg=PA78" class="external text external"><i>The Polycystic Ovary Syndrome</i></a>. Orient Blackswan. pp.<span>&nbsp;</span>78–. ISBN<span>&nbsp;</span><bdi>978-81-250-2633-4</bdi>.</cite></span></li><li id="cite_note-Hillard2013-266"> <span id="mw-reference-text-cite_note-Hillard2013-266" class="mw-reference-text"><cite id="CITEREFPaula_J._Adams_Hillard2013" class="citation book cs1">Paula J. Adams Hillard (29 March 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=vAA5Z5aqlUQC&pg=PT371  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vAA5Z5aqlUQC&pg=PT371'" tppabs="https://books.google.com/books?id=vAA5Z5aqlUQC&pg=PT371" class="external text external"><i>Practical Pediatric and Adolescent Gynecology</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>371–. ISBN<span>&nbsp;</span><bdi>978-1-118-53857-9</bdi>.</cite></span></li><li id="cite_note-DahlFeldman2006-267"> <span id="mw-reference-text-cite_note-DahlFeldman2006-267" class="mw-reference-text"><cite id="CITEREFDahlFeldmanGoldbergJaberi2006" class="citation journal cs1">Dahl, Marshall; Feldman, Jamie L.; Goldberg, Joshua M.; Jaberi, Afshin (2006). "Physical Aspects of Transgender Endocrine Therapy". <i>International Journal of Transgenderism</i>. <b>9</b> (3–4): 111–134. doi:<a href="javascript:if(confirm('https://doi.org/10.1300%2FJ485v09n03_06  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1300%2FJ485v09n03_06'" tppabs="https://doi.org/10.1300%2FJ485v09n03_06" class="external text external">10.1300/J485v09n03_06</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1553-2739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1553-2739'" tppabs="https://www.worldcat.org/issn/1553-2739" class="external text external">1553-2739</a>.</cite></span></li><li id="cite_note-PriorVigna1986-268"> <span id="mw-reference-text-cite_note-PriorVigna1986-268" class="mw-reference-text"><cite id="CITEREFPriorVignaWatsonDiewold" class="citation journal cs1">Prior JC, Vigna YM, Watson D, Diewold P, Robinow O. "Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic". <i>Journal of Sex Information &amp; Education Council of Canada</i> (1): 1–7.</cite></span></li><li id="cite_note-FisherMaggi2015-269"> <span id="mw-reference-text-cite_note-FisherMaggi2015-269" class="mw-reference-text"><cite id="CITEREFFisherMaggi2015" class="citation book cs1">Fisher, Alessandra Daphne; Maggi, Mario (2015). "Endocrine Treatment of Transsexual Male-to-Female Persons". <i>Management of Gender Dysphoria</i>. pp.<span>&nbsp;</span>83–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-88-470-5696-1_10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-88-470-5696-1_10'" tppabs="https://doi.org/10.1007%2F978-88-470-5696-1_10" class="external text external">10.1007/978-88-470-5696-1_10</a>. ISBN<span>&nbsp;</span><bdi>978-88-470-5695-4</bdi>.</cite></span></li><li id="cite_note-Dorfman2016-270"> <span id="mw-reference-text-cite_note-Dorfman2016-270" class="mw-reference-text"><cite id="CITEREFRalph_I._Dorfman2016" class="citation book cs1">Ralph I. Dorfman (5 December 2016). <a href="javascript:if(confirm('https://books.google.com/books?id=BbLfBAAAQBAJ&pg=PA392  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BbLfBAAAQBAJ&pg=PA392'" tppabs="https://books.google.com/books?id=BbLfBAAAQBAJ&pg=PA392" class="external text external"><i>Steroidal Activity in Experimental Animals and Man</i></a>. Elsevier Science. pp.<span>&nbsp;</span>392–. ISBN<span>&nbsp;</span><bdi>978-1-4832-7299-3</bdi>.</cite></span></li><li id="cite_note-MortonHall1999-271"> <span id="mw-reference-text-cite_note-MortonHall1999-271" class="mw-reference-text"><cite id="CITEREFI.K._MortonJudith_M._Hall1999" class="citation book cs1">I.K. Morton; Judith M. Hall (31 October 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=mqaOMOtk61IC&pg=PA261  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=mqaOMOtk61IC&pg=PA261'" tppabs="https://books.google.com/books?id=mqaOMOtk61IC&pg=PA261" class="external text external"><i>Concise Dictionary of Pharmacological Agents: Properties and Synonyms</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>261–. ISBN<span>&nbsp;</span><bdi>978-0-7514-0499-9</bdi>.</cite></span></li><li id="cite_note-Jjemba2008-272"> <span id="mw-reference-text-cite_note-Jjemba2008-272" class="mw-reference-text"><cite id="CITEREFPatrick_K._Jjemba2008" class="citation book cs1">Patrick K. Jjemba (3 October 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=2uhm9noGmrgC&pg=PA62  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2uhm9noGmrgC&pg=PA62'" tppabs="https://books.google.com/books?id=2uhm9noGmrgC&pg=PA62" class="external text external"><i>Pharma-Ecology: The Occurrence and Fate of Pharmaceuticals and Personal Care Products in the Environment</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>62–. ISBN<span>&nbsp;</span><bdi>978-0-470-37024-7</bdi>.</cite></span></li><li id="cite_note-DrugStats2016-273"> <span id="mw-reference-text-cite_note-DrugStats2016-273" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2019"</a>. <i>clincalc.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">22 December</span> 2018</span>.</cite></span></li><li id="cite_note-Springer2012-274"> <span id="mw-reference-text-cite_note-Springer2012-274" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266'" tppabs="https://books.google.com/books?id=Z5K-BwAAQBAJ&pg=PA266" class="external text external"><i>Benign Prostatic Hypertrophy</i></a>. Springer Science &amp; Business Media. 6 December 2012. pp.<span>&nbsp;</span>266–. ISBN<span>&nbsp;</span><bdi>978-1-4612-5476-8</bdi>.</cite></span></li><li id="cite_note-pmid1702565-275"> <span id="mw-reference-text-cite_note-pmid1702565-275" class="mw-reference-text"><cite id="CITEREFMatzkinBraf1991" class="citation journal cs1">Matzkin H, Braf Z (1991). "Endocrine treatment of benign prostatic hypertrophy: current concepts". <i>Urology</i>. <b>37</b> (1): 1–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2891%2980069-j  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2891%2980069-j'" tppabs="https://doi.org/10.1016%2F0090-4295%2891%2980069-j" class="external text external">10.1016/0090-4295(91)80069-j</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1702565  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1702565'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1702565" class="external text external">1702565</a>.</cite></span></li><li id="cite_note-pmid4104441-276"> <span id="mw-reference-text-cite_note-pmid4104441-276" class="mw-reference-text"><cite id="CITEREFCastroGriffithsEdwards1971" class="citation journal cs1">Castro JE, Griffiths HJ, Edwards DE (1971). "A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy". <i>Br J Surg</i>. <b>58</b> (7): 485–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fbjs.1800580703  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fbjs.1800580703'" tppabs="https://doi.org/10.1002%2Fbjs.1800580703" class="external text external">10.1002/bjs.1800580703</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4104441  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4104441'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4104441" class="external text external">4104441</a>.</cite></span></li><li id="cite_note-pmid29603164-277"> <span id="mw-reference-text-cite_note-pmid29603164-277" class="mw-reference-text"><cite id="CITEREFScottMenonWalsh1980" class="citation journal cs1">Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". <i>Cancer</i>. 45 Suppl 7: 1929–1936. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcncr.1980.45.s7.1929  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcncr.1980.45.s7.1929'" tppabs="https://doi.org/10.1002%2Fcncr.1980.45.s7.1929" class="external text external">10.1002/cncr.1980.45.s7.1929</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29603164  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29603164'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29603164" class="external text external">29603164</a>.</cite></span></li><li id="cite_note-pmid3540320-278"> <span id="mw-reference-text-cite_note-pmid3540320-278" class="mw-reference-text"><cite id="CITEREFSmith1987" class="citation journal cs1">Smith JA (January 1987). "New methods of endocrine management of prostatic cancer". <i>J. Urol</i>. <b>137</b> (1): 1–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-5347%2817%2943855-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-5347%2817%2943855-9'" tppabs="https://doi.org/10.1016%2FS0022-5347%2817%2943855-9" class="external text external">10.1016/S0022-5347(17)43855-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3540320  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3540320'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3540320" class="external text external">3540320</a>.</cite></span></li><li id="cite_note-Verma2016-279"> <span id="mw-reference-text-cite_note-Verma2016-279" class="mw-reference-text"><cite id="CITEREFVermaThompsonSwaninathan2016" class="citation journal cs1">Verma D, Thompson J, Swaninathan S (2016). <a href="javascript:if(confirm('http://www.pnas.org/content/early/2016/03/09/1523686113.abstract  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pnas.org/content/early/2016/03/09/1523686113.abstract'" tppabs="http://www.pnas.org/content/early/2016/03/09/1523686113.abstract" class="external text external">"Spironolactone blocks Epstein–Barr virus production by inhibiting EBV SM protein function"</a>. <i>Proceedings of the National Academy of Sciences</i>. <b>113</b> (13): 3609–3614. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.1523686113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.1523686113'" tppabs="https://doi.org/10.1073%2Fpnas.1523686113" class="external text external">10.1073/pnas.1523686113</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822607'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822607" class="external text external">4822607</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26976570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26976570'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26976570" class="external text external">26976570</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160324050609/http://www.pnas.org/content/early/2016/03/09/1523686113.abstract  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160324050609/http://www.pnas.org/content/early/2016/03/09/1523686113.abstract'" tppabs="https://web.archive.org/web/20160324050609/http://www.pnas.org/content/early/2016/03/09/1523686113.abstract" class="external text external">Archived</a> from the original on 24 March 2016.</cite></span></li><li id="cite_note-pmid15389184-280"> <span id="mw-reference-text-cite_note-pmid15389184-280" class="mw-reference-text"><cite id="CITEREFPelleCrawfordJames2004" class="citation journal cs1">Pelle MT, Crawford GH, James WD (October 2004). "Rosacea: II. Therapy". <i>J. Am. Acad. Dermatol</i>. <b>51</b> (4): 499–512, quiz 513–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2004.03.033  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2004.03.033'" tppabs="https://doi.org/10.1016%2Fj.jaad.2004.03.033" class="external text external">10.1016/j.jaad.2004.03.033</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15389184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15389184'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15389184" class="external text external">15389184</a>.</cite></span></li><li id="cite_note-GiurcăneanuMarinescu2016-281"> <span id="mw-reference-text-cite_note-GiurcăneanuMarinescu2016-281" class="mw-reference-text"><cite id="CITEREFGiurcăneanuMarinescuMerticariu2016" class="citation journal cs1">Giurcăneanu, Călin; Marinescu, Luminiţa; Merticariu, Andreea (2016). "Rosacea and its comorbidities". <i>Journal of Translational Medicine and Research</i>. <b>21</b> (1): 17. doi:<a href="javascript:if(confirm('https://doi.org/10.21614%2Fjtmr-21-1-68  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.21614%2Fjtmr-21-1-68'" tppabs="https://doi.org/10.21614%2Fjtmr-21-1-68" class="external text external">10.21614/jtmr-21-1-68</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2393-4999  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2393-4999'" tppabs="https://www.worldcat.org/issn/2393-4999" class="external text external">2393-4999</a>.</cite></span></li><li id="cite_note-Wollina2014-282"> <span id="mw-reference-text-cite_note-Wollina2014-282" class="mw-reference-text"><cite id="CITEREFWollina2014" class="citation book cs1">Wollina, Uwe (2014). "Nonclassical Treatments". <i>Pathogenesis and Treatment of Acne and Rosacea</i>. pp.<span>&nbsp;</span>713–717. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-540-69375-8_95  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-540-69375-8_95'" tppabs="https://doi.org/10.1007%2F978-3-540-69375-8_95" class="external text external">10.1007/978-3-540-69375-8_95</a>. ISBN<span>&nbsp;</span><bdi>978-3-540-69374-1</bdi>.</cite></span></li><li id="cite_note-pmid23594595-283"> <span id="mw-reference-text-cite_note-pmid23594595-283" class="mw-reference-text"><cite id="CITEREFSpoendlinVoegelJickMeier2013" class="citation journal cs1">Spoendlin J, Voegel JJ, Jick SS, Meier CR (October 2013). "Spironolactone may reduce the risk of incident rosacea". <i>J. Invest. Dermatol</i>. <b>133</b> (10): 2480–2483. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fjid.2013.186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fjid.2013.186'" tppabs="https://doi.org/10.1038%2Fjid.2013.186" class="external text external">10.1038/jid.2013.186</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23594595  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23594595'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23594595" class="external text external">23594595</a>.</cite></span></li><li id="cite_note-WernzeHerdegen2014-284"> <span id="mw-reference-text-cite_note-WernzeHerdegen2014-284" class="mw-reference-text"><cite id="CITEREFWernzeHerdegen2014" class="citation journal cs1">Wernze, Heinrich; Herdegen, Thomas (2014). "Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series". <i>Scandinavian Journal of Pain</i>. <b>5</b> (2): 63–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.sjpain.2013.12.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.sjpain.2013.12.003'" tppabs="https://doi.org/10.1016%2Fj.sjpain.2013.12.003" class="external text external">10.1016/j.sjpain.2013.12.003</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1877-8860  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1877-8860'" tppabs="https://www.worldcat.org/issn/1877-8860" class="external text external">1877-8860</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29913681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29913681'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29913681" class="external text external">29913681</a>.</cite></span></li><li id="cite_note-Kalso2014-285"> <span id="mw-reference-text-cite_note-Kalso2014-285" class="mw-reference-text"><cite id="CITEREFKalso2014" class="citation journal cs1">Kalso, Eija (2014). "From patient observation to potential new therapies—Is old spironolactone a new analgesic?". <i>Scandinavian Journal of Pain</i>. <b>5</b> (2): 61–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.sjpain.2014.02.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.sjpain.2014.02.006'" tppabs="https://doi.org/10.1016%2Fj.sjpain.2014.02.006" class="external text external">10.1016/j.sjpain.2014.02.006</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1877-8860  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1877-8860'" tppabs="https://www.worldcat.org/issn/1877-8860" class="external text external">1877-8860</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29913669  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29913669'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29913669" class="external text external">29913669</a>.</cite></span></li><li id="cite_note-pmid22946772-286"> <span id="mw-reference-text-cite_note-pmid22946772-286" class="mw-reference-text"><cite id="CITEREFMcElroyGuerdjikovaMoriO'Melia2012" class="citation journal cs1">McElroy SL, Guerdjikova AI, Mori N, O'Melia AM (2012). "Current pharmacotherapy options for bulimia nervosa and binge eating disorder". <i>Expert Opin Pharmacother</i>. <b>13</b> (14): 2015–26. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14656566.2012.721781  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14656566.2012.721781'" tppabs="https://doi.org/10.1517%2F14656566.2012.721781" class="external text external">10.1517/14656566.2012.721781</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22946772  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22946772'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22946772" class="external text external">22946772</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/xpironolactone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/xpironolactone'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/xpironolactone" class="external text external">"Spironolactone"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Spironolactone" style="padding:3px"><table class="nowraplinks mw-collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Spironolactone" style="font-size:114%;margin:0 4em"><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Topics</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Pharmacodynamics of spironolactone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Metabolites</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>7α-Thiomethylspironolactone (major)</li>
<li>Canrenone (minor)</li>
<li>6β-Hydroxy-7α-thiomethylspironolactone (minor)</li>
<li>7α-Thiospironolactone (minor)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Related drugs</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Spirolactone antimineralocorticoids: Canrenone</li>
<li>Potassium canrenoate</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">Eplerenone</a></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Medical_uses" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="background:#e8e8ff;background:#ccccff"><div id="Medical_uses" style="font-size:114%;margin:0 4em">Medical uses</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;font-size:114%"><div style="padding:0px">
<div role="navigation" class="navbox" aria-labelledby="Diuretics_(C03)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Diuretics_(C03)" style="font-size:114%;margin:0 4em">Diuretics (C03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Sulfonamides<br>(and <a href="Etacrynic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Etacrynic_acid" title="Etacrynic acid">etacrynic acid</a>)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">CA inhibitors (at PT)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Acetazolamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetazolamide" title="Acetazolamide">Acetazolamide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Loop (Na-K-Cl at AL)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Furosemide.htm" tppabs="https://ptable.com/wiki/compounds/A/Furosemide" title="Furosemide">Furosemide</a><sup>#</sup></li>
<li>Azosemide</li>
<li><a href="Bumetanide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bumetanide" title="Bumetanide">Bumetanide</a></li>
<li><a href="Etacrynic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Etacrynic_acid" title="Etacrynic acid">Etacrynic acid</a></li>
<li>Etozolin</li>
<li>Muzolimine</li>
<li>Ozolinone</li>
<li><a href="Piretanide.htm" tppabs="https://ptable.com/wiki/compounds/A/Piretanide" title="Piretanide">Piretanide</a></li>
<li><a href="Tienilic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Tienilic_acid" title="Tienilic acid">Tienilic acid</a></li>
<li><a href="Torasemide.htm" tppabs="https://ptable.com/wiki/compounds/A/Torasemide" title="Torasemide">Torasemide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Thiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazide" title="Thiazide">Thiazides</a> (Na-Cl at DCT,<br>Calcium-sparing)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Altizide</li>
<li><a href="Bendroflumethiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bendroflumethiazide" title="Bendroflumethiazide">Bendroflumethiazide</a></li>
<li>Butizide</li>
<li><a href="Chlorothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorothiazide" title="Chlorothiazide">Chlorothiazide</a></li>
<li>Cyclopenthiazide</li>
<li><a href="Cyclothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclothiazide" title="Cyclothiazide">Cyclothiazide</a></li>
<li>Epitizide</li>
<li><a href="Hydrochlorothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrochlorothiazide" title="Hydrochlorothiazide">Hydrochlorothiazide</a><sup>#</sup></li>
<li><a href="Hydroflumethiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroflumethiazide" title="Hydroflumethiazide">Hydroflumethiazide</a></li>
<li>Mebutizide</li>
<li><a href="Methyclothiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyclothiazide" title="Methyclothiazide">Methyclothiazide</a></li>
<li><a href="Polythiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Polythiazide" title="Polythiazide">Polythiazide</a></li>
<li><a href="Trichlormethiazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Trichlormethiazide" title="Trichlormethiazide">Trichlormethiazide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thiazide-likes (primarily DCT)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Quinethazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinethazone" title="Quinethazone">Quinethazone</a></li>
<li>Clopamide</li>
<li><a href="Chlortalidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlortalidone" title="Chlortalidone">Chlortalidone</a></li>
<li>Mefruside</li>
<li>Clofenamide</li>
<li><a href="Metolazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Metolazone" title="Metolazone">Metolazone</a></li>
<li><a href="Meticrane.htm" tppabs="https://ptable.com/wiki/compounds/A/Meticrane" title="Meticrane">Meticrane</a></li>
<li>Xipamide</li>
<li><a href="Indapamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indapamide" title="Indapamide">Indapamide</a></li>
<li>Clorexolone</li>
<li>Fenquizone</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Potassium-sparing (at CD)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">ESC blockers</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amiloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Amiloride" title="Amiloride">Amiloride</a><sup>#</sup></li>
<li><a href="Triamterene.htm" tppabs="https://ptable.com/wiki/compounds/A/Triamterene" title="Triamterene">Triamterene</a></li>
<li>Benzamil</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Aldosterone antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Spirolactones</i>
<ul><li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a><sup>#</sup></li>
<li><a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">Eplerenone</a></li>
<li>Potassium canrenoate</li>
<li>Canrenone</li></ul></li></ul>

<ul><li><i>Nonsteroidal</i>
<ul><li>Finerenone</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Osmotic diuretics (PT, DL)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mannitol.htm" tppabs="https://ptable.com/wiki/compounds/A/Mannitol" title="Mannitol">Mannitol</a><sup>#</sup></li>
<li><a href="Glycerol.htm" tppabs="https://ptable.com/wiki/compounds/A/Glycerol" title="Glycerol">Glycerol</a></li>
<li><a href="Urea.htm" tppabs="https://ptable.com/wiki/compounds/A/Urea" title="Urea">Urea</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Vasopressin receptor inhibitors<br>(DCT and CD)</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Vaptans</i>
<ul><li><a href="Conivaptan.htm" tppabs="https://ptable.com/wiki/compounds/A/Conivaptan" title="Conivaptan">Conivaptan</a></li>
<li>Mozavaptan</li>
<li>Satavaptan</li>
<li>Tolvaptan</li></ul></li></ul>

<ul><li><i>Others</i>
<ul><li><a href="Demeclocycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Demeclocycline" title="Demeclocycline">Demeclocycline</a></li>
<li><a href="Lithium_carbonate.htm" tppabs="https://ptable.com/wiki/compounds/A/Lithium_carbonate" title="Lithium carbonate">Lithium carbonate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Ethanol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethanol" title="Ethanol">Ethanol</a>, <a href="Isopropyl_alcohol.htm" tppabs="https://ptable.com/wiki/compounds/A/Isopropanol" title="Isopropanol" class="mw-redirect">Isopropanol</a>, 2M2B</li>
<li><i>mercurial diuretics</i> (<a href="Chlormerodrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlormerodrin" title="Chlormerodrin">Chlormerodrin</a>, Mersalyl, Meralluride)</li>
<li><a href="Theobromine.htm" tppabs="https://ptable.com/wiki/compounds/A/Theobromine" title="Theobromine">Theobromine</a></li>
<li>Cicletanine</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Acne-treating_agents_(D10)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Acne-treating_agents_(D10)" style="font-size:114%;margin:0 4em">Acne-treating agents (D10)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antibacterial</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Azelaic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Azelaic_acid" title="Azelaic acid">Azelaic acid</a></li>
<li><a href="Benzoyl_peroxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl_peroxide" title="Benzoyl peroxide">Benzoyl peroxide</a><sup>#</sup></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">8-Hydroxyquinoline</a></li>
<li>Blue light therapy</li>
<li><a href="Tea_tree_oil.htm" tppabs="https://ptable.com/wiki/compounds/A/Tea_tree_oil" title="Tea tree oil">Tea tree oil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Keratolytic</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Glycolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glycolic_acid" title="Glycolic acid">Glycolic acid</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid</a><sup>#</sup></li>
<li>Sulfur</li>
<li><a href="Benzoyl_peroxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl_peroxide" title="Benzoyl peroxide">Benzoyl peroxide</a><sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-inflammatory</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Nicotinamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotinamide" title="Nicotinamide">Nicotinamide</a></li>
<li><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a><sup>#</sup></li>
<li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin</a><sup>#</sup></li>
<li>Red light therapy</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antibiotics</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">Clindamycin</a></li>
<li><a href="Dapsone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dapsone" title="Dapsone">Dapsone</a></li>
<li><a href="Erythromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Erythromycin" title="Erythromycin">Erythromycin</a></li>
<li><a href="Sulfacetamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfacetamide" title="Sulfacetamide">Sulfacetamide</a></li>
<li>Tetracyclines (<a href="Lymecycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Lymecycline" title="Lymecycline">Lymecycline</a></li>
<li><a href="Minocycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Minocycline" title="Minocycline">Minocycline</a></li>
<li><a href="Doxycycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxycycline" title="Doxycycline">Doxycycline</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hormonal</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiandrogens
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a>)</li></ul></li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a>
<ul><li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li>Ethinylestradiol</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Retinoids</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Adapalene.htm" tppabs="https://ptable.com/wiki/compounds/A/Adapalene" title="Adapalene">Adapalene</a></li>
<li><a href="Isotretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isotretinoin" title="Isotretinoin">Isotretinoin</a></li>
<li>Motretinide</li>
<li><a href="Tazarotene.htm" tppabs="https://ptable.com/wiki/compounds/A/Tazarotene" title="Tazarotene">Tazarotene</a></li>
<li><a href="Tretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tretinoin" title="Tretinoin">Tretinoin</a></li>
<li>Trifarotene</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Benzamycin</li>
<li>Epristeride</li>
<li>Mesulfen</li>
<li>Pelretin</li>
<li>Stridex</li>
<li><a href="Tioxolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Tioxolone" title="Tioxolone">Tioxolone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combinations</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adapalene/benzoyl peroxide</li>
<li>Benzoyl peroxide/clindamycin</li>
<li>Clindamycin/tretinoin</li>
<li>Erythromycin/isotretinoin</li>
<li>Sulfacetamide/sulfur</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Other_dermatological_preparations_(D11)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Other_dermatological_preparations_(D11)" style="font-size:114%;margin:0 4em">Other dermatological preparations (D11)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-seborrheics</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul></li>
<li><i>Antifungals</i>
<ul><li><a href="Bifonazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Bifonazole" title="Bifonazole">Bifonazole</a></li>
<li>Cetrimonium bromide (cetrimide)</li>
<li>Ciclopirox olamine (ciclopirox)</li>
<li>Climbazole</li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Miconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Miconazole" title="Miconazole">Miconazole</a></li>
<li>Piroctone olamine</li>
<li><a href="Selenium_disulfide.htm" tppabs="https://ptable.com/wiki/compounds/A/Selenium_disulfide" title="Selenium disulfide">Selenium disulfide (selenium sulfide)</a></li>
<li><span class="new">Xenysalate</span></li>
<li><a href="Zinc_pyrithione.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc_pyrithione" title="Zinc pyrithione">Zinc pyrithione (pyrithione zinc)</a></li></ul></li>
<li><i>Antihistamines</i></li>
<li><i>Calcineurin inhibitors</i>
<ul><li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclosporin" title="Cyclosporin" class="mw-redirect">Cyclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li></ul></li>
<li><a href="Isotretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isotretinoin" title="Isotretinoin">Isotretinoin</a></li>
<li><i>Keratolytics</i>
<ul><li>Coal tar</li>
<li><a href="Resorcinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Resorcinol" title="Resorcinol">Resorcinol</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid</a></li>
<li><a href="Sulfur.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfur" title="Sulfur">Sulfur</a></li>
<li><a href="Urea.htm" tppabs="https://ptable.com/wiki/compounds/A/Urea" title="Urea">Urea</a> (urea-containing cream)</li></ul></li>
<li><i>Lithium salts</i>
<ul><li>Lithium gluconate</li>
<li>Lithium succinate</li></ul></li>
<li><i>Topical corticosteroids</i> (e.g., hydrocortisone)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Skin lightening</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Hydroquinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroquinone" title="Hydroquinone">Hydroquinone</a></li>
<li><a href="Mequinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Mequinol" title="Mequinol">Mequinol</a></li>
<li><a href="Monobenzone.htm" tppabs="https://ptable.com/wiki/compounds/A/Monobenzone" title="Monobenzone">Monobenzone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Skin darkening</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afamelanotide</li>
<li>Melanotan II</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-inflammatories</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Oxaceprol.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaceprol" title="Oxaceprol">Oxaceprol</a></li>
<li><a href="Gamma-Linolenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Gamma-Linolenic_acid" title="Gamma-Linolenic acid">Gamolenic acid</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Alitretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Alitretinoin" title="Alitretinoin">Alitretinoin</a></li>
<li><i>Topical corticosteroids</i> (e.g., hydrocortisone)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Alopecia treatments</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>5α-Reductase inhibitors</i> 
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul></li>
<li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Topilutamide (fluridil)</li></ul></li>
<li><i>Potassium channel openers</i>
<ul><li><a href="Minoxidil.htm" tppabs="https://ptable.com/wiki/compounds/A/Minoxidil" title="Minoxidil">Minoxidil</a></li></ul></li>
<li><i>Others</i>
<ul><li>Nepidermin</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hair growth inhibitors</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>5α-Reductase inhibitors</i>
<ul><li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li></ul></li>
<li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul></li>
<li><a href="Eflornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Eflornithine" title="Eflornithine">Eflornithine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Androgens (e.g., testosterone)</li>
<li><a href="Brimonidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Brimonidine" title="Brimonidine">Brimonidine</a></li>
<li><a href="Calcium_gluconate.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium_gluconate" title="Calcium gluconate">Calcium gluconate</a></li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>)</li>
<li>Hyaluronic acid</li>
<li><a href="Magnesium_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium_sulfate" title="Magnesium sulfate">Magnesium sulfate</a></li>
<li>Pregnenolone acetate</li>
<li>Progestogens (e.g., progesterone)</li>
<li><a href="Povidone-iodine.htm" tppabs="https://ptable.com/wiki/compounds/A/Povidone-iodine" title="Povidone-iodine">Povidone-iodine</a></li>
<li>Tiratricol</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Androgens_and_antiandrogens" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgens_and_antiandrogens" style="font-size:114%;margin:0 4em">Androgens and antiandrogens</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Androgens<br>(incl. <abbr>AAS</abbr>)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> Androstenediol dipropionate</li>
<li>Boldenone undecylenate</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a></li>
<li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li>
<li>Cloxotestosterone acetate</li>
<li>Prasterone (dehydroepiandrosterone, DHEA)</li>
<li>Prasterone enanthate (DHEA enanthate)</li>
<li>Prasterone sulfate (DHEA sulfate)</li>
<li>Quinbolone</li>
<li>Testosterone<sup>#</sup></li>
<li>Testosterone esters (e.g., testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone undecanoate, testosterone ester mixtures (Deposterona, Omnadren, Sustanon, Testoviron Depot))</li></ul>

<ul><li><i>Dihydrotestosterone derivatives:</i> Androstanolone (stanolone, dihydrotestosterone, DHT)</li>
<li>Androstanolone esters</li>
<li>Bolazine capronate</li>
<li>Drostanolone propionate (dromostanolone propionate)</li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a></li>
<li>Metenolone acetate (methenolone acetate)</li>
<li>Metenolone enanthate (methenolone enanthate)</li>
<li>Stenbolone acetate</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> Bolandiol dipropionate</li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norclostebol</li>
<li>Norclostebol acetate</li>
<li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li>
<li>Trenbolone acetate</li>
<li>Trenbolone hexahydrobenzylcarbonate (trenbolone cyclohexylmethylcarbonate)</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Metandienone (methandienone, methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)</li>
<li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a></li>
<li>Methyltestosterone 3-hexyl ether</li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone (thiomesterone)</li></ul>

<ul><li><i>17α-Alkylated dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> <a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Mibolerone</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li>Propetandrol (propethandrol)</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li>Progestins (e.g., <a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">ethisterone (ethynyltestosterone)</a>, <a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">levonorgestrel</a>, <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">norgestrel</a>, <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone (norethindrone)</a>, lynestrenol, norgestrienone)</li>
<li>Tibolone</li></ul>

<ul><li><i>Progesterone derivatives:</i> <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Progonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiestrogens (e.g., <a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">tamoxifen</a>, <a href="Clomifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Clomifene" title="Clomifene">clomifene</a>)</li>
<li>GnRH agonists (e.g., <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">GnRH (gonadorelin)</a>, <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>Gonadotropins (e.g., <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone"><abbr>LH</abbr></a>, <a href="Human_chorionic_gonadotropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin"><abbr>hCG</abbr></a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antiandrogens</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Abiraterone acetate</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone acetate</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Nomegestrol acetate</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>

<ul><li><i>Nonsteroidal:</i> Apalutamide</li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Darolutamide</li>
<li>Enzalutamide</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li>Topilutamide (fluridil)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Steroidogenesis<br>inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">5α-Reductase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li>Epristeride</li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abiraterone acetate</li>
<li><a href="Aminoglutethimide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoglutethimide" title="Aminoglutethimide">Aminoglutethimide</a></li>
<li>Bifluranol</li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Antigonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>D<sub>2</sub> receptor antagonists (prolactin releasers) (e.g., <a href="Domperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Domperidone" title="Domperidone">domperidone</a>, <a href="Metoclopramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoclopramide" title="Metoclopramide">metoclopramide</a>, <a href="Risperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Risperidone" title="Risperidone">risperidone</a>, <a href="Haloperidol.htm" tppabs="https://ptable.com/wiki/compounds/A/Haloperidol" title="Haloperidol">haloperidol</a>, <a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, <a href="Sulpiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulpiride" title="Sulpiride">sulpiride</a>)</li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., bifluranol, <a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">diethylstilbestrol</a>, <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)</li>
<li>GnRH agonists (e.g., <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>GnRH antagonists (e.g., <a href="Cetrorelix.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetrorelix" title="Cetrorelix">cetrorelix</a>)</li>
<li>Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>, megestrol acetate)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Androstenedione immunogens:</i> Androvax (androstenedione albumin)</li>
<li>Ovandrotone albumin (Fecundin)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Androgen receptor modulators</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>List of androgens/anabolic steroids</dd></dl></div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Mineralocorticoids_and_antimineralocorticoids_(H02)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Mineralocorticoids_and_antimineralocorticoids_(H02)" style="font-size:114%;margin:0 4em">Mineralocorticoids and antimineralocorticoids (H02)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mineralocorticoids</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Desoxycortone (desoxycorticosterone)
<ul><li>Desoxycortone esters</li></ul></li>
<li>Hydrocortisone (cortisol)
<ul><li>Hydrocortisone esters</li></ul></li>
<li><a href="Fludrocortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludrocortisone" title="Fludrocortisone">Fludrocortisone</a>
<ul><li>Fludrocortisone acetate</li></ul></li>
<li><a href="Methylprednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylprednisolone" title="Methylprednisolone">Methylprednisolone</a>
<ul><li>Methylprednisolone esters</li></ul></li>
<li><a href="Prednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisolone" title="Prednisolone">Prednisolone</a>
<ul><li>Prednisolone esters</li></ul></li>
<li><a href="Prednisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisone" title="Prednisone">Prednisone</a>
<ul><li>Prednisone esters</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antimineralocorticoids</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Canrenoate potassium (potassium canrenoate)</li>
<li>Canrenone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li><a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">Eplerenone</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li>Medrogestone</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Trimegestone</li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Amlodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amlodipine" title="Amlodipine">Amlodipine</a></li>
<li>Apararenone<sup>§</sup></li>
<li>Benidipine</li>
<li>Esaxerenone<sup>†</sup></li>
<li><a href="Felodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Felodipine" title="Felodipine">Felodipine</a></li>
<li>Finerenone<sup>†</sup></li>
<li><a href="Nifedipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifedipine" title="Nifedipine">Nifedipine</a></li>
<li><a href="Nimodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nimodipine" title="Nimodipine">Nimodipine</a></li>
<li><a href="Nitrendipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitrendipine" title="Nitrendipine">Nitrendipine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Synthesis modifiers</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Acetoxolone</li>
<li><a href="Aminoglutethimide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoglutethimide" title="Aminoglutethimide">Aminoglutethimide</a></li>
<li><a href="Carbenoxolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbenoxolone" title="Carbenoxolone">Carbenoxolone</a></li>
<li>Enoxolone</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Metyrapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Metyrapone" title="Metyrapone">Metyrapone</a></li>
<li><a href="Mitotane.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitotane" title="Mitotane">Mitotane</a></li>
<li><a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Mineralocorticoid receptor modulators</dd>
<dd>Glucocorticoids and antiglucocorticoids</dd>
<dd>List of corticosteroids</dd></dl></div></td></tr></tbody></table></div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Pharmacodynamics" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="background:#e8e8ff;background:#ccccff"><div id="Pharmacodynamics" style="font-size:114%;margin:0 4em">Pharmacodynamics</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;font-size:114%"><div style="padding:0px">
<div role="navigation" class="navbox" aria-labelledby="Androgen_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgen_receptor_modulators" style="font-size:114%;margin:0 4em">Androgen receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>AR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> <a href="4-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenediol" title="4-Androstenediol">4-Androstenediol</a></li>
<li>4-Dehydroepiandrosterone (4-DHEA)</li>
<li>4-Hydroxytestosterone</li>
<li><span class="new">4,17α-Dimethyltestosterone</span></li>
<li>5-Androstenedione</li>
<li>11-Ketotestosterone</li>
<li>11β-Hydroxyandrostenedione</li>
<li><a href="Adrenosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenosterone" title="Adrenosterone">Adrenosterone (11-ketoandrostenedione, 11-oxoandrostenedione)</a></li>
<li><a href="5-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Androstenediol" title="5-Androstenediol" class="mw-redirect">Androstenediol (5-androstenediol)</a>
<ul><li>Androstenediol 3β-acetate</li>
<li>Androstenediol 17β-acetate</li>
<li>Androstenediol diacetate</li>
<li>Androstenediol dipropionate</li></ul></li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenedione" title="4-Androstenedione" class="mw-redirect">Androstenedione (4-androstenedione)</a></li>
<li>Atamestane</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Boldenone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Boldenone'" tppabs="https://ptable.com/wiki/compounds/A/Boldenone" title="Boldenone">Boldenone</a>
<ul><li>Boldenone undecylenate</li></ul></li>
<li>Boldione (1,4-androstadienedione)</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a>
<ul><li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li></ul></li>
<li>Cloxotestosterone
<ul><li>Cloxotestosterone acetate</li></ul></li>
<li>Dehydroandrosterone</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA (androstenolone, prasterone; 5-DHEA)</a>
<ul><li>DHEA enanthate (prasterone enanthate)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA sulfate</a></li></ul></li>
<li><a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">Exemestane</a></li>
<li><a href="Formestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Formestane" title="Formestane">Formestane</a></li>
<li>Plomestane</li>
<li>Quinbolone</li>
<li>Silandrone</li>
<li>Testosterone<sup>#</sup> (+dutasteride)
<ul><li>Testosterone esters</li>
<li>Polytestosterone phloretin phosphate</li></ul></li></ul>

<ul><li><i>5α-Dihydrotestosterone derivatives:</i> 1-Androstenediol</li>
<li>1-Androstenedione</li>
<li>1-Androsterone (1-andro, 1-DHEA)</li>
<li>1-Testosterone</li>
<li>3α-Androstanediol</li>
<li>5α-Androst-2-en-17-one</li>
<li>7β-Hydroxyepiandrosterone</li>
<li>11-Ketodihydrotestosterone</li>
<li><a href="Androsterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Androsterone" title="Androsterone">Androsterone</a></li>
<li>Bolazine
<ul><li>Bolazine capronate</li></ul></li>
<li><span class="new">Dihydroethyltestosterone</span></li>
<li>Dihydrofluoxymesterone</li>
<li><span class="new">Dihydromethylandrostenediol</span></li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone (DHT)</a> (androstanolone, stanolone)
<ul><li>Dihydrotestosterone esters</li></ul></li>
<li><a href="Drostanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drostanolone" title="Drostanolone">Drostanolone</a>
<ul><li>Drostanolone propionate</li></ul></li>
<li><a href="Epiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Epiandrosterone" title="Epiandrosterone">Epiandrosterone</a></li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li>Mesabolone</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a>
<ul><li>Mesterolone cipionate</li></ul></li>
<li>Methyldiazinol</li>
<li>Nisterime
<ul><li>Nisterime acetate</li></ul></li>
<li>Prostanozol</li>
<li>Stenbolone
<ul><li>Stenbolone acetate</li></ul></li>
<li>Testifenon (testiphenon, testiphenone)</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> 7α-Methyl-19-norandrostenedione (MENT dione, trestione)</li>
<li>11β-Methyl-19-nortestosterone
<ul><li>11β-Methyl-19-nortestosterone dodecylcarbonate</li></ul></li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol
<ul><li>Bolandiol dipropionate</li></ul></li>
<li>Bolandione (19-nor-4-androstenedione)</li>
<li>Bolmantalate (nandrolone adamantoate)</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone
<ul><li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li></ul></li>
<li>LS-1727 (nandrolone 17β-<i>N</i>-(2-chloroethyl)-<i>N</i>-nitrosocarbamate)</li>
<li>Methoxydienone (methoxygonadiene)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a>
<ul><li>Nandrolone esters</li></ul></li>
<li>Norclostebol
<ul><li>Norclostebol acetate</li></ul></li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li><a href="Oxabolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone" title="Oxabolone">Oxabolone</a>
<ul><li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li></ul></li>
<li>Trenbolone
<ul><li>Trenbolone acetate</li>
<li>Trenbolone enanthate</li>
<li>Trenbolone hexahydrobenzylcarbonate</li>
<li>Trenbolone undecanoate</li></ul></li>
<li>Trendione</li>
<li>Trestolone (MENT)
<ul><li>Trestolone acetate</li>
<li>Trestolone enanthate</li></ul></li></ul>

<ul><li><i>5α-Dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronandrolone</li>
<li><span class="new">5α-Dihydrotrestolone</span></li>
<li>19-Norandrosterone</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethylandrostenediol (CDMA)</li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li>Chloromethylandrostenediol (CMA)</li>
<li>Enestebol</li>
<li>Ethyltestosterone</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Hydroxystenozole</li>
<li>Metandienone (methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)
<ul><li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol diacetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li></ul></li>
<li>Methylclostebol (chloromethyltestosterone)</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a> (+esterified estrogens)
<ul><li>Methyltestosterone 3-hexyl ether</li></ul></li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li>Desoxymethyltestosterone</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li>Metenolone
<ul><li>Metenolone acetate</li>
<li>Metenolone enanthate</li></ul></li>
<li>Methasterone</li>
<li>Methyl-1-testosterone</li>
<li>Methylepitiostanol</li>
<li>Methylstenbolone</li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> Bolenol</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Methyldienolone</li>
<li>Methylhydroxynandrolone (MOHN, MHN)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mibolerone</li>
<li>Norboletone</li>
<li>Norethandrolone</li>
<li>Propetandrol</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronorethandrolone</li>
<li>5α-Dihydronormethandrone</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Vinyl-19-nortestosterone derivatives:</i> Vinyltestosterone</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone (ethynyltestosterone)</a></li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyltestosterone derivatives:</i> 17α-Ethynyl-3α-androstanediol</li>
<li>17α-Ethynyl-3β-androstanediol</li>
<li>Dihydroethisterone</li></ul>

<ul><li><i>17α-Ethynyl-19-nortestosterone derivatives:</i> Δ<sup>4</sup>-Tibolone</li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol
<ul><li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li></ul></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol
<ul><li>Lynestrenol phenylpropionate</li></ul></li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Quingestanol
<ul><li>Quingestanol acetate</li></ul></li>
<li>Tibolone</li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyl-19-nortestosterone derivatives:</i> 5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li></ul>

<ul><li><i>Progesterone derivatives:</i> 6α-Methylprogesterone</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li></ul>

<ul><li><i>Others/unsorted:</i> 3-Keto-5α-abiraterone</li>
<li><a href="Androstane.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Androstane" title="5α-Androstane" class="mw-redirect">5α-Androstane</a></li>
<li>Alternariol</li>
<li>Cl-4AS-1</li>
<li>Drupanol</li>
<li><a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li>
<li>ZM-182345</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SARMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nonsteroidal:</i> <span class="new">198RL26</span></li>
<li><span class="new">ACP-105</span></li>
<li><span class="new">AC-262536</span></li>
<li>Acetothiolutamide</li>
<li>Andarine (acetamidoxolutamide, androxolutamide, GTx-007, S-4)</li>
<li><span class="new">BMS-564929</span></li>
<li><span class="new">DTIB</span></li>
<li>Enobosarm (ostarine, MK-2866, GTx-024, S-22)</li>
<li><span class="new">FTBU-1</span></li>
<li>GSK2881078</li>
<li><span class="new">GSK-4336A</span></li>
<li><span class="new">GSK-8698</span></li>
<li>LG-121071 (LGD-121071)</li>
<li>LGD-2226</li>
<li><span class="new">LGD-2941 (LGD-122941)</span></li>
<li>LGD-3303</li>
<li>LGD-4033</li>
<li>LY-2452473</li>
<li><span class="new">JNJ-26146900</span></li>
<li>JNJ-28330835</li>
<li><span class="new">JNJ-37654032</span></li>
<li><span class="new">ORM-11984</span></li>
<li><span class="new">R-1</span></li>
<li>RAD140</li>
<li>RU-59063</li>
<li><span class="new">S-1</span></li>
<li>S-23</li>
<li>S-40503</li>
<li><span class="new">S-101479</span></li>
<li>Triclosan</li></ul>

<ul><li><i>Steroidal:</i> <span class="new">EM-9017</span></li>
<li>MK-0773</li>
<li>TFM-4AS-1</li>
<li>YK-11</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 7α-Thioprogesterone</li>
<li>7α-Thiospironolactone</li>
<li>7α-Thiomethylspironolactone</li>
<li>11α-Hydroxyprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>Abiraterone</li>
<li>Abiraterone acetate</li>
<li>Allyltestosterone</li>
<li>Benorterone</li>
<li>BOMT</li>
<li>Canrenoic acid</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Clascoterone</li>
<li>Clometerone</li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li><a href="Cyproterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproterone" title="Cyproterone">Cyproterone</a></li>
<li>Cyproterone acetate</li>
<li>Delanterone</li>
<li>Delmadinone acetate</li>
<li>Dicirenone</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>DU-41165</li>
<li>Edogestrone</li>
<li><span class="new">EM-4350</span></li>
<li>EM-5854</li>
<li><span class="new">EM-5855</span></li>
<li><span class="new">EM-6537</span></li>
<li>Epitestosterone</li>
<li>Galeterone</li>
<li>Guggulsterone</li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Mespirenone</li>
<li>Metogest</li>
<li>Mexrenone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li>Nomegestrol acetate</li>
<li>Nordinone</li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Prorenone</li>
<li>Rosterolone</li>
<li><span class="new">RU-15328</span></li>
<li>SC-5233 (spirolactone)</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li>
<li>Spiroxasone</li>
<li>Topterone</li>
<li>Trimegestone</li>
<li>Trimethyltrienolone (R-2956)</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> 5<i>N</i>-Bicalutamide</li>
<li>AA560</li>
<li><span class="new">Antarlides</span></li>
<li><span class="new">Arabilin</span></li>
<li>Apalutamide</li>
<li>Atraric acid</li>
<li><span class="new">AZD-3514</span></li>
<li>Bakuchiol</li>
<li><span class="new">BAY-1024767</span></li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Bisphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol" title="Bisphenol">Bisphenols</a> (e.g., <a href="Bisphenol_A_diglycidyl_ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A_diglycidyl_ether" title="Bisphenol A diglycidyl ether">BADGE</a>, <span class="new">BFDGE</span>, <a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">bisphenol A</a>, bisphenol F, <a href="Bisphenol_S.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_S" title="Bisphenol S">bisphenol S</a>)</li>
<li><span class="new">BMS-501949</span></li>
<li><span class="new">BMS-570511</span></li>
<li>BMS-641988</li>
<li><span class="new">CH5137291</span></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Cioteronel</li>
<li>Cyanonilutamide</li>
<li>Darolutamide</li>
<li>DDT (via metabolite p,p’-DDE)</li>
<li><a href="Dieldrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dieldrin" title="Dieldrin">Dieldrin</a></li>
<li>DIMP</li>
<li><a href="Endosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Endosulfan" title="Endosulfan">Endosulfan</a></li>
<li>Enzalutamide</li>
<li>EPI-001</li>
<li>EPI-7386</li>
<li><a href="Fenarimol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenarimol" title="Fenarimol">Fenarimol</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li>Hydroxyflutamide</li>
<li>Inocoterone</li>
<li>Inocoterone acetate</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Ketodarolutamide</li>
<li>Lavender oil</li>
<li><span class="new">LG-105</span></li>
<li>LG-120907</li>
<li><span class="new">LGD-1331</span></li>
<li>Linuron</li>
<li><a href="Methiocarb.htm" tppabs="https://ptable.com/wiki/compounds/A/Methiocarb" title="Methiocarb">Methiocarb</a></li>
<li><span class="new"><i>N</i>-Butylbenzenesulfonamide</span></li>
<li><i>N</i>-Desmethylapalutamide</li>
<li><i>N</i>-Desmethylenzalutamide</li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li><span class="new">ONC1-13B</span></li>
<li>Pentomone</li>
<li><span class="new">PF-998425</span></li>
<li><a href="Phenothrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenothrin" title="Phenothrin">Phenothrin</a></li>
<li>Prochloraz</li>
<li><a href="Procymidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Procymidone" title="Procymidone">Procymidone</a></li>
<li>Proxalutamide</li>
<li>Ralaniten (EPI-002)</li>
<li>Ralaniten acetate (EPI-506)</li>
<li>RD-162</li>
<li><span class="new">Ro 2-7239</span></li>
<li><span class="new">Ro 5-2537</span></li>
<li>RU-22930</li>
<li>RU-56187</li>
<li>RU-57073</li>
<li>RU-58642</li>
<li>RU-58841</li>
<li>Seviteronel</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li>Topilutamide (fluridil)</li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li>Vinclozolin</li>
<li><span class="new">YM-580</span></li>
<li><span class="new">YM-92088</span></li>
<li><span class="new">YM-175735</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GPRC6A</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center;">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cations (incl. aluminum, <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">calcium</a>, <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>, <a href="Magnesium.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium" title="Magnesium">magnesium</a>, <a href="Strontium.htm" tppabs="https://ptable.com/wiki/compounds/A/Strontium" title="Strontium">strontium</a>, <a href="Zinc.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc" title="Zinc">zinc</a>)</li>
<li>Dehydroandrosterone</li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone</a></li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li><small>L</small>-α-Amino acids (incl. <a href="Arginine.htm" tppabs="https://ptable.com/wiki/compounds/A/Arginine" title="Arginine"><small>L</small>-arginine</a>, <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, <a href="Ornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ornithine" title="Ornithine"><small>L</small>-ornithine</a>)</li>
<li>Osteocalcin</li>
<li><abbr>SHBG</abbr></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogen receptor modulators</dd>
<dd>Progesterone receptor modulators</dd>
<dd>List of androgens/anabolic steroids</dd></dl>
</div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Estrogen_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Estrogen_receptor_modulators" style="font-size:114%;margin:0 4em">Estrogen receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>ER</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 2-Hydroxyestradiol</li>
<li>2-Hydroxyestrone</li>
<li>3-Methyl-19-methyleneandrosta-3,5-dien-17β-ol</li>
<li>3α-Androstanediol</li>
<li><span class="new">3α,5α-Dihydrolevonorgestrel</span></li>
<li><span class="new">3β,5α-Dihydrolevonorgestrel</span></li>
<li>3α-Hydroxytibolone</li>
<li>3β-Hydroxytibolone</li>
<li>3β-Androstanediol</li>
<li><a href="4-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenediol" title="4-Androstenediol">4-Androstenediol</a></li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenedione" title="4-Androstenedione" class="mw-redirect">4-Androstenedione</a></li>
<li>4-Fluoroestradiol</li>
<li>4-Hydroxyestradiol</li>
<li>4-Hydroxyestrone</li>
<li>4-Methoxyestradiol</li>
<li>4-Methoxyestrone</li>
<li><a href="5-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Androstenediol" title="5-Androstenediol" class="mw-redirect">5-Androstenediol</a></li>
<li>7-Oxo-DHEA</li>
<li>7α-Hydroxy-DHEA</li>
<li>7α-Methylestradiol</li>
<li>7β-Hydroxyepiandrosterone</li>
<li>8,9-Dehydroestradiol</li>
<li>8,9-Dehydroestrone</li>
<li>8β-VE2</li>
<li>10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED)</li>
<li>11β-Chloromethylestradiol</li>
<li>11β-Methoxyestradiol</li>
<li>15α-Hydroxyestradiol</li>
<li>16-Ketoestradiol</li>
<li>16-Ketoestrone</li>
<li>16α-Fluoroestradiol</li>
<li>16α-Hydroxy-DHEA</li>
<li>16α-Hydroxyestrone</li>
<li>16α-Iodoestradiol</li>
<li>16α-LE2</li>
<li>16β-Hydroxyestrone</li>
<li>16β,17α-Epiestriol (16β-hydroxy-17α-estradiol)</li>
<li>17α-Estradiol (<a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">alfatradiol</a>)</li>
<li>17α-Dihydroequilenin</li>
<li>17α-Dihydroequilin</li>
<li>17α-Epiestriol (16α-hydroxy-17α-estradiol)</li>
<li>17α-Ethynyl-3α-androstanediol</li>
<li>17α-Ethynyl-3β-androstanediol</li>
<li>17β-Dihydroequilenin</li>
<li>17β-Dihydroequilin</li>
<li>17β-Methyl-17α-dihydroequilenin</li>
<li>Abiraterone</li>
<li>Abiraterone acetate</li>
<li>Alestramustine</li>
<li>Almestrone</li>
<li>Anabolic steroids (e.g., <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and esters, <a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">methyltestosterone</a>, metandienone (methandrostenolone), <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">nandrolone</a> and esters, many others; via estrogenic metabolites)</li>
<li>Atrimustine</li>
<li>Bolandiol</li>
<li>Bolandiol dipropionate</li>
<li>Butolame</li>
<li>Clomestrone</li>
<li>Cloxestradiol
<ul><li>Cloxestradiol acetate</li></ul></li>
<li>Conjugated estriol</li>
<li>Conjugated estrogens</li>
<li>Cyclodiol</li>
<li>Cyclotriol</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA-S</a></li>
<li><i>ent</i>-Estradiol</li>
<li>Epiestriol (16β-epiestriol, 16β-hydroxy-17β-estradiol)</li>
<li>Epimestrol</li>
<li><a href="Equilenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Equilenin" title="Equilenin">Equilenin</a></li>
<li><a href="Equilin.htm" tppabs="https://ptable.com/wiki/compounds/A/Equilin" title="Equilin">Equilin</a></li>
<li>ERA-63 (ORG-37663)</li>
<li>Esterified estrogens</li>
<li>Estetrol</li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a>
<ul><li>Estradiol esters</li>
<li>Lipoidal estradiol</li>
<li>Polyestradiol phosphate</li></ul></li>
<li><a href="Estramustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Estramustine" title="Estramustine">Estramustine</a></li>
<li>Estramustine phosphate</li>
<li>Estrapronicate</li>
<li>Estrazinol</li>
<li><a href="Estriol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estriol" title="Estriol">Estriol</a>
<ul><li>Estriol esters</li>
<li>Polyestriol phosphate</li></ul></li>
<li>Estrofurate</li>
<li>Estrogenic substances</li>
<li>Estromustine</li>
<li><a href="Estrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrone" title="Estrone">Estrone</a>
<ul><li>Estrone esters</li>
<li>Estrone methyl ether</li>
<li>Estropipate</li></ul></li>
<li>Etamestrol (eptamestrol)</li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li>Ethinylestradiol
<ul><li>Ethinylestradiol 3-benzoate</li>
<li>Ethinylestradiol sulfonate</li></ul></li>
<li>Ethinylestriol</li>
<li>Ethylestradiol</li>
<li>Etynodiol</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li>Hexolame</li>
<li>Hippulin</li>
<li>Hydroxyestrone diacetate</li>
<li>Lynestrenol</li>
<li>Lynestrenol phenylpropionate</li>
<li><a href="Mestranol.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestranol" title="Mestranol">Mestranol</a></li>
<li>Methylestradiol</li>
<li>Moxestrol</li>
<li>Mytatrienediol</li>
<li>Nilestriol</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></li>
<li>Noretynodrel</li>
<li>Orestrate</li>
<li>Pentolame</li>
<li>Prodiame</li>
<li>Prolame</li>
<li>Promestriene</li>
<li>RU-16117</li>
<li>Quinestradol</li>
<li><a href="Quinestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Quinestrol" title="Quinestrol">Quinestrol</a></li>
<li>Tibolone</li></ul>

<ul><li><i>Nonsteroidal:</i> (R,R)-THC</li>
<li>(S,S)-THC</li>
<li>2,8-DHHHC</li>
<li><span class="new">β-LGND1</span></li>
<li>β-LGND2 (GTx-878)</li>
<li><span class="new">AC-186</span></li>
<li>Allenestrol</li>
<li>Allenolic acid</li>
<li>Benzestrol</li>
<li>Bifluranol</li>
<li>Bisdehydrodoisynolic acid</li>
<li>Butestrol</li>
<li>Carbestrol</li>
<li>D-15414</li>
<li>DCW234</li>
<li>Diarylpropionitrile</li>
<li><a href="Dienestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dienestrol" title="Dienestrol">Dienestrol</a>
<ul><li>Dienestrol diacetate</li></ul></li>
<li><a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">Diethylstilbestrol</a>
<ul><li>Diethylstilbestrol esters</li></ul></li>
<li>Dimestrol (dianisylhexene)</li>
<li>Dimethylstilbestrol</li>
<li>Doisynoestrol (fenocycline)</li>
<li>Doisynolic acid</li>
<li><a href="Efavirenz.htm" tppabs="https://ptable.com/wiki/compounds/A/Efavirenz" title="Efavirenz">Efavirenz</a></li>
<li>ERB-196 (WAY-202196)</li>
<li>Erteberel (SERBA-1, LY-500307)</li>
<li>Estrobin (DBE)</li>
<li>Fenestrel</li>
<li>FERb 033</li>
<li><a href="Fosfestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fosfestrol" title="Fosfestrol">Fosfestrol (diethylstilbestrol diphosphate)</a></li>
<li>Furostilbestrol (diethylstilbestrol difuroate)</li>
<li>GTx-758</li>
<li>Hexestrol
<ul><li>Hexestrol esters</li></ul></li>
<li>ICI-85966 (Stilbostat)</li>
<li>M2613</li>
<li><i>meso</i>-Butestrol</li>
<li><i>meso</i>-Hexestrol</li>
<li>Mestilbol</li>
<li><a href="Methallenestril.htm" tppabs="https://ptable.com/wiki/compounds/A/Methallenestril" title="Methallenestril">Methallenestril</a></li>
<li>Methestrol</li>
<li>Methestrol dipropionate</li>
<li>Paroxypropione</li>
<li>Pentafluranol</li>
<li>Phenestrol</li>
<li>Prinaberel (ERB-041, WAY-202041)</li>
<li>Propylpyrazoletriol</li>
<li>Quadrosilan</li>
<li><span class="new">SC-3296</span></li>
<li>SC-4289</li>
<li>SERBA-2</li>
<li>SKF-82,958</li>
<li>Terfluranol</li>
<li>Triphenylbromoethylene</li>
<li>Triphenylchloroethylene</li>
<li>Triphenyliodoethylene</li>
<li>Triphenylmethylethylene (triphenylpropene)</li>
<li>WAY-166818</li>
<li><span class="new">WAY-169916</span></li>
<li>WAY-200070</li>
<li>WAY-204688 (SIM-688)</li>
<li>WAY-214156</li></ul>

<ul><li><i>Unknown/unsorted:</i> ERB-26</li>
<li>ERA-45</li>
<li>ERB-79</li>
<li>ZK-283197</li></ul>

<ul><li><i>Xenoestrogens:</i> <a href="Anise.htm" tppabs="https://ptable.com/wiki/compounds/A/Anise" title="Anise">Anise</a>-related (e.g., <a href="Anethole.htm" tppabs="https://ptable.com/wiki/compounds/A/Anethole" title="Anethole">anethole</a>, anol, dianethole, dianol, photoanethole)</li>
<li>Chalconoids (e.g., <a href="Isoliquiritigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoliquiritigenin" title="Isoliquiritigenin">isoliquiritigenin</a>, <a href="Phloretin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phloretin" title="Phloretin">phloretin</a>, <a href="Phlorizin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phlorizin" title="Phlorizin">phlorizin (phloridzin)</a>, wedelolactone)</li>
<li>Coumestans (e.g., <a href="Coumestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumestrol" title="Coumestrol">coumestrol</a>, psoralidin)</li>
<li><a href="Flavonoid.htm" tppabs="https://ptable.com/wiki/compounds/A/Flavonoid" title="Flavonoid">Flavonoids</a> (incl. 7,8-DHF, 8-prenylnaringenin, <a href="Apigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Apigenin" title="Apigenin">apigenin</a>, <a href="Baicalein.htm" tppabs="https://ptable.com/wiki/compounds/A/Baicalein" title="Baicalein">baicalein</a>, <a href="Baicalin.htm" tppabs="https://ptable.com/wiki/compounds/A/Baicalin" title="Baicalin">baicalin</a>, <a href="Biochanin_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Biochanin_A" title="Biochanin A">biochanin A</a>, <a href="Calycosin.htm" tppabs="https://ptable.com/wiki/compounds/A/Calycosin" title="Calycosin">calycosin</a>, <a href="Catechin.htm" tppabs="https://ptable.com/wiki/compounds/A/Catechin" title="Catechin">catechin</a>, <a href="Daidzein.htm" tppabs="https://ptable.com/wiki/compounds/A/Daidzein" title="Daidzein">daidzein</a>, daidzin, ECG, <a href="Epigallocatechin_gallate.htm" tppabs="https://ptable.com/wiki/compounds/A/Epigallocatechin_gallate" title="Epigallocatechin gallate">EGCG</a>, <a href="Catechin.htm" tppabs="https://ptable.com/wiki/compounds/A/Epicatechin" title="Epicatechin" class="mw-redirect">epicatechin</a>, <a href="Equol.htm" tppabs="https://ptable.com/wiki/compounds/A/Equol" title="Equol">equol</a>, <a href="Formononetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Formononetin" title="Formononetin">formononetin</a>, glabrene, glabridin, <a href="Genistein.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistein" title="Genistein">genistein</a>, <a href="Genistin.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistin" title="Genistin">genistin</a>, <a href="Glycitein.htm" tppabs="https://ptable.com/wiki/compounds/A/Glycitein" title="Glycitein">glycitein</a>, <a href="Kaempferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Kaempferol" title="Kaempferol">kaempferol</a>, <a href="Liquiritigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Liquiritigenin" title="Liquiritigenin">liquiritigenin</a>, mirificin, <a href="Myricetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Myricetin" title="Myricetin">myricetin</a>, <a href="Naringenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Naringenin" title="Naringenin">naringenin</a>, <span class="new">penduletin</span>, pinocembrin, <a href="Prunetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prunetin" title="Prunetin">prunetin</a>, puerarin, <a href="Quercetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Quercetin" title="Quercetin">quercetin</a>, tectoridin, tectorigenin)</li>
<li>Lavender oil</li>
<li>Lignans (e.g., enterodiol, enterolactone, nyasol (<i>cis</i>-hinokiresinol))</li>
<li>Metalloestrogens (e.g., <a href="Cadmium.htm" tppabs="https://ptable.com/wiki/compounds/A/Cadmium" title="Cadmium">cadmium</a>)</li>
<li>Pesticides (e.g., alternariol, <a href="Dieldrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dieldrin" title="Dieldrin">dieldrin</a>, <a href="Endosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Endosulfan" title="Endosulfan">endosulfan</a>, <a href="Fenarimol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenarimol" title="Fenarimol">fenarimol</a>, HPTE, <a href="Methiocarb.htm" tppabs="https://ptable.com/wiki/compounds/A/Methiocarb" title="Methiocarb">methiocarb</a>, <a href="Methoxychlor.htm" tppabs="https://ptable.com/wiki/compounds/A/Methoxychlor" title="Methoxychlor">methoxychlor</a>, <a href="Triclocarban.htm" tppabs="https://ptable.com/wiki/compounds/A/Triclocarban" title="Triclocarban">triclocarban</a>, triclosan)</li>
<li>Phytosteroids (e.g., <a href="Digitoxin.htm" tppabs="https://ptable.com/wiki/compounds/A/Digitoxin" title="Digitoxin">digitoxin</a> (digitalis), <a href="Diosgenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Diosgenin" title="Diosgenin">diosgenin</a>, guggulsterone)</li>
<li><a href="Phytosterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Phytosterol" title="Phytosterol">Phytosterols</a> (e.g., β-sitosterol, <a href="Campesterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Campesterol" title="Campesterol">campesterol</a>, <a href="Stigmasterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stigmasterol" title="Stigmasterol">stigmasterol</a>)</li>
<li>Resorcylic acid lactones (e.g., zearalanone, α-zearalenol, β-zearalenol, <a href="Zearalenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Zearalenone" title="Zearalenone">zearalenone</a>, <a href="Zeranol.htm" tppabs="https://ptable.com/wiki/compounds/A/Zeranol" title="Zeranol">zeranol (α-zearalanol)</a>, taleranol (teranol, β-zearalanol))</li>
<li>Steroid-like (e.g., deoxymiroestrol, miroestrol)</li>
<li>Stilbenoids (e.g., <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Resveratrol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Resveratrol'" tppabs="https://ptable.com/wiki/compounds/A/Resveratrol" title="Resveratrol">resveratrol</a>, <a href="Rhaponticin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rhaponticin" title="Rhaponticin">rhaponticin</a>)</li>
<li>Synthetic xenoestrogens (e.g., alkylphenols, <a href="Bisphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol" title="Bisphenol">bisphenols</a> (e.g., <a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">BPA</a>, BPF, <a href="Bisphenol_S.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_S" title="Bisphenol S">BPS</a>), DDT, parabens, <a href="Polybrominated_biphenyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Polybrominated_biphenyl" title="Polybrominated biphenyl">PBBs</a>, PHBA, phthalates, <a href="Polychlorinated_biphenyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Polychlorinated_biphenyl" title="Polychlorinated biphenyl">PCBs</a>)</li>
<li>Others (e.g., agnuside, <span class="new">rotundifuran</span>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SERMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">2-Phenylbenzofuran</span></li>
<li><span class="new">2-Phenylbenzothiophene</span></li>
<li>4'-Hydroxynorendoxifen</li>
<li>27-Hydroxycholesterol</li>
<li>Acefluranol</li>
<li>Acolbifene</li>
<li>Afimoxifene</li>
<li>Anordiol</li>
<li>Anordrin</li>
<li>Arzoxifene</li>
<li>Bazedoxifene</li>
<li>Brilanestrant</li>
<li>Broparestrol</li>
<li><a href="Chlorotrianisene.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorotrianisene" title="Chlorotrianisene">Chlorotrianisene</a></li>
<li><a href="Clomifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Clomifene" title="Clomifene">Clomifene</a></li>
<li>Clomifenoxide</li>
<li><span class="new">CN-55945-27</span></li>
<li><a href="Cyclofenil.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclofenil" title="Cyclofenil">Cyclofenil</a></li>
<li><span class="new">D-15413</span></li>
<li>Desmethylchlorotrianisene</li>
<li>Droloxifene</li>
<li>Elacestrant</li>
<li>Enclomifene</li>
<li>Endoxifen</li>
<li>Etacstil (GW-5638, DPC-974)</li>
<li>Ethamoxytriphetol (MER-25)</li>
<li>Femarelle</li>
<li>Fispemifene</li>
<li><span class="new">GW-7604</span></li>
<li><span class="new">ICI-55548</span></li>
<li><a href="Idoxifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Idoxifene" title="Idoxifene">Idoxifene</a></li>
<li>Lasofoxifene</li>
<li>Levormeloxifene</li>
<li>LN-1643</li>
<li>LN-2299</li>
<li><span class="new">LY-117018</span></li>
<li>Menerba</li>
<li>Miproxifene</li>
<li>Miproxifene phosphate</li>
<li><span class="new">MRL-37</span></li>
<li>Nafoxidine</li>
<li>Nitromifene</li>
<li>NNC 45-0095</li>
<li><span class="new">NNC 45-0320</span></li>
<li><span class="new">NNC 45-0781</span></li>
<li><span class="new">NNC 45-1506</span></li>
<li>Ormeloxifene</li>
<li>Ospemifene</li>
<li>Panomifene</li>
<li>Pipendoxifene</li>
<li><span class="new">Promensil</span></li>
<li><a href="Raloxifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Raloxifene" title="Raloxifene">Raloxifene</a></li>
<li>Rimostil (P-081)</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li><span class="new">SS1010</span></li>
<li><a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">Tamoxifen</a></li>
<li>TAS-108 (SR-16234)</li>
<li><a href="Toremifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Toremifene" title="Toremifene">Toremifene</a></li>
<li>Trioxifene</li>
<li><span class="new">TZE-5323</span></li>
<li><span class="new">U-11555A</span></li>
<li><span class="new">U-11634</span></li>
<li><span class="new">Y-134</span></li>
<li>Zindoxifene</li>
<li>Zuclomifene</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>(R,R)-THC</li>
<li>7β-Hydroxy-DHEA</li>
<li><span class="new">Chloroindazole</span></li>
<li>Cytestrol acetate</li>
<li><span class="new">EM-800 (SCH-57050)</span></li>
<li>Epitiostanol</li>
<li><span class="new">ERA-90</span></li>
<li><span class="new">ERB-88</span></li>
<li><a href="Fulvestrant.htm" tppabs="https://ptable.com/wiki/compounds/A/Fulvestrant" title="Fulvestrant">Fulvestrant (ICI-182780)</a></li>
<li><a href="Glyceollin.htm" tppabs="https://ptable.com/wiki/compounds/A/Glyceollin" title="Glyceollin">Glyceollins</a> (I, <span class="new">II</span>, III, <span class="new">IV</span>)</li>
<li>ICI-164384</li>
<li><span class="new">MDL-101906</span></li>
<li>Mepitiostane</li>
<li>Methylepitiostanol</li>
<li>Methylpiperidinopyrazole</li>
<li>MIBE</li>
<li><span class="new">Oxabicycloheptene sulfonate</span></li>
<li><a href="Phenytoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenytoin" title="Phenytoin">Phenytoin</a></li>
<li>PHTPP</li>
<li>Prochloraz</li>
<li><span class="new">RU-39411</span></li>
<li><span class="new">RU-58668</span></li>
<li><span class="new">SS1020</span></li>
<li>TAS-108 (SR-16234)</li>
<li>ZB716</li>
<li><span class="new">ZK-164015</span></li>
<li><span class="new">ZK-191703</span></li></ul>

<ul><li><i>Coregulator-binding modulators:</i> ERX-11</li></ul>

<ul><li><i>Noncompetitive inhibitors:</i> <a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GPER</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="2-Methoxyestradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/2-Methoxyestradiol" title="2-Methoxyestradiol">2-Methoxyestradiol</a></li>
<li>7β-Hydroxyepiandrosterone</li>
<li>Afimoxifene (4-hydroxytamoxifen)</li>
<li><a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">Aldosterone</a></li>
<li><a href="Atrazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Atrazine" title="Atrazine">Atrazine</a></li>
<li><a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">Bisphenol A</a></li>
<li><a href="Daidzein.htm" tppabs="https://ptable.com/wiki/compounds/A/Daidzein" title="Daidzein">Daidzein</a></li>
<li>DDT (p,p'-DDT, <span class="new">o',p'-DDE</span>)</li>
<li>Diarylpropionitrile</li>
<li><a href="Equol.htm" tppabs="https://ptable.com/wiki/compounds/A/Equol" title="Equol">Equol</a></li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li>Ethinylestradiol</li>
<li><a href="Fulvestrant.htm" tppabs="https://ptable.com/wiki/compounds/A/Fulvestrant" title="Fulvestrant">Fulvestrant (ICI-182780)</a></li>
<li><span class="new">G-1</span></li>
<li><a href="Genistein.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistein" title="Genistein">Genistein</a></li>
<li><span class="new">GPER-L1</span></li>
<li><span class="new">GPER-L2</span></li>
<li>Hydroxytyrosol</li>
<li><a href="Kepone.htm" tppabs="https://ptable.com/wiki/compounds/A/Kepone" title="Kepone">Kepone</a></li>
<li><a href="Niacin.htm" tppabs="https://ptable.com/wiki/compounds/A/Niacin" title="Niacin">Niacin</a></li>
<li><a href="Nicotinamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotinamide" title="Nicotinamide">Nicotinamide</a></li>
<li><a href="Nonylphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Nonylphenol" title="Nonylphenol">Nonylphenol</a></li>
<li><a href="Oleuropein.htm" tppabs="https://ptable.com/wiki/compounds/A/Oleuropein" title="Oleuropein">Oleuropein</a></li>
<li><a href="Polychlorinated_biphenyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Polychlorinated_biphenyl" title="Polychlorinated biphenyl">PCBs</a> (<span class="new">2,2',5'-PCB-4-OH</span>)</li>
<li>Propylpyrazoletriol</li>
<li><a href="Quercetin.htm" tppabs="https://ptable.com/wiki/compounds/A/Quercetin" title="Quercetin">Quercetin</a></li>
<li><a href="Raloxifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Raloxifene" title="Raloxifene">Raloxifene</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Resveratrol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Resveratrol'" tppabs="https://ptable.com/wiki/compounds/A/Resveratrol" title="Resveratrol">Resveratrol</a></li>
<li><span class="new">STX</span></li>
<li><a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">Tamoxifen</a></li>
<li>Tectoridin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>CCL18</li>
<li><a href="Estriol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estriol" title="Estriol">Estriol</a></li>
<li><span class="new">G-15</span></li>
<li><span class="new">G-36</span></li>
<li>MIBE</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Unknown</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">Diethylstilbestrol</a></li>
<li><a href="Zearalenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Zearalenone" title="Zearalenone">Zearalenone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>Androgen receptor modulators</dd>
<dd>Progesterone receptor modulators</dd>
<dd>List of estrogens</dd></dl>
</div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Mineralocorticoid_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Mineralocorticoid_receptor_modulators" style="font-size:114%;margin:0 4em">Mineralocorticoid receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>MR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>11-Dehydrocorticosterone (11-oxocorticosterone, 17-deoxycortisone)
<ul><li><span class="new">11-Dehydrocorticosterone acetate</span></li></ul></li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone (desoxycortone, deoxycortone, desoxycorticosterone)</a>
<ul><li>Desoxycortone esters</li></ul></li>
<li>11-Deoxycortisol (cortodoxone, cortexolone)
<ul><li>Cortifen (cortiphen, kortifen)</li>
<li><span class="new">Cortodoxone acetate</span></li></ul></li>
<li>11β-Hydroxyprogesterone</li>
<li><span class="new">16α,18-Dihydroxy-11-deoxycorticosterone</span></li>
<li><span class="new">17α-Hydroxyaldosterone</span></li>
<li><span class="new">18-Hydroxy-11-deoxycorticosterone</span></li>
<li>19-Norprogesterone</li>
<li><a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">Aldosterone</a></li>
<li><a href="Corticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Corticosterone" title="Corticosterone">Corticosterone</a>
<ul><li><span class="new">Corticosterone acetate</span></li>
<li><span class="new">Corticosterone benzoate</span></li></ul></li>
<li><a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">Cortisol</a> (hydrocortisone)
<ul><li>Benzodrocortisone (hydrocortisone benzoate)</li>
<li><a href="Hydrocortamate.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrocortamate" title="Hydrocortamate">Hydrocortamate (hydrocortisone diethylaminoacetate)</a></li>
<li>Hydrocortisone esters</li></ul></li>
<li><a href="Cortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisone" title="Cortisone">Cortisone</a>
<ul><li>Cortisone acetate</li></ul></li>
<li><a href="Fludrocortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludrocortisone" title="Fludrocortisone">Fludrocortisone (fludrocortone)</a>
<ul><li>Fludrocortisone acetate</li></ul></li>
<li>Mometasone
<ul><li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li></ul></li>
<li><a href="Prednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisolone" title="Prednisolone">Prednisolone</a>
<ul><li>Prednazate</li>
<li>Prednazoline</li>
<li><a href="Prednicarbate.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednicarbate" title="Prednicarbate">Prednicarbate (prednisolone ethylcarbonate propionate)</a></li>
<li><a href="Prednimustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednimustine" title="Prednimustine">Prednimustine</a></li>
<li>Prednisolamate (prednisolone diethylaminoacetate)</li>
<li>Prednisolone esters</li></ul></li>
<li><a href="Prednisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisone" title="Prednisone">Prednisone</a>
<ul><li>Prednisone esters</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 6β-Hydroxy-7α-thiomethylspironolactone</li>
<li><span class="new">7α-Acetylthio-17α-hydroxyprogesterone</span></li>
<li>7α-Thiomethylspironolactone (SC-26519)</li>
<li>7α-Thioprogesterone (SC-8365)</li>
<li>7α-Thiospironolactone (SC-24813)</li>
<li>16α-Hydroxyprogesterone</li>
<li>17α-Hydroxyprogesterone (hydroxyprogesterone)</li>
<li>18-Deoxyaldosterone</li>
<li><span class="new">18,19-Dinorprogesterone</span></li>
<li>Canrenoate potassium (potassium canrenoate)</li>
<li>Canrenoic acid (canrenoate)</li>
<li>Canrenone (canrenoate y-lactone)</li>
<li>Dicirenone</li>
<li>Dimethisterone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li><a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">Eplerenone</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li>Guggulsterone</li>
<li>Hydroxyprogesterone caproate</li>
<li>Medrogestone</li>
<li>Mespirenone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mexrenoate potassium</li>
<li>Mexrenoic acid (mexrenoate)</li>
<li>Mexrenone</li>
<li>Oxprenoic acid (oxprenoate)</li>
<li>Oxprenoate potassium (RU-28318)</li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Prorenoate potassium</li>
<li>Prorenoic acid (prorenoate)</li>
<li>Prorenone</li>
<li><span class="new">RO-14-9012</span></li>
<li><span class="new">RU-26752</span></li>
<li>SC-5233 (spirolactone)</li>
<li>SC-8109</li>
<li><span class="new">SC-11927 (CS-1)</span></li>
<li><span class="new">SC-19886</span></li>
<li><span class="new">SC-27169</span></li>
<li>Spirorenone</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spiroxasone</li>
<li>Tibolone</li>
<li>Trimegestone</li>
<li><span class="new">ZK-91587</span></li>
<li><span class="new">ZK-97894</span></li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Amlodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amlodipine" title="Amlodipine">Amlodipine</a></li>
<li>Apararenone</li>
<li>Benidipine</li>
<li><span class="new">BR-4628</span></li>
<li>Esaxerenone</li>
<li><a href="Felodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Felodipine" title="Felodipine">Felodipine</a></li>
<li>Finerenone</li>
<li><span class="new">Miricorilant (CORT-118335)</span></li>
<li><a href="Nifedipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifedipine" title="Nifedipine">Nifedipine</a></li>
<li><a href="Nimodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nimodipine" title="Nimodipine">Nimodipine</a></li>
<li><a href="Nitrendipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitrendipine" title="Nitrendipine">Nitrendipine</a></li>
<li><span class="new">PF-03882845</span></li>
<li><span class="new">SM-368229</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Mineralocorticoids and antimineralocorticoids</dd>
<dd>Glucocorticoid receptor modulators</dd>
<dd>List of corticosteroids</dd></dl>
</div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Progesterone_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Progesterone_receptor_modulators" style="font-size:114%;margin:0 4em">Progesterone receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Progesterone derivatives:</i> 3β-Dihydroprogesterone</li>
<li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>6α-Methylprogesterone</li>
<li>9α-Bromo-11-ketoprogesterone</li>
<li>11-Dehydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone</a></li>
<li>16α-Hydroxyprogesterone</li>
<li><span class="new">17α-Methyl-11-deoxycorticosterone acetate</span></li>
<li>20α-Dihydroprogesterone</li>
<li>20β-Dihydroprogesterone</li>
<li>Dimepregnen</li>
<li><a href="Diosgenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Diosgenin" title="Diosgenin">Diosgenin</a></li>
<li>P1-185</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Progesterone 3-acetyl enol ether</li>
<li>Quingestrone</li></ul>

<ul><li><i>Retroprogesterone derivatives:</i> 20α-Dihydrodydrogesterone</li>
<li>20α-Dihydrotrengestone</li>
<li>DU-41164</li>
<li>DU-41165</li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li>Retroprogesterone</li>
<li>Ro 6-3129</li>
<li>Trengestone</li></ul>

<ul><li><i>17α-Substituted progesterone derivatives:</i> 6α-Methyl-17α-bromoprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>16-Methylene-17α-hydroxyprogesterone acetate</li>
<li>17α-Bromoprogesterone</li>
<li>17α-Hydroxyprogesterone (hydroxyprogesterone)</li>
<li>17α-Methylprogesterone</li>
<li>Acetomepregenol (mepregenol diacetate)</li>
<li>Algestone</li>
<li>Algestone acetonide</li>
<li>Algestone acetophenide</li>
<li>Anagestone</li>
<li>Anagestone acetate</li>
<li><span class="new">Bromethenmadinone</span></li>
<li>Bromethenmadinone acetate</li>
<li>Butagest (buterol)</li>
<li>Chlormadinone</li>
<li>Chlormadinone acetate</li>
<li>Chlormadinone caproate</li>
<li><span class="new">Chlormethenmadinone</span></li>
<li>Chlormethenmadinone acetate</li>
<li>Cismadinone</li>
<li>Cismadinone acetate</li>
<li>Clogestone</li>
<li>Clogestone acetate</li>
<li>Clomegestone</li>
<li>Clomegestone acetate</li>
<li>Cymegesolate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone</li>
<li>Delmadinone acetate</li>
<li>Edogestrone</li>
<li>Flugestone</li>
<li>Flugestone acetate</li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a></li>
<li>Fluorometholone acetate</li>
<li>Flumedroxone</li>
<li>Flumedroxone acetate</li>
<li>Fluoromedroxyprogesterone acetate</li>
<li>Gestaclone</li>
<li>Haloprogesterone</li>
<li>Hydromadinone</li>
<li>Hydromadinone acetate</li>
<li>Hydroxyprogesterone acetate</li>
<li>Hydroxyprogesterone caproate (hydroxyprogesterone hexanoate)</li>
<li>Hydroxyprogesterone heptanoate (hydroxyprogesterone enanthate)</li>
<li>Hydroxyprogesterone heptanoate benzilic acid hydrazone</li>
<li>Mecigestone (pentarane B)</li>
<li>Medrogestone</li>
<li><a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">Medroxyprogesterone</a></li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Medroxyprogesterone caproate</li>
<li><a href="Megestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Megestrol" title="Megestrol">Megestrol</a></li>
<li>Megestrol acetate</li>
<li>Megestrol caproate</li>
<li>Melengestrol</li>
<li>Melengestrol acetate</li>
<li>Methenmadinone</li>
<li>Methenmadinone acetate</li>
<li>Methenmadinone caproate</li>
<li>Mometasone</li>
<li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Pentagestrone</li>
<li>Pentagestrone acetate</li>
<li>Pentarane A</li>
<li>Proligestone</li></ul>

<ul><li><i>19-Norprogesterone derivatives:</i> 17α-Methyl-19-norprogesterone</li>
<li>18-Methylsegesterone acetate</li>
<li>19-Norprogesterone</li>
<li>Amadinone</li>
<li>Amadinone acetate</li>
<li>Demegestone</li>
<li><span class="new">Fluoro ethyl norprogesterone</span></li>
<li><span class="new">Fluoro furanyl norprogesterone</span></li>
<li>Gestadienol</li>
<li>Gestadienol acetate</li>
<li>Gestonorone acetate (gestronol acetate)</li>
<li>Gestonorone caproate (gestronol hexanoate)</li>
<li>Gestronol (gestonorone)</li>
<li>Nomegestrol</li>
<li>Nomegestrol acetate</li>
<li>Norgestomet</li>
<li>ORG-2058</li>
<li>Oxogestone</li>
<li>Oxogestone phenpropionate (xinogestone)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Segesterone</li>
<li>Segesterone acetate (nestorone)</li>
<li>Trimegestone</li></ul>

<ul><li><i>Testosterone derivatives:</i> Progestins: 6,6-Difluoronorethisterone</li>
<li>6,6-Difluoronorethisterone acetate</li>
<li>17α-Allyl-19-nortestosterone</li>
<li><a href="Allylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Allylestrenol" title="Allylestrenol">Allylestrenol</a></li>
<li>Altrenogest</li>
<li>Chloroethynylnorgestrel</li>
<li>Cingestol</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li>Dienogest</li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone</a></li>
<li>Ethynerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol</li>
<li>Lynestrenol phenylpropionate</li>
<li>Metynodiol</li>
<li>Metynodiol diacetate</li>
<li>Norelgestromin</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone (norethindrone)</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li>Noretynodrel</li>
<li>Norgesterone</li>
<li><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Norvinisterone</li>
<li>Oxendolone</li>
<li>Quingestanol</li>
<li>Quingestanol acetate</li>
<li>Tibolone</li>
<li>Tigestol</li>
<li>Tosagestin; Anabolic–androgenic steroids: 11β-Methyl-19-nortestosterone</li>
<li>11β-Methyl-19-nortestosterone dodecylcarbonate</li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol</li>
<li>Bolandiol dipropionate</li>
<li>Bolandione</li>
<li>Dimethisterone</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone</li>
<li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol (ethylnandrol)</a></li>
<li>Methyldienolone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone (R-1881)</a></li>
<li>Methoxydienone (methoxygonadiene)</li>
<li>Mibolerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a></li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethandrolone, normethisterone)</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li>
<li>Trenbolone (trienolone)</li>
<li>Trenbolone esters (e.g., trenbolone acetate, trenbolone enanthate)</li>
<li>Trendione</li>
<li>Trestolone</li>
<li>Trestolone acetate</li></ul>

<ul><li><i>Spirolactone derivatives:</i> Canrenoic acid</li>
<li>Canrenone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Mespirenone</li>
<li>Potassium canrenoate</li>
<li>Prorenone</li>
<li>SC-5233 (spirolactone)</li>
<li>SC-8109</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li></ul>

<ul><li><i>Nonsteroidal:</i> 3,8-Dihydrodiligustilide</li>
<li>LG-2527</li>
<li><span class="new">LG-100128</span></li>
<li>Riligustilide</li>
<li><span class="new">RWJ-26819</span></li>
<li><span class="new">RWJ-49853</span></li>
<li><span class="new">RWJ-60130</span></li>
<li>Tanaproget</li>
<li>ZM-182345</li></ul>

<ul><li><i>Unknown:</i> ORG-47241</li>
<li>ORG-201745</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SPRMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Dihydroethisterone</li>
<li>5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li>
<li>Asoprisnil</li>
<li>Asoprisnil ecamate</li>
<li>Guggulsterone</li>
<li><span class="new">J1042</span></li>
<li><span class="new">LG-120838</span></li>
<li>Metapristone (RU-42633)</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone (RU-486)</a></li>
<li><span class="new">ORF-9371</span></li>
<li>ORF-9326</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RMI-12936</span></li>
<li>Telapristone</li>
<li>Ulipristal acetate</li>
<li>Vilaprisan</li>
<li><span class="new">ZK-137316</span></li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Apigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Apigenin" title="Apigenin">Apigenin</a></li>
<li><a href="Kaempferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Kaempferol" title="Kaempferol">Kaempferol</a></li>
<li><span class="new">LG-120920</span></li>
<li><a href="Naringenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Naringenin" title="Naringenin">Naringenin</a></li>
<li><span class="new">PRA-910</span></li>
<li><a href="Syringic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Syringic_acid" title="Syringic acid">Syringic acid</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Aglepristone</li>
<li>Lilopristone</li>
<li>Lonaprisan</li>
<li>Onapristone</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-31806</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RTI 3021–022</span></li>
<li>Toripristone</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> Darolutamide</li>
<li><span class="new">LG-001447</span></li>
<li><span class="new">LG-100127</span></li>
<li><span class="new">LG-100128</span></li>
<li><span class="new">LG-120830</span></li>
<li><span class="new">LG-121046</span></li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li><span class="new">ZM-150271</span></li>
<li><span class="new">ZM-172406</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>mPR</abbr><br>(<abbr>PAQR</abbr>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>5β-Dihydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycortisone (21-hydroxyprogesterone)</a></li>
<li>11-Deoxycortisol (17α,21-dihydroxyprogesterone)</li>
<li>17α-Hydroxyprogesterone</li>
<li><a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">Allopregnanolone</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>Androgen receptor modulators</dd>
<dd>Estrogen receptor modulators</dd>
<dd>List of progestogens</dd></dl>
</div></td></tr></tbody></table></div>

<div role="navigation" class="navbox" aria-labelledby="Xenobiotic-sensing_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Xenobiotic-sensing_receptor_modulators" style="font-size:114%;margin:0 4em">Xenobiotic-sensing receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>CAR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">6,7-Dimethylesculetin</span></li>
<li><a href="Amiodarone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amiodarone" title="Amiodarone">Amiodarone</a></li>
<li><a href="Artemisinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemisinin" title="Artemisinin">Artemisinin</a></li>
<li><span class="new">Benfuracarb</span></li>
<li><a href="Carbamazepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbamazepine" title="Carbamazepine">Carbamazepine</a></li>
<li><a href="Carvedilol.htm" tppabs="https://ptable.com/wiki/compounds/A/Carvedilol" title="Carvedilol">Carvedilol</a></li>
<li><a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li><a href="Chrysin.htm" tppabs="https://ptable.com/wiki/compounds/A/Chrysin" title="Chrysin">Chrysin</a></li>
<li><span class="new">CITCO</span></li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">Cyclophosphamide</a></li>
<li><a href="Cypermethrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cypermethrin" title="Cypermethrin">Cypermethrin</a></li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a> (prasterone)</li>
<li><a href="Efavirenz.htm" tppabs="https://ptable.com/wiki/compounds/A/Efavirenz" title="Efavirenz">Efavirenz</a></li>
<li><a href="Ellagic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ellagic_acid" title="Ellagic acid">Ellagic acid</a></li>
<li><a href="Griseofulvin.htm" tppabs="https://ptable.com/wiki/compounds/A/Griseofulvin" title="Griseofulvin">Griseofulvin</a></li>
<li><a href="Methoxychlor.htm" tppabs="https://ptable.com/wiki/compounds/A/Methoxychlor" title="Methoxychlor">Methoxychlor</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Nefazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nefazodone" title="Nefazodone">Nefazodone</a></li>
<li><a href="Nevirapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nevirapine" title="Nevirapine">Nevirapine</a></li>
<li><a href="Nicardipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicardipine" title="Nicardipine">Nicardipine</a></li>
<li><span class="new">Octicizer</span></li>
<li><a href="Permethrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Permethrin" title="Permethrin">Permethrin</a></li>
<li><a href="Phenobarbital.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenobarbital" title="Phenobarbital">Phenobarbital</a></li>
<li><a href="Phenytoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenytoin" title="Phenytoin">Phenytoin</a></li>
<li>Pregnanedione (5β-dihydroprogesterone)</li>
<li><a href="Reserpine.htm" tppabs="https://ptable.com/wiki/compounds/A/Reserpine" title="Reserpine">Reserpine</a></li>
<li><span class="new">TCPOBOP</span></li>
<li><a href="Telmisartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Telmisartan" title="Telmisartan">Telmisartan</a></li>
<li><a href="Tolnaftate.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolnaftate" title="Tolnaftate">Tolnaftate</a></li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a></li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">3,17β-Estradiol</span></li>
<li><span class="new">3α-Androstanol</span></li>
<li>3α-Androstenol</li>
<li><span class="new">3β-Androstanol</span></li>
<li><span class="new">17-Androstanol</span></li>
<li><a href="Allyl_isothiocyanate.htm" tppabs="https://ptable.com/wiki/compounds/A/Allyl_isothiocyanate" title="Allyl isothiocyanate">AITC</a></li>
<li>Ethinylestradiol</li>
<li>Meclizine</li>
<li><span class="new">Nigramide J</span></li>
<li><a href="Okadaic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Okadaic_acid" title="Okadaic acid">Okadaic acid</a></li>
<li>PK-11195</li>
<li><span class="new">S-07662</span></li>
<li><span class="new">T-0901317</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PXR</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> 17α-Hydroxypregnenolone</li>
<li>17α-Hydroxyprogesterone</li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%944-Androstenedione" title="Δ4-Androstenedione" class="mw-redirect">Δ<sup>4</sup>-Androstenedione</a></li>
<li><a href="Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%945-Androstenediol" title="Δ5-Androstenediol" class="mw-redirect">Δ<sup>5</sup>-Androstenediol</a></li>
<li>Δ<sup>5</sup>-Androstenedione</li>
<li><span class="new">AA-861</span></li>
<li>Allopregnanediol</li>
<li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">Allopregnanedione (5α-dihydroprogesterone)</a></li>
<li><a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">Allopregnanolone (brexanolone)</a></li>
<li>Alpha-Lipoic acid</li>
<li>Ambrisentan</li>
<li>AMI-193</li>
<li>Amlodipine besylate</li>
<li>Antimycotics</li>
<li><a href="Artemisinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemisinin" title="Artemisinin">Artemisinin</a></li>
<li><a href="Aurothioglucose.htm" tppabs="https://ptable.com/wiki/compounds/A/Aurothioglucose" title="Aurothioglucose">Aurothioglucose</a></li>
<li>Bile acids</li>
<li><a href="Bithionol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bithionol" title="Bithionol">Bithionol</a></li>
<li><a href="Bosentan.htm" tppabs="https://ptable.com/wiki/compounds/A/Bosentan" title="Bosentan">Bosentan</a></li>
<li><span class="new">Bumecaine</span></li>
<li>Cafestol</li>
<li><a href="Cephaloridine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cephaloridine" title="Cephaloridine">Cephaloridine</a></li>
<li><a href="Cefradine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cephradine" title="Cephradine" class="mw-redirect">Cephradine</a></li>
<li><a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li>Ciglitazone</li>
<li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">Clindamycin</a></li>
<li>Clofenvinfos</li>
<li><a href="Chloroxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chloroxine" title="Chloroxine">Chloroxine</a></li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Colforsin.htm" tppabs="https://ptable.com/wiki/compounds/A/Colforsin" title="Colforsin">Colforsin</a></li>
<li><a href="Corticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Corticosterone" title="Corticosterone">Corticosterone</a></li>
<li><a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">Cyclophosphamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Demecolcine.htm" tppabs="https://ptable.com/wiki/compounds/A/Demecolcine" title="Demecolcine">Demecolcine</a></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a> (prasterone)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a> (prasterone sulfate)</li>
<li>Dibunate sodium</li>
<li>Diclazuril</li>
<li><a href="Dicloxacillin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicloxacillin" title="Dicloxacillin">Dicloxacillin</a></li>
<li><a href="Dimercaprol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimercaprol" title="Dimercaprol">Dimercaprol</a></li>
<li><span class="new">Dinaline</span></li>
<li><a href="Docetaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Docetaxel" title="Docetaxel">Docetaxel</a></li>
<li>Docusate calcium</li>
<li>Dodecylbenzenesulfonic acid</li>
<li>Dronabinol</li>
<li>Droxidopa</li>
<li><a href="Vinburnine.htm" tppabs="https://ptable.com/wiki/compounds/A/Eburnamonine" title="Eburnamonine" class="mw-redirect">Eburnamonine</a></li>
<li>Ecopipam</li>
<li>Enzacamene</li>
<li>Epothilone B</li>
<li><a href="Erythromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Erythromycin" title="Erythromycin">Erythromycin</a></li>
<li>Famprofazone</li>
<li><span class="new">Febantel</span></li>
<li><a href="Felodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Felodipine" title="Felodipine">Felodipine</a></li>
<li><a href="Fenbendazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenbendazole" title="Fenbendazole">Fenbendazole</a></li>
<li><a href="Fentanyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Fentanyl" title="Fentanyl">Fentanyl</a></li>
<li><a href="Flucloxacillin.htm" tppabs="https://ptable.com/wiki/compounds/A/Flucloxacillin" title="Flucloxacillin">Flucloxacillin</a></li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a></li>
<li><a href="Griseofulvin.htm" tppabs="https://ptable.com/wiki/compounds/A/Griseofulvin" title="Griseofulvin">Griseofulvin</a></li>
<li>Guggulsterone</li>
<li><a href="Haloprogin.htm" tppabs="https://ptable.com/wiki/compounds/A/Haloprogin" title="Haloprogin">Haloprogin</a></li>
<li>Hetacillin potassium</li>
<li><a href="Hyperforin.htm" tppabs="https://ptable.com/wiki/compounds/A/Hyperforin" title="Hyperforin">Hyperforin</a></li>
<li><i>Hypericum perforatum</i> (St John's wort)</li>
<li>Indinavir sulfate</li>
<li>Lasalocid sodium</li>
<li><a href="Levothyroxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levothyroxine" title="Levothyroxine">Levothyroxine</a></li>
<li><a href="Linolenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Linolenic_acid" title="Linolenic acid">Linolenic acid</a></li>
<li><span class="new">LOE-908</span></li>
<li><a href="Loratadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loratadine" title="Loratadine">Loratadine</a></li>
<li><a href="Lovastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lovastatin" title="Lovastatin">Lovastatin</a></li>
<li>Meclizine</li>
<li><a href="Metacycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Metacycline" title="Metacycline">Metacycline</a></li>
<li><a href="Methylprednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylprednisolone" title="Methylprednisolone">Methylprednisolone</a></li>
<li><a href="Metyrapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Metyrapone" title="Metyrapone">Metyrapone</a></li>
<li><a href="Mevastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mevastatin" title="Mevastatin">Mevastatin</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Nafcillin.htm" tppabs="https://ptable.com/wiki/compounds/A/Nafcillin" title="Nafcillin">Nafcillin</a></li>
<li><a href="Nicardipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicardipine" title="Nicardipine">Nicardipine</a></li>
<li><a href="Nicotine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotine" title="Nicotine">Nicotine</a></li>
<li><a href="Nifedipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifedipine" title="Nifedipine">Nifedipine</a></li>
<li>Nilvadipine</li>
<li><a href="Nisoldipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nisoldipine" title="Nisoldipine">Nisoldipine</a></li>
<li>Norelgestromin</li>
<li><a href="Omeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Omeprazole" title="Omeprazole">Omeprazole</a></li>
<li><a href="Orlistat.htm" tppabs="https://ptable.com/wiki/compounds/A/Orlistat" title="Orlistat">Orlistat</a></li>
<li><a href="Oxatomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxatomide" title="Oxatomide">Oxatomide</a></li>
<li><a href="Paclitaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Paclitaxel" title="Paclitaxel">Paclitaxel</a></li>
<li><a href="Phenobarbital.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenobarbital" title="Phenobarbital">Phenobarbital</a></li>
<li><a href="Piperine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperine" title="Piperine">Piperine</a></li>
<li><a href="Plicamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Plicamycin" title="Plicamycin">Plicamycin</a></li>
<li><a href="Prednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisolone" title="Prednisolone">Prednisolone</a></li>
<li><a href="Pregnanediol.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnanediol" title="Pregnanediol">Pregnanediol</a></li>
<li>Pregnanedione (5β-dihydroprogesterone)</li>
<li>Pregnanolone</li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li>Pregnenolone 16α-carbonitrile</li>
<li>Proadifen</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Quingestrone</li>
<li><a href="Reserpine.htm" tppabs="https://ptable.com/wiki/compounds/A/Reserpine" title="Reserpine">Reserpine</a></li>
<li>Reverse triiodothyronine</li>
<li><a href="Rifampicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rifampicin" title="Rifampicin">Rifampicin</a></li>
<li><a href="Rifaximin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rifaximin" title="Rifaximin">Rifaximin</a></li>
<li><a href="Rimexolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Rimexolone" title="Rimexolone">Rimexolone</a></li>
<li>Riodipine</li>
<li><a href="Ritonavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Ritonavir" title="Ritonavir">Ritonavir</a></li>
<li><a href="Simvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Simvastatin" title="Simvastatin">Simvastatin</a></li>
<li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spiroxatrine</li>
<li><span class="new">SR-12813</span></li>
<li><span class="new">Suberoylanilide</span></li>
<li>Sulfisoxazole</li>
<li><a href="Suramin.htm" tppabs="https://ptable.com/wiki/compounds/A/Suramin" title="Suramin">Suramin</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><span class="new">Tenylidone</span></li>
<li><a href="Terconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Terconazole" title="Terconazole">Terconazole</a></li>
<li>Testosterone isocaproate</li>
<li><a href="Tetracycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetracycline" title="Tetracycline">Tetracycline</a></li>
<li>Thiamylal sodium</li>
<li><a href="Thiothixene.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiothixene" title="Thiothixene" class="mw-redirect">Thiothixene</a></li>
<li>Thonzonium bromide</li>
<li>Tianeptine</li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a></li>
<li><a href="Troleandomycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Troleandomycin" title="Troleandomycin">Troleandomycin</a></li>
<li><span class="new">Tropanyl 3,5-dimethulbenzoate</span></li>
<li><a href="Zafirlukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Zafirlukast" title="Zafirlukast">Zafirlukast</a></li>
<li><a href="Zeranol.htm" tppabs="https://ptable.com/wiki/compounds/A/Zeranol" title="Zeranol">Zeranol</a></li></ul>

<ul><li><i>Antagonists:</i> <a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Sesamin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sesamin" title="Sesamin">Sesamin</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd></dl>
</div></td></tr></tbody></table></div></div></td></tr></tbody></table></div>





























<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-12" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Spironolactone&oldid=972429347  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Spironolactone&oldid=972429347'" tppabs="https://en.wikipedia.org/wiki/?title=Spironolactone&oldid=972429347">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>